INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Beesline deo whitening fragrance-free spray 150 ml', 14997, 'بيزلين ديو سبراي مفتح خالي من العطر 150 مل', '225', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Beesline > pharma cruise medical', 'Spray', 'بخاخ', '150 ml', '1', NULL, NULL, 'active ingredients alum rock vitamin e aloe vera ginger soybean vitamin c lumiskin teflose lactic acid sodium lactate vitamin b3 & propolis. a skin-friendly spray deodorant with 72hr antiperspirant action to prevent moisture & body odour. all the while de', NULL, 780, '2022-07-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kava 150mg 12 caps.', 21268, 'كافا 150مجم 12 كبسولة', '11', NULL, 'Psychiatric.mood stabilizers', 'Psychiatric.mood stabilizers', NULL, 'Kava-kava', 'October pharma', 'Cap', 'كبسولة', '150mg', '2', NULL, NULL, NULL, '6221088020139', 912, '2023-01-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ketoprof 200mg 14 e.r. caps.', 21391, 'كيتوبروف 200 مجم 14 كبسولة', '15', NULL, 'Nsaid.propionic acid derivatives', 'Nsaid.propionic acid derivatives', NULL, 'Ketoprofen', 'Adwia', 'Cap', 'كبسولة', '200mg', '2', NULL, NULL, NULL, NULL, 986, '2022-07-28', NULL, 0, 'For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.', 'The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. ', 'Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Wellssage massage gel 50gm', 31618, 'ويلساج مساج جل 50 جم', '75', '60', 'Massage gel', 'Massage gel', NULL, 'Camphor oil+peppermint oil+eucalyptus oil', 'Smartic > wellness pharma', 'Gel', 'جل', '50gm', '1', NULL, NULL, 'massage gel', NULL, 737, '2025-06-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Allercet cold 10 caps', 13775, 'الليرست كولد 10 كبسولات', '15', NULL, 'Antihistamine.antiallergy.combined with vasoconstrictor agent', 'Antihistamine.antiallergy.combined with vasoconstrictor agent', NULL, 'Cetirizine+paracetamol(acetaminophen)+pseudoephedrine', 'Global napi pharmaceuticals', 'Cap', 'كبسولة', NULL, '1', 'علاج التهاب الجيوب الأنفية.', NULL, NULL, '6223002145669', 2161, '2022-12-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dexa-ibufen 400mg 20 f.c. tab.', 17418, 'ديكسا ايبوفين 400 مجم 20 قرص', '22', NULL, 'Nsaid.propionic acid derivatives', 'Nsaid.propionic acid derivatives', NULL, 'Dexibuprofen', 'Sigma > hochster pharmaceutical industries', 'Tab', 'أقراص', '400mg', '2', NULL, NULL, 'a type of medicine called a non-steroidal anti-inflammatory drug (nsaid). nsaids are used to relieve pain and inflammation. what is it used for? osteoarthritis. pain in the muscles bones or joints. period pain (dysmenorrhea). toothache. warning! this medi', NULL, 1111, '2022-07-18', NULL, 0, 'For more information, refer to [ibuprofen].', 'Like common NSAIDs, dexibuprofen is an active enantiomer of [ibuprofen] that suppresses the prostanoid synthesis in the inflammatory cells via inhibition of the COX-2 isoform of the arachidonic acid COX.[T28] For more information, refer to [ibuprofen].', 'For more information, refer to [ibuprofen].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cipro 500mg 10 f.c.tab.', 16363, 'سيبرو 500مجم 10 أقراص', '53', '36', 'Antibiotic.quinolone', 'Antibiotic.quinolone', NULL, 'Ciprofloxacin', 'Memphis', 'Tab', 'أقراص', '500mg', '1', 'مضاد حيوى واسع المدى يستخدم فى علاج العديد من الالتهابات', NULL, NULL, '6221050032191', 7232, '2024-07-26', NULL, 0, 'Ciprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493]



Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478]



A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493]



A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475]



A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487]', 'Ciprofloxacin acts on bacterial topoisomerase II (DNA gyrase) and topoisomerase IV.[A178885] Ciprofloxacin''s targeting of the alpha subunits of DNA gyrase prevents it from supercoiling the bacterial DNA which prevents DNA replication.[A178876,A178882]', 'Ciprofloxacin is a second generation fluoroquinolone that is active against many Gram negative and Gram positive bacteria.[A178870,L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] It produces its action through inhibition of bacterial DNA gyrase and topoisomerase IV.[A178885] Ciprofloxacin binds to bacterial DNA gyrase with 100 times the affinity of mammalian DNA gyrase.[A178894] There is no cross resistance between fluoroquinolones and other classes of antibiotics, so it may be of clinical value when other antibiotics are no longer effective.[A178894] Ciprofloxain and its derivatives are also being investigated for its action against malaria, cancers, and AIDS.[A178885]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bretta win 120 ml spray', 6981, 'بريتا وين سبراي 120 مل', '145', NULL, 'Massage spray', 'Massage spray', NULL, 'Tocopheryl acetate+bht+eucalyptusglobulus oil+eugenia caryphyllus flower oil+thymus vulgaris oil+glycerin+propylene glycol+diazolidinyleurea+potassiumsorbate+mentha piperita oil+paraffinum liquidum+betaine+menthol+panthenol+cinnamonum camphora oil+(curcuma longa/glycyrrhiza uralensis) root extract+linoleic acid +', 'Bretta', 'Spray', 'بخاخ', '120 ml', '1', NULL, NULL, NULL, NULL, 863, '2025-08-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Augmentin 156 mg/5 ml susp. 80 ml', 14625, 'اوجمنتين 156مجم/5مل معلق 80 مل', '99', '69', 'Penicillins.penicillin with b-lactamase inhibitor.antibiotic', 'Penicillins.penicillin with b-lactamase inhibitor.antibiotic', NULL, 'Amoxicillin+clavulanic acid', 'Mup > smithkline beecham', 'Susp', 'معلق', '156 mg', '1', 'مضاد حيوي', NULL, 'amoxicillin is an analog of ampicillin derived from the basic penicillin nucleus 6-aminopenicillanic acid clavulanic acid is produced by the fermentation of streptomyces clavuligerus. it is a beta-lactam structurally related to the penicillins and possess', '6221045011323', 1819, '2024-08-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ciprofloxiraz 750mg 10 f.c. tab.', 16388, 'سيبروفلوكسيراز 750مجم 10 قرص', '89', '59.5', 'Antibiotic.quinolone', 'Antibiotic.quinolone', NULL, 'Ciprofloxacin', 'Debeiky > nali pharma international', 'Tab', 'أقراص', '750mg', '1', NULL, NULL, NULL, NULL, 1267, '2025-10-18', NULL, 0, 'Ciprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493]



Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478]



A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493]



A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475]



A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487]', 'Ciprofloxacin acts on bacterial topoisomerase II (DNA gyrase) and topoisomerase IV.[A178885] Ciprofloxacin''s targeting of the alpha subunits of DNA gyrase prevents it from supercoiling the bacterial DNA which prevents DNA replication.[A178876,A178882]', 'Ciprofloxacin is a second generation fluoroquinolone that is active against many Gram negative and Gram positive bacteria.[A178870,L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] It produces its action through inhibition of bacterial DNA gyrase and topoisomerase IV.[A178885] Ciprofloxacin binds to bacterial DNA gyrase with 100 times the affinity of mammalian DNA gyrase.[A178894] There is no cross resistance between fluoroquinolones and other classes of antibiotics, so it may be of clinical value when other antibiotics are no longer effective.[A178894] Ciprofloxain and its derivatives are also being investigated for its action against malaria, cancers, and AIDS.[A178885]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bride cream 60 gm', 15478, 'برايد كريم 60 جم', '23', NULL, 'Whitening topical', 'Whitening topical', NULL, 'Liquorice extract+bearberry extract+vitamin c+ascorbyl palmitate+stearic acid+propylene glycol+bees', 'Hi-care > gamaces leader co.', 'Cream', 'كريم', '60 gm', '1', NULL, NULL, 'fairness cream', NULL, 758, '2022-07-21', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Royal jelly 1000mg 12 caps', 26374, 'رويال جيلي 1000مجم 12 كبسولة', '88', '55', 'Multivitamins', 'Multivitamins', NULL, 'Royal jelly', 'Pharco', 'Cap', 'كبسولة', '1000mg', '1', NULL, NULL, NULL, '6223000010389', 3613, '2024-03-29', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vorigrand 40mg oral susp. 75 ml', 29594, 'فوريجراند 40مجم شراب معلق 75مل', '250', NULL, 'Antifungals.triazoles', 'Antifungals.triazoles', NULL, 'Voriconazole', 'Badr pharma > delta grand pharma', 'Susp', 'معلق', '40mg', '1', NULL, NULL, NULL, NULL, 800, '2022-07-14', NULL, 0, 'For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by <i>Scedosporium apiospermum</i> and <i>Fusarium</i> spp.[L9821, L15571] ', 'Voriconazole is used to treat fungal infections caused by a variety of organisms but including _Aspergillus spp._ and _Candida spp_. Voriconazole is a triazole antifungal exhibiting fungistatic activity against fungal pathogens.[A236050, A236045, L9821] Like other triazoles, voriconazole binds to 14-alpha sterol demethylase, also known as CYP51, and inhibits the demethylation of lanosterol as part of the ergosterol synthesis pathway in yeast and other fungi. The lack of sufficient ergosterol disrupts fungal cell membrane function and limits fungal cell growth. With fungal growth limited, the host''s immune system is able to clear the invading organism.', 'Voriconazole is a fungistatic triazole antifungal used to treat infections by inhibiting fungal growth.[L9821] It is known to cause hepatotoxic and photosensitivity reactions in some patients.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Varipan cream 60 gm', 27398, 'فاريبان كريم 60 جم', '35', NULL, 'Treatment of varicose veins', 'Treatment of varicose veins', NULL, NULL, 'Awaa', 'Cream', 'كريم', '60 gm', '2', NULL, NULL, 'treatment of varicose veins', '6224008851110', 697, '2022-10-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Flare day cream spf 30+ 60 gm', 4922, 'فلير كريم للتفتيح النهاري 60 جم', '110', '105', 'Whitening topical', 'Whitening topical', NULL, 'Kojic acid+etoline+vitamin c+bearberry+melon+liquorice+glutathione', 'Egyptian company for cosmetics > infinity pharm', 'Cream', 'كريم', '60 gm', '1', NULL, NULL, NULL, '6224001133886', 678, '2024-05-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lucente lumini eye serum 20 gm', 16034, 'لوسينت لوميني سيروم لمحيط العين 20 جم', '260', NULL, 'Eye contour', 'Eye contour', NULL, 'Niacinamide+arbutin+vitamin c complex', 'Macro group pharmaceuticals', 'Serum', 'سيروم', '20 gm', '1', NULL, NULL, NULL, NULL, 770, '2022-09-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Retarpen 1.2 m.i.u. vial', 25940, 'ريتاربين 1.2 وحدة امبول', '11', NULL, 'Antibiotic', 'Antibiotic', NULL, 'Benzathine penicillin g', 'Sandoz > october pharma', 'Vial', 'فيال', NULL, '1', NULL, NULL, 'description benzylpenicillin (penicillin g) is narrow spectrum antibiotic used to treat infections caused by susceptible bacteria. it is a natural penicillin antibiotic that is administered intravenously or intramuscularly due to poor oral absorption. pen', '6221088060050', 2048, '2022-12-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Serigabtin 75 mg 20 caps.', 10352, 'سيريجابتن 75 مجم 20 قرص', '58', NULL, 'Anti-epileptic.gaba analogs', 'Anti-epileptic.gaba analogs', NULL, 'Pregabalin', 'Sedico > serio pharm-egypt', 'Cap', 'كبسولة', '75 mg', '2', 'علاج الصرع -- تقليل التشنجات التي تصاحب الصرع', NULL, NULL, '6225000092112', 1273, '2022-12-08', NULL, 0, 'Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.[L7066]', 'Although the mechanism of action has not been fully elucidated, studies involving structurally related drugs suggest that presynaptic binding of pregabalin to voltage-gated calcium channels is key to the antiseizure and antinociceptive effects observed in animal models.[L7066]  



By binding presynaptically to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, pregabalin modulates the release of several excitatory neurotransmitters including glutamate, substance-P, norepinephrine, and calcitonin gene related peptide.[A31163] In addition, pregabalin prevents the alpha2-delta subunit from being trafficked from the dorsal root ganglia to the spinal dorsal horn, which may also contribute to the mechanism of action.[A36628] 



Although pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA or benzodiazepine receptors.[A31165]  ', 'Although the structure of pregabalin is similar to gamma-aminobutyric acid (GABA), it does not bind to GABA receptors.[A31163,A187190] Instead, it binds the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system.[A31163,A187190] Pregabalin does not modulate dopamine receptors, serotonin receptors, opiate receptors, sodium channels or cyclooxygenase activity.[A187190] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fungiban 1% top. gel 15 gm', 5201, 'فانجيبان 1% جل 15جرام', '11', NULL, 'Antifungals.allylamines', 'Antifungals.allylamines', NULL, 'Terbinafine', 'Multi-apex', 'Gel', 'جل', '1%', '1', NULL, NULL, 'about terbinafine a synthetic allylamine derivative antifungal. mechanism of action of terbinafine terbinafine is a fungicidal drug. it interfere the conversion of squalene to ergosterol by inhibiting the enzyme squalene epoxidase.this results in accumula', '6223003201890', 1264, '2023-01-25', NULL, 0, 'Terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by _Trichophyton_ species, _Microsporum canis_, _Epidermophyton floccosum_,[L9068] and _Tinea_ species.[L9065] Terbinafine hydrochloride also treats yeast infections of the skin caused by _Candida_ species and _Malassezia furfur_.[L9068]', 'Terbinafine inhibits the enzyme squalene monooxygenase (also called squalene epoxidase), preventing the conversion of squalene to 2,3-oxydosqualene, a step in the synthesis of ergosterol.[A1279,A1281,L9068] This inhibition leads to decreased ergosterol, which would normally be incorporated into the cell wall, and accumulation of squalene.[A1281,L9068]



Generation of a large number of squalene containing vesicles in the cytoplasm may leach other lipids away from, and further weaken, the cell wall.[A1281]', 'Terbinafine is an allylamine antifungal that inhibits squalene epoxidase (also known as squalene monooxygenase) to prevent the formation of ergosterol and cause an accumulation of squalene, weakening the cell wall of fungal cells.[A1279,A1281,L9068] Terbinafine distributes into tissues and has a long terminal elimination half life, so the duration of action is long.[A1279] Overdose with terbinafine is rare, even above the therapeutic dose, so the therapeutic index is wide.[L9065,L9068] Patients taking oral terbinafine should have liver function tests performed prior to treatment to reduce the risk of liver injury.[L9065]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vanish 10/40mg 7 f.c. tabs.', 28971, 'فانيش 10/40مجم 7 اقراص', '45', NULL, 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', 'Antihyperlipidemic.cholesterol absorption inhibitors.combined with statin', NULL, 'Ezetimibe+simvastatin', 'Egyphar', 'Tab', 'أقراص', '40mg', '1', 'علاج زيادة الدهون الثلاثية في الدم -- تقليل نسبة الكوليسترول في الدم -- الوقاية من امراض القلب', NULL, 'about ezetimibe cholesterol absorption inhibitor 2-azetidinone derivative hypolipidemic agent. mechanism of action of ezetimibe it reduces the absorption of cholesterol from the intestine by localising at the brush border of the small intestine where it i', NULL, 2024, '2023-02-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ugalko for women 30 sachets', 474, 'اوجالكو للسيدات 30 كيس', '400', NULL, 'Diatry supplement', 'Diatry supplement', NULL, 'L_carnitine 500mg+l- arginine 500mg+acetyl-l-carnitine 250 mg+ascorbic acid 90mg+n- acetyl cysteine 50mg+vitamin e 30mg+iron 7mg+vitamin b5 6mg+zinc 5mg+beta-carotene 4.8mg+folic acid (680 mcg dfe) 400mcg+selenium 27.5mcg+vitamin d3 (200 iu) 5mcg+vitamin b12 2.5mcg+vitamin b6 2mcg+copper0.5mcg', 'Larose pharma', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, NULL, NULL, 902, '2022-09-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cyanaro 1% eye drops 2.5 ml', 16985, 'سيانارو 1% قطرة عين 2.5 مل', '34', '22.5', 'Antibiotic.macrolide', 'Antibiotic.macrolide', NULL, 'Azithromycin', 'Rameda > talent pharma', 'Drops', 'نقط', '1%', '1', 'مضاد حيوى واسع المدى يستخدم فى علاج العديد من الالتهابات', NULL, 'description: azithromycin is a semi-synthetic macrolide antibiotic of the azalide class. mechanism of action azithromycin binds to the 50s subunit of the 70s bacterial ribosomes and therefore inhibits rna-dependent protein synthesis in bacterial cells. in', '6225000351615', 2868, '2024-09-30', NULL, 0, 'Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label].



Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. 



**Adults**:



Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.

Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage.



Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_.



Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.



**Pediatric Patients**



Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy.



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.', 'In order to replicate, bacteria require a specific process of protein synthesis, enabled by ribosomal proteins [A6505]. Azithromycin binds to the 23S rRNA of the bacterial 50S ribosomal subunit. It stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit [FDA label], [A14179]. This results in the control of various bacterial infections [A174193], [FDA label].   The strong affinity of macrolides, including azithromycin, for bacterial ribosomes, is consistent with their broad‐spectrum antibacterial activities [A174193].





Azithromycin is highly stable at a low pH, giving it a longer serum half-life and increasing its concentrations in tissues compared to erythromycin [A174175]. 



', 'Macrolides stop bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections [A174175].

Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose [A174172].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Clearty topical lotion 100 ml', 16496, 'كليرتي غسول 100 مل', '134', '90', 'Whitening topical', 'Whitening topical', NULL, NULL, 'Hi-care > novex', 'Lotion', 'لوشن', '100 ml', '1', NULL, NULL, 'indications : skin lightening. helps in treatment of dark patches in intimate areas.', '7695033253924', 1494, '2024-02-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ramazodef 400mg 10 f.c. tab.', 25637, 'رامازوديف 400مجم 10 اقراص', '11', NULL, 'Nsaid.propionic acid derivatives', 'Nsaid.propionic acid derivatives', NULL, 'Dexibuprofen', 'Future pharmaceutical industries (fpi)', 'Tab', 'أقراص', '400mg', '1', NULL, NULL, 'a type of medicine called a non-steroidal anti-inflammatory drug (nsaid). nsaids are used to relieve pain and inflammation. what is it used for? osteoarthritis. pain in the muscles bones or joints. period pain (dysmenorrhea). toothache. warning! this medi', NULL, 862, '2022-07-21', NULL, 0, 'For more information, refer to [ibuprofen].', 'Like common NSAIDs, dexibuprofen is an active enantiomer of [ibuprofen] that suppresses the prostanoid synthesis in the inflammatory cells via inhibition of the COX-2 isoform of the arachidonic acid COX.[T28] For more information, refer to [ibuprofen].', 'For more information, refer to [ibuprofen].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Buscopan 10 mg 20 sugar c.tabs.', 15571, 'بسكوبان 10مجم 20 قرص', '56', '37.5', 'Colon.antispasmodic', 'Colon.antispasmodic', NULL, 'Hyoscin-n-butylbromid', 'Cid > boehringer ingelheim', 'Tab', 'أقراص', '10 mg', '2', 'علاج المغص والام البطن', NULL, NULL, '6223003992262', 5083, '2025-05-30', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kansartan 150mg 30 tab.', 6763, 'كانزارتان 150مجم 30 قرص', '105', '76.5', 'Antihypertensive.angiotensin blocker', 'Antihypertensive.angiotensin blocker', NULL, 'Irbesartan', 'Hikma pharma > chemipharm', 'Tab', 'أقراص', '150mg', '3', 'غلاج ارتفاع ضغط الدم', NULL, 'about irbesartan angiotensin ii receptor blocker a non-peptide compound antihypertensive. mechanism of action of irbesartan it is a competitive antagonist of angiotensin-2 at at-1 receptor. it decreases peripheral resistance and lowers bp in hypertensive', '6222006501778', 1745, '2025-05-06', NULL, 0, 'Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria.[L7456] A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.[L7459]', 'Irbesartan prevents angiotensin II binding to the AT<sub>1</sub> receptor in tissues like vascular smooth muscle and the adrenal gland.[L7456,L7459] Irbesartan and its active metabolite bind the AT<sub>1</sub> receptor with 8500 times more affinity than they bind to the AT<sub>2</sub> receptor.[L7456,L7459] Irbesartan''s prevention of angiotensin II binding causes vascular smooth muscle relaxation and prevents the secretion of aldosterone, lowering blood pressure.[L7456,L7459]



Angiotensin II would otherwise bind to the AT<sub>1</sub> receptor, inducing vasoconstriction and aldosterone secretion, raising blood pressure.[L7456,L7459]', 'Irbesartan is an angiotensin receptor blocker used to treat hypertension and diabetic nephropathy.[L7456,L7459] It has a long duration of action as it is usually taken once daily and a wide therapeutic index as doses may be as low as 150mg daily but doses of 900mg/day were well tolerated in healthy human subjects.[L7456,L7459,A181165]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aptamil junior (aptajunior) 3 advance premium+ milk 400 gm', 14329, 'ابتاميل جونيور ابتاجونيور 3 ادفانس بريميوم+ لبن اطفال 400 جم', '380', '370', 'Milk products.second stage (age 6-12 months)', 'Milk products.second stage (age 6-12 months)', NULL, 'Milk formula stage 3', 'Nutricia cuijk b.v. > united partners company', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, 'this is third stage milk of aptamil. not to replace mother s milk. for infants from 1-3 years age. to be used within one month from opening.', NULL, 987, '2025-06-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tetanus antitoxin (a.t.s) 1500 i.u. 1amp.(n/a)', 11326, 'تيتانوس مصل انتي توكسين 1500 وحدة دولية 1 امبول', '3', NULL, 'Anti tetanus serum', 'Anti tetanus serum', NULL, 'Tetenus vaccine', 'Sinochem ningbo imp.-china > international trading office', 'Amp', 'أمبول', NULL, '1', NULL, NULL, NULL, NULL, 2148, '2022-10-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sinostrum 7 sachets', 31360, 'سينوستروم 7 اكياس', '75', '58', 'Immunity and git health inhancer', 'Immunity and git health inhancer', NULL, 'High concentration bovine colostrum+6 strains of probiotic 5 billion cfu+prebiotic+casecidins+vitamins+minerals', 'Amcomed for pharmaceutical and chemical industries > bromed', 'Sachet', 'أكياس', NULL, '1', 'مدعم ومقوي للمناعة و لعلاج اضطرابات الجهاز الهضمي', NULL, 'immunity booster & git health inhancer indication : -for infants (0 to 4 months): use 1/2 sachet per day -for infants and children (4 months up to 12 years of age): use 1 full sachet daily', NULL, 5972, '2025-08-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Delmenda 10mg 28 f.c.tab.', 17206, 'ديلميندا 10 مجم 28 قرص', '40', NULL, 'Nmda receptor antagonists', 'Nmda receptor antagonists', NULL, 'Memantine', 'Delta pharma', 'Tab', 'أقراص', '10mg', '4', NULL, NULL, 'about memantine n-methyl-d-aspartate receptor antagonist dopamine d2 agonist antidementia agent in alzheimer`s disease. mechanism of action of memantine memantine in an uncompetitive (low to moderate affinity to) nmda (n-methyl-d-aspartate) receptor antag', NULL, 948, '2022-07-24', NULL, 0, 'Memantine is used to manage moderate to severe Alzheimer''s dementia [FDA label]. 



A more recent systemic review and meta-analysis [A177106] indicates that memantine is beneficial as a first line drug for the treatment of Alzheimer''s dementia.  Cholinesterase inhibitors may be added to memantine for further beneficial effects on behavioral symptoms and other symptoms of dementia [A177106].', 'Continuous activation of the N-methyl-D-aspartate (NMDA) receptors in the central nervous system caused by _glutamate_ is thought to cause some of the Alzheimer''s disease symptoms. This overactivation is thought to contribute to neurotoxicity due to the excitatory properties of glutamate [T556]. The pharmacological effect of memantine likely occurs via the drug''s behavior as an uncompetitive (open-channel) NMDA receptor antagonist, preventing glutamate action on this receptor.  Memantine has a preference for the NMDA receptor-operated cation channels. Despite these antagonist effects, memantine has not been proven to prevent or retard the neurodegeneration seen in patients diagnosed with Alzheimer’s disease [FDA label].', '**General effects**



This drug inhibits calcium influx into cells that is normally caused by chronic NMDA receptor activation by glutamate [A1640]. This leads to the improvement of Alzheimer''s dementia symptoms, demonstrated by increased cognition and other beneficial central nervous system effects [A1640]. 



**Effects on neuroplasticity**



Like other NMDA receptor antagonists, memantine at high doses can reduce neuronal synaptic plasticity that is involved in learning and memory processes. At lower concentrations, which are normally used in the clinical setting, memantine can enhance neuronal synaptic plasticity in the brain, improve memory, and act as a neuroprotectant against the destruction of neurons caused by excitatory neurotransmitters [A1639]. 



**Effect on various receptors**



Memantine has demonstrated minimal activity for GABA, benzodiazepine, dopamine, adrenergic, histamine, and glycine receptors, as well as voltage-dependent Ca2+, Na+ or K+ channels. This drug has shown antagonist activity at the 5HT3 receptors. Laboratory studies suggest that memantine does not affect the reversible inhibition of the acetylcholinesterase normally caused by donepezil, galantamine, or tacrine [FDA label].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Costareb 100mg 30 tabs.', 16841, 'كوستاريب 100مجم 30 قرص', '105', '69', 'Peptic ulcer', 'Peptic ulcer', NULL, 'Rebamipide', 'Averroes pharma-egypt', 'Tab', 'أقراص', '100mg', '3', 'قرحة المعدة والحموضة', NULL, NULL, '6224008179443', 12732, '2025-07-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Enrich oral drops 30 ml', 4196, 'انريتش نقط فم 30 مل', '40', '26', 'Anemia.iron supplement', 'Anemia.iron supplement', NULL, 'Ferric hydroxide polymaltose', 'Marcyrl co.', 'Drops', 'نقط', '30 ml', '1', NULL, NULL, NULL, '6223003570354', 6645, '2024-11-27', NULL, 0, 'Ferric carboxymaltose is an iron replacement product indicated for the treatment of iron deficiency anemia in patients ≥1 year of age who have an intolerance to, or unsatisfactory response from, oral iron therapy,[L49379] and in adult patients who have non-dialysis-dependent chronic kidney disease.[L49379] It is also indicated to treat iron deficiency and improve exercise capacity in adult patients with NYHA class II or III heart failure.[L49379]', 'Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron.[L49379]', 'When measured using positron emission tomography (PET), the red cell uptake of 59-Fe and 52-Fe from INJECTAFER ranged from 61% to 99%.[L49379] In patients with iron deficiency, the red cell uptake ranged from 91% to 99%.[L49379] In patients with renal anemia, the red cell uptake ranged from 61% to 84%.[L49379]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Inlyta 5mg 56 f.c. tablets', 20844, 'انليتا 5مجم 56 قرص', '34,435', '25365', 'Antineoplastic', 'Antineoplastic', NULL, 'Axitinib', 'Pfizer', 'Tablet', 'أقراص', '5mg', '4', 'مضاد للاورام السرطانية', NULL, NULL, NULL, 2519, '2024-08-24', NULL, 0, 'Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.', 'Axitinib selectively blocks the tyrosine kinase receptors VEGFR-1 (vascular endothelial growth factor receptor), VEGFR-2, and VEGFR-3.', 'Axitinib prevents the progression of cancer by inhibiting angiogenesis and blocking tumor growth.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Asutec 300mg 20 caps', 14510, 'اسيوتك 300مجم 20 كبسول', '42', NULL, 'Joints arthritis', 'Joints arthritis', NULL, 'Avocado oil+soya bean oil', 'Marcyrl co. > pharma green', 'Cap', 'كبسولة', '300mg', '2', 'علاج التهاب المفاصل', NULL, NULL, NULL, 6267, '2022-10-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Caldin zinc susp. 120 ml', 15690, 'كالدين زنك معلق شرب 120 مل', '55', '30', 'Calcium supplement', 'Calcium supplement', NULL, 'Calcium carbonate+magnesium carbonate+vitamin d3+zinc', 'Al esraa pharmaceutical optima', 'Susp', 'معلق', '120 ml', '1', 'مكمل غذائي بالكالسيوم والزنك', NULL, NULL, '6223004160493', 3778, '2025-05-28', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nutri baby 1 milk 400 gm', 23838, 'نوتري بيبي 1 لبن اطفال 400 جرام', '150', NULL, 'Milk products.first stage (age 0-6 months)', 'Milk products.first stage (age 0-6 months)', NULL, 'Milk formula stage 1', 'Geo-poland co. ltd. > egyptian pharmaceutical trading company', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, 'not to replace mother s milk. for infants from 0-6 months age. to be used within one month from opening.', NULL, 1378, '2023-01-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Endosentana 10 mg 10 f.c. tabs.', 18307, 'اندوسينتانا 10 مجم 10 قرص', '462', NULL, 'Pulmonary hypertension', 'Pulmonary hypertension', NULL, 'Ambrisentan', 'Rameda', 'Tab', 'أقراص', '10 mg', '1', NULL, NULL, 'ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. the peptide endothelin constricts muscles in blood vessels increasing blood pressure. ambrisentan which relaxes those muscles is an endothelin receptor antagonist and is s', NULL, 1395, '2022-07-12', NULL, 0, 'Ambrisentan is indicated for treatment of idiopathic (‘primary’) pulmonary arterial hypertension (IPAH) and pulmonary arterial hypertension (PAH) associated with connective tissue disease in patients with WHO functional class II or III symptoms. In the United States of America, ambrisentan is also indicated in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.', 'Endothelin-1 (ET-1) is an endogenous peptide that acts on the endothelin type A (ETA) and endothelin type B (ETB) receptors in vascular smooth muscle and endothelium. ETA-mediated actions include vasoconstriction and cell proliferation, whereas ETB predominantly mediates vasodilation, anti-proliferation, and ET-1 clearance. In patients with pulmonary arterial hypertension, ET-1 levels are increased and correlate with increased right arterial pressure and severity of disease.

Ambrisentan is one of several newly developed vasodilator drugs that selectively target the endothelin type A (ETA) receptor, inhibiting its action and preventing vasoconstriction. Selective inhibition of the ETA receptor prevents phospholipase C-mediated vasoconstriction and protein kinase C-mediated cell proliferation. Endothelin type B (ETB) receptor function is not significantly inhibited, and nitric oxide and prostacyclin production, cyclic GMP- and cyclic AMP-mediated vasodilation, and endothelin-1 (ET-1) clearance is preserved.', 'Ambrisentan 10 mg daily had no significant effect on the QTc interval, whereas a 40 mg daily dose of ambrisentan increased mean QTc at tmax by 5 ms with an upper 95% confidence limit of 9 ms. Significant QTc prolongation is not expected in patients taking ambrisentan without concomitant metabolic inhibitors. 

Plasma concentrations of B-type natriuretic peptide (BNP) in patients who received ambrisentan for 12 weeks were significantly decreased. Two Phase III placebo-controlled studies demonstrated a decrease in BNP plasma concentrations by 29% in the 2.5 mg group, 30% in the 5 mg group, and 45% in the 10 mg group (p < 0.001 for each dose group) and an increase by 11% in the placebo group.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Joifit 30 caps', 21177, 'جويفيت 30 كبسولة', '10', NULL, 'Antirheumatic.osteoarthritis.anabolic agents', 'Antirheumatic.osteoarthritis.anabolic agents', NULL, 'Methyl sulphonyl methane', 'Pharopharma', 'Cap', 'كبسولة', NULL, '1', 'علاج حالات التهاب المفاصل والغضاريف -- بناء انسجة المفاصل والغضاريف -- مضاد لالتهاب المفاصل والعظام -- مضاد للروماتيزم -- تقليل الام المفاصل والركبة -- زيادة لزوجة السائل الغضروفي -- تقليل التورم الناتج من الالتهاب.', NULL, NULL, '6221094158802', 3929, '2023-02-11', NULL, 0, 'For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).', 'Photosensitization following application of methyl aminolevulinate cream occurs through the metabolic conversion of methyl aminolevulinate (prodrug) to photoactive porphyrins (PAP), which accumulates in the skin lesions to which the cream has been applied. When exposed to light of appropriate wavelength and energy, the accumulated photoactive porphyrins produce a photodynamic reaction, resulting in a cytotoxic process dependent upon the simultaneous presence of oxygen. The absorption of light results in an excited state of porphyrin molecules, and subsequent spin transfer from photoactive porphyrins to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals.', 'After topical application of methyl aminolevulinate, porphyrins will accumulate intracellularly in the treated skin lesions. The intracellular porphyrins (including PpIX) are photoactive, fluorescing compounds and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments, in particular the mitochondria. Light activation of accumulated porphyrins leads to a photochemical reaction and thereby phototoxicity to the light-exposed target cells.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Megestron 150mg/ml i.m.vial', 22484, 'ميجيسترون 150مجم/مل فيال عضل', '7', NULL, 'Contraceptives', 'Contraceptives', NULL, 'Medroxyprogesterone', 'Schering plough', 'Vial', 'فيال', '150mg', '1', NULL, NULL, 'about medroxyprogesterone progestogenic hormone hormonal contraceptive. mechanism of action of medroxyprogesterone it is a progestin derivative exerts it`s action through nuclear progesterone receptors situated in female genital tract breast cns and pitui', NULL, 996, '2022-07-18', NULL, 0, 'Medroxyprogesterone acetate (MPA) oral tablets are indicated to treat secondary amenorrhea, reduce the incidence of endometrial hyperplasia in postmenopausal women, and to treat abnormal uterine bleeding due to hormonal imbalance, not organic pathology.[L8657] Oral tablets containing MPA and conjugated estrogens are indicated to prevent postmenopausal osteoporosis and to treat moderate to severe menopausal symptoms such as vasomotor symptoms, vulvar atrophy, and vaginal atrophy.[L8660] Subcutaneous MPA is indicated to prevent pregnancy and manage pain associated with endometriosis.[L8663] Intramuscular MPA is indicated to prevent pregnancy,[L8666] and at higher concentrations for palliative treatment of endometrial or renal carcinoma.[L8669]', 'Medroxyprogesterone acetate (MPA) inhibits the production of gonadotropin, preventing follicular maturation and ovulation, which is responsible for it’s ability to prevent pregnancy.[L8660] This action also thins the endometrium.[L8660] MPA reduces nuclear estrogen receptors and DNA synthesis in epithelial cells of the endometrium.[L8660] MPA can also induce p53 dependant apoptosis in certain cancer cell lines,[A186134] and inhibit GABA-A receptors.[A186140]', 'Medroxyprogesterone acetate (MPA) inhibits gonadotropin production, reduces nuclear estrogen receptors and DNA synthesis in epithelial cells of the endometrium, and induces p53 dependant apoptosis in cancer cell lines.[L8660,A186134] MPA oral tablets have a half life of 40-60 hours and other formulations can have half lives that are considerably longer, so the duration of action is long.[A186086,A186095] The therapeutic window is wide as patients may take doses ranging from 5mg orally daily to 1000mg as a depo injection weekly.[L8657,L8660,L8663,L8666,L8669] Long term use of MPA is associated with a reduction in bone density and patients who taking MPA during adolescence may have lower peak bone mass than untreated patients, which can also increase the risk of osteoporosis and fractures in the future.[L8657,L8660,L8663,L8666,L8669]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ceftazidime 0.5gm vial', 2281, 'سيفتازيديم 0.5جم فيال', '14', NULL, 'Antibiotic', 'Antibiotic', NULL, 'Ceftazidime', 'Company', 'Vial', 'فيال', '0.5gm', '1', NULL, NULL, NULL, NULL, 1908, '2023-05-23', NULL, 0, 'Ceftazidime is indicated for the treatment of lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections (including peritonitis), and central nervous system infections (including meningitis) caused by susceptible bacteria.[L32935]



Ceftazidime is indicated in combination with [avibactam] to treat infections caused by susceptible Gram-negative organisms, including complicated intra-abdominal infections (cIAI), in conjunction with [metronidazole], and complicated urinary tract infections (cUTI), including pyelonephritis, in patients aged three months and older. This combination is also indicated to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older.[L45128]



In all cases, to mitigate the risk of bacterial resistance and preserve clinical efficacy, ceftazidime should only be used for infections that are confirmed or strongly suspected to be caused by susceptible bacterial strains.[L32935, L45128]', 'The bacterial cell wall, which is located at the periphery of Gram-positive bacteria and within the periplasm of Gram-negative bacteria, comprises a glycopeptide polymer synthesized through cross-linking of glycans to peptide stems on alternating saccharides, which is known commonly as peptidoglycan.[A232920] Cell wall formation, recycling, and remodelling require numerous enzymes, including a family of enzymes with similar active site character despite distinct and sometimes overlapping roles as carboxypeptidases, endopeptidases, transpeptidases, and transglycosylases, known as "penicillin-binding proteins" (PBPs). The number of PBPs differs between bacteria, in which some are considered essential and others redundant. In general, inhibition of one or more essential PBPs results in impaired cell wall homeostasis, loss of cell integrity, and is ultimately bactericidal.[A232920, A232925, A232930]



Ceftazidime is a semisynthetic third-generation cephalosporin with broad activity against numerous Gram-negative and some Gram-positive bacteria.[L32935] Like other β-lactam antibiotics, ceftazidime exhibits its bactericidal effect primarily through direct inhibition of specific PBPs in susceptible bacteria.[A232935] _In vitro_ experiments in Gram-negative bacteria such as _Escherichia coli_, _Pseudomonas aeruginosa_, _Acinetobacter baumannii_, and _Klebsiella pneumoniae_ suggest that ceftazidime primarily binds to PBP3, with weaker binding to PBP1a/1b and PBP2 as well; although binding to other PBPs, such as PBP4, is detectable, the concentrations required are much greater than those achieved clinically.[A232935, A16721, A232940, A232945, A232950] Similarly, ceftazidime showed binding to _Staphylococcus aureus_ PBP 1, 2, and 3 with a much lower affinity for PBP4.[A16721] Recent data for _Mycobacterium abcessus_ suggest that ceftazidime can inhibit PonA1, PonA2, and PbpA at intermediate concentrations.[A232930]', 'Ceftazidime is a semisynthetic, broad-spectrum, third-generation cephalosporin antibiotic that is bactericidal through inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin-binding protein 3 (PBP3).[L32935] Among cephalosporins, ceftazidime is notable for its resistance to numerous β-lactamases and its broad spectrum of activity against Gram-negative bacteria, including _Pseudomonas aeruginosa_.[A232935] However, it is less active than first- and second-generation cephalosporins against _Staphylococcus aureus_ and other Gram-positive bacteria and also has low activity against anaerobes.[A232935, A233160] Ceftazidime has confirmed activity against clinically relevant Gram-negative bacteria including _Citrobacter_ spp., _Enterobacter_ spp., _Klebsiella_ spp., _Proteus_ spp., _Serratia spp., _Escherichia coli_, _Haemophilus influenzae_, _Neisseria meningitidis_, _Pseudomonas aeruginosa_, and some Gram-positive bacteria including _Staphylococcus_ spp. and _Streptococcus_ spp. There are also _in vitro_ data for ceftazidime efficacy against a wide variety of other bacteria, such as _Acinetobacter baumannii_ and _Neisseria gonorrhoeae_, but no clear clinical studies to support the use of ceftazidime for infections caused by these bacteria.[L32935]



Although β-lactam antibiotics like ceftazidime are generally well tolerated, there remains a risk of serious acute hypersensitivity reactions, which is higher in patients with a known allergy to ceftazidime or any other β-lactam antibiotic. As with all antibiotics, ceftazidime may result in the overgrowth of non-susceptible organisms and potentially serious effects including _Clostridium difficile_-associated diarrhea (CDAD); CDAD should be considered in patients who develop diarrhea and, in confirmed cases, supportive care initiated immediately. Ceftazidime is primarily renally excreted such that high and prolonged serum concentrations can occur in patients with renal insufficiency, leading to seizures, nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia. Treatment may lead to the development or induction of resistance with a risk of treatment failure. Periodic susceptibility testing should be considered, and monotherapy failure may necessitate the addition of another antibiotic such as an aminoglycoside. Cephalosporin use may decrease prothrombin activity, which may be improved by exogenous vitamin K. Inadvertent intra-arterial administration of ceftazidime may result in distal necrosis.[L32935]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Genebaby d 400 i.u./drop 180 oral drops 5.04 ml', 31946, 'جينبيبي فيتامين دال 400 وحدة دولية', '60', NULL, 'Vitamin d', 'Vitamin d', NULL, 'Cholecalciferol(vitamin d3)', 'Copad egypt > genesis pharma', 'Drops', 'نقط', '5.04 ml', '1', NULL, NULL, 'description derivative of 7-dehydroxycholesterol formed by ultraviolet rays breaking of the c9-c10 bond. it differs from ergocalciferol in having a single bond between c22 and c23 and lacking a methyl group at c24 indication for the treatment of vitamin d', NULL, 1034, '2023-03-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kevork 500 mg 10 f.c.tabs.', 21404, 'كيفورك 500 مجم 10 قرص', '93', '70', 'Antibiotic.quinolone', 'Antibiotic.quinolone', NULL, 'Levofloxacin', 'Organopharma', 'Tab', 'أقراص', '500 mg', '2', NULL, NULL, 'about levofloxacin third generation fluoroquinolone (or quinolone) a broad spectrum antiinfective. mechanism of action of levofloxacin levofloxacin is a broad spectrum antibacterial agent. it act by inhibiting the enzyme dna gyrase (topoisomerase 2) and t', '6224000908065', 901, '2024-03-23', NULL, 0, 'In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate.[L11638,L11692] The oral formulation is also indicated in both adults and children 6 months of age and older for the post-exposure management of inhalational anthrax caused by _Bacillus anthracis_ and for the treatment and/or prophylaxis of plague caused by _Yersinia pestis_.[L11638]



In its ophthalmic formulation, levofloxacin is indicated for the treatment of bacterial conjunctivitis caused by susceptible organisms.[L11641] An inhalational solution available in Canada is indicated for the management of cystic fibrosis patients aged 18 years or older with chronic pulmonary _Pseudomonas aeruginosa_ infections.[L11689]', 'Levofloxacin, like other fluoroquinolone antibiotics, exerts its antimicrobial activity via the inhibition of two key bacterial enzymes: DNA gyrase and topoisomerase IV.[L11638] Both targets are type II topoisomerases, but have unique functions within the bacterial cell. DNA gyrase is an enzyme found only in bacteria that introduces negative supercoils into DNA during replication - this helps to relieve torsional strain caused by the introduction of positive supercoils during replication, and these negative supercoils are essential for chromosome condensation and the promotion of transcription initiation.[A31453] It is comprised of four subunits (two A subunits and two B subunits) of which the A subunits appear to be the target of fluoroquinolone antibiotics.[A190663] Bacterial topoisomerase IV, in addition to contributing to the relaxation of positive supercoils, is essential at the terminal stages of DNA replication and functions to “unlink” newly replicated chromosomes to allow for the completion of cell division.[A31453]



Inhibition of these enzymes by levofloxacin likely occurs via complexation with the topoisomerase enzymes.[A31453] The end result is a blockade of DNA replication, thus inhibiting cell division and resulting in cell death.', 'Levofloxacin is bactericidal and exerts its antimicrobial effects via inhibition of bacterial DNA replication.[L11638] It has a relatively long duration of action in comparison with other antibiotics that allows for once or twice daily dosing. Levofloxacin is associated with QTc-interval prolongation and should be used with caution in patients with other risk factors for prolongation (e.g. hypokalemia, concomitant medications).[L11638]



Levofloxacin has demonstrated _in vitro_ activity against a number of aerobic gram-positive and gram-negative bacteria and may carry some activity against certain species of anaerobic bacteria[L11638] and other pathogens such as _Chlamydia_ and _Legionella_.[A190663] Resistance to levofloxacin may develop, and is generally due to mutations in DNA gyrase or topoisomerase IV, or via alterations to drug efflux.[L11638,A31453] Cross-resistance may occur between levofloxacin and other fluoroquinolones, but is unlikely to develop between levofloxacin and other antibiotic classes (e.g. macrolides) due to significant differences in chemical structure and mechanism of action.[L11638]



As antimicrobial susceptibility patterns are geographically distinct, local antibiograms should be consulted to ensure adequate coverage of relevant pathogens prior to use.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sweetal 1g*25 sachets', 11090, 'سويتال 1 جم 25 كيس', '35', '30', 'Sweetener', 'Sweetener', NULL, 'Sorbitol+sucralose', 'Biopharm egypt > hygint pharmaceuticals-egypt', 'Sachet', 'أكياس', NULL, '1', 'سكر صناعي', NULL, NULL, '6225000177840', 930, '2024-01-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Avene high protection mineral cream spf 50 - 50 ml', 14706, 'افين كريم معدني عالي الحماية 50 مل', '285', NULL, NULL, NULL, NULL, NULL, 'Pierre - fabre france > biotech egypt', 'Cream', 'كريم', '50 ml', '1', NULL, NULL, '100% mineral broad-spectrum sun protection cream for even the most sensitive and intolerant skin. avï¿½ne white sun care offers 100% mineral chemical filter-free sunscreen products to provide broad spectrum uva/ uvb protection without irritation. it is sa', NULL, 668, '2022-07-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Healsec 20mg 14 caps', 5956, 'هيلسك 20مجم 14 كبسولة', '47', '30.5', 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Omeprazole', 'Borg', 'Cap', 'كبسولة', '20mg', '1', 'الحموضة و قرحة المعدة', NULL, NULL, '6223002570485', 3361, '2024-07-31', NULL, 0, 'Omeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the following purposes:



• Treatment of active duodenal ulcer in adults 



• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer

recurrence in adults 



• Treatment of active benign gastric ulcer in adults 



• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.



• Treatment of symptomatic gastroesophageal reflux disease (GERD) in

patients 1 year of age and older 



• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in

patients 1 month of age and older 



• Maintenance of healing of EE due to acid-mediated GERD in patients 1

year of age and older 



• Pathologic hypersecretory conditions in adults', 'Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K(+)-ATPase of the proton pump [A175180], expressed in high quantities by the parietal cells of the stomach. ATPase is an enzyme on the parietal cell membrane that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid) [A174295].



Omeprazole is a member of a class of antisecretory compounds, the substituted _benzimidazoles_, that stop gastric acid secretion by selective inhibition of the _H+/K+ ATPase_ enzyme system. Proton-pump inhibitors such as omeprazole bind covalently to cysteine residues via disulfide bridges on the alpha subunit of the _H+/K+ ATPase_ pump, inhibiting gastric acid secretion for up to 36 hours [A175192].  This antisecretory effect is dose-related and leads to the inhibition of both basal and stimulated acid secretion, regardless of the stimulus [FDA label].  



**Mechanism of H. pylori eradication**



Peptic ulcer disease (PUD) is frequently associated with _Helicobacter pylori_ bacterial infection (NSAIDs) [A175195]. The treatment of H. pylori infection may include the addition of omeprazole or other proton pump inhibitors as part of the treatment regimen [FDA label], [A175198]. 

_H. pylori_ replicates most effectively at a neutral pH [A175213]. Acid inhibition in H. pylori eradication therapy, including proton-pump inhibitors such as omeprazole, raises gastric pH, discouraging the growth of H.pylori [A175198]. It is generally believed that proton pump inhibitors inhibit the _urease_ enzyme, which increases the pathogenesis of H. pylori in gastric-acid related conditions [A175216].   ', '**Effects on gastric acid secretion**



This drug decreases gastric acid secretion [FDA label]. After oral administration, the onset of the antisecretory effect of omeprazole is usually achieved within one hour, with the maximum effect occurring by 2 hours after administration. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days [FDA label].



**Effects on serum gastrin**



In studies of 200 or more patients, serum gastrin levels increased during the first 1-2 weeks of daily administration of therapeutic doses of omeprazole. This occurred in a parallel fashion with the inhibition of acid secretion. No further increase in serum gastrin occurred with continued omeprazole administration. Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may lead to false positive results in diagnostic studies for neuroendocrine tumors [FDA label].



**Enterochromaffin-like (ECL) cell effects**



Human gastric biopsy samples have been obtained from more than 3000 pediatric and adult patients treated with omeprazole in long-term clinical studies. The incidence of enterochromaffin-like cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia have been identified in these patients. These studies, however, are of insufficient in power and duration to draw conclusions on the possible influence of long-term administration of omeprazole in the development of any premalignant or malignant conditions [FDA label]. 



**Other effects**



Systemic effects of omeprazole in the central nervous system, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2-4 weeks, showed no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin [FDA label]. 





', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ribavarin 400mg 12caps.', 26056, 'ريبافارين 400مجم 12 كبسول', '29', NULL, 'Antiviral.nucleoside', 'Antiviral.nucleoside', NULL, 'Ribavirin', 'Memphis', 'Cap', 'كبسولة', '400mg', '1', NULL, NULL, 'about ribavirin a nucleoside antimetabolite triazole derivative antiviral. mechanism of action of ribavirin ribavirin is a nucleoside analogue and it is phosphorylated by adenosine kinase enzyme in the host cell to form ribavirin monophosphate.this will i', NULL, 748, '2022-07-13', NULL, 0, 'Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates [A19644].



The addition of ribavirin in Technivie therapy indicated for treating HCV genotype 1a and 4 infections is recommended in patients with or without cirrhosis. 



Resistance: viral genetic determinants resulting in variable response to ribavirin therapy has not been yet determined. ', 'Ribavirin is reported to have several mechanism of actions that lead to inhibition of viral RNA and protein synthesis. 

After activation by adenosine kinase to ribavirin mono-, di-, and triphosphate metabolites. Ribavirin triphosphate (RTP) is the predominant metabolite which directly inhibits viral mRNA polymerase by binding to the nucleotide binding site of the enzyme. This prevents the binding of the correct nucleotides, leading to a reduction in viral replication or to the production of defective virions [A19645]. RTP also demonstrates an inhibitory action on viral mRNA guanylyltransferase and mRNA 2′-O-methyltransferase of dengue virus. Inhibition of these enzymes disrupts the posttranslational capping of the 5′ end of viral mRNA through ribavirin being incorporated at the 5′ end in place of guanosine and preventing the cap methylation step. 



Inhibition of host inosine monophosphate dehydrogenase (IMPDH) and subsequent depletion of GTP pool is proposed to be another mechanism of action of ribavirin. IMPDH catalyzes the rate-limiting step where inosine 5′-monophosphate is converted to xanthine monophosphate during guanosine monophosphate (GMP) synthesis. GMP is later converted to guanosine triphoshpate (GTP). Ribavirin monophosphate mimics inosine 5′-monophosphate and acts as a competitive inhibitor of IMPDH. Inhibited de novo synthesis of guanine nucleotides and decreased intracellular GTP pools leads to a decline in viral protein synthesis and limit replication of viral genomes [A19645].



Ribavirin acts as a mutagen in the target virus to cause an ''error catastrophe'' due to increased viral mutations. RTP pairs with cytidine triphosphate or uridine triphosphate with equal efficiency and to block HCV RNA elongation. It causes premature termination of nascent HCV RNA and increases mutagenesis by producing defective virions [A19645].



Ribavirin also exerts an immunomodulatory action of the host to the virus by shifting a Th2 response in favor of a Th1 phenotype. Th2 response and production of type 2 cytokines such as IL-4, IL-5, and IL-10 stimulates the humoral response which enhances immunity toward the virus [A19645]. Ribavirin enhanced induction of interferon-related genes, including the interferon-α receptor, and down-regulation of genes involved in interferon inhibition, apoptosis, and hepatic stellate cell activation in vitro [A19644]. ', 'Ribavirin mediates direct antiviral activity against a number of DNA and RNA viruses by increasing the mutation frequency in the genomes of several RNA viruses. It is a member of the nucleoside antimetabolite drugs that interfere with duplication of the viral genetic material. The drug inhibits the activity of the enzyme RNA dependent RNA polymerase, due to its resemblence to building blocks of the RNA molecules. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Osteocare 30 tabs', 9427, 'اوستيوكير 30 قرص', '150', '100', 'Calcium supplement', 'Calcium supplement', NULL, 'Calcium carbonate+magnesium carbonate+vitamin d3+zinc', 'Vitabiotics', 'Tab', 'أقراص', NULL, '2', 'مكمل غذائى لدعم صحة العظام والوقاية من الكساح وهشاشة العظام', NULL, NULL, '6224001078033', 19747, '2024-11-04', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Savi scar gel 30 gm', 31307, 'سافي سكار جل 30 جم', '450', '245', 'Skin care.scar therapy', 'Skin care.scar therapy', NULL, 'Triple silicon+collagen+salicylic a+hyaluronate sod.', 'Dreams > savi pharma', 'Gel', 'جل', '30 gm', '1', NULL, NULL, 'silicon gel for the scar back to normal appearance', NULL, 1727, '2024-10-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Geneca ray sun screen spf 50+ lotion 200 ml', 19666, 'جينيكا راي صن سكرين بمعامل حماية 50 لوسيون 200 مل', '220', NULL, 'Sun block', 'Sun block', NULL, 'Sun protection formula', '> bio geneca pharmaceuticals', 'Lotion', 'لوشن', '200 ml', '1', NULL, NULL, NULL, NULL, 715, '2022-08-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ketoral plus hair shampoo 125ml', 21393, 'كيتورال بلس شامبو للشعر 125 مل', '95', '70', 'Hair care', 'Hair care', NULL, 'Aqua+sodium lauryl ether sulphate+pirocton olamine+olive oil+panthenol+methyl paraben+propyl paraben', 'Mash premiere', 'Amp', 'أمبول', '125ml', '1', NULL, NULL, 'anti-dandruff hair shampoo', '6222001406054', 1240, '2023-12-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Microlut 0.03mg 35 coated tab.', 22725, 'ميكرولوت 0.03مجم 35 اقراص', '36', NULL, 'Contraceptives', 'Contraceptives', NULL, 'Levonorgestrel', 'Bayer schering > bayer healthcare', 'Tab', 'أقراص', '0.03mg', '1', NULL, NULL, NULL, NULL, 5621, '2022-07-15', NULL, 0, '**Emergency contraception**



Levonorgestrel, in the single-agent emergency contraceptive form, is indicated for the prevention of pregnancy after the confirmed or suspected failure of contraception methods or following unprotected intercourse. It is distributed by prescription for patients under 17, and over the counter for those above this age.[L7760] This levonorgestrel-only form of contraception is not indicated for regular contraception and must be taken as soon as possible within 72 hours after intercourse.[A181976,L7760] It has shown a lower efficacy when it is used off label within 96 hours.[T659]



**Long-term contraception or nonemergency contraception**



In addition to the above indication in emergency contraception, levonorgestrel is combined with other contraceptives in contraceptive formulations designed for regular use, for example with ethinyl estradiol.[L7766] It is used in various hormone-releasing intrauterine devices for long-term contraception ranging for a duration of 3-5 years.[L7778,L7781,L7787] Product labeling for Mirena specifically mentions that it is recommended in women who have had at least 1 child and can be indicated for the prevention of pregnancy for up to 8 years.[L7778,L42950] A subdermal implant is also available for the prevention of pregnancy for up to 5 years.[L7823]



**Hormone therapy and off-label uses**



Levonorgestrel is prescribed in combination with estradiol as hormone therapy during menopause to manage vasomotor symptoms and to prevent osteoporosis.[L7805]Off-label, levonorgestrel may be used to treat menorrhagia, endometrial hyperplasia, and endometriosis.[T659]', '**Mechanism of action on ovulation**



Oral contraceptives containing levonorgestrel suppress gonadotropins, inhibiting ovulation. Specifically, levonorgestrel binds to progesterone and androgen receptors and slows the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus. This process results in the suppression of the normal physiological luteinizing hormone (LH) surge that precedes ovulation. It inhibits the rupture of follicles and viable egg release from the ovaries. Levonorgestrel has been proven to be more effective when administered before ovulation.[T659]



**Mechanism of action in cervical mucus changes**



Similar to other levonorgestrel-containing contraceptives, the intrauterine (IUD) forms of levonorgestrel likely prevent pregnancy by increasing the thickness of cervical mucus, interfering with the movement and survival of sperm, and inducing changes in the endometrium, where a fertilized ovum is usually implanted.[L7778,L7781] Levonorgestrel is reported to alter the consistency of mucus in the cervix, which interferes with sperm migration into the uterus for fertilization. Levonorgestrel is not effective after implantation has occurred.[A181976] 

Interestingly, recent evidence has refuted the commonly believed notion that levonorgestrel changes the consistency of cervical mucus when it is taken over a short-term period, as in emergency contraception. Over a long-term period, however, levonorgestrel has been proven to thicken cervical mucus.[A181976] The exact mechanism of action of levonorgestrel is not completely understood and remains a topic of controversy and ongoing investigation.[A181976,L7760]



*Effects on implantation**



The effects of levonorgestrel on endometrial receptivity are unclear, and the relevance of this mechanism to the therapeutic efficacy of levonorgestrel is contentious.[A175372,A218666] Prescribing information for levonorgestrel IUDs state that they exert local morphological changes to the endometrium (e.g. stromal pseudodecidualization, glandular atrophy) that may play a role in their contraceptive activity.[L7778,L7781]



**Mechanism of action in hormone therapy**



When combined with estrogens for the treatment of menopausal symptoms and prevention of osteoporosis, levonorgestrel serves to lower the carcinogenic risk of unopposed estrogen therapy via the inhibition of endometrial proliferation. Unregulated endometrial proliferation sometimes leads to endometrial cancer after estrogen use.[L7808]', 'Levonorgestrel prevents pregnancy by interfering with ovulation, fertilization, and implantation. The levonorgestrel-only containing emergency contraceptive tablet is 89% effective if it is used according to prescribing information within 72 hours after intercourse.[A181976,A181988] The intrauterine and implantable devices releasing levonorgestrel are more than 99% in preventing pregnancy.[A182123,L7778,L7781] Levonorgestrel utilized as a component of hormonal therapy helps to prevent endometrial carcinoma associated with unopposed estrogen administration.[A182042]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Panadol night 20 f.c. tabs', 24479, 'بانادول نايت 20 قرص', '48', NULL, 'Cold products', 'Cold products', NULL, 'Paracetamol(acetaminophen)+diphenhydramine', 'Glaxo smithkline', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, NULL, 2670, '2022-07-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tri tect acne soap 100 gm', 11628, 'تراي تيكت صابونة لحب الشباب 100 جم', '60', '50', 'Soap', 'Soap', NULL, NULL, 'Dr. chabrawichi factories > macro group pharmaceuticals', 'Soap', 'صابون', '100 gm', '1', 'صابونة حب الشباب', NULL, '*medicated soap for prophylaxes & helping in managing all types of acne with extra sebum absorbing power. *decreases severity of acne in adults & teenagers. *controls excessive sebum secretion in oily & sensitive skin. use: lather soap on face or skin lea', '6224000437299', 5300, '2025-03-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Syntocinon 5 i.u./ml i.m/i.v 5 amp.', 11118, 'سينتوسينون 5 وحدات دولية/مل 5 امبولات', '52', '30', 'Smooth muscle constrictor', 'Smooth muscle constrictor', NULL, 'Oxytocin', 'Novartis > mylan', 'Amp', 'أمبول', NULL, '5', NULL, NULL, NULL, '6221042404050', 2273, '2024-11-25', NULL, 0, 'Administration of exogenous oxytocin is indicated in the antepartum period to initiate or improve uterine contractions for vaginal delivery in situations where there is fetal or maternal concern.[L31433] For example, It may be used to induce labor in cases of Rh sensitization, maternal diabetes, preeclampsia at or near term, and when delivery is indicated due to prematurely ruptured membranes.[A229018,L31433] Importantly, oxytocin is not approved or indicated for elective induction of labor. Oxytocin may be used to reinforce labor in select cases of uterine inertia and as adjunctive therapy in the management of incomplete or inevitable abortion. In the postpartum period, oxytocin may be used to induced contractions in the 3rd stage of labor and to control postpartum bleeding or hemorrhage.[L31433]', 'Oxytocin plays a vital role in labour and delivery.[A228928] The hormone is produced in the hypothalamus and is secreted from the paraventricular nucleus to the posterior pituitary where it is stored.[A228928,A228958] It is then released in pulses during childbirth to induce uterine contractions.[A228928]



The concentration of oxytocin receptors on the myometrium increases significantly during pregnancy and reaches a peak in early labor.[L31433] Activation of oxytocin receptors on the myometrium triggers a downstream cascade that leads to increased intracellular calcium in uterine myofibrils which strengthens and increases the frequency of uterine contractions.[L31433,A228958,A228718]



In humans, most hormones are regulated by negative feedback; however, oxytocin is one of the few that is regulated by positive feedback.[A228958] The head of the fetus pushing on the cervix signals the release of oxytocin from the posterior pituitary of the mother.[A228958] Oxytocin then travels to the uterus where it stimulates uterine contractions.[A228958] The elicited uterine contractions will then stimulate the release of increasing amounts of oxytocin.[A228958] This positive feedback loop will continue until parturition.[A228958]



Since exogenously administered and endogenously secreted oxytocin result in the same effects on the female reproductive system, synthetic oxytocin may be used in specific instances during the antepartum and postpartum period to induce or improve uterine contractions.[A228958,L31433]', 'Oxytocin is a nonapeptide, pleiotropic hormone that exerts important physiological effects.[A228718, A228723] It is most well known to stimulate parturition and lactation, but also has important physiological influences on metabolic and cardiovascular functions, sexual and maternal behaviour, pair bonding, social cognition, and fear conditioning.[A228718,A228998,A229013] 



It is worth noting that oxytocin receptors are not limited to the reproductive system but can be found in many peripheral tissues and in central nervous system structures including the brain stem and amygdala.[A228998,A229003,A229008,A229013]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cidodian depot i.m. 1 amp.', 2566, 'سيدوديان-متخزن امبول عضل', '60', '27', NULL, NULL, NULL, 'Estradiol valerate+prasterone enanthate', 'Cid', 'Amp', 'أمبول', NULL, '1', 'علاج الاعراض الحركية المصاحبة لانقطاع الطمث -- علاج ضمور المهبل -- علاج نقص الاستروجين', NULL, 'indication for the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness burning pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). mechanism of action estradiol enters', '6221043012742', 3275, '2024-11-12', NULL, 0, 'Estradiol is indicated in various preparations for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of postmenopausal osteoporosis. It is also used for the treatment of breast cancer (only for palliation therapy) in certain men or women with metastatic disease, and for the treatment of androgen-dependent prostate cancer (only for palliation therapy).[L11485,L11494,L11497] It is also used in combination with other hormones as a component of oral contraceptive pills for preventing pregnancy (most commonly as [DB00977], a synthetic form of estradiol).



**A note on duration of treatment**



Recommendations for treatment of menopausal symptoms changed drastically following the release of results and early termination of the Women''s Health Initiative (WHI) studies in 2002 as concerns were raised regarding estrogen use.[A31626] Specifically, the combined estrogen–progestin group was discontinued after about 5 years of follow up due to a statistically significant increase in invasive breast cancer and in cardiovascular events.[A31627] 



Following extensive critique of the WHI results, Hormone Replacement Therapy (HRT) is now recommended to be used only for a short period (for 3-5 years postmenopause) in low doses, and in women without a history of breast cancer or increased risk of cardiovascular or thromboembolic disease.[A31628] Estrogen for postmenopausal symptoms should always be given with a progestin component due to estrogen''s stimulatory effects on the endometrium; in women with an intact uterus, unopposed estrogen has been shown to promote the growth of the endometrium which can lead to endometrial hyperplasia and possibly cancer over the long-term. 



', 'Estrogen is found in the the breast, uterine, ovarian, skin, prostate, bone, fat, and brain tissues. The main source of estrogen in adult women during the reproductive period of life is the ovarian follicle, which secretes 70 to 500 mcg of estradiol each day. After menopause, however, the majority of endogenous estrogen is produced by transformation of androstenedione (which is secreted by the adrenal cortex) to estrone in the peripheral tissues. Both estrone and its sulphate conjugated form, estrone sulphate, represent the most abundant estrogens found in postmenopausal women.[L11530] 



Estradiol, however, is considerably more potent than estrone and estriol at the estrogen receptor (ER). As a result, the higher estrone concentration in postmenopausal population, can cause various undesirable effects. These effects may include hot flashes, chills, vaginal dryness, mood swings, irregular menstruation, and chills, in addition to sleep problems.[L11530]



Estradiol workings by binding to subtypes of the estrogen receptor: estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ). It also exerts potent agonism of G Protein-coupled estrogen receptor (GPER), which is recognized an important regulator of this drug''s rapid effects. Once the estrogen receptor has bound to its ligand, it enters the nucleus of the target cell, regulating gene transcription and formation of of messenger RNA. This mRNA makes contact with ribosomes producing specific proteins that express the effect of estradiol upon the target cell. Agonism of estrogen receptors increases pro-estrogenic effects, leading to the relief of vasomotor and urogenital symptoms of a postmenopausal or low estradiol state.[A31620,L11485,L11497]



', 'Estradiol acts on the on the estrogen receptors to relieve vasomotor systems (such as hot flashes) and urogenital symptoms (such as vaginal dryness and dyspareunia).[A190402,A190405,A190408]



Estradiol has also been shown to exert favorable effects on bone density by inhibiting bone resorption. Estrogen appears to inhibit bone resorption [A190402,L11560] and may have beneficial effects on the plasma lipid profile.[A190405,L11530] Estrogens cause an increase in hepatic synthesis of various proteins, which include sex hormone binding globulin (SHBG), and thyroid-binding globulin (TBG).  Estrogens are known to suppress the formation of follicle-stimulating hormone (FSH) in the anterior pituitary gland.[L11485] 



**A note on hyper-coagulable state, cardiovascular health, and blood pressure**



Estradiol may cause an increased risk of cardiovascular disease, DVT, and stroke, and its use should be avoided in patients at high risk of these conditions.[L11560]  Estrogen induces a hyper-coagulable state, which is also associated with both estrogen-containing oral contraceptive (OC) use and pregnancy. Although estrogen causes an increase in levels of plasma renin and angiotensin. Estrogen-induced increases in angiotensin, causing sodium retention, which is likely to be the mechanism causing hypertension after oral contraceptive treatment.[A190402]

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Plentopine 10mg m.r. 10 f.c.tab.', 25006, 'بلينتوبين 10مجم 10 اقراص', '28', NULL, 'Antihypertensive.selective calcium channel blocker', 'Antihypertensive.selective calcium channel blocker', NULL, 'Felodipine', 'International drug agency (idi) > novell pharma', 'Tab', 'أقراص', '10mg', '1', NULL, NULL, 'about felodipine a selective calcium channel blocker dihydropyridine derivative anti hypertensive. mechanism of action of felodipine felodipine is a vasoselective long acting dihydropyridine ca channel blocker. it exerts antihypertensive antianginal actio', NULL, 752, '2023-04-28', NULL, 0, 'For the treatment of mild to moderate essential hypertension. ', 'Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.', 'Felodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor.  Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Omegal man 30cap', 33323, 'اوميجال مان 30 كبسولة', '495', '450', 'Omega 3 supplement', 'Omega 3 supplement', NULL, 'High purified omega 3+coenzyme q10+selenium+zinc', 'Xeedia', 'Cap', 'كبسولة', NULL, '3', 'مكمل غذائي يوفر الحماية ضد أمراض القلب والأوعية الدموية .', NULL, NULL, '6224010509368', 7147, '2025-01-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Centrum select 120 tab', 2340, 'سنتروم سيليكت 120 قرص', '185', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Multivitamins', 'Pfizer', 'Tab', 'أقراص', NULL, '12', NULL, NULL, NULL, NULL, 1141, '2022-09-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ugalko for men 30 sachets', 467, 'اوجالكو للرجال 30 كيس', '500', NULL, 'Diatry supplement', 'Diatry supplement', NULL, 'L-carnitine  2g acetyl l-carnitine 1 g ascorbic acid 180 mg citric acid 100 mg co-q10 40mg zinc 20 mg folic acid (680 mcg dfe) 400 mcg selenium 100 mcg vitamin b12', 'Larose pharma', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, NULL, NULL, 2133, '2022-09-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Prontomutim 100mg 30 tabs', 5212, 'برونتوميوتيم 100مجم 30 قرص', '72', '49.5', 'Antimuscarinic.irritable bowel syndrome', 'Antimuscarinic.irritable bowel syndrome', NULL, 'Trimebutine', 'Medizen', 'Tab', 'أقراص', '100mg', '3', '1- علاج حالات ارتجاع المريء والمعدة. 2- القيء والغثيان والترجيع وعدم قبول الطعام. 3- تحسين حركية الأمعاء لتصريف الطعام. 4- الشعور بتوقف الطعام في الصدر. 5- القولون العصبي واضطراب الجهاز الهضمي. 6- حالات الإمساك المزمن وآلام البطن. 7- حالات المغص و الانتفاخ والتقلصات.', NULL, NULL, '6222012401918', 1338, '2024-10-18', NULL, 0, 'Indicated for symptomatic treatment of irritable bowel syndrome (IBS) and treatment of postoperative paralytic ileus following abdominal surgery. ', 'At high concentrations, trimebutine is shown to inhibit the extracellular Ca2+ influx in the smooth muscle cells through voltage dependent L-type Ca2+ channels and further Ca2+ release from intracellular Ca2+ stores [A19691, A19689]. Trimebutine is suggested to bind to the inactivated state of the calcium channel with high affinity. Reduced calcium influx attenuates membrane depolarization and decrease colon peristalsis. It also inhibits outward K+ currents in response to membrane depolarization of the GI smooth muscle cells at resting conditions through inhibition of delayed rectifier K+ channels and Ca2+ dependent K+ channels, which results in induced muscle contractions [A19691, A19695]. Trimebutine binds to mu opioid receptors with more selectivity compared to delta or kappa opioid receptors but with lower affinity than their natural ligands. Its metabolites (N-monodesmethyl-trimebutine or nor-trimebutine), are also shown to bind to opoid receptors on brain membranes and myenteric synaptosomes [A19692]. ', 'Trimebutine is a spasmolytic agent that acts directly on smooth muscle to modulate gastric motility. It shows a "dual function" that stimulates or inhibits spontaneous contractions depending on the concentration and prior contractile activity in the preparation. Targeting ion conductance that regulates GI motility, trimebutine inhibits the inward calcium currents and calcium-dependent potassium currents in a concentration-dependent manner [A19691]. At lower concentrations (1-10uM), trimebutine depolarizes the resting membrane potential without affecting the amplitude of contractions, which is thought to be mediated by inhibition of outward potassium currents. It is also shown to activate T-type Ca2+ channel and increase gastric emptying, intestinal and colonic contractility [A19690]. At higher concentrations (100-300uM), reduced amplitude of spontaneous contractions and action potentials is thought to be mediated by inhibition of L-type Ca2+ channels and inward calcium current [A19691]. Trimebutine mediates a local anesthetic action by acting as a weak agonist at mu opioid receptors.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gasec 20 mg 14 caps', 5341, 'جازيك 20مجم 14 كبسولة', '38', NULL, 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Omeprazole', 'Mup > acino', 'Cap', 'كبسولة', '20 mg', '2', NULL, NULL, NULL, NULL, 1184, '2023-04-18', NULL, 0, 'Omeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the following purposes:



• Treatment of active duodenal ulcer in adults 



• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer

recurrence in adults 



• Treatment of active benign gastric ulcer in adults 



• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.



• Treatment of symptomatic gastroesophageal reflux disease (GERD) in

patients 1 year of age and older 



• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in

patients 1 month of age and older 



• Maintenance of healing of EE due to acid-mediated GERD in patients 1

year of age and older 



• Pathologic hypersecretory conditions in adults', 'Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K(+)-ATPase of the proton pump [A175180], expressed in high quantities by the parietal cells of the stomach. ATPase is an enzyme on the parietal cell membrane that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid) [A174295].



Omeprazole is a member of a class of antisecretory compounds, the substituted _benzimidazoles_, that stop gastric acid secretion by selective inhibition of the _H+/K+ ATPase_ enzyme system. Proton-pump inhibitors such as omeprazole bind covalently to cysteine residues via disulfide bridges on the alpha subunit of the _H+/K+ ATPase_ pump, inhibiting gastric acid secretion for up to 36 hours [A175192].  This antisecretory effect is dose-related and leads to the inhibition of both basal and stimulated acid secretion, regardless of the stimulus [FDA label].  



**Mechanism of H. pylori eradication**



Peptic ulcer disease (PUD) is frequently associated with _Helicobacter pylori_ bacterial infection (NSAIDs) [A175195]. The treatment of H. pylori infection may include the addition of omeprazole or other proton pump inhibitors as part of the treatment regimen [FDA label], [A175198]. 

_H. pylori_ replicates most effectively at a neutral pH [A175213]. Acid inhibition in H. pylori eradication therapy, including proton-pump inhibitors such as omeprazole, raises gastric pH, discouraging the growth of H.pylori [A175198]. It is generally believed that proton pump inhibitors inhibit the _urease_ enzyme, which increases the pathogenesis of H. pylori in gastric-acid related conditions [A175216].   ', '**Effects on gastric acid secretion**



This drug decreases gastric acid secretion [FDA label]. After oral administration, the onset of the antisecretory effect of omeprazole is usually achieved within one hour, with the maximum effect occurring by 2 hours after administration. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days [FDA label].



**Effects on serum gastrin**



In studies of 200 or more patients, serum gastrin levels increased during the first 1-2 weeks of daily administration of therapeutic doses of omeprazole. This occurred in a parallel fashion with the inhibition of acid secretion. No further increase in serum gastrin occurred with continued omeprazole administration. Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may lead to false positive results in diagnostic studies for neuroendocrine tumors [FDA label].



**Enterochromaffin-like (ECL) cell effects**



Human gastric biopsy samples have been obtained from more than 3000 pediatric and adult patients treated with omeprazole in long-term clinical studies. The incidence of enterochromaffin-like cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia have been identified in these patients. These studies, however, are of insufficient in power and duration to draw conclusions on the possible influence of long-term administration of omeprazole in the development of any premalignant or malignant conditions [FDA label]. 



**Other effects**



Systemic effects of omeprazole in the central nervous system, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2-4 weeks, showed no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin [FDA label]. 





', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Immunate 250 iu fviii / 190 iu vwf vial i.v.', 20742, 'اميونات 250/190وحدة دولية فيال', '775', NULL, 'Blood coagulation factor', 'Blood coagulation factor', NULL, 'Coagulation factor viii+von willebrand factor', 'Baxter ag > takeda', 'Vial', 'فيال', '250 iu', '1', NULL, NULL, NULL, NULL, 825, '2022-07-15', NULL, 0, 'For treatment of hemorrhagic complications in hemophilia A and B.', 'NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.', 'Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Strongville men nourishing cream 120 gm', 31421, 'سترونج فيل كريم مغذي للشعر للرجال 120 جم', '195', '175', 'Hair care', 'Hair care', NULL, NULL, 'Egyptian company for cosmetics > parkville', 'Cream', 'كريم', '120 gm', '1', NULL, NULL, 'the active ingredients in it are similar to minoxidil without side effects. strong ville men hair care group was developed with the addition of one of the strongest effective substances to treat hair loss (procapil lotion) which has been extensively resea', '6224001133480', 814, '2024-05-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Alzepizil 10mg 14 f.c. tab.', 13874, 'الزيبيزيل 10 مجم 14 قرص', '107', '70', 'Central acetylcholinesterase inhibitor', 'Central acetylcholinesterase inhibitor', NULL, 'Donepezil', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '10mg', '2', NULL, NULL, 'about donepezil central acetylcholinesterase inhibitor antidementia agent in alzheimer`s disease. mechanism of action of donepezil alzheimer`s disease may result from a deficiency in neurotransmitters used by nerves in the brain to communicate with one an', '6223002141678', 1041, '2024-04-10', NULL, 0, 'Donepezil, administered orally[L7916] or via transdermal delivery system,[L41125] is indicated for the treatment of dementia of the Alzheimer''s type. It is also available as an extended-release capsule in combination with [memantine] for the treatment of moderate-to-severe dementia of the Alzheimer''s type in patients previously stabilized on 10mg of donepezil hydrochloride once daily.[L7937] 



Off-label uses include the management of vascular dementia, Parkinson''s Disease-associated dementia, and Lewy body dementia, amongst others.[A182333,T668]', '

The commonly accepted cholinergic hypothesis[A182369] proposes that a portion of the cognitive and behavioral decline associated with Alzheimer''s are the result of decreased cholinergic transmission in the central nervous system. Donepezil selectively and reversibly inhibits the acetylcholinesterase enzyme, which normally breaks down acetylcholine. The main pharmacological actions of this drug are believed to occur as the result of this enzyme inhibition, enhancing cholinergic transmission, which relieves the symptoms of Alzheimer''s dementia. In addition to the above, other mechanisms of action of donepezil are possible, including the opposition of glutamate-induced excitatory transmission via downregulation of NMDA receptors and the regulation of amyloid proteins, which have demonstrated significant effects on the disease process of Alzheimer''s.[A182333,A182351,A182444] Other possible targets for donepezil may also include the inhibition various inflammatory signaling pathways, exerting neuroprotective effects.[A182339,A182393]', 'By inhibiting the acetylcholinesterase enzyme, donepezil improves the cognitive and behavioral signs and symptoms of Alzheimer''s Disease, which may include apathy, aggression, confusion, and psychosis.[A182333,A182408]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Swixflur s 0.1% eye drops 5 ml', 27783, 'سويكسفلور اس 0.1% قطرة', '4', NULL, 'Glucocorticoid', 'Glucocorticoid', NULL, 'Fluorometholone', 'Chemipharm', 'Drops', 'نقط', '0.1%', '1', NULL, NULL, 'about fluorometholone (eye.prep.) a synthetic glucocorticoid in steroid responsive inflammations of eye( topical anti-inflammatory). mechanism of action of fluorometholone (eye.prep.) the drug exerts its pharmacological action by penetrating and binding t', NULL, 880, '2022-07-13', NULL, 0, 'For the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.', 'There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Their primary target is the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes.', 'Corticosteroids such as fluorometholone inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sim albustix d 8/12.5mg 30 tabs.', 257, 'البستكس دي 32/ 12.5مجم 30 قرص', '144', '87', 'Antihypertensive. combined angiotensin blocker with diuretic', 'Antihypertensive. combined angiotensin blocker with diuretic', NULL, 'Candesartan cilexetil+hydrochlorothiazide', 'Sigma > concord pharmaceutical industries', 'Tab', 'أقراص', '12.5mg', '3', NULL, NULL, NULL, '8992500115150', 1305, '2023-08-30', NULL, 0, 'May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.', 'Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.', 'Candesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dandel hair shampoo 250ml', 3300, 'داندل شامبو 250 مل', '180', '150', 'Hair care', 'Hair care', NULL, 'Zinc pyrithione+selenium sulphide+olive oil+aloe vera+tocopherol+castor oil+tea tree oil+argan oil+panthenol', 'Egyptian company for cosmetics > infinity pharm', 'Amp', 'أمبول', '250ml', '1', NULL, NULL, NULL, '6224001133176', 1298, '2025-05-20', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Carbotinol 50mg/5ml i.v. inf.(n/a)', 2050, 'كاربوتينول 50مجم 1 محاليل', '144', NULL, 'Antineoplastic', 'Antineoplastic', NULL, 'Carboplatin', 'Hikma specialized pharmaceuticals', 'Unknown', 'غير محدد', '50mg', '1', NULL, NULL, 'description an organoplatinum compound that possesses antineoplastic activity. indication for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents for the palliative treatment of patien', NULL, 813, '2022-09-21', NULL, 0, 'Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]', 'Carboplatin predominantly acts by attaching alkyl groups to the nucleotides, leading to the formation of monoadducts, and DNA fragmenting when repair enzymes attempt to correct the error.[A230158,L32253] 2% of carboplatin''s activity comes from DNA cross-linking from a base on one strand to a base on another, preventing DNA strands from separating for synthesis or transcription.[A230158,A1472] Finally, carboplatin can induce a number of different mutations.[A230158]', 'Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Carboplatin has a long duration of action as it is given every 4 weeks, and a narrow therapeutic index.[L32253] Patients should be counselled regarding bone marrow suppression and anemia.[L32253]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Topicrem corrective day cream spf 20 - 40ml', 28311, 'توبيكريم كريم للحماية من الشمس 20-40مل', '389', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Laboratoire dermatologique > spring', 'Cream', 'كريم', '40ml', '1', NULL, NULL, '*whitening and moisturizing cream for all types of skin. *can be used during pregnancy. *can be used on sensitive areas.', NULL, 619, '2022-07-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cyramza 100mg/10ml vial i.v. inf.', 17018, 'سيرامزا 100 مجم / 10 مل فيال', '15,534', '11400', 'Antineoplastic', 'Antineoplastic', NULL, 'Ramucirumab', 'Eli lilly', 'Vial', 'فيال', '100mg', '1', NULL, NULL, 'ramucirumab is a fully human monoclonal antibody (igg1) developed for the treatment of solid tumors. it is directed against the vascular endothelial growth factor receptor 2 (vegfr2). by binding to vegfr2 it works as a receptor antagonist blocking the bin', NULL, 661, '2024-11-10', NULL, 0, 'Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with [paclitaxel] for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with [erlotinib], for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor exon 19 deletions or exon 21 (L858R) point mutations. It is also indicated in combination with [docetaxel] for the treatment of metastatic non-small cell lung cancer in patients who have progressed following prior platinum-based chemotherapy. Patients who have EGFR or ALK genomic aberrations should also have disease progression following FDA-approved therapy for these aberrations. Ramucirumab, in combination with FOLFIRI ([folinic acid], [fluorouracil], and [irinotecan]), is indicated for the treatment of metastatic colorectal cancer in patients who have progressed following therapy with [bevacizumab], [oxaliplatin], and a fluoropyrimidine. Lastly, ramucirumab is indicated for the treatment of hepatocellular carcinoma in patients with an alpha-fetoprotein level ≥400 ng/mL and have previously been treated with [sorafenib].[L40938]', 'Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Innogen cream 100gm', 32993, 'انوجين كريم 100 جم', '120', '100', 'Skin care', 'Skin care', NULL, 'Zinc oxide+borage seed oil+rosa canine flower oil+wheat proteins+licorice extract+calendula extract+allantoin+d-panthenol+chamomile+vit e', 'Advent', 'Cream', 'كريم', '100gm', '1', NULL, NULL, 'is a soothing cream with a unique formula for the extra protection and relief of the delicate skin of infant and child (diaper area) from irritants. ï- relieves diaper rash discomfort from the first use ï- creamy formula that glides on smoothly and wipes', NULL, 489, '2025-08-31', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('T.b.zide 50 mg 100 tab', 11126, 'تي بي زايد 50 مجم 100 قرص', '16', NULL, 'Antitubercular', 'Antitubercular', NULL, 'Isoniazid', 'El nasr', 'Tab', 'أقراص', '50 mg', '1', 'مضاد حيوي يستخدم للعلاج والوقاية من مرض السل', NULL, NULL, NULL, 1979, '2022-08-21', NULL, 0, 'Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.[L45369]', 'Isoniazid is a prodrug and must be activated by bacterial catalase. Specficially, activation is associated with reduction of the mycobacterial ferric KatG catalase-peroxidase by hydrazine and reaction with oxygen to form an oxyferrous enzyme complex. Once activated, isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular <i>Mycobacterium tuberculosis</i> organisms. Specifically isoniazid inhibits InhA, the enoyl reductase from <i>Mycobacterium tuberculosis</i>, by forming a covalent adduct with the NAD cofactor. It is the INH-NAD adduct that acts as a slow, tight-binding competitive inhibitor of InhA.', 'Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically <i>M. tuberculosis</i>, <i>M. bovis</i> and <i>M. kansasii</i>. It is a highly specific agent, ineffective against other microorganisms. Isoniazid is bactericidal when mycobacteria grow rapidly and bacteriostatic when they grow slowly.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nuxe prodigieux dd medium cream 30 ml', 23892, 'نوكس كريم 30مل', '345', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Nuxe laboratory > biotech egypt', 'Cream', 'كريم', '30 ml', '1', NULL, NULL, 'multi-protective and beautifying the crï-me prodigieuseï- dd cream helps to maintain beautiful skin and a glowing complexion in a polluted urban environment. its smooth lightweight texture divinely glides onto your skin. its bare-skin effect shade blends', NULL, 596, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Novescar cream 30 gm', 23794, 'نوفسكار كريم 30 جرام', '95', NULL, 'Scar therapy', 'Scar therapy', NULL, NULL, 'Hi-care > novell pharma', 'Cream', 'كريم', '30 gm', '1', 'لعلاج الندوب بالجلد', NULL, NULL, NULL, 3166, '2022-03-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lipomax 40mg 10 f.c. tabs. (n/a)', 21907, 'ليبوماكس 40 مجم 10 اقراص', '45', NULL, 'Antihyperlipidemic.statins', 'Antihyperlipidemic.statins', NULL, 'Atorvastatin', 'Saja pharmaceuticals > multipharma', 'Tab', 'أقراص', '40mg', '1', NULL, NULL, 'description : is a member of the drug class known as statins. dose: adult po- initial- the recommended dose is 10 mg daily. maximum: 80 mg/day. indication : may be used as primary prevention in individuals with multiple risk factors for coronary heart dis', '3701711060143', 771, '2022-07-23', NULL, 0, 'Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.[A177397]



Dyslipidemia describes an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025] 



Atorvastatin is indicated, in combination with dietary modifications, to prevent cardiovascular events in patients with cardiac risk factors and/or abnormal lipid profiles.[A177397]



Atorvastatin can be used as a preventive agent for myocardial infarction, stroke, revascularization, and angina, in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factors.[A177397]



Atorvastatin may be used as a preventive agent for non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure and angina in patients with coronary heart disease.[A177397]



Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]', 'Atorvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A177388,A181421] Atorvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low-density lipoprotein (LDL) receptors, which increases hepatic uptake of LDL. Atorvastatin also reduces Very-Low-Density Lipoprotein-Cholesterol (VLDL-C), serum triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) containing particles, but increases High-Density Lipoprotein Cholesterol (HDL-C). 



_In vitro_ and _in vivo_ animal studies also demonstrate that atorvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] These effects include improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response. Statins were also found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an essential role in leukocyte trafficking and T cell activation.[A181559]', 'Atorvastatin is an oral antilipemic agent that reversibly inhibits HMG-CoA reductase. It lowers total cholesterol, low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), non-high density lipoprotein-cholesterol (non-HDL-C), and triglyceride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease, and high ratios are associated with a higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality.[A174580,A181087,A181406,A181925] 



Elevated cholesterol levels (and high low-density lipoprotein (LDL) levels in particular) are an important risk factor for the development of CVD.[A181087] Clinical studies have shown that atorvastatin reduces LDL-C and total cholesterol by 36-53%.[A177415] In patients with dysbetalipoproteinemia, atorvastatin reduced the levels of intermediate-density lipoprotein cholesterol.[A177397] It has also been suggested that atorvastatin can limit the extent of angiogenesis, which can be useful in the treatment of chronic subdural hematoma.[A177388]



**Myopathy/Rhabdomyolysis**



Atorvastatin, like other HMG-CoA reductase inhibitors, is associated with a risk of drug-induced myopathy characterized by muscle pain, tenderness, or weakness in conjunction with elevated levels of creatine kinase (CK). Myopathy often manifests as rhabdomyolysis with or without acute renal failure secondary to myoglobinuria. The risk of statin-induced myopathy is dose-related, and the symptoms of myopathy are typically resolved upon drug discontinuation. Results from observational studies suggest that 10-15% of people taking statins may experience muscle aches at some point during treatment.[A182258]



**Liver Dysfunction**



Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (> 3 times the upper limit of normal [ULN] occurring on two or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. This effect appears to be dose-related.[F4670,F4673]



**Endocrine Effects**



Statins are associated with a risk of increased serum HbA1c and glucose levels. An _in vitro_ study demonstrated a dose-dependent cytotoxic effect on human pancreatic islet β cells following treatment with atorvastatin. Moreover, insulin secretion rates decreased relative to control.[A182012]



HMG-CoA reductase inhibitors interfere with cholesterol synthesis and may theoretically interfere with the production of adrenal and/or gonadal steroids. Clinical studies with atorvastatin and other HMG-CoA reductase inhibitors have suggested that these agents do not affect plasma cortisol concentrations, basal plasma testosterone concentration, or adrenal reserve. However, the effect of statins on male fertility has not been fully investigated. The effects of statins on the pituitary-gonadal axis in premenopausal women are unknown.[F4673]



**Cardiovascular**



Significant decreases in circulating ubiquinone levels in patients treated with atorvastatin and other statins have been observed. The clinical significance of a potential long-term statin-induced deficiency of ubiquinone has not been established. It has been reported that a decrease in myocardial ubiquinone levels could lead to impaired cardiac function in patients with borderline congestive heart failure.[F4673]



**Lipoprotein A**



In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by the concomitant increase in Lp(a) lipoprotein concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease.[F4673] Further studies have demonstrated statins affect Lp(a) levels differently in patients with dyslipidemia depending on their apo(a) phenotype; statins increase Lp(a) levels exclusively in patients with the low molecular weight apo(a) phenotype.[A181418]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vena remek conditioner 240 ml', 29086, 'فينا ريميك 240مل', '99', NULL, 'Hair care', 'Hair care', NULL, 'Shea butter+argan oil+jojoba oil+vitamin e+panthenol+bht', 'Dreams el habboba > vena health care', 'Conditioner', 'بلسم', '240 ml', '1', NULL, NULL, 'hair rejuvenation conditioner anti hair shaft abnormalities', NULL, 878, '2022-07-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ostalo 30 coated tablets', 12900, 'اوستالو 30 قرص', '267', NULL, 'Prevents progression of osteoarthritis', 'Prevents progression of osteoarthritis', NULL, 'Glucosamine sulfate 500mg+chondroitin sulfate 400mg+methylsulfonylmethane (msm) 400mg', 'P.medex', 'Tablet', 'أقراص', NULL, '3', NULL, NULL, NULL, NULL, 664, '2022-08-18', NULL, 0, 'Glucosamine is generally used over the counter in the symptomatic treatment of osteoarthritis and joint pain,[A2352] frequently combined with chondroitin sulfate and/or ibuprofen.[L32699]', 'The mechanism of action of glucosamine in joint health is unclear,[A231894] however there are several possible mechanisms that contribute to its therapeutic effects. Because glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage,[A232289] glucosamine supplements may help to rebuild cartilage and treat the symptoms of arthritis.  Some in vitro studies show evidence that glucosamine reduces inflammation via inhibition of interferon gamma[A12619,A12616,A12621]  and Nuclear factor kappa B subunit 65 (NF-κB p65),[A12616,A232284] improving the symptoms of arthritis and joint pain. Clinical relevance is unknown at this time.', 'The administration of glucosamine, in theory, provides a building block towards the synthesis of glycosaminoglycans, slowing the progression of osteoarthritis and relieving symptoms of joint pain. Studies to this date examining the efficacy of glucosamine sulfate have been inconclusive. Glycosaminoglycans contribute to joint cartilage elasticity, strength, and flexibility.[A232144] A systematic review of various studies and guidelines determined that modest improvements were reported for joint pain and function in patients taking glucosamine. A consistent joint space narrowing was observed, but with an unclear clinical significance.[A231894]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fiesto 90mg 4 delayed release caps.', 4861, 'فيستو 90مجم 4 كبسولات', '48', NULL, 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Fluoxetine', 'International drug agency (idi) > sina pharm', 'Cap', 'كبسولة', '90mg', '1', NULL, NULL, 'about fluoxetine selective serotonin reuptake inhibitor antidepressant. mechanism of action of fluoxetine fluoxetine preferentially inhibits the re-uptake of serotonin (5 ht) in the cns nerve terminals .this will result in an increased concentration of ne', '6221051820469', 986, '2022-12-05', NULL, 0, 'Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present.[L7664] Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression.[L7664] Fluoxetine is additionally indicated for the treatment of female patients with premenstrual dysphoric disorder (PMDD).[L40833]', 'The monoaminergic hypothesis of depression emerged in 1965 and linked depression with dysfunction of neurotransmitters such as noradrenaline and serotonin.[L7721] Indeed, low levels of serotonin have been observed in the cerebrospinal fluid of patients diagnosed with depression.[A181793] As a result of this hypothesis, drugs that modulate levels of serotonin such as fluoxetine were developed.[L7721]



Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and as the name suggests, it exerts it''s therapeutic effect by inhibiting the presynaptic reuptake of the neurotransmitter serotonin.[A181673] As a result, levels of 5-hydroxytryptamine (5-HT) are increased in various parts of the brain.[L7721] Further, fluoxetine has high affinity for 5-HT transporters, weak affinity for noradrenaline transporters and no affinity for dopamine transporters indicating that it is 5-HT selective.[L7721]



Fluoxetine interacts to a degree with the 5-HT<sub>2C</sub> receptor and it has been suggested that through this mechanism, it is able to increase noradrenaline and dopamine levels in the prefrontal cortex.[L7721]', 'Fluoxetine blocks the serotonin reuptake transporter in the presynaptic terminal, which ultimately results in sustained levels of 5-hydroxytryptamine (5-HT) in certain brain areas.[L7721] However, fluoxetine binds with relatively poor affinity to 5-HT, dopaminergic, adrenergic, cholinergic, muscarinic, and histamine receptors which explains why it has a far more desirable adverse effect profile compared to earlier developed classes of antidepressants such as tricyclic antidepressants.[L7721][A181673] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aphtarine oral gel 10 ml', 14291, 'افتارين جيل 10 مل', '35', NULL, 'Oral care', 'Oral care', NULL, NULL, 'Vitro-bio > egyptian promotion center', 'Gel', 'جل', '10 ml', '1', NULL, NULL, 'assists with the healing if oral sores -it forms a film over the lesion so reduce pain and accelerate healing -apply 3-4 times and avoid eating or drinking for 10-15 minutes after each application.', NULL, 795, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Beclozone 0.025% cream 20 gm', 14967, 'بيكلوزون 0.025% كريم 20 جم', '5', NULL, 'Anti-inflammatory.glucocorticoid steroid', 'Anti-inflammatory.glucocorticoid steroid', NULL, 'Beclomethasone dipropionate', 'Memphis', 'Cream', 'كريم', '0.025%', '1', NULL, NULL, 'about beclomethasone dipropionate potent glucocorticoid potent anti-inflammatory agent in respiratory tract and nasal passages. indications : 1.eczema 2.psoriasis 3.contact dermatitis 4.anal and vulval pruritis 5.inflammation of the skin contra-indication', NULL, 924, '2023-04-27', NULL, 0, 'Indicated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. The aerosol form of beclomethasone diproprionate is not indicated for the relief of acute bronchospasm.[L6871]



Indicated for intranasal use to relieve the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis and prevent the recurrence of nasal polyps following surgical removal.[L6880]



Indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age and older.[L10782] Corticosteroid-responsive dermatoses include psoriasis, contact dermatitis (dermatitis venenata), atopic dermatitis (infantile eczema, allergic dermatitis), neurodermatitis (lichen simplex chronicus, lichen planus, eczema, eczematous dermatitis), intertrigo, dyshidroses (pompholyx), seborrheic dermatitis, exfoliative dermatitis, solar dermatitis, stasis dermatitis, and anogenital and senile pruritus.[L6886]', 'Beclomethasone dipropionate is a corticosteroid and prodrug that is rapidly activated by hydrolysis to the active monoester, 17 monopropionate (17-BMP), which mediates anti-inflammatory actions. 17-BMP has been shown _in vitro_ to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 13 times that of dexamethasone and 25 times that of beclomethasone dipropionate.[L6871] Upon binding of the ligand, the glucocorticoid receptors dimerize and translocate into the nucleus, where they subsequently bind to glucocorticoid response elements (GRE) on glucocorticoid-responsive genes, leading to changes in transcription. There are several proposed mechanisms for the anti-inflammatory action of corticosteroids. Corticosteroids may work by increasing the transcription of genes coding for anti-inflammatory proteins, including lipocortin-1 and interleukin-10.[A179875] Corticosteroids were also shown to inhibit the expression of multiple genes that encode pro-inflammatory factors, such as cytokines, chemokines, and adhesion molecules, that are activated during the chronic inflammatory process.[A31449] This is thought to be due to the direct inhibitory interaction between activated glucocorticoid receptors and activated pro-inflammatory transcription factors, such as nuclear factor-kappa B and activator protein-1.[A179875] Chronic inflammation is often characterized by enhanced expression of these transcription factors that bind to and activate coactivator molecules, which then acetylate core histones to switch on gene transcription to further amplify the inflammatory process.[A31449] Corticosteroids suppress the multiple inflammatory gene expression by promoting histone deacetylation, resulting in tighter coiling of DNA and reduced access of transcription factors to their binding sites.[A179875] ', 'Inflammatory conditions, including asthma, dermatoses, and allergic rhinitis, involve the activation of cascades by inflammatory mediators. Inflammation is a primary defense mechanism and the homeostatic response of the immune system; however, a prolonged inflammatory response in certain disorders may lead to tissue damage, pain, and swelling. Beclomethasone dipropionate works by attenuating the inflammatory responses associated with asthma, allergic rhinitis, nasal polyps, and corticosteroid-responsive dermatoses. It suppresses the actions of inflammatory cells, such as mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils. It also inhibits the release of inflammatory mediators, such as histamine, eicosanoids, leukotrienes, and cytokines.[L6871] Beclomethasone dipropionate is reported to exhibit potent topical activity while possessing low systemic effects.[A179845] 



Beclomethasone dipropionate is a corticosteroid drug with anti-inflammatory and vasoconstrictive effects used to treat chronic inflammatory processes such as asthma, allergic rhinitis, corticosteroid-responsive dermatoses. When inhaled, it improves lung function, decreases airway hyper-reactivity, and reduces the severity of asthmatic symptoms.[A180160] Although inhaled corticosteroids, including beclomethasone dipropionate, are reported to mainly act locally in the lungs, systemic effects such as disruption of hypothalamic-pituitary-adrenal (HPA) axis function, bone turnover, osteoporosis, and growth suppression may still be observed with chronic use or high dose administration. There were varying findings from clinical studies examining the effect of beclomethasone dipropionate on growth suppression in pediatric patients.[A180160] It was shown to suppress the hypothalamo-pituitary-adrenal (HPA) axis in a dose-dependent manner.[A179917] HPA axis is a central hormonal response system to stress and activation of HPA axis leads to the production of endogenous steroid hormone production.[A179920] Long-term use of high-dose systemic corticosteroids, including those inhaled, was often associated with signs and symptoms of adrenal insufficiency when exposed to stress conditions, such as trauma, surgery, or infections. As corticosteroids work by suppressing the immune system, there may be an increased risk for developing infections.[L6871] Cases of _Candida albicans_ infection of the mouth and throat have been reported with inhaled beclomethasone dipropionate therapy.[A180010]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ovu prime 40 hgc', 7233, 'اوفيو برايم 40 كبسولة', '350', NULL, 'Multivitamin used for enhancing fertility and ovulation', 'Multivitamin used for enhancing fertility and ovulation', NULL, 'Myo-inositol+chiro inositol+methylfolate+vitamin d3', 'Prime solutions', 'Unknown', 'غير محدد', NULL, '1', NULL, NULL, NULL, NULL, 883, '2025-08-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Peptofam 10mg 20 chewable tab.', 24718, 'بيبتوفام 10مجم 20 قرص', '15', NULL, 'Peptic ulcer.anti-histamine.h2 antagonist', 'Peptic ulcer.anti-histamine.h2 antagonist', NULL, 'Famotidine', 'Arab caps', 'Tab', 'أقراص', '10mg', '2', NULL, NULL, 'about famotidine guanidine:thiazole derivative a histamine h2-receptor antagonist anti-secretory antiulcer. mechanism of action of famotidine famotidine is a h2 (histamine) receptor antagonist. histamine is the most potent stimulus of acid secretion and a', NULL, 843, '2022-07-14', NULL, 0, 'Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.[L11139]



It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.[L11139]



The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.[L11142]



Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.[L11166,L11172]', 'Histamine acts as a local hormone that stimulates the acid output by parietal cells via a paracrine mechanism. Neuroendocrine cells called enterochromaffin-like (ECL) cells lie close to the parietal cells and regulate the basal secretion of histamine. Histamine release is also promoted from stimulation by acetylcholine and gastrin, a peptide hormone. Gastrin (G) cells release gastrin, which works on CCK<sub>2</sub> receptors on ECL cells. This action promotes the release of histamine from ECL cells. Upon release, histamine acts on H<sub>2</sub> receptors expressed on the basolateral membrane of parietal cells, leading to increased intracellular cAMP levels and activated proton pumps on parietal cells. Proton pump releases more protons into the stomach, thereby increasing the secretion of acid. [T28] In conditions that are associated with acid hypersecretion such as ulcers, there is a loss of regulation of acid secretion. Famotidine works on H<sub>2</sub> receptors and blocks the actions of histamine.[L11166]', 'Famotidine decreases the production of gastric acid, suppresses acid concentration and pepsin content, and decreases the volume of gastric secretion. Famotidine inhibits both basal and nocturnal gastric acid secretion, as well as acid secretion stimulated by food, caffeine, insulin, and pentagastrin.[L11139,L11142]



Famotidine has a dose-dependent therapeutic action, with the highest dose having the most extended duration of action and the highest inhibitory effect on gastric acid secretion. Following oral administration, the onset of action is within one hour, and the peak effect is reached within 1-3 hours. The duration of effect is about 10-12 hours.[A189459]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Quitapex 300mg xr 30 f.c. tab.', 25561, 'كويتابيكس 300مجم اكس ار 30 قرص', '336', '253.5', 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Quetiapine', 'Multi-apex', 'Tab', 'أقراص', '300mg', '3', NULL, NULL, NULL, '6223003204525', 2277, '2025-02-04', NULL, 0, 'Quetiapine is used in the symptomatic treatment of schizophrenia.  In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.[L8546]



Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson''s disease.[A185438,A185447,T685]

', 'Although the mechanism of action of quetiapine is not fully understood, several proposed mechanisms exist. In schizophrenia, its actions could occur from the antagonism of dopamine type 2 (D2) and serotonin 2A (5HT2A) receptors. In bipolar depression and major depression, quetiapine''s actions may be attributed to the binding of this drug or its metabolite to the norepinephrine transporter. Additional effects of quetiapine, including somnolence, orthostatic hypotension, and anticholinergic effects, may result from the antagonism of H1 receptors, adrenergic α1 receptors, and muscarinic M1 receptors, respectively.[A2189,A185438,L8546]', 'Quetiapine improves the positive and negative symptoms of schizophrenia and major depression by acting on various neurotransmitter receptors, such as the serotonin and dopamine receptors. In bipolar disorder, it improves both depressive and manic symptoms.[A2189,A185441,A185444]



**A note on suicidality in young patients and administration in the elderly**



Quetiapine can cause suicidal thinking or behavior in children and adolescents and should not be given to children under 10 years of age. It is important to monitor for suicidality if this drug is given to younger patients. In addition, this drug is not indicated for the treatment of psychosis related to dementia due to an increased death rate in elderly patients taking this drug.[L8546]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bee tonic 10 cap', 1369, 'بي تونك 10 ك', '27', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Bee pollen-royal jelly-propolis', 'Arab caps > master med pharma', 'Cap', 'كبسولة', NULL, '1', NULL, NULL, NULL, NULL, 807, '2022-09-19', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Selsun blue 207 ml dual action shampoo (n/a)', 10310, 'سيلسن بلو 207 مل شامبو', '48', NULL, 'Hair care', 'Hair care', NULL, 'Selenium sulfide', 'Famar > ramco', 'Amp', 'أمبول', '207 ml', '1', NULL, NULL, 'anti-dandruff shampoo', NULL, 837, '2023-04-28', NULL, 0, 'For treatment of tinea versicolor, tinea capitis, dandruff and seborrheic dermatitis of the scalp.', 'Topical selenium sulfide may act by an antimitotic action, resulting in a reduction in the turnover of epidermal cells. It also has local irritant, antibacterial, and mild antifungal activity, which may contribute to its effectiveness. An antimitotic mechanism of action is suggested by data showing that selenium sulfide decreases the rate of incorporation of radioactively labeled thymidine into the DNA of dermal epithelial cells. The following organisms are generally considered susceptible to selenium sulfide in vitro: <i>Malassezia furfur</i>, <i>Microsporum sp.</i> including <i>Microsporum audouinii</i> and <i>Microsporum canis</i>, <i>Pityrosporon sp.</i>, <i>Trichophyton sp.</i> including <i>Trichophyton schoenleinii</i> and <i>Trichophyton tonsurans</i>. Selenium sulfide has been shown to be sporicidal to <i>T. tonsurans</i>, the most common etiologic agent of tinea capitis. One in-vitro study demonstrated that 2.5% selenium sulfide was equivalent in sporicidal activity to both 1% and 2% zinc pyrithione.', 'Selenium sulfide is an antifungal agent often used in shampoos for the treatment of dandruff and seborrheic dermatitis. Selenium sulfide is highly active in inhibiting the growth of <i>P. ovale</i>. It is also a proven cytostatic agent, slowing the growth of both hyperproliferative and normal cells in dandruff and seborrheic dermatitis. A 0.6% micronized form of selenium sulfide is also safe and effective for dandruff.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tetracycline 250 mg 36 caps. b.p 2012', 28086, 'تيتراسيكلين 250مجم 12 كبسول', '25', NULL, 'Antibiotic.tetracycline', 'Antibiotic.tetracycline', NULL, 'Tetracycline', 'Arab drug company.', 'Cap', 'كبسولة', '250 mg', '1', NULL, NULL, 'about tetracycline a broad-spectrum polyketide antibiotic tetracycline derivative. mechanism of action of tetracycline tetracycline is a broad spectrum antibiotic which has more specific action against gram positive organisms than gram negative organisms.', NULL, 697, '2022-08-17', NULL, 0, 'Used to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin.', 'Tetracycline passively diffuses through porin channels in the bacterial membrane and reversibly binds to the 30S ribosomal subunit, preventing binding of tRNA to the mRNA-ribosome complex, and thus interfering with protein synthesis.', 'Tetracycline is a short-acting antibiotic that  inhibits bacterial growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. It also binds to some extent to the 50S ribosomal subunit. This binding is reversible in nature. Additionally tetracycline may alter the cytoplasmic membrane of bacteria causing leakage of intracellular contents, such as nucleotides, from the cell. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Medexavy 120 ml syrup', 3737, 'ميديكسافي شراب 120 مل', '60', NULL, 'Anti cough', 'Anti cough', NULL, 'Ivy+licorice+thyme', 'Medex', 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, NULL, NULL, 801, '2025-05-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('My sweet baby n syrup 125 ml', 8479, 'ماي سويت بيبي ان شراب 125 مل', '50', '45', 'Git disturbance', 'Git disturbance', NULL, 'Caraway oil+cinnamon+peppermint+cardamom', 'Amoun', 'Syrup', 'شراب', '125 ml', '1', NULL, NULL, 'to improve gastro-intestinal functions', '6221025048332', 3030, '2025-01-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ceporex 250 mg/5ml syrup 60 ml', 2382, 'كيبوركس 250مجم/5مل معلق 60 مل', '24', '18', 'Antibiotic.cephalosporin.first-generation', 'Antibiotic.cephalosporin.first-generation', NULL, 'Cefalexin', 'Glaxo smithkline', 'Syrup', 'شراب', '250 mg', '1', NULL, NULL, 'about cefalexin a first-generation cephalosporin antibiotic. mechanism of action cephalexin is a 1st generation cephalosporin which exerts its bactericidal action against both gram positive & gram negative organisms by inhibiting bacterial cell wall synth', '6221045000662', 1714, '2024-11-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Frezyderm cream 30 gm', 7706, 'فريزيديرم كريم 30 جم', '90', NULL, 'Hemorrhoids', 'Hemorrhoids', NULL, 'Hamamelis citrus+zinc oxide+lido ex+chamomile+mustard gtn+ammi visnaga ex+liposom', 'Dreams > spendix inc', 'Cream', 'كريم', '30 gm', '1', NULL, NULL, NULL, NULL, 843, '2025-10-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rivamep 1.5 mg 20 caps.', 26197, 'ريفاميب 1.5مجم 20 كسبولات', '33', NULL, 'Anticholinesterase', 'Anticholinesterase', NULL, 'Rivastigmine', 'Mepaco', 'Cap', 'كبسولة', '1.5 mg', '2', NULL, NULL, 'about rivastigmine a central reversible non competitive anticholinesterase antidementia. mechanism of action of rivastigmine alzheimer`s disease may result from a deficiency in neurotransmitters used by nerves in the brain to communicate with one another.', NULL, 654, '2022-07-25', NULL, 0, 'For the treatment of mild to moderate dementia associated with Parkinson''s disease or of the Alzheimer''s type.', 'Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.', 'Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. An early pathophysiological feature of Alzheimer''s disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine''s action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine''s effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Alphilac 20 enteric coated tabs.', 5547, 'الفيلاك 20 قرص', '115', NULL, 'Anti inflammatory + anti odematus + analgesic + anti oxidant + healing promoter', 'Anti inflammatory + anti odematus + analgesic + anti oxidant + healing promoter', NULL, 'Trypsin+bromelain+rutoside', 'Lilac pharma', 'Tab', 'أقراص', NULL, '1', NULL, NULL, NULL, NULL, 1138, '2025-06-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Viroclear 500 mg 10 tab.', 29405, 'فيروكلير 500مجم 10 اقراص', '50', NULL, 'Antiviral.nucleoside', 'Antiviral.nucleoside', NULL, 'Valacyclovir', 'Alfacure pharmaceuticals', 'Tab', 'أقراص', '500 mg', '1', NULL, NULL, 'indication for the treatment or suppression of cold sores (herpes labialis) herpes zoster (shingles) genital herpes in immunocompetent individuals and recurrent genital herpes in hiv-infected individuals. mechanism of action valaciclovir is phosphorylated', '6224000875077', 904, '2022-12-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Motival 20 tab.', 8360, 'موتيفال 20 قرص', '25', '9', 'Psychiatric.mood stabilizers', 'Psychiatric.mood stabilizers', NULL, 'Fluphenazine+nortiptyline', 'Smithkline beecham', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, '6224001007378', 5384, '2024-04-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Retin a 0.05% gel 30 gm', 25943, 'ريتنا 0.05% جل 30جم', '22', NULL, 'Anti-acne', 'Anti-acne', NULL, 'Tretinoin', 'Janssen cilag', 'Gel', 'جل', '0.05%', '1', NULL, NULL, 'about tretinoin retinoid vitamin a metabolite anti-acne in hyperpigmentation. mechanism of action of tretinoin tretinoin is all trans retinoic acid (acid form of vitamin a). tretinoin is a potent comedolytic. it stimulates mitosis and epidermal cell turno', NULL, 908, '2022-07-24', NULL, 0, 'Oral tretinoin is indicated for induction of remission in adults and pediatric patients one year of age and older with acute promyelocytic leukemia (APL), characterized by the presence of t(15;17) translocation or presence of PML/RARα gene expression and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated.[L45349]



Topical tretinoin is also indicated alone [L45389] or in combination with [benzoyl peroxide] [L34869] or [clindamycin] [L45384] for the treatment of acne vulgaris. It is also used in prescription and over-the-counter for treating various skin conditions such as melasma,[L45394] hyperpigmentation,[A257474] and photoaging [A258180] alone or in combination with other drugs.', 'The exact mechanism of action of tretinoin in skin conditions and acute promyelocytic leukemia (APL) has not been fully elucidated; however, several proposed mechanisms exist. Tretinoin is believed to exert its pharmacological actions by binding to and activating two types of nuclear receptors - retinoic acid receptors (RARs) alpha, beta, and gamma and retinoid X receptors (RXRs). In the human skin, RARs (especially RAR-alpha) form heterodimers with RXR to act as inducible transcription regulators of genes involved in cell differentiation by binding to retinoic acid response elements.[A257724,A258185] Tretinoin binds to RXRs to promote epidermal proliferation. It also blocks the actions of inflammatory mediators, enhancing procollagen production and collagen type I and III formations.[A257474,A257629,A257609,A257699] Some animal and human studies suggest that tretinoin induces the expression of transforming growth factor beta (TGF-β), which stimulates the transcription of several types of collagen messenger RNA. Collagen formation curtails further solar UV-induced skin damage and aging processes.[A257699]



Acne is associated with abnormal follicular formation from excessive keratinization of epithelial cells. Tretinoin promotes cornified cell detachment and enhances keratinocyte shedding. It also stimulates mitotic activity and loosely-adherent corneocyte turnover to expel comedo contents, reducing microcomedo precursor lesions of acne vulgaris.[A257474,L34869] Tretinoin may reduce epidermal melanin and pigmentation by increasing keratinocyte turnover and reducing tyrosinase activity.[A257609,A258180]



RAR-alpha and -beta have also been implicated in APL.[A257724] APL is characterized by a t(15;17) chromosomal translocation, which fuses the promyelocytic myeloid leukemia (PML) gene with the RAR-alpha gene.[A257689,A257694] The resulting PML-RAR-alpha fusion protein plays a role in the pathogenesis of APL by aberrating promyelocyte differentiation. The PML-RAR-alpha fusion protein is found to be predominant in leukemic cells, exerting a dominant negative effect on RAR, RXR and PML function.[A257689] Tretinoin induces terminal differentiation in hemopoietic precursor cell lines and APL cells.[A257694] Tretinoin is believed to promote caspase-mediated cleavage and proteasome-dependent degradation to cause apoptosis and degradation of the PML-RAR-alpha fusion protein.[A257474] It may also convert the fusion protein from a transcription repressor to an activator.[A257474]', 'Tretinoin is a vitamin A derivative that promotes cell production, proliferation, and differentiation. When used topically, tretinoin regulates epidermal cell turnover and collagen production. It also prevents collagen loss, reduces inflammation, and blocks the induction of matrix metalloproteinase (MMP), which are enzymes that disrupt collagen and elastic fibres.[A257474,A257629,A257609,A258180] In short-term and long-term studies, topical application of tretinoin at doses ranging from 0.001% to 0.1% was associated with improvements in clinical signs of photoaging and fine wrinkles, increased epidermal thickness, compaction of the stratum corneum, and decreased melanin content.[A257684,A258180,A258185,A257699] It also improved melanocyte differentiation and distribution, promotion of epidermal hyperplasia, and angiogenesis.[A257699]



Tretinoin exhibits antineoplastic activities when given orally.[L45349] Tretinoin was shown to induce differentiation in tumour cells.[A257694] It induced cytodifferentiation and decreased acute promyelocytic leukemia (APL) cell proliferation in culture and _in vivo_. In patients with APL, tretinoin promoted the initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission.[L45349]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bendafolin 10mg/ml soln. for i.m./i.v. inj. or inf.', 15058, 'بندافولين 10 مجم / مل للحقن العضل/الوريد', '270', NULL, 'Folic acid supplement', 'Folic acid supplement', NULL, 'Leucovorin calcium+folinic acid+calcium folinate', 'Wasserburger arzneimittel work > pharmakon pharmaceuticals', 'Inj', 'حقن', '10mg', '1', NULL, NULL, 'about folinic acid (5-formyl tetrahydrofolate) 5-formyl tetrahydrofolate generally administered as calcium or sodium folinate is an is one active form in a group of vitamins known as folates. mechanism of action of folinic acid (5-formyl tetrahydrofolate)', NULL, 910, '2022-07-08', NULL, 0, 'For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.', 'As leucovorin is a derivative of folic acid, it can be used to increase levels of folic acid under conditions favoring folic acid inhibition (following treatment of folic acid antagonists such as methotrexate). Leucovorin enhances the activity of fluorouracil by stabilizing the bond of the active metabolite (5-FdUMP) to the enzyme thymidylate synthetase.', 'Leucovorin is one of several active, chemically reduced derivatives of folic acid. It is useful as an antidote to drugs which act as folic acid antagonists. Leucovorin is a mixture of the diastereoisomers of the 5-formyl derivative of tetrahydrofolic acid (THF). The biologically active compound of the mixture is the (-)-l-isomer, known as Citrovorum factor or (-)-folinic acid. Leucovorin does not require reduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of &ldquo;one-carbon&rdquo; moieties. Administration of leucovorin can counteract the therapeutic and toxic effects of folic acid antagonists such as methotrexate, which act by inhibiting dihydrofolate reductase. Leucovorin has also been used to enhance the activity of fluorouracil.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Calendenavil 40 mg 14 del. rel. caps.', 15693, 'كاليندينافيل 40مجم 14 كبسولة', '38', NULL, 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Esomeprazole', 'Debeiky', 'Cap', 'كبسولة', '40 mg', '2', 'يستخدم فى علاج قرحة المعدةو قرحة الاثني عشر.علاج التهاب المريء.علاج جرثومة المعدة أو البكتيريا الملوية البوابية (بالإنجليزية: H-pylori).علاج الارتجاع المريئي', NULL, NULL, NULL, 1167, '2022-07-07', NULL, 0, 'Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome. ', 'Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole''s duration of antisecretory effect that persists longer than 24 hours.[FDA Label]

', 'Esomeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and <i>H. pylori</i> eradication to reduce the risk of duodenal ulcer recurrence. Esomeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup> ATPase at the secretory surface of the gastric parietal cell. By doing so, it inhibits acid secretion into the gsatric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.



Esomeprazole is the s-isomer of [DB00338], which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as [DB00338], without any significant differences between the two compounds _in vitro_. 



PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.[A177577, A177580]



Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as esomeprazole has been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.[A177571]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Active hair cream 100 gm', 13414, 'اكتيف هير كريم 100 جم', '110', '99', 'Hair care', 'Hair care', NULL, 'Garlic ext+aloe vera oil+panthenol+lavender oil+vit(e+c)+peppermint oil+jojoba oil+emu oil+olive oil', 'Hi-care > avano pharma', 'Cream', 'كريم', '100 gm', '1', NULL, NULL, '*indications: hair loss for men & women. damaged & split end hair. itching & inflammation of the scalp. hair dryness & dandruff.', NULL, 958, '2024-07-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dapilart 10 mg 28 tabs', 23654, 'دابيلارت 10مجم 28 قرص', '216', NULL, 'Anti-diabetic.secretagogues.sglt2 inhibitors', 'Anti-diabetic.secretagogues.sglt2 inhibitors', NULL, 'Dapagliflozin', 'Mash premier', 'Tab', 'أقراص', '10 mg', '4', NULL, NULL, NULL, '6222001402858', 1943, '2023-02-06', NULL, 0, 'Dapagliflozin is indicated as an adjunct treatment, alongside diet and exercise, to improve glycemic control in patients ≥10 years of age with type 2 diabetes mellitus.[L51023,A6757,A6758] For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure.[L46372] Dapagliflozin is also indicated to either reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.[L46372] Combination products with dapagliflozin also exist, either as a dapagliflozin-saxagliptin or dapagliflozin-metformin hydrochloride formulation.[L38724,L38729] Both are used as an adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes.[L38724,L38729]', 'Dapagliflozin inhibits the sodium-glucose cotransporter 2(SGLT2) which is primarily located in the proximal tubule of the nephron.[A6757] SGLT2 facilitates 90% of glucose reabsorption in the kidneys and so its inhibition allows for glucose to be excreted in the urine.[A6757] This excretion allows for better glycemic control and potentially weight loss in patients with type 2 diabetes mellitus.[A6757] ', 'Dapagliflozin also reduces sodium reabsorption and increases the delivery of sodium to the distal tubule. This may influence several physiological functions including, but not restricted to, lowering both pre- and afterload of the heart and downregulation of sympathetic activity, and decreased intraglomerular pressure which is believed to be mediated by increased tubuloglomerular feedback.[L48246]



Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following the administration of dapagliflozin. Dapagliflozin doses of 5 or 10 mg per day in patients with type 2 diabetes mellitus for 12 weeks resulted in excretion of approximately 70 grams of glucose in the urine per day at Week 12. A near-maximum glucose excretion was observed at the dapagliflozin daily dose of 20 mg. This urinary glucose excretion with dapagliflozin also results in increases in urinary volume. After discontinuation of dapagliflozin, on average, the elevation in urinary glucose excretion approaches baseline by about 3 days for the 10 mg dose.[L48246]



Dapagliflozin was not associated with clinically meaningful prolongation of QTc interval at daily doses up to 150 mg (15 times the recommended maximum dose) in a study of healthy subjects. In addition, no clinically meaningful effect on QTc interval was observed following single doses of up to 500 mg (50 times the recommended maximum dose) of dapagliflozin in healthy subjects.[L48246]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Prostenal forte fta 30 pc wm eg', 3819, 'بروستينال فورت 30 قطعة', '305', NULL, NULL, NULL, NULL, NULL, 'Company', 'Unknown', 'غير محدد', NULL, '3', NULL, NULL, NULL, '8596024028011', 1039, '2022-12-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Smecta 3gm 10 sachet', 27101, 'سميكتا 3جم 10 اكياس', '11', NULL, 'Antidiarrheal', 'Antidiarrheal', NULL, 'Dioctahedral smectite', 'Amriya > ipsen', 'Sachet', 'أكياس', '3gm', '1', NULL, NULL, 'mode of action dioctahedral has adsorbent properties and is used in the management of diarrhoea. dioctahedral has unique properties that allow for the adsorption of different toxins (such as rotavirus e. coli and staphylococcus). dioctahedral interacts wi', '6221075180013', 1062, '2023-04-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Viridio acne prone skin 200 ml facial cleanser', 1537, 'فيريدو اكني برون سكين منظف للوجه 200 مل', '155', NULL, 'Facial cleanser', 'Facial cleanser', NULL, 'Salicylic acid+azelaic acid+tea tree oil+hyaluronic acid+zinc pca', 'Yami pharmaceutical', 'Cleanser', 'منظف', '200 ml', '1', NULL, NULL, NULL, NULL, 946, '2022-12-03', NULL, 0, 'Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts.', 'Salicylic acid directly irreversibly inhibits COX-1 and COX-2 to decrease conversion of arachidonic acid to precursors of prostaglandins and thromboxanes. Salicylate''s use in rheumatic diseases is due to it''s analgesic and anti-inflammatory activity. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. Salicylic acid allows cells of the epidermis to more readily slough off. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid competitively inhibits oxidation of uridine-5-diphosphoglucose (UDPG) with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of the glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to a phenolic acceptor. Inhibition of mucopoly saccharide synthesis is likely responsible for the slowing of wound healing with salicylates.', 'Salicylic acid treats acne by causing skin cells to slough off more readily, preventing pores from clogging up. This effect on skin cells also makes salicylic acid an active ingredient in several shampoos meant to treat dandruff. Use of straight salicylic solution may cause hyperpigmentation on unpretreated skin for those with darker skin types (Fitzpatrick phototypes IV, V, VI), as well as with the lack of use of a broad spectrum sunblock. Subsalicylate in combination with bismuth form the popular stomach relief aid known commonly as Pepto-Bismol. When combined the two key ingredients help control diarrhea, nausea, heartburn, and even gas. It is also very mildly anti-biotic.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Plendil 10mg 30 prolonged release f.c. tab.', 25003, 'بلينديل 10مجم 30 قرص', '113', '75', 'Antihypertensive.selective calcium channel blocker', 'Antihypertensive.selective calcium channel blocker', NULL, 'Felodipine', 'Astra zeneca > healthy family', 'Tab', 'أقراص', '10mg', '3', NULL, NULL, 'about felodipine a selective calcium channel blocker dihydropyridine derivative anti hypertensive. mechanism of action of felodipine felodipine is a vasoselective long acting dihydropyridine ca channel blocker. it exerts antihypertensive antianginal actio', '6223003270216', 1334, '2023-09-16', NULL, 0, 'For the treatment of mild to moderate essential hypertension. ', 'Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.', 'Felodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor.  Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kerabind 20 tabs', 7577, 'كيرابيند 20 قرص', '195', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Selenium+cysteine+collagen+methionine+zinc', 'Staygreen', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, NULL, 864, '2025-10-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Janojoint 30tab', 31801, 'جانوجوينت 30 قرص', '290', '220', 'Chondroprotective', 'Chondroprotective', NULL, 'Collagen type ll+glucosamine sulfate+chondroitin+vitc+vite+vitd+vitb12+folic acid+zinc+ginger+copper+manganese+selenium', 'Pharma zad > dolavet pharma', 'Tab', 'أقراص', NULL, '3', 'مكمل غذائى يستخدم لحماية الغضاريف', NULL, 'combination of 13 synergistic ingredients for management of osteoarthritis and improve health bone and cartilage', NULL, 1703, '2025-08-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lifeglobin syrup 120 ml', 1128, 'لايف جلوبين شراب 120 مل', '65', '55', 'Multivitamins with iron', 'Multivitamins with iron', NULL, 'Iron+zinc+vitamin c+folate+b12+cu+lysine', 'Copad egypt > life pharma international', 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, 'multivitamins and heamatinic', NULL, 893, '2025-07-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gly skin cream 50 gm', 19961, 'جلاي سكين كريم للجلد 50 جرام', '30', NULL, 'Healing topical', 'Healing topical', NULL, NULL, 'Nikim co. > international egyptian co.', 'Cream', 'كريم', '50 gm', '1', 'يستخدم لعلاج الجروح، الحروق، التقرحات، تشققات الكعب، وحلمة الثدي.علاج الطفح الجلدي الحاد.طفح الحفاض.الاكزيما، وخدوش الجلد.', NULL, 'healing cream', NULL, 1246, '2022-06-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Keratohyl 30 capsules', 8829, 'كيراتوهيل 30 كبسولة', '315', '270', NULL, NULL, NULL, 'Hyaluronic acid+keartin+biotin', 'Atlas pharma', 'Capsule', 'كبسولة', NULL, '3', NULL, NULL, NULL, NULL, 2222, '2025-12-08', NULL, 0, 'The intra-articular preparations of hyaluronic acid are indicated for knee pain associated with osteoarthritis.[L32228] Hyaluronic acid is used in cosmetic applications to prevent and reduce the appearance of wrinkles on the face, and as a dermal filler to correct facial imperfections or other imperfections on other parts of the body.[L32208,L32223] It is frequently an ingredient in topical applications for wound healing and symptomatic treatment of skin irritation from various causes.[L32198] Hyaluronic acid may also be indicated in ophthalmological preparations or oral capsules to treat discomfort caused by dry eyes or conjunctivitis and for its protective qualities during and before eye surgery.[A230128,L32213] Finally, hyaluronic acid can be used off-label to coat the bladder for relief of interstitial cystitis symptoms.[A230533]', 'General principles and hyaluronic acid receptor binding 



Hyaluronic acid works by two basic mechanisms: serving as a passive structural molecule or serving as signaling molecule, depending on the molecule size. The physicochemical properties of high molecular weight HA contribute to passive structural effects, demonstrating hygroscopicity and viscoelasticity and improving hydration, water balance, and structural integrity. As a signalling  molecule interacting with proteins, HA causes several opposing effects based on molecular weight: pro- or anti-inflammatory effects, promotion or inhibition of cell migration, and activating or inhibiting cell division.[A230133] 



Hyaluronic acid exerts its therapeutic effects through binding to three primary types of cell surface receptors: CD44 (a membrane glycoprotein), the receptor for hyaluronate-mediated motility (RHAMM), and the Intercellular Adhesion Molecule 1 (ICAM-1). CD44 is considered the most widely distributed receptor for hyaluronic acid, demonstrating cellular interactions with osteopontin, collagen, and matrix metalloproteinases (MMPs).  High and low molecular weight hyaluronic acids demonstrate differing molecular and cellular mechanisms in their interaction with CD44 receptors. Some examples of these effects include modification of chondrocyte survival pathways in addition to alteration of apoptosis pathways.  Lymphatic vessel endothelial hyaluronan receptor (LYVE-1), and hyaluronic acid receptor for endocytosis (HARE), (also known as Stabilin-2) also bind to hyaluronic acid.[A230128] 



Hyaluronic acid for skin conditions and cosmetics



Hyaluronic acid''s anionic proprieties cause it to attract water and induce swelling, increasing tissue volume and skin structural integrity. The aging process is associated with reduced production of skin hyaluronic acid and collagen, causing the appearance of wrinkles and the loss of facial volume. Dermal fillers of hyaluronic acid replace lost tissue volume, imparting a full and youthful appearance to skin that has lost its elasticity. Hyaluronic acid fillers contain cross-linked hyaluronic acid particles, rendering a concentrated substance with resistance to various forms of physical and chemical breakdown. The cosmetic benefits of hyaluronic acid filler may last up to 6 months, depending on the brand and technique used for injection.[L32193] Additionally, dermal hyaluronic acid fillers are known to increase the production of fibroblasts[L32193], supporting wound healing and offering relief from irritating and inflammatory skin conditions.[A230118]





Hyaluronic acid for joint pain



Most cells in the human body are capable of synthesizing HA. It is a primary component of the extracellular matrix (ECM) and can be found in bone marrow, cartilage, and synovial fluid in joints.[A230128] In osteoarthritis, the concentration of naturally occurring hyaluronic acid gradually decreases, lowering the viscosity of synovial fluid that protects joints from excess friction. Administration of intra-articular hyaluronic acid increases viscosity of synovial joint fluid, reducing friction and subsequently relieving painful arthritic symptoms.[L32193]





Hyaluronic acid for ophthalmic conditions and ophthalmological procedures



Solutions of hyaluronic acid with a concentration greater than 0.1% moisturize the surface of the eyes to treat symptoms of dry eye while improving the stabilization of tear film, replenishing deficiencies of HA, reducing friction, and preventing binding of foreign substances to the ocular tissue.[A230128,L32193] Hyaluronic acid is frequently used during and after ophthalmological surgeries and plays important roles by virtue of its moisturizing, viscoelastic, and protective properties. It promotes tissue healing of the corneal epithelium and other parts of the eye following ophthalmological surgery, minimizing the risk of adhesions and free radical formation.[A230128]

', 'HA has long-acting lubricant, shock absorbing, joint stabilizing, and water balancing properties.[A230128,L32193] It is similar to the naturally occurring glycosaminoglycan (GAG) in joints. Hyaluronic acid works by acting as a lubricant and shock absorber, facilitating joint mobility and thereby reducing osteoarthritic pain.  Hyaluronic acid has antioxidative, anti-inflammatory, and analgesic effects.[A230128] The water-balancing properties and viscoelasticity of hyaluronic acid are beneficial in cosmetic injections, imparting volume and reducing the appearance of imperfections and wrinkles.[L32193] Due to the abovementioned properties, HA has a protective effect on the eyes and cornea.[A230133]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nizatect 300mg 20 caps.', 23647, 'نزانيكت 300مجم 20 كبسول', '43', NULL, 'Peptic ulcer.anti-histamine.h2 antagonist', 'Peptic ulcer.anti-histamine.h2 antagonist', NULL, 'Nizatidine', 'Marcyrl co.', 'Cap', 'كبسولة', '300mg', '2', NULL, NULL, 'indication for the treatment of acid-reflux disorders (gerd) peptic ulcer disease active benign gastric ulcer and active duodenal ulcer. pharmacodynamics nizatidine is a competitive reversible inhibitor of histamine at the histamine h2-receptors particula', '6223003570477', 722, '2022-12-07', NULL, 0, 'For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.', 'Nizatidine competes with histamine for binding at the H<sub>2</sub>-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.', 'Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Green - alpha 3 miu/ml (2ml) inj.', 20061, 'جرين الفا 3 مليون وحدة دولية / مل (2 مل)', '60', NULL, 'Antiviral .interferon alfa', 'Antiviral .interferon alfa', NULL, 'Interferon alfa-2a', 'Koria green cross > eimc', 'Inj', 'حقن', '2ml', '1', NULL, NULL, 'indication for the treatment of chronic hepatitis c hairy cell leukemia aids-related kaposi s sarcoma and chronic myelogenous leukemia. also for the treatment of oral warts arising from hiv infection. mechanism of action interferon alpha binds to type i i', NULL, 714, '2022-07-25', NULL, 0, 'For the treatment of venereal or genital warts caused by the Human Papiloma Virus.', 'Interferon alpha binds to type I interferon receptors (IFNAR1 and IFNAR2c) which, upon dimerization, activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon alpha binds less stably to type I interferon receptors than interferon beta.', 'Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2''-5'' oligoadenylate synthetase (2''-5'' A synthetase) and protein kinase R.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ecatrova 20mg 21 tabs', 2693, 'ايكاتروفا 20مجم 21 قرص', '120', '51', NULL, NULL, NULL, NULL, 'Mn egypt', 'Tab', 'أقراص', '20mg', '1', NULL, NULL, NULL, NULL, 943, '2025-04-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Panspect eye /ear drops', 24506, 'بانسبيكت نقط للعين والاذن', '5', NULL, NULL, NULL, NULL, 'Gramicidin+neomycin+polymyxin', 'Sigma tec > october pharma', 'Drops', 'نقط', NULL, '1', NULL, NULL, 'about gramicidin gramicidin is active against most of the gram positive bacteria and some gram negative bacteria. its use is limited to topical use only since systemic use may produce haemolysis.gramicidin produces its action by increasing the permeabilit', NULL, 647, '2022-07-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Arthrohold plus 30 caps.', 6087, 'ارثروهولد بلس 30 كبسولة', '390', NULL, 'Dietary supplement', 'Dietary supplement', NULL, 'Avocado soya bean+hyaluronic acid+msm+bromelain+boswellia seratta+vitd', 'Parkville', 'Cap', 'كبسولة', NULL, '1', NULL, NULL, NULL, NULL, 738, '2022-08-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Simethicone 2% oral drops (30ml)', 10473, 'سايميثيكون 2% نقط فم 30 مل', '24', '14', 'Antiflatulent', 'Antiflatulent', NULL, 'Simethicone', 'Amriya', 'Drops', 'نقط', '2%', '1', 'علاج الانتفاخات -- تقليل الالام المعدة -- علاج الغازات في المعدة', NULL, NULL, '6221075200315', 3807, '2024-07-24', NULL, 0, 'Simethicone is indicated for the treatment of bloating, pressure, and cramps caused by gas.[L31533] Simethicone is also used as part of bowel preparation for colonoscopies.[A228343] ', 'Simethicone is a surfactant that decreases the surface tension of gas bubbles in the gastrointestinal tract, more easily allowing gas to exit the body.[A228308]', 'Simethicone decreases the surface tension of gas bubbles in the gastrointestinal tract, facilitating their expulsion.[A228308] It has a short duration of action as it is generally given as needed, and a wide therapeutic index as it is not systemically absorbed.[A228308]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Alkeran 2mg 25 tablets', 361, 'الكيران 2مجم 25 قرص', '91', NULL, 'Antineoplastic', 'Antineoplastic', NULL, 'Melphalan', 'Aspen pharma trading limited > egyptian pharmaceutical trading company', 'Tablet', 'أقراص', '2mg', '1', 'مضاد اورام', NULL, NULL, '5010706009820', 1580, '2022-12-01', NULL, 0, 'Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma.[L47890] It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.[L40928]



Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.[L47895]', 'Melphalan is an alkylating agent of the bischloroethylamine type.[L47890] It is believed to be taken up by tumour cells via a neutral amino acid active pathway shared by leucine.[A261155] Melphalan binds at the N7 position of guanine and induces inter-strand cross-links in DNA, disrupting DNA synthesis or transcription. It can also cause DNA-protein cross-linking and induce lesions in RNA, proteins, and lipids.[A1635, A230158, A230163, A261155, A261171, L47890] Melphalan is cytotoxic in resting and rapidly dividing tumour cells.[L47890]', 'Melphalan possesses cytotoxic, immunosuppressive, and myeloablative activities.[A261150, L40928] Melphalan produces chromosomal aberrations _in vitro_ and _in vivo_; thus, it is considered to be potentially leukemogenic in humans. It also causes dose-limiting bone marrow suppression. The peak mean heart rate increased by 20 bpm from baseline following melphalan 100 mg/m<sup>2</sup> for two consecutive days in multiple myeloma patients undergoing autologous stem cell transplantation.[L47890]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Well femme stretch mark cream 100 gm', 3944, 'ويل فيم كريم علامات التمدد سترتش مارك 100 جم', '200', NULL, 'Stretch mark.firming', 'Stretch mark.firming', NULL, 'Allantoin+tea tree oil+aloe vera extract+menthol+chamomile+thymus vulgaris', 'Smartec > wellness pharma', 'Cream', 'كريم', '100 gm', '1', NULL, NULL, NULL, NULL, 1554, '2022-08-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Trivastal 20mg 30 sugar coated tab.', 28552, 'تريفستال 20مجم 30 قرص', '10', NULL, 'Anti-ischemic', 'Anti-ischemic', NULL, 'Piribedil', 'Servier', 'Tab', 'أقراص', '20mg', '3', NULL, NULL, 'about piribedil a piperazine derivative dopamine agonist antiparkinsonism antidyskinetic. mechanism of action of piribedil the exact mechanism of action is not known. a lesion in the nigra striatum may be responsible for parkinson`s disease which results', NULL, 958, '2022-10-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Solantra anti-wrinkle cream 50 ml', 27236, 'سولانترا كريم مضاد للتجاعيد 50 مل', '350', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Mash premiere', 'Cream', 'كريم', '50 ml', '1', NULL, NULL, NULL, NULL, 2837, '2023-02-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Arozole 100mg 14 caps.', 14419, 'اروزول 100مجم 14 كبسولة', '62', NULL, 'Antifungals.triazoles', 'Antifungals.triazoles', NULL, 'Itraconazole', 'Alfacure pharmaceuticals', 'Cap', 'كبسولة', '100mg', '2', NULL, NULL, NULL, NULL, 838, '2022-12-03', NULL, 0, 'Itraconazole is indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients:[L50051, L50056]



- Blastomycosis, pulmonary and extrapulmonary

- Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis, and

- Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy



It is also indicated for the treatment of the following fungal infections in non-immunocompromised patients:[L50051]



- Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium)

- Onychomycosis of the fingernail due to dermatophytes (tinea unguium).



Itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis.[L50061]', 'Itraconazole mediates its antifungal activity by inhibiting 14α-demethylase, a fungal cytochrome P450 enzyme that converts lanosterol to ergosterol, a vital component of fungal cell membranes.[L50051] The azole nitrogen atoms in the chemical structure of itraconazole form a complex with the active site, or the haem iron, of the fungal enzyme to impede its function.[A34257, A263232] The accumulation of lanosterol and 14-methylated sterols results in increased permeability of the fungal cell membrane, and modified membrane-bound enzyme activity, and dysregulated chitin synthesis.[A34257, A263222, A263227] Other proposed mechanisms of action of itraconazole include the inhibition of fungal cytochrome c oxidative and peroxidative enzymes that also lead to the disruption of fungal cell membranes.[A34257]', 'Itraconazole is an antifungal agent that inhibits cell growth and promotes cell death of fungi.[A34257] It exhibits in vitro activity against _Blastomyces dermatitidis_, _Histoplasma capsulatum_, _Histoplasma duboisii_, _Aspergillus flavus_, _Aspergillus fumigatus_, and _Trichophyton_ species.[L50051]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cialong 10mg 4 f.c.tablets', 16292, 'سيالونج 10مجم 4 اقراص', '36', NULL, 'Tonic for men', 'Tonic for men', NULL, 'Tadalafil', 'Borg', 'Tablet', 'أقراص', '10mg', '1', 'مقوي للرجال', NULL, NULL, '62213007571314', 8497, '2023-05-17', NULL, 0, 'Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with [finasteride] for the treatment of benign prostatic hypertrophy (BPH).[L39095,L39439] It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with [macitentan] or other endothelin-1 antagonists.[L39100,L39105,L50622]', 'Tadalafil is a selective phosphodiesterase-5 (PDE5) inhibitor that produces several downstream effects with the most common therapeutic effect being smooth muscle relaxation. [L39095] Patients may experience ED due to a variety of causes including psychogenic, neurogenic, vasculogenic, iatrogenic, or endocrine. [A242392] These causes result in dysfunction of penile smooth muscle relaxation through either disrupted neuronal signaling or direct influence on smooth muscle cells. During sexual arousal, non-adrenergic non-cholinergic (NANC) neurons release nitric oxide (NO). Nitric oxide stimulates guanylate cyclase which converts guanosine triphosphate to cyclic guanosine monophosphate (cGMP).[A242287, A242377] cGMP activates the cGMP-dependent kinase (PKG) in a signal cascade which activates K+ channels leading to inhibition of Ca2+ channels, inhibits platelet activation, and inhibits smooth muscle cell proliferation while inducing apoptosis. This signal cascade is attenuated by PDE5 which breaks the phosphodiester bond of cGMP, converting it to GMP. Inhibition of PDE5 by tadalafil increases signaling via the PKG cascade which supports penile smooth muscle relaxation during sexual arousal by decreasing Ca2+ entry into smooth muscle cells. This smooth muscle relaxation allows blood to fill the corpus cavernosum thereby producing an erection.



In PAH, blood pressure in the pulmonary arteries is raised due to a variety of mechanisms stemming from endothelial dysfunction.[A242377] Decreased production of NO and prostacyclin reduce vasodilatory signaling while overproduction of endothelin-1 and thromboxane increase vasoconstriction. Inflammation, thromboses, and hypoxia later contribute to vascular remodeling which further reduces luminal size. The resultant increase in blood pressure reduces the capacity for gas exchange and increases afterload at the right ventricle, producing symptoms of dyspnea, fatigue, and dizziness as well as leading to right-sided heart failure. Tadalafil exerts its therapeutic effect in PAH through boosting NO-cGMP signaling to contribute to smooth muscle relaxation as with ED.



Lastly, tadalafil is used to treat BPH.[L39095] BPH produces urinary dysfunction through hyperproliferation of the epithelial and smooth muscle layers of the prostate.[A242382] The increased size of the prostate blocks urine flow through the urethra resulting in higher residual volumes due to incomplete emptying. Tadalafil does not appear to exert its benefit via smooth muscle relaxation of the prostate. It may instead exert its effect through a mix of increased oxygenation and decreased inflammation, which decreases tissue remodeling, and inhibition of cell proliferation through the cGMP cascade.



The decreased affinity for PDE6 compared to other PDE5 inhibitors may explain the decreased incidence of visual side effects as PDE6 is present in the eye and contributes to color vision.[L39100, L39105, A242287]', 'Tadalafil exerts a therapeutic effect in ED by increasing sexual stimulation-dependant smooth muscle relaxation in the penis, allowing the corpus cavernosum to fill with blood to produce an erection.[A242287, A242377] Smooth muscle relaxation in the pulmonary vasculature helps to produce vasodilation in PAH which reduces blood pressure in the pulmonary arteries.[A242377] In BPH, tadalafil may contribute to decreased smooth muscle cell proliferation which may reduce the size of the prostate and relieve the anatomical obstruction which produces urinary symptoms of BPH.[A242382] The decreased affinity of tadalafil for PDE6 compared to other PDE5 inhibitors may explain the reduced incidence of visual side effects.[L39100, L39105, A242287]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Astracalmito syrup', 32450, 'استراكالميتو شراب', '57', '38', 'Anti cough', 'Anti cough', NULL, 'Ivy leaf+thyme', 'Astratech', 'Syrup', 'شراب', NULL, '1', 'مكمل غذائى مضاد للسعال ويدعم الجهاز التنفسي', NULL, 'supports the respiratory system and bronchodilator', NULL, 1209, '2025-08-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lipinorm 20mg 7 f.c.tab.', 21884, 'ليبينورم 20 مجم 7 اقراص', '40', '21.6', 'Antihyperlipidemic.statins', 'Antihyperlipidemic.statins', NULL, 'Atorvastatin', 'Mup', 'Tab', 'أقراص', '20mg', '1', NULL, NULL, 'description : is a member of the drug class known as statins. dose: adult po- initial- the recommended dose is 10 mg daily. maximum: 80 mg/day. indication : may be used as primary prevention in individuals with multiple risk factors for coronary heart dis', '6221508510110', 1332, '2025-07-04', NULL, 0, 'Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.[A177397]



Dyslipidemia describes an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025] 



Atorvastatin is indicated, in combination with dietary modifications, to prevent cardiovascular events in patients with cardiac risk factors and/or abnormal lipid profiles.[A177397]



Atorvastatin can be used as a preventive agent for myocardial infarction, stroke, revascularization, and angina, in patients without coronary heart disease but with multiple risk factors and in patients with type 2 diabetes without coronary heart disease but multiple risk factors.[A177397]



Atorvastatin may be used as a preventive agent for non-fatal myocardial infarction, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure and angina in patients with coronary heart disease.[A177397]



Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]', 'Atorvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A177388,A181421] Atorvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low-density lipoprotein (LDL) receptors, which increases hepatic uptake of LDL. Atorvastatin also reduces Very-Low-Density Lipoprotein-Cholesterol (VLDL-C), serum triglycerides (TG) and Intermediate Density Lipoproteins (IDL), as well as the number of apolipoprotein B (apo B) containing particles, but increases High-Density Lipoprotein Cholesterol (HDL-C). 



_In vitro_ and _in vivo_ animal studies also demonstrate that atorvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] These effects include improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response. Statins were also found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an essential role in leukocyte trafficking and T cell activation.[A181559]', 'Atorvastatin is an oral antilipemic agent that reversibly inhibits HMG-CoA reductase. It lowers total cholesterol, low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), non-high density lipoprotein-cholesterol (non-HDL-C), and triglyceride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease, and high ratios are associated with a higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality.[A174580,A181087,A181406,A181925] 



Elevated cholesterol levels (and high low-density lipoprotein (LDL) levels in particular) are an important risk factor for the development of CVD.[A181087] Clinical studies have shown that atorvastatin reduces LDL-C and total cholesterol by 36-53%.[A177415] In patients with dysbetalipoproteinemia, atorvastatin reduced the levels of intermediate-density lipoprotein cholesterol.[A177397] It has also been suggested that atorvastatin can limit the extent of angiogenesis, which can be useful in the treatment of chronic subdural hematoma.[A177388]



**Myopathy/Rhabdomyolysis**



Atorvastatin, like other HMG-CoA reductase inhibitors, is associated with a risk of drug-induced myopathy characterized by muscle pain, tenderness, or weakness in conjunction with elevated levels of creatine kinase (CK). Myopathy often manifests as rhabdomyolysis with or without acute renal failure secondary to myoglobinuria. The risk of statin-induced myopathy is dose-related, and the symptoms of myopathy are typically resolved upon drug discontinuation. Results from observational studies suggest that 10-15% of people taking statins may experience muscle aches at some point during treatment.[A182258]



**Liver Dysfunction**



Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (> 3 times the upper limit of normal [ULN] occurring on two or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. This effect appears to be dose-related.[F4670,F4673]



**Endocrine Effects**



Statins are associated with a risk of increased serum HbA1c and glucose levels. An _in vitro_ study demonstrated a dose-dependent cytotoxic effect on human pancreatic islet β cells following treatment with atorvastatin. Moreover, insulin secretion rates decreased relative to control.[A182012]



HMG-CoA reductase inhibitors interfere with cholesterol synthesis and may theoretically interfere with the production of adrenal and/or gonadal steroids. Clinical studies with atorvastatin and other HMG-CoA reductase inhibitors have suggested that these agents do not affect plasma cortisol concentrations, basal plasma testosterone concentration, or adrenal reserve. However, the effect of statins on male fertility has not been fully investigated. The effects of statins on the pituitary-gonadal axis in premenopausal women are unknown.[F4673]



**Cardiovascular**



Significant decreases in circulating ubiquinone levels in patients treated with atorvastatin and other statins have been observed. The clinical significance of a potential long-term statin-induced deficiency of ubiquinone has not been established. It has been reported that a decrease in myocardial ubiquinone levels could lead to impaired cardiac function in patients with borderline congestive heart failure.[F4673]



**Lipoprotein A**



In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by the concomitant increase in Lp(a) lipoprotein concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease.[F4673] Further studies have demonstrated statins affect Lp(a) levels differently in patients with dyslipidemia depending on their apo(a) phenotype; statins increase Lp(a) levels exclusively in patients with the low molecular weight apo(a) phenotype.[A181418]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Parofen 30 oblong tab.', 9652, 'باروفين 30 قرص', '69', '54', 'Nsaid', 'Nsaid', NULL, 'Ibuprofen+paracetamol(acetaminophen)', 'Unipharma co.', 'Tab', 'أقراص', NULL, '3', NULL, NULL, 'ibuprofen is a type of medicine called a non-steroidal anti-inflammatory drug (nsaid). it works by blocking the action of a substance in the body called cyclo-oxygenase (cox). cyclo-oxygenase is involved in the production of various chemicals in the body', '6224000730727', 5207, '2025-04-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bobai hydrocare sunscreen antishine gel 60 gm', 5834, 'بوباي هيدروكير صنسكرين مضاد للمعان الجلد جل 60 جم', '295', NULL, NULL, NULL, NULL, NULL, 'Parkville', 'Gel', 'جل', '60 gm', '1', NULL, NULL, NULL, '6224008073635', 994, '2022-08-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Titech 20 pills', 31496, 'تيتك 20 حبة', '75', '50', 'Multivitamin', 'Multivitamin', NULL, 'Calcium+vitamin c+vitamin d', 'Pharmazad > dawatech', 'Unknown', 'غير محدد', NULL, '1', 'مكمل غذائى يدعم نمو العظام والجهاز المناعى للجسم', NULL, 'pills suppored by calcium vitamin c vit d for hypocalcemia', NULL, 1197, '2025-09-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Stalevo 200/50/200mg 30 f.c. tab', 27443, 'ستاليفو 200/50/200مجم 30 قرص', '435', '290', 'Antiparkinsonism', 'Antiparkinsonism', NULL, 'Carbidopa+entacapone+levodopa', 'Novartis', 'Tab', 'أقراص', '200mg', '3', '- لعلاج مرض باركنسون', NULL, NULL, NULL, 1073, '2024-12-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nitrofurinal 200mg 12 caps.', 23633, 'نيتروفورينال 200مجم 12 كبسول', '5', NULL, 'Antidiarrheal', 'Antidiarrheal', NULL, 'Nifuroxazide', 'Pharopharma', 'Cap', 'كبسولة', '200mg', '1', NULL, NULL, 'indicationsssinfectious diarrhea in children and adults chronic colitis enterocolitis as an adjunctive treatment in combined therapy of intestinal dysbiosis.sscontraindicationsshypersensitivity to 5-nitrofurane derivatives and/or other components of the d', NULL, 1034, '2022-07-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cipro-sol 200mg/100ml i.v. vial', 16398, 'سيبرو سول 200 مجم / 100 مل فيال', '27', NULL, 'Antibiotic.quinolone', 'Antibiotic.quinolone', NULL, 'Ciprofloxacin', 'Pharmaceutical solution industries > al kamal importing & marketing co', 'Vial', 'فيال', '200mg', '1', NULL, NULL, 'about ciprofloxacin it is a broad spectrum fluoroquinolone with activity against pseudomonas aeruginosa. indications for ciprofloxacin 1.urinary tract infection 2.respiratory tract infection 3.bone and joint infections 4.infectious diarrhoea 5.gonorrhoea', NULL, 1031, '2022-07-16', NULL, 0, 'Ciprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493]



Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478]



A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493]



A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475]



A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487]', 'Ciprofloxacin acts on bacterial topoisomerase II (DNA gyrase) and topoisomerase IV.[A178885] Ciprofloxacin''s targeting of the alpha subunits of DNA gyrase prevents it from supercoiling the bacterial DNA which prevents DNA replication.[A178876,A178882]', 'Ciprofloxacin is a second generation fluoroquinolone that is active against many Gram negative and Gram positive bacteria.[A178870,L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] It produces its action through inhibition of bacterial DNA gyrase and topoisomerase IV.[A178885] Ciprofloxacin binds to bacterial DNA gyrase with 100 times the affinity of mammalian DNA gyrase.[A178894] There is no cross resistance between fluoroquinolones and other classes of antibiotics, so it may be of clinical value when other antibiotics are no longer effective.[A178894] Ciprofloxain and its derivatives are also being investigated for its action against malaria, cancers, and AIDS.[A178885]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Slimax 10mg 30 cap', 10565, 'سليماكس 10مجم 30 كبسولة', '45', NULL, 'Monoamine oxidase inhibitor', 'Monoamine oxidase inhibitor', NULL, 'Sibutramine hydrochloride monohydrate', 'Multi apex pharm', 'Cap', 'كبسولة', '10mg', '3', 'تقليل الشهية -- انقاص الوزن -- تقليل الكوليسترول في الدم', NULL, NULL, '6223003201654', 2188, '2022-12-15', NULL, 0, 'For the treatment of obesity.', 'Sibutramine produces its therapeutic effects by inhibition of norepinephrine (NE), serotonin (5-hydroxytryptamine, 5-HT), and to a lesser extent, dopamine reuptake at the neuronal synapse. By inhibiting the reuptake of these neurotransmitters, sibutramine promotes a sense of satiety and decrease in appetite, thereby reducing food intake. Data from animal studies also suggest that sibutramine may also increase energy expenditure through thermogenic effects in both the basal and fed states, but this has not been confirmed in humans. Sibutramine and its major pharmacologically active metabolites (M1 and M2) do not act via release of monoamines. ', 'Sibutramine is an orally administered agent for the treatment of obesity. Sibutramine exerts its pharmacological actions predominantly via its secondary (M1) and primary (M2) amine metabolites. The parent compound, sibutramine, is a potent inhibitor of serotonin and norepinephrine reuptake <i>in vivo</i>, but not <i>in vitro</i>. However, metabolites M1 and M2 inhibit the reuptake of these neurotransmitters both <i>in vitro</i> and <i>in vivo</i>. In human brain tissue, M1 and M2 also inhibit dopamine reuptake <i>in vitro</i>, but with ~3-fold lower potency than for the reuptake inhibition of serotonin or norepinephrine. Sibutramine, M1 and M2 exhibit no evidence of anticholinergic or antihistaminergic actions. In addition, receptor binding profiles show that sibutramine, M1 and M2 have low affinity for serotonin (5-HT<sub>1</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2C</sub>), norepinephrine (b, b1, b3, a1 and a2), dopamine (D1 and D2), benzodiazepine, and glutamate (NMDA) receptors. These compounds also lack monoamine oxidase inhibitory activity <i>in vitro</i> and <i>in vivo</i>.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sedokast 4mg 7 chewable tabs', 10253, 'سيدوكاست 4مجم 7 اقراص مضغ', '22', '11', 'Asthma.anti-inflammatory.leukotriene antagonist', 'Asthma.anti-inflammatory.leukotriene antagonist', NULL, 'Montelukast', 'Sedico', 'Tab', 'أقراص', '4mg', '1', 'علاج للربو.', NULL, NULL, '6221042121162', 2006, '2024-12-23', NULL, 0, 'Montelukast is indicated for:



(a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304];



(b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and



(c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307].



Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331]



Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328]



Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an ''as required'' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]', 'Cysteinyl leukotrienes (CysLT) like LTC4, LTD4, and LTE4, among others, are eicosanoids released by a variety of cells like mast cells and eosinophils.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] When such CysLT bind to corresponding CysLT receptors like CysLT type-1 receptors located on respiratory airway smooth muscle cells, airway macrophages, and on various pro-inflammatory cells like eosinophils and some specific myeloid stem cells activities that facilitate the pathophysiology of asthma and allergic rhinitis are stimulated.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, CysLT-mediated airway bronchoconstriction, occluding mucous secretion, vascular permeability, and eosinophil recruitment are all types of effects that facilitate asthma.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Alternatively, in allergic rhinitis, CysLTs are released by the nasal mucosa when exposed to allergens during both early and late phase reactions and participate in eliciting symptoms of allergic rhinitis like a congested nose and airway.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Subsequently, montelukast is a leukotriene receptor antagonist that binds with high affinity and selectivity to the CysLT type 1 receptor, which consequently assists in inhibiting any physiological actions of CysLTs like LTC4, LTD4, and LTE4 at the receptor that may facilitate asthma or allergic rhinitis.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'Montelukast is a leukotriene receptor antagonist that demonstrates a marked affinity and selectivity to the cysteinyl leukotriene receptor type-1 in preference to many other crucial airway receptors like the prostanoid, cholinergic, or beta-adrenergic receptors.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] As a consequence, the agent can elicit substantial blockage of LTD4 leukotriene-mediated bronchoconstriction with doses as low as 5 mg.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Moreover, a placebo-controlled, crossover study (n=12) demonstrated that montelukast is capable of inhibiting early and late phase bronchoconstriction caused by antigen challenge by 75% and 57% respectively.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, it has been documented that montelukast can cause bronchodilation as soon as within 2 hours of oral administration.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] This action can also be additive to the bronchodilation caused by the concomitant use of a beta agonist.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Nevertheless, clinical investigations performed with adults 15 years of age and older revealed that no additional clinical benefit is obtained when doses of montelukast greater than 10 mg a day are used.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Additionally, in clinical trials with adults and pediatric asthmatic patients aged 6 to 14 years, it was also determined that montelukast can reduce mean peripheral blood eosinophils by about 13% to 15% from baseline in comparison to placebo during double-blind treatment periods.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] At the same time, in patients aged 15 years and older who were experiencing seasonal allergic rhinitis, the use of montelukast caused a median reduction of 13% in peripheral blood eosinophil counts when compared to placebo as well.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Leflumine 20mg 10 tabs.', 21679, 'ليفليومين 20 مجم 10 أقراص', '50', NULL, 'Immunosuppressive agent.antirheumatic antiviral agent.pyrimidine synthesis inhibitor', 'Immunosuppressive agent.antirheumatic antiviral agent.pyrimidine synthesis inhibitor', NULL, 'Leflunomide', 'International drug agency (idi)', 'Tab', 'أقراص', '20mg', '1', NULL, NULL, 'about leflunomide a pyrimidine synthesis inhibitor isoxazole derivative disease-modifying antirheumatic drug. mechanism of action of leflunomide this immunomodulatory drug inhibits dihydroorotate dehydrogenase (an enzyme involved in de novo pyrimidine syn', NULL, 829, '2022-07-16', NULL, 0, 'For the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.', 'Leflunomide is a prodrug that is rapidly and almost completely metabolized following oral administration to its pharmacologically active metabolite, A77 1726. This metabolite is responsible for essentially all of the drug''s activity in-vivo. The mechanism of action of leflunomide has not been fully determined, but appears to primarily involve regulation of autoimmune lymphocytes. It has been suggested that leflunomide exerts its immunomodulating effects by preventing the expansion of activated autoimmune lymphocytes via interferences with cell cycle progression. In-vitro data indicates that leflunomide interferes with cell cycle progression by inhibiting dihydroorotate dehydrogenase (a mitochondrial enzyme involved in de novo pyrimidine ribonucleotide uridine monophosphate (rUMP)synthesis) and has antiproliferative activity. Human dihydroorotate dehydrogenase consists of 2 domains: an α/β-barrel domain containing the active site and an α-helical domain that forms a tunnel leading to the active site. A77 1726 binds to the hydrophobic tunnel at a site near the flavin mononucleotide. Inhibition of dihydroorotate dehydrogenase by A77 1726 prevents production of rUMP by the de novo pathway; such inhibition leads to decreased rUMP levels, decreased DNA and RNA synthesis, inhibition of cell proliferation, and G1 cell cycle arrest. It is through this action that leflunomide inhibits autoimmune T-cell proliferation and production of autoantibodies by B cells. Since salvage pathways are expected to sustain cells arrested in the G1 phase, the activity of leflunomide is cytostatic rather than cytotoxic. Other effects that result from reduced rUMP levels include interference with adhesion of activated lymphocytes to the synovial vascular endothelial cells, and increased synthesis of immunosuppressive cytokines such as transforming growth factor-β (TGF-β). Leflunomide is also a tyrosine kinase inhibitor. Tyrosine kinases activate signalling pathways leading to DNA repair, apoptosis and cell proliferation. Inhibition of tyrosine kinases can help to treating cancer by preventing repair of tumor cells. ', 'Leflunomide is a pyrimidine synthesis inhibitor indicated in adults for the treatment of active rheumatoid arthritis (RA). RA is an auto-immune disease characterized by high T-cell activity. T cells have two pathways to synthesize pyrimidines: the salvage pathways and the de novo synthesis. At rest, T lymphocytes meet their metabolic requirements by the salvage pathway. Activated lymphocytes need to expand their pyrimidine pool 7- to 8-fold, while the purine pool is expanded only 2- to 3-fold. To meet the need for more pyrimidines, activated T cells use the de novo pathway for pyrimidine synthesis. Therefore, activated T cells, which are dependent on de novo pyrimidine synthesis, will be more affected by leflunomide''s inhibition of dihydroorotate dehydrogenase than other cell types that use the salvage pathway of pyrimidine synthesis.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Megaflow cream 60 gm', 22472, 'ميجافلو كريم 60 جرام', '140', '23.5', NULL, NULL, NULL, 'Medical grade honey+cmc+lanolin+vit c+vit e', 'Smartec > omegamax', 'Cream', 'كريم', '60 gm', '1', NULL, NULL, NULL, NULL, 1431, '2025-07-10', NULL, 0, 'For use as a source of clean air [FDA Label].', 'Air is approximately 21% oxygen which enters the body through the lungs, crossing the alveolar membrane to reach systemic circulation [T36]. One there it is bound by hemoglobin and transported to tissues thoughout the body where it is used as a terminal electron acceptor in oxidative phosphorylation. This allows efficient generation of adenosine triphosphate, the primary storage molecule for energy, in the mitochondria.', 'Acts as a source of clean air to support respiration [FDA Label].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vizimpro 45 mg 30 tabs.', 5099, 'فيزيمبرو 45 مجم 30 قرص', '30,750', NULL, 'Antineoplastic - 2nd generation egfr tyrosine kinase inhibitor', 'Antineoplastic - 2nd generation egfr tyrosine kinase inhibitor', NULL, 'Dacomitinib', 'Pfizer', 'Tab', 'أقراص', '45 mg', '1', NULL, NULL, NULL, NULL, 743, '2025-06-23', NULL, 0, 'Dacomitinib is indicated as the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as verified by an FDA-approved test.[L4812]



Lung cancer is the leading cause of cancer death and NSCLC accounts for 85% of lung cancer cases. From the cases of NSCLC, approximately 75% of the patients present a late diagnosis with metastatic and advanced disease which produces a survival rate of 5%. The presence of a mutation in EGFR accounts for more than the 60% of the NSCLC cases and the overexpression of EGFR is associated with frequent lymph node metastasis and poor chemosensitivity.[A40018, A19201]', 'Dacomitinib is an irreversible small molecule inhibitor of the activity of the human epidermal growth factor receptor (EGFR) family (EGFR/HER1, HER2, and HER4) tyrosine kinases. It achieves irreversible inhibition via covalent bonding to the cysteine residues in the catalytic domains of the HER receptors.[A40011] The affinity of dacomitinib has been shown to have an IC50 of 6 nmol/L.[A40009]



The ErbB or epidermal growth factor (EGF) family plays a role in tumor growth, metastasis, and treatment resistance by activating downstream signal transduction pathways such as such as Ras-Raf-MAPK, PLCgamma-PKC-NFkB and PI3K/AKT through the tyrosine kinase-driven phosphorylation at the carboxy-terminus.[A39624] Around 40% of cases show amplification of EGFR gene and 50% of the cases present the _EGFRvIII_ mutation which represents a deletion that produces a continuous activation of the tyrosine kinase domain of the receptor.[A40016]', 'Preclinical data suggested that dacomitinib increases the inhibition of the epidermal growth factor receptor kinase domain as well as the activity in cell lines harboring resistance mutations such as T790M. This activity further produced a significant reduction of EGFR phosphorylation and cell viability. In these studies, non-small cell lymphoma cancer cell lines with L858R/T790M mutations where used and an IC50 of about 280 nmol/L was observed.[A40010]



In clinical trials with patients with advanced non-small cell lung carcinoma who progressed after chemotherapy, there was an objective response rate of 5% with a progression-free survival of 2.8 months and an overall survival of 9.5 months. As well, phase I/II studies showed positive dacomitinib activity despite prior failure with tyrosine kinase inhibitors.[A40009]



Phase III clinical trials (ARCHER 1050), done in patients suffering from advanced or metastatic non-small cell lung carcinoma with EGFR-activating mutations, reported a significant improvement in progression-free survival when compared with gefitinib.[A40015]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Finastura 5mg 30 f.c.tab.', 4866, 'فيناستورا 5مجم 30 قرص', '111', '79.5', '5 alpha-reductase inhibitor', '5 alpha-reductase inhibitor', NULL, 'Finasteride', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '5mg', '3', 'يستخدم في تضخم البروستاتا الحميد--سرطان البروستاتا من المرحلة الأولى', NULL, 'about finasteride 5 alpha-reductase inhibitor synthetic anti-androgen. mechanism of action of finasteride this synthetic 4-azasteroid derivative competitively inhibits steroid 5alpha reductase which is an enzyme responsible for active androgen dehydrotest', '6223002142545', 20134, '2024-12-30', NULL, 0, 'Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy.[L10565] A combination product with [tadalafil] is also used for the symptomatic treatment of BPH for up to 26 weeks.[L39439]



Finasteride is also indicated for the treatment of male pattern hair loss (androgenetic alopecia, hereditary alopecia, or common male baldness) in male patients.[L6235]', 'Finasteride acts as a competitive and specific inhibitor of Type II 5α-reductase, a nuclear-bound steroid intracellular enzyme primarily located in the prostatic stromal cell that converts the androgen testosterone into the more active metabolite, 5α-dihydrotestosterone (DHT).[A2132] DHT is considered to be the primary androgen playing a role in the development and enlargement of the prostate gland. It serves as the hormonal mediator for the hyperplasia upon accumulation within the prostate gland.[A178270] DHT displays a higher affinity towards androgen receptors in the prostate gland compared to testosterone[T28] and by acting on the androgen receptors, DHT modulates genes that are responsible for cell proliferation.[A178279] Responsible for the production of DHT together with type I 5α-reductase, the type II 5α-reductase isozyme is primarily found in the prostate, seminal vesicles, epididymides, and hair follicles as well as liver.[L6235] Although finasteride is 100-fold more selective for type II 5α-reductase than for the type I isoenzyme,[A178183] chronic treatment with this drug may have some effect on type I 5α-reductase, which is predominantly expressed in sebaceous glands of most regions of skin, including the scalp, and liver. It is proposed that the type I 5α-reductase and type II 5α-reductase is responsible for the production of one-third and two-thirds of circulating DHT, respectively. 



The mechanism of action of Finasteride is based on its preferential inhibition of Type II 5α-reductase through the formation of a stable complex with the enzyme _in vitro_ and _in vivo_.[L10565] Finasteride works selectively, where it preferentially displays a 100-fold selectivity for the human Type II 5α-reductase over type I enzyme.[L6235] Inhibition of Type II 5α-reductase blocks the peripheral conversion of testosterone to DHT, resulting in significant decreases in serum and tissue DHT concentrations, minimal to moderate increase in serum testosterone concentrations, and substantial increases in prostatic testosterone concentrations. As DHT appears to be the principal androgen responsible for stimulation of prostatic growth, a decrease in DHT concentrations will result in a decrease in prostatic volume (approximately 20-30% after 6-24 months of continued therapy). It is suggested that increased levels of DHT can lead to potentiated transcription of prostaglandin D2, which promotes the proliferation of prostate cancer cells.[A178189] In men with androgenic alopecia, the mechanism of action has not been fully determined, but finasteride has shown to decrease scalp DHT concentration to the levels found in the hairy scalp, reduce serum DHT, increase hair regrowth, and slow hair loss. Another study suggests that finasteride may work to reduce bleeding of prostatic origin by inhibiting vascular endothelial growth factor (VEGF) in the prostate, leading to atrophy and programmed cell death.[A178183] This may bestow the drug therapeutic benefits in patients idiopathic prostatic bleeding, bleeding during anticoagulation, or bleeding after instrumentation.[A178183]', 'Finasteride is an antiandrogenic compound that works by suppressing the production of serum and intraprostatic dihydrotestosterone (DHT) in men via inhibiting the enzyme responsible for the biosynthesis of DHT. The maximum effect of a rapid reduction in serum DHT concentration is expected to be observed 8 hours following administration of the first dose.[L10565] In a single man receiving a single oral dose of 5 mg finasteride for up to 4 years, there was a reduction in the serum DHT concentrations by approximately 70% and the median circulating level of testosterone increased by approximately 10-20% within the physiologic range. [L10565] In a double-blind, placebo-controlled study, finasteride reduced intraprostatic DHT level by 91.4% but finasteride is not expected to decrease the DHT levels to castrate levels since circulating testosterone is also converted to DHT by the type 1 isoenzyme expressed in other tissues.[A2132] It is expected that DHT levels return to normal within 14 days upon discontinuation of the drug.[L6244] In a study of male patients with benign prostatic hyperplasia prior to prostatectomy, the treatment with finasteride resulted in an approximate 80% lower DHT content was measured in prostatic tissue removed at surgery compared to placebo.[L10565] While finasteride reduces the size of the prostate gland by 20%, this may not correlate well with improvement in symptoms.[A178273] The effects of finasteride are reported to be more pronounced in male patients with enlarged prostates (>25 mL) who are at the greatest risk of disease progression.[A2132]



In phase III clinical studies, oral administration of finasteride in male patients with male pattern hair loss promoted hair growth and prevented further hair loss by 66% and 83% of the subjects, respectively, which lasted during two years'' treatment.[A178222] The incidences of these effects in treatment groups were significantly higher than that of the group receiving a placebo.[A178222] Following finasteride administration, the levels of DHT in the scalp skin was shown to be reduced by more than 60%, indicating that the DHT found in scalp is derived from both local DHT production and circulating DHT.[A178195] The effect of finasteride on scalp DHT is likely seen because of its effect on both local follicular DHT levels as well as serum DHT levels.[A178195]. There is evidence from early clinical observations and controlled studies that finasteride may reduce bleeding of prostatic origin.[A178183]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Polyfresh 0.2% eye drops 10 ml', 25039, 'بولي فريش 0.2% قطرة للعين 10 مل', '63', '47', 'Analgesic anti-inflammatory.eye surgery.tissue lubricant', 'Analgesic anti-inflammatory.eye surgery.tissue lubricant', NULL, 'Sodium hyaluronate', 'Orchidia pharmaceutical industries', 'Drops', 'نقط', '0.2%', '1', NULL, NULL, NULL, '6224000219369', 8506, '2024-09-07', NULL, 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Amylamisk 428.6 mg', 7409, 'اميلاميسك 428.6 مجم', '165', NULL, 'Digestive enzyme', 'Digestive enzyme', NULL, 'Alpha amylase', 'Mts- med', 'Unknown', 'غير محدد', '428.6 mg', '1', NULL, NULL, NULL, NULL, 967, '2025-09-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Idelma whitening cream 50 gm', 20700, 'ايدلما كريم للتبييض 50 جم', '50', NULL, 'Whitening topical', 'Whitening topical', NULL, 'Dragostate-11+liquorice extract+vitamin c+collagen+glycerin+arbutin+melaslow+kojic acid+melon extrac', 'Egyptian company for cosmetics > mg pharma', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, NULL, NULL, 816, '2022-07-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sanso d3 400 i.u./ml oral drops 60 ml', 3966, 'سانسو د3 400 وحدة دولية/مل نقط للفم 60 مل', '120', '80', 'Vitamin d', 'Vitamin d', NULL, 'CHOLECALCIFEROL(VITAMIN D3)', 'AUG PHARMA', 'Drops', 'نقط', '60 ml', '1', NULL, NULL, NULL, NULL, 1092, '2025-01-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Venlatrope 100 mg 30 ext.rel.tabs.', 31557, 'فينلاتروبي 100مجم 30 قرص ممتد المفعول', '204', '156', 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Desvenlafaxine', 'Eva pharma', 'Tab', 'أقراص', '100 mg', '3', NULL, NULL, 'it s a serotonin and norepinephrine reuptake inhibitor(snri) is indicated for the treatment of major depressive disorder (mdd).', NULL, 710, '2025-01-29', NULL, 0, 'Desvenlafaxine is indicated for the treatment of major depressive disorder in adults.[L47936] It has also been used off-label to treat hot flashes in menopausal women.[A261166]', 'The exact mechanism of the antidepressant action of desvenlafaxine is unknown but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.[L47936] Particularly, desvenlafaxine has been found to inhibit the serotonin, norepinephrine, and dopamine transporters with varying degrees of affinity. Desvenlafaxine inhibits serotonin transporters with 10 times the affinity of norepinephrine transporters, and dopamine transporters with the lowest affinity.[A6991] ', 'Desvenlafaxine is a selective serotonin and norepinephrine reuptake inhibitor.[A6990,A6991,L47936] It lacks significant activity on muscarinic-cholinergic, H<sub>1</sub>-histaminergic, or &alpha;<sub>1</sub>-adrenergic receptors <i>in vitro</i>, or inhibitory activity against monoamine oxidase.[L47936] Desvenlafaxine does not appear to exert activity against calcium, chloride, potassium and sodium ion channels and also lacks monoamine oxidase (MAO) inhibitory activity.[A6991] It was also shown to lack significant activity against the cardiac potassium channel, hERG, <i>in vitro</i>.[A36975]



Electrocardiograms were obtained from 1,492 desvenlafaxine treated patients with major depressive disorder and 984 placebo-treated patients in clinical studies lasting up to 8 weeks. No clinically relevant differences were observed between desvenlafaxine treated and placebo-treated patients for QT, QTc, PR, and QRS intervals. In a thorough QTc study with prospectively determined criteria, desvenlafaxine did not cause QT prolongation. No difference was observed between placebo and desvenlafaxine treatments for the QRS interval.[L47936] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Benefix 1000 i.u. vial', 15067, 'بينيفكس 1000وحدة دولية فيال', '11,590', '5168', 'Blood-coagulation factor', 'Blood-coagulation factor', NULL, 'Blood-coagulation factor ix', 'Wyeth pharmaceuticals company > pfizer', 'Vial', 'فيال', NULL, '1', NULL, NULL, 'benefix coagulation factor ix (recombinant) is a human blood coagulation factor indicated in adult and pediatric patients with hemophilia b (congenital factor ix deficiency or christmas disease) for the control and prevention of bleeding episodes and peri', NULL, 941, '2024-09-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Montana calcium 30 f.c. tabs.', 22938, 'مونتانا كالسيوم 30 اقراص', '53', NULL, 'Calcium supplement plus vitamin d', 'Calcium supplement plus vitamin d', NULL, 'Calcium+vitamin d3', 'Arab caps > master med pharma', 'Tab', 'أقراص', NULL, '6', NULL, NULL, NULL, NULL, 914, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pentastatin 20 mg 28 f.c. tabs.', 24690, 'بنتاستاتين 20مجم 28 قرص', '136', '106', 'Antihyperlipidemic.statins', 'Antihyperlipidemic.statins', NULL, 'Rosuvastatin', 'Penta pharma-egypt', 'Tab', 'أقراص', '20 mg', '4', 'خافض للكوليسترول', NULL, 'about rosuvastatin statin hmg-coa reductase inhibitor antilipemic. mechanism of action of rosuvastatin it is a hypolipidaemic statin which competitively inhibits the conversion of 3-hydroxy-3-methyl glutaryl coenzyme a (hmg coa) to mevalonate. the drug ex', NULL, 6196, '2024-12-10', NULL, 0, 'The FDA monograph states that rosuvastatin is indicated as an adjunct to diet in the treatment of triglyceridemia, Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia), and Homozygous Familial Hypercholesterolemia.[F4649]



The Health Canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol (Total-C), LDL-C, ApoB, the Total-C/HDL-C ratio and triglycerides (TG) and for increasing HDL-C in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate. It is also indicated for the prevention of major cardiovascular events (including risk of myocardial infarction, nonfatal stroke, and coronary artery revascularization) in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease.[F4652]



Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD. Statin-indicated conditions include diabetes mellitus, clinical atherosclerosis (including myocardial infarction, acute coronary syndromes, stable angina, documented coronary artery disease, stroke, trans ischemic attack (TIA), documented carotid disease, peripheral artery disease, and claudication), abdominal aortic aneurysm, chronic kidney disease, and severely elevated LDL-C levels.[A181087, A181406]', 'Rosuvastatin is a statin medication and a competitive inhibitor of the enzyme HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, which catalyzes the conversion of HMG-CoA to mevalonate, an early rate-limiting step in cholesterol biosynthesis.[A181421] Rosuvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low density lipoprotein (LDL) receptors which increases hepatic uptake of LDL. Rosuvastatin also inhibits hepatic synthesis of very low density lipoprotein (VLDL).[F4649] The overall effect is a decrease in plasma LDL and VLDL. 



In vitro and in vivo animal studies also demonstrate that rosuvastatin exerts vasculoprotective effects independent of its lipid-lowering properties, also known as the pleiotropic effects of statins.[A181424] This includes improvement in endothelial function, enhanced stability of atherosclerotic plaques, reduced oxidative stress and inflammation, and inhibition of the thrombogenic response.



Statins have also been found to bind allosterically to β2 integrin function-associated antigen-1 (LFA-1), which plays an important role in leukocyte trafficking and in T cell activation.[A181559]



Rosuvastatin exerts an anti-inflammatory effect on rat mesenteric microvascular endothelium by attenuating leukocyte rolling, adherence and transmigration.[A1807] The drug also modulates nitric oxide synthase (NOS) expression and reduces ischemic-reperfusion injuries in rat hearts.[A1787] Rosuvastatin increases the bioavailability of nitric oxide[A1807,A1799,A1787] by upregulating NOS[A1791] and by increasing the stability of NOS through post-transcriptional polyadenylation.[A1796] It is unclear as to how rosuvastatin brings about these effects though they may be due to decreased concentrations of mevalonic acid.', 'Rosuvastatin is a synthetic, enantiomerically pure antilipemic agent. It is used to lower total cholesterol, low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), non-high density lipoprotein-cholesterol (non-HDL-C), and trigleride (TG) plasma concentrations while increasing HDL-C concentrations. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, rosuvastatin reduces the risk of cardiovascular morbidity and mortality.[A181087, A181406]



Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403]



**Skeletal Muscle Effects**



Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including rosuvastatin. These risks can occur at any dose level, but are increased at the highest dose (40 mg). Rosuvastatin should be prescribed with caution in patients with predisposing factors for myopathy (e.g., age ≥ 65 years, inadequately treated hypothyroidism, renal impairment).



The risk of myopathy during treatment with rosuvastatin may be increased with concurrent administration of some other lipid-lowering therapies (such as [fenofibrate] or [niacin]), [gemfibrozil], [cyclosporine], [atazanavir]/[ritonavir], [lopinavir]/ritonavir, or [simeprevir].  Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors, including rosuvastatin, coadministered with [colchicine], and caution should therefore be exercised when prescribing these two medications together.[F4649] 



Real-world data from observational studies has suggested that 10-15% of people taking statins may experience muscle aches at some point during treatment.[A182258]



**Liver Enzyme Abnormalities**



Increases in serum transaminases have been reported with HMG-CoA reductase inhibitors, including rosuvastatin. In most cases, the elevations were transient and resolved or improved on continued therapy or after a brief interruption in therapy. There were two cases of jaundice, for which a relationship to rosuvastatin therapy could not be determined, which resolved after discontinuation of therapy. There were no cases of liver failure or irreversible liver disease in these trials.[F4649]



**Endocrine Effects**



Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including rosuvastatin calcium tablets. Based on clinical trial data with rosuvastatin, in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus.[F4649]



An in vitro study found that [atorvastatin], [pravastatin], [rosuvastatin], and [pitavastatin] exhibited a dose-dependent cytotoxic effect on human pancreas islet β cells, with reductions in cell viability of 32, 41, 34 and 29%, respectively, versus control]. Moreover, insulin secretion rates were decreased by 34, 30, 27 and 19%, respectively, relative to control.[A182012]



HMG-CoA reductase inhibitors interfere with cholesterol synthesis and lower cholesterol levels and, as such, might theoretically blunt adrenal or gonadal steroid hormone production. Rosuvastatin demonstrated no effect upon nonstimulated cortisol levels and no effect on thyroid metabolism as assessed by TSH plasma concentration. In rosuvastatin treated patients, there was no impairment of adrenocortical reserve and no reduction in plasma cortisol concentrations. Clinical studies with other HMG-CoA reductase inhibitors have suggested that these agents do not reduce plasma testosterone concentration. The effects of HMG-CoA reductase inhibitors on male fertility have not been studied. The effects, if any, on the pituitarygonadal axis in premenopausal women are unknown.[F4652]



**Cardiovascular**



Ubiquinone levels were not measured in rosuvastatin clinical trials, however significant decreases in circulating ubiquinone levels in patients treated with other statins have been observed. The clinical significance of a potential long-term statin-induced deficiency of ubiquinone has not been established. It has been reported that a decrease in myocardial ubiquinone levels could lead to impaired cardiac function in patients with borderline congestive heart failure.[F4652]



**Lipoprotein A**



In some patients, the beneficial effect of lowered total cholesterol and LDL-C levels may be partly blunted by a concomitant increase in the Lipoprotein(a) [Lp(a)] concentrations. Present knowledge suggests the importance of high Lp(a) levels as an emerging risk factor for coronary heart disease. It is thus desirable to maintain and reinforce lifestyle changes in high-risk patients placed on rosuvastatin therapy.[F4652] Further studies have demonstrated statins affect Lp(a) levels differently in patients with dyslipidemia depending on their apo(a) phenotype; statins increase Lp(a) levels exclusively in patients with the low molecular weight apo(a) phenotype.[A181418]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Diusex 20mg/2ml 5 amp.', 17728, 'ديوسيكس 20 مجم / 2 مل 5 امبولات', '12', NULL, 'Diuretic.loop', 'Diuretic.loop', NULL, 'Furosemide', 'Global napi pharmaceuticals > al delta pharmaceuticals trading co.', 'Amp', 'أمبول', '20mg', '5', NULL, NULL, 'description a benzoic-sulfonamide-furan. it is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. mechanism of action furosemide a loop diuretic inhibits water reabsorption in the nephron by blocking the', '6221035016291', 744, '2023-04-18', NULL, 0, 'Furosemide is indicated for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome, in adults and pediatric patients.[L7958] 



Oral furosemide is indicated alone for the management of mild to moderate hypertension or severe hypertension in combination with other antihypertensive medications.[L9659]



Intravenous furosemide is indicated as adjunctive therapy in acute pulmonary edema when a rapid onset of diuresis is desired.[L7958]



Subcutaneous furosemide is indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure. This drug formulation is not indicated for emergency situations or in patients with acute pulmonary edema.[L43408]', 'Furosemide promotes diuresis by blocking tubular reabsorption of sodium and chloride in the proximal and distal tubules, as well as in the thick ascending loop of Henle. This diuretic effect is achieved through the competitive inhibition of sodium-potassium-chloride cotransporters (NKCC2) expressed along these tubules in the nephron, preventing the transport of sodium ions from the lumenal side into the basolateral side for reabsorption. This inhibition results in increased excretion of water along with sodium, chloride, magnesium, calcium, hydrogen, and potassium ions.[L7961] As with other loop diuretics, furosemide decreases the excretion of uric acid.[T28] 



Furosemide exerts direct vasodilatory effects, which results in its therapeutic effectiveness in the treatment of acute pulmonary edema. Vasodilation leads to reduced responsiveness to vasoconstrictors, such as angiotensin II and noradrenaline, and decreased production of endogenous natriuretic hormones with vasoconstricting properties. It also leads to increased production of prostaglandins with vasodilating properties. Furosemide may also open potassium channels in resistance arteries.[T28] The main mechanism of action of furosemide is independent of its inhibitory effect on carbonic anhydrase and aldosterone.[L7958] ', 'Furosemide manages hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome. Furosemide is a potent loop diuretic that works to increase the excretion of Na+ and water by the kidneys by inhibiting their reabsorption from the proximal and distal tubules, as well as the loop of Henle.[L7958] It works directly acts on the cells of the nephron and indirectly modifies the content of the renal filtrate.[T28] Ultimately, furosemide increases the urine output by the kidney. Protein-bound furosemide is delivered to its site of action in the kidneys and secreted via active secretion by nonspecific organic transporters expressed at the luminal site of action.[A31831,L7958] 



Following oral administration, the onset of the diuretic effect is about 1 and 1.5 hours [L7958], and the peak effect is reached within the first 2 hours.[L7961] The duration of effect following oral administration is about 4-6 hours but may last up to 8 hours.[L9659] Following intravenous administration, the onset of effect is within 5 minutes, and the peak effect is reached within 30 minutes. The duration of action following intravenous administration is approximately 2 hours. Following intramuscular administration, the onset of action is somewhat delayed.[L7958]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Schisolazine 5 mg 30 orodispersible tabs.', 26606, 'سكيزولازين 5مجم 30 قرص', '161', '90', 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Olanzapine', 'Wadi elneel benta > pharco', 'Tab', 'أقراص', '5 mg', '3', NULL, NULL, 'indication for the acute and maintenance treatment of schizophrenia and related psychotic disorders as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. intramuscular olanzapine is indicated for the rapid control of agitated patien', NULL, 1019, '2024-02-08', NULL, 0, 'Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.[A177014] 



Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.[FDA label]



As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.[A177014]



Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.[FDA label]



Schizophrenia is a complex biochemical brain disorder that affects the person''s ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.[L5936]



Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.[L5939]



Olanzapine is also indicated in combination with [samidorphan] for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.[L34359]', 'The activity of olanzapine is achieved by the antagonism of multiple neuronal receptors including the dopamine receptor D1, D2, D3 and D4 in the brain, the serotonin receptors 5HT2A, 5HT2C, 5HT3 and 5HT6, the alpha-1 adrenergic receptor, the histamine receptor H1 and multiple muscarinic receptors.[A176993, A176999]



As abovementioned, olanzapine presents a wide profile of targets, however, its antagonistic effect towards the dopamine D2 receptor in the mesolimbic pathway is key as it blocks dopamine from having a potential action at the post-synaptic receptor. The binding of olanzapine to the dopamine D2 receptors is easily dissociable and hence, it allows for a certain degree of dopamine neurotransmission.[A177014]



On the other hand, olanzapine acts in the serotonin 5HT2A receptors in the frontal cortex in a similar manner than the reported on dopamine D2 receptors. This determined effect allows for a decrease in adverse effects.[A177014]', 'The effect of olanzapine in the D2 receptor is reported to produce the positive effects of this drug such as a decrease in hallucinations, delusions, disorganized speech, disorganized thought, and disorganized behavior. On the other hand, its effect on the serotonin 5HT2A receptor prevents the onset of anhedonia, flat affect, alogia, avolition and poor attention.[A177014] Based on the specific mechanism of action, olanzapine presents a higher affinity for the dopamine D2 receptor when compared to the rest of the dopamine receptor isotypes. This characteristic significantly reduces the presence of side effects.[T554]



Clinical trials for the original use of olanzapine demonstrated significant effectiveness in the treatment of schizophrenia and bipolar disorder in adults and acute manic or mixed episodes associated with bipolar disorder in adolescents.[A177008]



The effect of olanzapine on dopamine and serotonin receptors has been suggested to reduce chemotherapy-induced nausea and vomiting as those receptors are suggested to be involved in this process. For this effect, several clinical trials have been conducted and it has been shown that olanzapine can produce a significant increase in total control of nausea and vomiting.[A176993] In a high-level study of the effect of olanzapine for this condition, a complete response on the delay phase was observed in 84% of the individual and control of emesis of over 80% despite the phase.[A176999]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vermin 100mg/5ml susp. 30ml', 12232, 'فيرمين 100مجم/5مل معلق 30مل', '10', '4', 'Anthelmintic', 'Anthelmintic', NULL, 'Mebendazole', 'Memphis', 'Susp', 'معلق', '100mg', '1', 'طارد للديدان', NULL, 'about mebendazole a benzimidazole derivative anthelmintic. mechanism of action of mebendazole mebendazole is a benzimidazole used as a broad spectrum anthelminthic which acts by blocking glucose uptake in the parasite and depletion of its glycogen stores.', '6221050090030', 1826, '2025-01-01', NULL, 0, 'For the treatment of <i>Enterobius vermicularis</i> (pinworm), <i>Trichuris trichiura</i> (whipworm), <i>Ascaris lumbricoides</i> (common roundworm), <i>Ancylostoma duodenale</i> (common hookworm), <i>Necator americanus</i> (American hookworm) in single or mixed infections.', 'Mebendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.', 'Mebendazole is a (synthetic) broad-spectrum anthelmintic. The principal mode of action for Mebendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Becal cream 40 gm', 14963, 'بيكال كريم 40 جم', '75', '40', 'Anti-acne', 'Anti-acne', NULL, NULL, 'Egyptian company for cosmetics > ballance pharma', 'Cream', 'كريم', '40 gm', '1', 'علاج حب الشباب -- تقليل الالتهابات -- تقليل الحكة والاحمرار', NULL, 'for acne prone skin. use once at night.', NULL, 1595, '2025-08-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pyritrust 1 gm/100ml soln. i.v. inf.', 25518, 'بيريترست 1جم/100مل محلول', '28', '22.5', 'Antipyretic', 'Antipyretic', NULL, 'Paracetamol(acetaminophen)', 'Global napi pharmaceuticals > pharma trust citical co.', 'Sol', 'محلول', '1 gm', '1', NULL, NULL, 'about paracetamol acetanilide derivative non narcotic analgesic antipyretic. mechanism of action of paracetamol paracetamol has analgesic and antipyretic action. it is more active on cyclo-oxygenase enzyme in brain. peripherally it is a poor inhibitor of', '6223004901683', 986, '2023-09-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dostinex 0.5 mg 2 tabs.', 3857, 'دوستينكس 0.5 مجم 2 قرص', '172', '118.5', 'Dopamine agonist and prolactin inhibitor', 'Dopamine agonist and prolactin inhibitor', NULL, 'Cabergoline', 'Pfizer', 'Tab', 'أقراص', '0.5 mg', '1', 'مضاد لهرمون اللبن -- علاج بعض حالات تأخر الحمل في السيدات -- مضاد لهرمون البرولاكتين لتنشيف اللبن بعد فطام الطفل', NULL, 'description cabergoline an ergot derivative is a long-acting dopamine agonist and prolactin inhibitor. it is used to treat hyperprolactinemic disorders and parkinsonian syndrome. cabergoline possesses potent agonist activity on dopamine d2 receptors. indi', '43544524323', 19778, '2024-11-10', NULL, 0, 'For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease. ', 'The dopamine D<sub>2</sub> receptor is a 7-transmembrane G-protein coupled receptor associated with G<sub>i</sub> proteins. In lactotrophs, stimulation of dopamine D<sub>2</sub> causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca<sup>2+</sup> from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D<sub>2</sub> receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, &alpha;<sub>1</sub>,- and &alpha;<sub>2</sub>- adrenergic, and 5-HT<sub>1</sub>- and 5-HT<sub>2</sub>-serotonin receptors.', 'Cabergoline stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D<sub>1</sub> and D<sub>5</sub> subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub> subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D<sub>2</sub> and D<sub>3</sub> receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D<sub>2</sub>- and D<sub>3</sub>-receptors. It also exhibits: agonist activity (in order of decreasing binding affinities) on 5-hydroxytryptamine (5-HT)<sub>2B</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>1D</sub>, dopamine D<sub>4</sub>, 5-HT<sub>1A</sub>, dopamine D<sub>1</sub>, 5-HT<sub>1B</sub> and 5-HT<sub>2C</sub> receptors and antagonist activity on &alpha;<sub>2B</sub>, &alpha;<sub>2A</sub>, and &alpha;<sub>2C</sub> receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT<sub>2A</sub> agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Niplo cream 30gm', 23612, 'نيبلو كريم 30 جم', '14', NULL, 'Moisturizing topicals', 'Moisturizing topicals', NULL, 'Stearic acid+cetyl alcohol+triethanolamine+sesame oil+almond oil+jojoba oil+wheat germ oil+panthenol', 'Egyptian canadian for drug', 'Cream', 'كريم', '30gm', '1', NULL, NULL, 'moisturizing cream for cracked nipples.', NULL, 729, '2022-07-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zofatrone 8mg/4ml 3 amp. for i.v/i.m inj.', 29992, 'زوفاترون 8مجم/4مل 3 امبول', '126', '85.5', '5-ht3 receptor antagonist', '5-ht3 receptor antagonist', NULL, 'Ondansetron', 'Eva pharma', 'Inj', 'حقن', '8mg', '3', NULL, NULL, 'about ondansetron selective serotonin 5-ht3 receptor antagonist imidazole derivative antiemetic. mechanism of action of ondansetron ondansetron is a selective 5ht3 receptor antagonist. 5ht3 receptors are present in vagal nerve terminals and chemoreceptor', '6223004515835', 913, '2024-08-15', NULL, 0, 'In the adult patient population:

i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:

- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and

- the prevention and treatment of postoperative nausea and vomiting



ii) intravenously administered ondansetron injection formulations are indicated for:

- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and

- the prevention and treatment of postoperative nausea and vomiting



In the pediatric (4-18 years of age) patient population:

i) ondansetron was effective and well tolerated when given to children 4-12 years of age for the treatment of post-chemotherapy induced nausea and vomiting,

ii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for the treatment of children 3 years of age or younger,

iii) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of post-radiotherapy induced nausea and vomiting, and

iV) ondansetron tablets, ondansetron ODT, ondansetron injection are not indicated for use in any age group of the pediatric population for the treatment of postoperative nausea and vomiting



In the geriatric (>65 years of age) patient population:

i) efficacy and tolerance of ondansetron were similar to that observed in younger adults for the treatment of post-chemotherapy and radiotherapy-induced nausea and vomiting, and

ii) clinical experience in the use of ondansetron in the prevention and treatment of postoperative nausea and vomiting is limited and is not indicated for use in the geriatric patient population ', 'Ondansetron is a selective antagonist of the serotonin receptor subtype, 5-HT3 [F3178, F3181, F3184].



Cytotoxic chemotherapy and radiotherapy are associated with the release of serotonin (5-HT) from enterochromaffin cells of the small intestine, presumably initiating a vomiting reflex through stimulation of 5-HT3 receptors located on vagal afferents [F3178, F3181, F3184]. Ondansetron may block the initiation of this reflex. Activation of vagal afferents may also cause a central release of serotonin from the chemoreceptor trigger zone of the area postrema, located on the floor of the fourth ventricle [F3178, F3181, F3184]. Thus, the antiemetic effect of ondansetron is probably due to the selective antagonism of 5-HT3 receptors on neurons located in either the peripheral or central nervous systems, or both [F3178, F3181, F3184].



Although the mechanisms of action of ondansetron in treating postoperative nausea and vomiting and cytotoxic induced nausea and vomiting may share similar pathways, the role of ondansetron in opiate-induced emesis has not yet been formally established [F3181, F3184].', 'Ondansetron is a highly specific and selective serotonin 5-HT<sub>3</sub> receptor antagonist, not shown to have activity at other known serotonin receptors and with low affinity for dopamine receptors [FDA Label], [A1160, A1161]. The serotonin 5-HT<sub>3</sub> receptors are located on the nerve terminals of the vagus in the periphery, and centrally in the chemoreceptor trigger zone of the area postrema [FDA Label], [A1160, A1161]. The temporal relationship between the emetogenic action of emetogenic drugs and the release of serotonin, as well as the efficacy of antiemetic agents, suggest that chemotherapeutic agents release serotonin from the enterochromaffin cells of the small intestine by causing degenerative changes in the GI tract [FDA Label], [A1160, A1161]. The serotonin then stimulates the vagal and splanchnic nerve receptors that project to the medullary vomiting center, as well as the 5-HT<sub>3</sub> receptors in the area postrema, thus initiating the vomiting reflex, causing nausea and vomiting [FDA Label], [A1160, A1161].



Moreover, the effect of ondansetron on the QTc interval was evaluated in a double-blind, randomized, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women [F3181, F3184]. Ondansetron was tested at single doses of 8 mg and 32 mg infused intravenously over 15 minutes [F3181, F3184]. At the highest tested dose of 32 mg, prolongation of the Fridericia-corrected QTc interval (QT/RR0.33=QTcF) was observed from 15 min to 4 h after the start of the 15 min infusion, with a maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction of 19.6 (21.5) msec at 20 min [F3181, F3184]. At the lower tested dose of 8 mg, QTc prolongation was observed from 15 min to 1 h after the start of the 15-minute infusion, with a maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction of 5.8 (7.8) msec at 15 min [F3181, F3184]. The magnitude of QTc prolongation with ondansetron is expected to be greater if the infusion rate is faster than 15 minutes [F3181, F3184]. The 32 mg intravenous dose of ondansetron must not be administered [F3181, F3184]. No treatment-related effects on the QRS duration or the PR interval were observed at either the 8 or 32 mg dose [F3181, F3184].



An ECG assessment study has not been performed for orally administered ondansetron [F3181, F3184]. On the basis of pharmacokinetic-pharmacodynamic modelling, an 8 mg oral dose of ondansetron is predicted to cause a mean QTcF increase of 0.7 ms (90% CI -2.1, 3.3) at steady-state, assuming a mean maximal plasma concentration of 24.7 ng/mL (95% CI 21.1, 29.0) [F3181, F3184]. The magnitude of QTc prolongation at the recommended 5 mg/m2 dose in pediatrics has not been studied, but pharmacokinetic-pharmacodynamic modeling predicts a mean increase of 6.6 ms (90% CI 2.8, 10.7) at maximal plasma concentrations [F3181, F3184]. 



In healthy subjects, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time [F3178]. Multiday administration of ondansetron has been shown to slow colonic transit in healthy subjects [F3178]. Ondansetron has no effect on plasma prolactin concentrations [F3178].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Irontec 20 chew. pieces', 20973, 'ايرونتيك 20 قطعة قابلة للمضغ', '85', '48', 'Iron supplement', 'Iron supplement', NULL, 'Iron+zinc+folic acid', 'Covertina > amoun tec', 'Piece', 'قطعة', NULL, '2', 'يحتوي على الحديد', NULL, NULL, NULL, 1000, '2025-08-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Spasmorest 10 mg/ml 6 i.m. amp.', 10775, 'سبازمورست 10مجم/مل 6 امبولات', '7', NULL, 'Antimuscarinic.irritable bowel syndrome', 'Antimuscarinic.irritable bowel syndrome', NULL, 'Dicyclomine', 'Misr', 'Amp', 'أمبول', '10 mg', '6', 'مضاد للتقلصات', NULL, 'about dicyclomine anticholinergic antimuscarinic antispasmodic and in urinary incontinence. mechanism of action of dicyclomine dicyclomine is an anticholinergic drug. it exerts its action by inhibiting muscarinic (((cholinergic))) receptors on smooth musc', NULL, 825, '2023-04-27', NULL, 0, 'Dicyclomine is indicated for the treatment of functional bowel disorder and irritable bowel syndrome.[L7967]', 'Dicyclomine achieves its action partially through direct antimuscarinic activity of the M1, M3, and M2 receptors; and partially through antagonism of bradykinin and histamine.[A6556,A182555,A234659,L7967] Dicyclomine non-competitively inhibits the action of bradykinin and histamine, resulting in direct action on the smooth muscle, and decreased strength of contractions seen in spasms of the ileum.[A182555]', 'Dicyclomine is an anticholinergic drug used to relax the smooth muscles of the intestines.[L7967] It''s duration of action is not especially long as it is usually taken 4 times daily with individual doses of 20-40mg orally or 10-20mg by intramuscular injection.[L7967] Dicyclomine should not be administered intravenously.[L7967]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Diolax 7.5mg 20*10 tab.', 17683, 'ديولاكس 7.5مجم 20*10 قرص', '36', NULL, 'Laxative', 'Laxative', NULL, 'Sennoside', 'Hikma pharma', 'Tab', 'أقراص', '7.5mg', '20', NULL, NULL, NULL, NULL, 1130, '2023-01-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ivypto 120 ml syrup', 8362, 'ايفيبتو شراب 120 مل', '65', NULL, 'Mucolytic and expectorant cough therapy', 'Mucolytic and expectorant cough therapy', NULL, 'Ivy leaves extract 50 mg+n-acetyl-l-cysteine 50 mg+zinc gluconate 13.065 mg/5 ml', 'Care theraputica for pharmaceuticals', 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, NULL, NULL, 725, '2025-12-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Farcozol plus susp. 120ml', 18831, 'فاركوزول بلس معلق 120 مل', '13', '6', 'Antiprotozoal.nitroimidazole', 'Antiprotozoal.nitroimidazole', NULL, 'Diloxanide furoate+metronidazole', 'Pharco', 'Susp', 'معلق', '120ml', '1', NULL, NULL, NULL, '6221151002413', 973, '2024-12-11', NULL, 0, 'Diloxanide is used alone as a primary agent in the treatment of asymptomatic (cyst passers) intestinal amebiasis caused by Entamoeba histolytica. Diloxanide may also be used concurrently, or sequentially, with other agents such as the nitroimidazoles (eg. metronidazole) in the treatment of invasive or extraintestinal forms of amebiasis.

', 'Unknown. Diloxanide may inhibit protein synthesis. ', 'Diloxanide is a luminal amebicide, however the mechanism of action of diloxanide is unknown. Diloxanide destroys the trophozoites of E. histolytica that eventually form into cysts. The cysts are then excreted by persons infected with asymptomatic amebiasis. Diloxanide furoate is a prodrug, and is hydrolyzed in the gastrointestinal tract to produce diloxanide, the active ingredient. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Myocool cream 60 gm', 8504, 'ميوكول كريم 60 جرام', '85', '71', 'Massage', 'Massage', NULL, 'Winter green oil+peppermint oil+silicon oil+cetyl alcohol+propyl paraben+petrolium jelly+stearic aci', 'Leader cosmetics > purex health care', 'Cream', 'كريم', '60 gm', '1', 'آلام أسفل الظهر وعرق النسا.', NULL, NULL, '6224008843412', 10907, '2025-05-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Propylthiouracil 50mg 20 tab. b.p 2002', 25370, 'بروبايلثيويوراسيل 50مجم 20 اقراص', '14', NULL, 'Antithyroid', 'Antithyroid', NULL, 'Propylthiouracil', 'Memphis', 'Tab', 'أقراص', '50mg', '2', NULL, NULL, 'about propylthiouracil a thioamide derivative antithyroid drug. mechanism of action of propylthiouracil it is an antithyroid drug which inhibits thyroid hormone synthesis. it binds to thyroid peroxidase and inhibits oxidation of iodide or iodotyrosil resi', NULL, 1399, '2022-07-12', NULL, 0, 'Used to manage hyperthyroidism which is due to an overactive thyroid gland (Grave''s disease).', 'Propylthiouracil binds to thyroid peroxidase and thereby inhibits the conversion of iodide to iodine. Thyroid peroxidase normally converts iodide to iodine (via hydrogen peroxide as a cofactor) and also catalyzes the incorporation of the resulting iodide molecule onto both the 3 and/or 5 positions of the phenol rings of tyrosines found in thyroglobulin. Thyroglobulin is degraded to produce thyroxine (T4) and tri-iodothyronine (T3), which are the main hormones produced by the thyroid gland. Therefore propylthiouracil effectively inhibits the production of new thyroid hormones.', 'Propylthiouracil is a thiourea antithyroid agent. Grave''s disease is the most common cause of hyperthyroidism. It is an autoimmune disease where an individual''s own antibodies attach to thyroid stimulating hormone receptors within cells of the thyroid gland and then trigger overproduction of thyroid hormone. The two thyroid hormones manufactured by the thyroid gland, thyroxine (T4) and triiodothyronine (T3), are formed by combining iodine and a protein called thyroglobulin with the assistance of an enzyme called peroxidase. PTU inhibits iodine and peroxidase from their normal interactions with thyroglobulin to form T4 and T3. This action decreases thyroid hormone production. PTU also interferes with the conversion of T4 to T3, and, since T3 is more potent than T4, this also reduces the activity of thyroid hormones. The actions and use of propylthiouracil are similar to those of methimazole.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aphrofemine 100mg 30 f.c. tabs', 14290, 'افروفيمين 100مجم 30 قرص', '600', NULL, 'Women need', 'Women need', NULL, 'Flibanserin', 'Mash premiere > biomed pharmaceuticals', 'Tab', 'أقراص', '100mg', '3', 'لزيادة الرغبة للسيدات', NULL, NULL, NULL, 2939, '2023-04-02', NULL, 0, 'For the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. ', 'Flibansetrin has high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors. It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to reduction in serotonin levels and increase in dopamine and norepinephrine levels, all of which may play part in reward processing. ', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nox topical lotion 120ml', 23819, 'نوكس لوشن 120مل', '10', NULL, 'Soothing topical', 'Soothing topical', NULL, 'Zinc oxide+menthol crystals+thyme oil+coconut oil+glycerin+beeswax+stearic acid+cetyl alcohol+isopro', 'Leader cosmetics > a-one pharma', 'Lotion', 'لوشن', '120ml', '1', NULL, NULL, 'soothing lotion', NULL, 827, '2022-07-09', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nervoter 30 caps', 3581, 'نيرفوتر 30 كبسولة', '497', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Alpha-lipoic acid+vitaminsb6+b12+d3', 'Total future', 'Cap', 'كبسولة', NULL, '3', NULL, NULL, NULL, NULL, 1230, '2025-04-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cibacen 10 mg 7 tab', 2546, 'سيباسين 10مجم 7 اقراص', '19', NULL, 'Antihypertensive ace', 'Antihypertensive ace', NULL, 'Benazepril', 'Novartis', 'Tab', 'أقراص', '10 mg', '1', NULL, NULL, NULL, NULL, 989, '2022-09-22', NULL, 0, 'Benazepril is indicated for the treatment of hypertension[A840]. It may be used alone or in combination with thiazide diuretics[FDA Label].', 'Benazeprilat, the active metabolite of Benazepril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II[FDA Label]. Inhibition of ACE results in decreased plasma angiotensin II[FDA Label]. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion[FDA Label].', 'Benazepril, an angiotensin-converting enzyme (ACE) inhibitor, is a prodrug which, when hydrolyzed by esterases to its active Benazeprilat[A836], is used to treat hypertension and heart failure, to reduce proteinuria and renal disease in patients with nephropathies, and to prevent stroke, myocardial infarction, and cardiac death in high-risk patients[A840,A838,A837]. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals[A840,A836]. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II[FDA Label]. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex[FDA Label].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zetadidox 10/10 mg 30 tabs.', 2563, 'زيتاديتوكس 10/10مجم 30 قرص', '66', '37.5', 'Antiemetic', 'Antiemetic', NULL, 'Doxylamine succinate+pyridoxine hcl(vitamin b6)', 'Zeta pharma', 'Tab', 'أقراص', '10 mg', '3', NULL, NULL, NULL, '200406423018', 1864, '2025-01-20', NULL, 0, 'Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.', 'Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1&nbsp;receptors. It also has substantial sedative and anticholinergic effects.', 'Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Famox 250mg/5ml susp. 60ml', 18789, 'فاموكس 250 مجم / 5 مل معلق 60 مل', '14', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Penicillins.penicillin with b-lactamase inhibitor', NULL, 'Amoxicillin+flucloxacillin', 'Sedico > top pharm', 'Susp', 'معلق', '250mg', '1', NULL, NULL, 'amoxycillin and flucloxacillin ï¿½ generally exhibit an additive effect against sensitive bacteria and bacteria that are sensitive to amoxycillin or to flucloxacillin remain sensitive to the combination showing that antagonism does not occur when the two', NULL, 821, '2022-07-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bi-profenid 150mg 20 scored tabs.', 1587, 'باي بروفينيد 150مجم 20 قرص', '54', '37', 'Nsaid.propionic acid derivatives .analgesic .antipyretic', 'Nsaid.propionic acid derivatives .analgesic .antipyretic', NULL, 'Ketoprofen', 'Sanofi', 'Tab', 'أقراص', '150mg', '2', 'مسكن قوي للصداع وآلام الأسنان.', NULL, NULL, '6223003990350', 23310, '2024-12-07', NULL, 0, 'For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.', 'The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. ', 'Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ginroy 20 caps', 7768, 'جينروي 20 كبسولة', '140', NULL, 'Multivitamin', 'Multivitamin', NULL, 'Royal jelly 300 mg+ginseng300 mg+licorice roots 100mg', 'Abo el enen pharm', 'Cap', 'كبسولة', NULL, '2', NULL, NULL, NULL, NULL, 830, '2025-10-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Intraperitoneal dialysis sol. anhydrous dextrose 4.25% (acetate)', 20908, 'انترابيريتونيال دياليسيس محلول اندهيريس ديكستروز 4.25% اسيتات', '12', NULL, 'Sterile solution', 'Sterile solution', NULL, 'Calcium chloride+glucose (dextrose)+magnesium chloride+sodium acetate+sodium chloride+sodi', 'El nasr', 'Sol', 'محلول', '4.25%', '1', NULL, NULL, NULL, NULL, 798, '2022-08-03', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Glucose 40% (mottahedoon) i.v. inf. 500 ml', 19924, 'جلوكوز 40% المتحدون محلول وريدي زجاجة 500 مل', '5', NULL, 'Sterile solution', 'Sterile solution', NULL, 'Glucose (dextrose)', 'Al mottahedoon pharma', 'Unknown', 'غير محدد', '40%', '1', NULL, NULL, 'about glucose monosaccharide aldohexose nutritive sweetner. mechanism of action of glucose glucose is a simple carbohydrate and is used as energy source in man. it is readily converted to fat which provides a rich store of energy in concentrated form. glu', NULL, 1025, '2022-07-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Clavimox 625 mg 12 f.c.tabs.', 2717, 'كلافيموكس 625مجم 12 قرص', '107', '73.5', 'Penicillins.penicillin with b-lactamase inhibitor', 'Penicillins.penicillin with b-lactamase inhibitor', NULL, 'Amoxicillin+clavulanic acid', 'Pharco', 'Tab', 'أقراص', '625 mg', '3', 'مضاد حيوي', NULL, NULL, '6221151015734', 9898, '2024-12-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pelembap urea cream 60 gm', 4622, 'بليمباب يوريا كريم 60 جم', '100', NULL, 'Smoothens rough dry skin', 'Smoothens rough dry skin', NULL, 'Urea 10%+ceramide+panthenol', 'Yojeen', 'Cream', 'كريم', '60 gm', '1', NULL, NULL, NULL, NULL, 834, '2025-06-18', NULL, 0, 'Urea is used topically for debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails.[L41484]', NULL, 'Urea is a keratolytic emollient that works to treat or prevent dry, rough, scaly, itchy skin.[L41484]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sanoplex 24 chewable tabs.', 26505, 'سانوبلكس 24 قرص مضغ', '139', '109', 'Iron supplement', 'Iron supplement', NULL, 'Iron(ferrous fumarate)+vitamins (b12+folic acid+b6)', 'El shorouk > zeta bio', 'Tab', 'أقراص', NULL, '2', 'مكمل غذائي -- مصدر للحديد -- علاج حالات الانيميا -- مصدر لفيتامين ب -- مقوي اعصاب --', NULL, 'ultimate bioactive iron formula specially formulated for support anemic patient and restoring the normal blood hemoglobin level specially before during and after pregnancy. ** helps in restoring the normal blood hemoglobin level in the following cases. be', NULL, 3750, '2025-08-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('De-prostyl-2 6 supp.', 17298, 'دي-بروستيل-2 6 اقماع لبوس', '4', NULL, 'Prostate disorder', 'Prostate disorder', NULL, 'Chamomile+ichthammol+potassium iodide', 'Cid', 'Supp', 'لبوس', NULL, '1', 'علاج تضخم البروستاتا.', NULL, 'antispasmodic anxiolytic anti-inflammatory and some antimutagenic and cholesterol-lowering effects for chamomile.chamomile has sped healing time of wounds.', '6221043012476', 1243, '2022-12-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lacosanad 100 mg 20 f.c. tabs.', 12338, 'لاكوساناد 100مجم 20 قرص', '120', NULL, 'Anti-epileptic', 'Anti-epileptic', NULL, 'Lacosamide', 'Inad pharma', 'Tab', 'أقراص', '100 mg', '2', NULL, NULL, NULL, NULL, 885, '2022-12-30', NULL, 0, 'In the US and Europe, lacosamide is indicated for the treatment of partial-onset seizures in children and adults.[L49191, L49196, L49201] In Canada, it is reserved for use in adults.[L49206]



It is also used as an adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients four years of age and older.[L49191, L49201]



The extended-release capsules of lacosamide are indicated for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.[L49196]', 'Caused by neuronal hyperexcitability, seizures in epilepsy involve sustained firing of sodium-dependent action potentials. The slow inactivation process, intrinsic to voltage-gated sodium channel functioning, has been implicated in the paroxysmal depolarizing shifts associated with epileptic activity.[A262616] The exact mechanism of action of lacosamide is not fully known; however, in vitro electrophysiological studies have shown that lacosamide selectively enhances the slow inactivation of voltage-gated sodium channels, shifting the slow inactivation curve to more hyperpolarized potentials and augmenting the maximal fraction of channels in the slow inactivated state.[A262686] This results in the stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing.[A262616, L49191] Lacosamide does not affect the fast component of voltage-gated sodium currents, unlike traditional sodium channel blockers.[A262616]', 'Lacosamide is an antiepileptic drug with high oral potency, stereoselectivity,[A262686] and anticonvulsant effects.[A262616] By blocking sensory neuronal voltage-gated sodium channels that mediate neuropathic pain responses, lacosamide was shown to possess analgesic activity.[A4071, A262616] Lacosamide is a chiral functionalized amino acid. The S-stereoisomer does not exhibit antiepileptic activity.[A262616]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Trexozola 2.5 mg 10 f.c.tabs', 314, 'تريكسوزولا 2.5مجم 10 اقراص', '197', '150', 'Non-steroidal aromatase inhibitor', 'Non-steroidal aromatase inhibitor', NULL, 'Letrozole', 'TECHNOPHARMA', 'Tab', 'أقراص', '2.5 mg', '1', 'أقراص منشطة للحمل تستعمل أيضًا لعلاج بعض الأورام التي تصيب النساء.', NULL, NULL, '6224008302421', 7032, '2024-08-28', NULL, 0, 'Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer.[L11623] Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal women with HR+ and human epidermal growth factor 2 (HER2) negative advanced or metastatic breast cancer.[L11626]', 'Letrozole is a non-steroidal type II aromatase inhibitor.[A1559] It blocks the active site, and therefore the electron transfer chain of CYP19A1.[A1559] This competitive inhibition prevents the conversion of androgens to estrogen.[A1559] This action leads to a reduction in uterine weight and elevated leuteinizing hormone.[L11623] In postmenopausal women, the action of aromatase is responsible for the majority of estrogen production.[L11623] With reduced availability of estrogen, estrogen-dependant tumors regress.[L11623] Third generation aromatase inhibitors do not significantly affect cortisol, aldosterone, and thyroxine levels.[A190546]', 'Letrozole is an aromatase inhibitor used in the treatment of breast cancer. Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization. As breast tissue is stimulated by estrogens, decreasing their production is a way of suppressing recurrence of the breast tumor tissue.



Letrozole is a third generation type II aromatase inhibitor used to treat estrogen dependant breast cancers.[L11623] It has a long duration of action as it has a half life of over 42 hours in breast cancer patients.[A190546,A190555,L11623] Patients should be counselled regarding the risk of interstitial lung disease, pneumonitis, QT prolongation, elevated transaminase levels, neutropenia, and embryo-fetal toxicity.[L11623]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Doucheal-n intimate feminine wash 250 ml', 3860, 'دوشيال-ان غسول مطهر 250 مل', '48', '45', 'Vaginal wash', 'Vaginal wash', NULL, 'Chlorhexidine+chlorocresol+hexamidine', 'Mash premiere', 'Unknown', 'غير محدد', '250 ml', '1', 'غسول مطهر للسيدات', NULL, 'mechanism of action of chlorhexidine this drug has positive charge so it attach to the negative charge cell wall. this destabilizes and destroys the integrity and penetrates bacterial cell membranes. it results precipitation of the cytoplasm and interfere', '6222001407785', 4180, '2023-12-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Napizole 20mg 14 cap', 8568, 'نابيزول 20مجم 14 كبسولة', '62', '41.5', 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Omeprazole', 'Global napi pharmaceuticals', 'Cap', 'كبسولة', '20mg', '1', NULL, NULL, NULL, '6223002145980', 3174, '2024-07-04', NULL, 0, 'Omeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the following purposes:



• Treatment of active duodenal ulcer in adults 



• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer

recurrence in adults 



• Treatment of active benign gastric ulcer in adults 



• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.



• Treatment of symptomatic gastroesophageal reflux disease (GERD) in

patients 1 year of age and older 



• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in

patients 1 month of age and older 



• Maintenance of healing of EE due to acid-mediated GERD in patients 1

year of age and older 



• Pathologic hypersecretory conditions in adults', 'Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K(+)-ATPase of the proton pump [A175180], expressed in high quantities by the parietal cells of the stomach. ATPase is an enzyme on the parietal cell membrane that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid) [A174295].



Omeprazole is a member of a class of antisecretory compounds, the substituted _benzimidazoles_, that stop gastric acid secretion by selective inhibition of the _H+/K+ ATPase_ enzyme system. Proton-pump inhibitors such as omeprazole bind covalently to cysteine residues via disulfide bridges on the alpha subunit of the _H+/K+ ATPase_ pump, inhibiting gastric acid secretion for up to 36 hours [A175192].  This antisecretory effect is dose-related and leads to the inhibition of both basal and stimulated acid secretion, regardless of the stimulus [FDA label].  



**Mechanism of H. pylori eradication**



Peptic ulcer disease (PUD) is frequently associated with _Helicobacter pylori_ bacterial infection (NSAIDs) [A175195]. The treatment of H. pylori infection may include the addition of omeprazole or other proton pump inhibitors as part of the treatment regimen [FDA label], [A175198]. 

_H. pylori_ replicates most effectively at a neutral pH [A175213]. Acid inhibition in H. pylori eradication therapy, including proton-pump inhibitors such as omeprazole, raises gastric pH, discouraging the growth of H.pylori [A175198]. It is generally believed that proton pump inhibitors inhibit the _urease_ enzyme, which increases the pathogenesis of H. pylori in gastric-acid related conditions [A175216].   ', '**Effects on gastric acid secretion**



This drug decreases gastric acid secretion [FDA label]. After oral administration, the onset of the antisecretory effect of omeprazole is usually achieved within one hour, with the maximum effect occurring by 2 hours after administration. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days [FDA label].



**Effects on serum gastrin**



In studies of 200 or more patients, serum gastrin levels increased during the first 1-2 weeks of daily administration of therapeutic doses of omeprazole. This occurred in a parallel fashion with the inhibition of acid secretion. No further increase in serum gastrin occurred with continued omeprazole administration. Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may lead to false positive results in diagnostic studies for neuroendocrine tumors [FDA label].



**Enterochromaffin-like (ECL) cell effects**



Human gastric biopsy samples have been obtained from more than 3000 pediatric and adult patients treated with omeprazole in long-term clinical studies. The incidence of enterochromaffin-like cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia have been identified in these patients. These studies, however, are of insufficient in power and duration to draw conclusions on the possible influence of long-term administration of omeprazole in the development of any premalignant or malignant conditions [FDA label]. 



**Other effects**



Systemic effects of omeprazole in the central nervous system, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2-4 weeks, showed no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin [FDA label]. 





', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aranesp 40mcg 4 pref. syringe', 14358, 'ارانيسب 40 ميكرو 4 حقن', '5,919', '3965', 'Hematopoietic.erythropoiesis-stimulating agent (esa)', 'Hematopoietic.erythropoiesis-stimulating agent (esa)', NULL, 'Darbepoetin alfa', 'Amgen > multipharma', 'Syringe', 'حقنة', '40mcg', '4', NULL, NULL, 'darbepoetin alfa is a synthetic form of erythropoietin. it stimulates erythropoiesis (increases red blood cell levels) and is used to treat anemia commonly associated with chronic renal failure and cancer chemotherapy.', NULL, 2214, '2024-11-08', NULL, 0, 'For the treatment of anemia (from renal transplants or certain HIV treatment)', 'Darbepoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin. Erythropoietin interacts with

progenitor stem cells to increase red cell production. Binding of erythropoietin to the erythropoietin receptor leads to receptor dimerization, which facilitates activation of JAK-STAT signaling pathways within the cytosol. Activated STAT (signal transducers and activators of transcription) proteins are then translocated to the nucleus where they serve as transcription factors which regulate the activation of specific genes involved in cell division or differentiation.', 'Darbepoetin alfa is used in the treatment of anemia. It is involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ronyca syrup120 ml', 4640, 'رونيكا شراب 120مل', '79', NULL, 'Dietry supplement', 'Dietry supplement', NULL, 'Vitamin D3 (cholecalciferol 150 IU) Calcium (calcium carbonate 300mg) Magnesium (magnesium hydroxide 150mg) Zinc (zinc gluconate 6mg) & other ingredients (Sucrose + Glycerin + Propylene glycol + With fruits & flavor + carboxymethylcellulose sodium + Polysorbate 80 + methylparaben sodium + Butylparaben sodium + Hydrochloric acid + Purified water)', NULL, 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, NULL, NULL, 1247, '2025-06-19', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Monicort cream 20 gm', 8288, 'مونيكورت كريم 20 جم', '24', '7', 'Antifungal with glucocorticoid', 'Antifungal with glucocorticoid', NULL, 'Hydrocortisone+miconazole', 'Pharopharma', 'Cream', 'كريم', '20 gm', '1', NULL, NULL, NULL, '6221094110077', 1742, '2025-03-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Occumycine eye drops 5 ml', 23926, 'اوكيومايسن قطرة عين 5 مل', '6', NULL, 'Antibiotic with glucocorticoid', 'Antibiotic with glucocorticoid', NULL, 'Chloramphenicol+dexamethasone', 'Pharco', 'Drops', 'نقط', '5 ml', '1', 'مضاد حيوي -- كورتيزون', NULL, 'about chloramphenicol bacteriostatic antibiotic a systemic broad ? spectrum antibacterial agent. mechanism of action of chloramphenicol chloramphenicol is a broad spectrum antibiotic which is primarily bacteriostatic & exerts some bactericidal action at h', NULL, 926, '2022-06-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Doloket 2.5% top. gel 15 gm', 17784, 'دولوكيت 2.5% جل 15 جرام', '5', NULL, 'Nsaid.propionic acid derivatives', 'Nsaid.propionic acid derivatives', NULL, 'Ketoprofen', 'Sigma', 'Gel', 'جل', '2.5%', '1', NULL, NULL, 'about ketoprofen nsaid propionic acid derivative analgesic antipyretic antiinflammatory. mechanism of action of ketoprofen it inhibits cyclo oxygenase enzymes both cox1 and cox2.these cyclooxygenase enzyme catalyses the synthesis of prostaglandins from ar', NULL, 966, '2022-07-15', NULL, 0, 'For symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, primary dysmenorrhea and mild to moderate pain associated with musculotendinous trauma (sprains and strains), postoperative (including dental surgery) or postpartum pain.', 'The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. ', 'Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cutistad 1% topical spray 40 ml', 3200, 'كوتيستاد 1% محلول سبراي 40 مل', '15', NULL, 'Antifungals.imidazoles', 'Antifungals.imidazoles', NULL, 'Clotrimazole', 'Global napi pharmaceuticals > stada', 'Spray', 'بخاخ', '1%', '1', NULL, NULL, 'how does it work? clotrimazole which is an antifungal medicine used to treat infections with fungi and yeasts. mechanism: clotrimazole kills fungi and yeasts by interfering with their cell membranes. it works by stopping the fungi from producing a substan', '6223002148851', 1881, '2023-02-06', NULL, 0, '**Topical preparations**



Clotrimazole topical cream is indicated for the topical treatment of the following dermal infections [F3088], [F3121]:



Tinea pedis, tinea cruris, and tinea corporis due to _Trichophyton rubrum_, _Trichophyton mentagrophytes_, _Epidermophyton floccosum_



Candidiasis due to _Candida albicans_



Tinea versicolor due to _Malassezia furfur_



Diaper rash infected by _Candida albicans_





In some preparations, clotrimazole may be combined with betamethasone dipropionate, a corticosteroid [F3121]. 



**Oral preparations**



The oral troche preparation is indicated for the local treatment of oropharyngeal candidiasis [FDA label].  It is also indicated as a prophylactic drug to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions such as chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation [FDA label]. Troche preparations are not indicated for the treatment of any systemic mycoses [FDA label].', 'Clotrimazole acts primarily by damaging the permeability barrier in the cell membrane of fungi. Clotrimazole causes inhibition of ergosterol biosynthesis, an essential constituent of fungal cell membranes. If ergosterol synthesis is either completely or partially inhibited, the cell is no longer able to construct an intact and functional cell membrane [F3088],[F3100]. Because ergosterol directly promotes the growth of fungal cells in a hormone‐like fashion, rapid onset of the above events leads to dose-dependent inhibition of fungal growth [A174094].



Though decreased ergosterol, due to the inhibition of lanosterol 14-demethylase (also known as _CYP51_) [A174094] is accepted to be primarily responsible for the antimycotic properties of clotrimazole, this drug also shows other pharmacological effects. These include the inhibition of sarcoplasmic reticulum Ca2+‐ATPase,  depletion of intracellular calcium, and blocking of calcium‐dependent potassium channels and voltage‐dependent calcium channels [A174094]. The action of clotrimazole on these targets accounts for other effects of this drug that are separate from its antimycotic activities [A174094].', 'Clotrimazole is a broad-spectrum antifungal agent that inhibits the growth of pathogenic yeasts by changing the permeability of cell membranes. The action of clotrimazole is fungistatic at concentrations of drug up to 20 mcg/mL and may be fungicidal _in vitro_ against Candida albicans and other species of the genus Candida at higher concentrations [FDA label]. Unfortunately, resistance to clotrimazole, which was rare in the past, is now common in various patient populations [A174094]. 



Clotrimazole is generally considered to be a fungistatic, and not a fungicidal drug, although this contrast is not absolute, as clotrimazole shows fungicidal properties at higher concentrations [A174094].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zinc-sedico 20mg/5ml pd. for oral sol', 29954, 'زنك سيديكو 20مجم/5مل باودر لعمل محلول بالفم', '8', NULL, 'Zinc supplement', 'Zinc supplement', NULL, 'Zinc', 'Sedico', 'Sol', 'محلول', '20mg', '1', NULL, NULL, NULL, NULL, 1001, '2022-06-16', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Glipizide-cid 5 mg 20 tab.', 19851, 'جليبيزيد سيد 5 مجم 20 قرص', '11', NULL, 'Anti-diabetic.secretagogues.sulfonylurea', 'Anti-diabetic.secretagogues.sulfonylurea', NULL, 'Glipizide', 'Cid', 'Tab', 'أقراص', '5 mg', '2', 'علاج مرضى السكري', NULL, NULL, '6223000011140', 1286, '2022-05-27', NULL, 0, 'Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.[label] ', 'Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with increasing prevalence worldwide. Characterized by higher-than-normal levels of blood glucose, T2DM is a complex disorder that arises from the interaction between genetic, environmental and behavioral risk factors. Insulin is a peptide hormone that plays a critical role in regulating blood glucose levels. In response to high blood glucose levels, insulin promotes the uptake of glucose into the liver, muscle cells, and fat cells for storage. Although there are multiple events occurring that lead to the pathophysiology of T2DM, the disorder mainly involves insulin insensitivity as a result of insulin resistance, declining insulin production, and eventual failure of beta cells of pancreatic islets that normally produce insulin.[A179554] Early management with lifestyle intervention, such as controlled diet and exercise, is critical in reducing the risk of long-term secondary complications, such as cardiovascular mortality.



Glipizide, like other sulfonylurea drugs, is an insulin secretagogue, which works by stimulating the insulin release from the pancreatic beta cells thereby increasing the plasma concentrations of insulin.[A177715] Thus, the main therapeutic action of the drug depends on the functional beta cells in the pancreatic islets.[L6739] Sulfonylureas bind to the sulfonylurea receptor expressed on the pancreatic beta-cell plasma membrane, leading to the closure of the ATP-sensitive potassium channel and reduced potassium conductance. This results in depolarization of the pancreatic beta cell and opening of the voltage-sensitive calcium channels, promoting calcium ion influx. Increased intracellular concentrations of calcium ions in beta cells stimulates the secretion, or exocytosis, of insulin granules from the cells.[label,T28] Apart from this main mechanism of action, the blood-glucose-lowering effect of glipizide involves increased peripheral glucose utilization via stimulating hepatic gluconeogenesis and by increasing the number and sensitivity of insulin receptors.[A177715]', 'Glipizide is a blood glucose-lowering agent. The initial onset of blood glucose-lowering effect occurs around 30 minutes post-administration with the duration of action lasting for about 12 to 24 hours.[L6739] While the chronic use of glipizide does not result in elevations in the fasting insulin levels over time, the postprandial insulin response, or insulin response to a meal, is observed to be enhanced, even after 6 months of treatment.[label] The main therapeutic actions of glipizide primarily occur at the pancreas where the insulin release is stimulated, but glipizide also mediates some extrapancreatic effects, such as the promotion of insulin signaling effects on the muscles, fat, or liver cells.[L6745] Due to its action on the endogenous cells, sulfonylureas including glipizide is associated with a risk for developing hypoglycemia and weight gain in patients receiving the drug.[A179554,T28] Chronic administration of glipizide may result in down-regulation of the sulfonylurea receptors on pancreatic beta cells, which are molecular targets of the drug, leading to a reduced effect on insulin secretion.[A177715] 



Like other sulfonylureas, glipizide may work on pancreatic delta (δ) cells and alpha (α) cells to stimulate the secretion of somatostatin and suppress the secretion of glucagon, which are peptide hormones that regulate neuroendocrine and metabolic pathways. Other than its primary action on the pancreas, glipizide also exerts other biological actions outside of the pancreas, or "extrapancreatic effects", which is similar to other members of the sulfonylurea drug class. Glipizide may enhance the glucose uptake into the skeletal muscles and potentiate the action of insulin in the liver. Other effects include inhibited lipolysis in the liver and adipose tissue, inhibited hepatic glucose output, and increased uptake and oxidation of glucose. It has also been demonstrated by several studies that the chronic therapeutic use of sulfonylureas may result in an increase in insulin receptors expressed on monocytes, adipocytes, and erythrocytes.[A177715]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Conafutal 500/600 mg 20 f.c.tabs.', 4160, 'كونافيوتال 500600مجم 20 قرص', '148', '103', 'Quinolone antibiotic with antiprotozoal', 'Quinolone antibiotic with antiprotozoal', NULL, 'Ciprofloxacin+tinidazole', 'Future pharmaceutical industries (fpi)', 'Tab', 'أقراص', '600 mg', '2', 'مضاد حيوى ومضاد للطفيليات', NULL, NULL, '6223004190629', 3451, '2024-07-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kabiven sol. for inf.', 21215, 'كابيفين محلول معقم للتنقيط الوريدي', '180', NULL, 'Sterile solution', 'Sterile solution', NULL, 'Amino acids+electrolytes+glucose (dextrose)+lipids', 'Fresenius kabi', 'Sol', 'محلول', NULL, '1', NULL, NULL, 'features 3-chamber bag with separate compartments providing a combination of amino acids lipid glucose and electrolytes. indications parenteral nutrition for patients and children above two years of age when oral or enteral nutrition is impossible insuffi', NULL, 962, '2022-08-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cholerose plus 5/10mg 28 f.c.tabs.', 16260, 'كوليروز بلس 5/10مجم 28 قرص', '120', '86', 'Antihyperlipidemic.statins', 'Antihyperlipidemic.statins', NULL, 'Ezetimibe+rosuvastatin', 'Marcyrl co.', 'Tab', 'أقراص', '10mg', '4', 'علاج ارتفاع الكوليستيرول في الدم', NULL, NULL, '6223003574987', 1224, '2024-08-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Haemokion 10mg/ml 3 amp.', 20172, 'هيموكيون 10 مجم / مل 3 امبولات', '36', '7.7', 'Vitamin k', 'Vitamin k', NULL, 'Vitamin k1', 'Amoun', 'Amp', 'أمبول', '10mg', '3', NULL, NULL, 'about vitamin k fat soluble vitamin antihemorrhagic. mechanism of action of vitamin k phytonadione (vitamin k1) is a synthetic form of vitamin k and is lipid soluble. vitamin k acts as a cofactor in the synthesis of coagulation proteins; prothrombin facto', '6221025007926', 2364, '2025-08-12', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cholestate 10mg 10 f.c. tabs.', 16265, 'كولستات 10 مجم 10 أقراص', '29', NULL, 'Antihyperlipidemic.statins', 'Antihyperlipidemic.statins', NULL, 'Pravastatin', 'Hi-pharm', 'Tab', 'أقراص', '10mg', '1', 'يعمل على خفض الدهون والكوليسترول بالجسم', NULL, 'about pravastatin sodium hmg-coa reductase inhibitor statins antilipemic. mechanism of action of pravastatin sodium it is an active hydrophilic statin which competitively inhibits the conversion of 3-hydroxy-3-methyl glutaryl coenzyme a (hmg coa) to meval', NULL, 1059, '2022-08-05', NULL, 0, 'Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.[T274]



As well, pravastatin can be used as a secondary prevention agent for cardiovascular events in patients with clinically evident coronary heart disease. This indication includes the reduction of risk of total mortality by reducing coronary death, myocardial infarction, undergoing myocardial revascularization procedures, stroke, and stroke/transient ischemic attack as well as to slow the progression of coronary atherosclerosis.[T274]



The term cardiovascular events correspond to all the incidents that can produce damage to the heart muscle including the interruption of blood flow.[L6028]



As adjunctive therapy to diet, pravastatin is used in:



- Patients with primary hypercholesterolemia and mixed dyslipidemias including hyperlipidemia type IIa and IIb.

- Patients with elevated serum triglycerides including type IV hyperlipidemia.

- Patients with heterozygous familial hypercholesterolemia in patients over 8 years of age with low-density lipoprotein (LDL) cholesterol higher than 190 mg/dl after diet modifications or LDL levels higher than 160 mg/dl and familial history of premature cardiovascular diseases or at least two cardiovascular risk factors.[T274]



In patients that do not respond adequately to diet, pravastatin is used to treat patients with primary dysbetalipoproteinemia (type III hyperlipidemia).[T274] 



Dyslipidemia is defined as an elevation of plasma cholesterol, triglycerides or both as well as to the presence of low levels of high-density lipoprotein. This condition represents an increased risk for the development of atherosclerosis.[L6025]', 'Pravastatin is a specific inhibitor of the hepatic HMG-CoA reductase in humans.[T274] The inhibition of this enzyme produces a reduction in cholesterol biosynthesis as HMG-CoA reductase activity is an early-limiting step in cholesterol biosynthesis.[A177397]



The inhibitory mechanism of action produces a reduction in cholesterol synthesis which in order has been observed to increase the number of LDL receptors on cell surfaces and an enhancement in receptor-mediated metabolism of LDL and clearance.[A177415]



On the other hand, pravastatin-driven inhibition of LDL production inhibits hepatic synthesis of VLDL as the LDL is the precursor for these molecules.[A177436]', 'The action of pravastatin on the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase produces an increase in the expression of hepatic LDL receptors which in order decreases the plasma levels of LDL cholesterol.[T274]



The effect of pravastatin has been shown to significantly reduce the circulating total cholesterol, LDL cholesterol, and apolipoprotein B. As well, it modestly reduces very low-density-lipoproteins (VLDL) cholesterol and triglycerides while increasing the level of high-density lipoprotein (HDL) cholesterol and apolipoprotein A.[F4603]



In clinical trials with patients with a history of myocardial infarction or angina with high total cholesterol, pravastatin decreased the level of total cholesterol by 18%, decreased of LDL by 27%, decreased of triglycerides by 6% and increased of high-density lipoprotein (HDL) by 4%. As well, there was reported a decrease in risk of death due to coronary disease of 24%.[A177682] 



When coadministered with [cholestyramine], pravastatin can reduce by 50% the levels of LDL and slow the progression of atherosclerosis and the risk of myocardial infarction and death.[T274]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Esmatac 40 mg 14 d.r. caps.', 4395, 'ازماتاك 40مجم 14 كبسولة', '72', '42', 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Esomeprazole', 'Egpi', 'Cap', 'كبسولة', '40 mg', '2', 'قرحة المعدة والحموضة', NULL, NULL, '6223003930905', 15635, '2024-07-14', NULL, 0, 'Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome. ', 'Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole''s duration of antisecretory effect that persists longer than 24 hours.[FDA Label]

', 'Esomeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and <i>H. pylori</i> eradication to reduce the risk of duodenal ulcer recurrence. Esomeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup> ATPase at the secretory surface of the gastric parietal cell. By doing so, it inhibits acid secretion into the gsatric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.



Esomeprazole is the s-isomer of [DB00338], which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as [DB00338], without any significant differences between the two compounds _in vitro_. 



PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.[A177577, A177580]



Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as esomeprazole has been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.[A177571]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rubivamin 1000mcg 5 amp.', 26393, 'روبيفامين 1000مكجم 5 امبولات', '43', '27.5', 'Vitamin b', 'Vitamin b', NULL, 'Cyanocobalamine', 'Misr', 'Amp', 'أمبول', '1000mcg', '5', 'مصدر لفيتامين ب', NULL, NULL, '6221035016185', 3270, '2024-04-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nouvelle oral gel 30 gm', 23763, 'نوفل جل بالفم 30 جم', '40', NULL, 'Oral care', 'Oral care', NULL, 'Tea tree oil+glycerin+vitamin c+chamomile+pepperment oil+sodium fluoride', 'Hi-care > smart marketing', 'Gel', 'جل', '30 gm', '1', 'جل مطهر للفم -- يقلل الرائحة الكريهة -- يقلل الالتهابات الاسنان واللثة -- يقلل الالام الاسنان واللثة', NULL, NULL, NULL, 1213, '2023-07-15', NULL, 0, 'Indicated for topical use to help protect against infection in minor cuts, scrapes, and burns. No FDA-approved therapeutic indications.', 'The components of tea tree oil, particularly terpinen-4-ol and α-terpineol, mediate antimicrobial actions by disrupting the structural and functional integrity of bacterial membrane. Hydrocarbons are capable of partitioning into the cell and cytoplasmic membrane of microorganisms and disrupt their vital functions, which may result in leakage of ions such as potassium, and the inhibition of respiration [A32439]. Eventually, cell lysis may occur due to weakening of the cell wall, and loss of turgor pressure and subsequent rupture of the cytoplasmic membrane [A32441]. The loss of 260-nm-absorbing material may be indicative of a damaged cytoplasmic membrane and loss of nucleic acids [A32441]. In _E. coli_, perturbed potassium homeostasis, glucose-dependent respiration, cell morphology, and ability to exclude propidium iodide was observed. 



Tea tree oil also mediates its antifungal actions in a similar way, where it alters the permeability of Candida albicans and inhibits its respiration in a dose-dependent manner [A32439]. Plasma and mitochondrial membranes of fungal species are also thought to be negatively affected by inhibition of glucose-induced medium acidification by tea tree oil, which involves inhibition of membrane ATPase responsible for the expulsion of protons [A32439]. Tea tree oil also inhibits the formation of germ tubes, or mycelial conversion, in _C. albicans_, thereby disrupting cell morphogenesis [A32439]. Water-soluble fraction of TTO, terpinen-4-ol, and α-terpineol, can inhibit the lipopolysaccharide-induced production of the inflammatory mediators such as TNF-α, IL-1β and IL-10 by human peripheral monocytes by approximately 50% and that of prostaglandin E2 by about 30% after 40 h [A32439]. These components of tea tree oil may also suppress superoxide production by agonist-stimulated monocytes and decrease the production of reactive oxygen species by both stimulated neutrophils and monocytes [A32439].', 'Tea tree oil exhibits antibacterial, antifungal, antiviral, and antiprotozoal activities [A32439]. It mostly mediates bactericidal actions at concentrations of 1.0% or less in most bacteria such as _Staphylococcus aureus_ and _Escherichia coli_, and causes bacteriostatic effects at lower concentrations [A32439]. Organisms such as commensal skin staphylococci and micrococci, _Enterococcus faecalis_, and Pseudomonas aeruginosa_emphasized text_ were susceptible to tea tree oil concentrations of 2% [A32439]. It is proposed that water-soluble components of tea tree oil are capable in inducing anti-inflammatory actions; terpinen-4-ol attenuates the vasodilation and plasma extravasation associated with histamine-induced inflammation in humans [A32438].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lorvinomega 1000mg 20caps', 13866, 'لورفينوميجا 1000مجم 20 كبسولة', '150', NULL, 'Multivitamin', 'Multivitamin', NULL, 'Omega 3+eba+dha', 'Bio top pharma', 'Cap', 'كبسولة', '1000mg', '2', 'اوميجا لتقوية الذاكرة وتجديد نشاط الجسم', NULL, NULL, '6224002637031', 2120, '2022-09-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Opiraline 100mg 10 f.c.tab.', 24147, 'اوبيرالين 100مجم 10 اقراص', '32', NULL, 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Sertraline', 'El-obour', 'Tab', 'أقراص', '100mg', '1', NULL, NULL, 'about sertraline selective serotonin reuptake inhibitor (ssri) antidepressant antidepressant mechanism of action of sertraline sertraline blocks the re-uptake of neurotransmitter serotonin from the synapse in to the presynaptic nerve terminal in the cns.', '6223004600104', 836, '2022-12-07', NULL, 0, 'Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]

', 'Sertraline selectively inhibits the reuptake of serotonin (5-HT) at the presynaptic neuronal membrane, thereby increasing serotonergic activity. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission.[T28,L9016] These changes are believed to be responsible for the antidepressant action and beneficial effects in obsessive-compulsive (and other anxiety related disorders). It has been hypothesized that obsessive-compulsive disorder, like depression, is also caused by the disregulation of serotonin.[A187165]



In animal studies, chronic administration of sertraline results in down-regulation of brain norepinephrine receptors.[L9016] Sertraline displays affinity for sigma-1 and 2 receptor binding sites[A31941], but binds with stronger affinity to sigma-1 binding sites.[A31940] In vitro, sertraline shows little to no affinity for GABA, dopaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors.[L9016] It exerts weak inhibitory actions on the neuronal uptake of norepinephrine and dopamine[A1844] and exhibits no inhibitory effects on the monoamine oxidase enzyme.[L9016]', 'Sertraline improves or relieves the symptoms of depression, OCD, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder via the inhibition of serotonin reuptake.[A187075,L9016] Clinical studies have shown that it improves cognition in depressed patients.[A1846] It has less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not exert significant anticholinergic, antihistamine, or adrenergic (alpha1, alpha2, beta) blocking activity.[A1844] The onset of action and beneficial effects are usually noticed after 4-6 weeks, for reasons that are not fully understood and currently under investigation.[A188493,L10677]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Polysaccharide meningococcal a+c vaccine 50mcg/0.5ml (50doses) vial', 25051, 'بوليساكرايد مينينجوكوكال لقاح 50مكجم/0.5مل امبول', '250', NULL, 'Vaccine', 'Vaccine', NULL, 'Vaccine meningitis (group a+c)', 'Sanofi pasteur-france > etimex-egypt', 'Vial', 'فيال', '50mcg', '1', NULL, NULL, NULL, NULL, 890, '2022-07-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Amoflux 500mg vial', 612, 'اموفلوكس 500مجم فيال', '6', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Penicillins.penicillin with b-lactamase inhibitor', NULL, 'Amoxicillin+flucloxacillin', 'Rameda > delta pharma', 'Vial', 'فيال', '500mg', '1', 'مضاد حيوي', NULL, NULL, NULL, 1119, '2022-10-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hybisc 20 f.c. tab.', 20588, 'هاي بيسك 20 قرص', '17', NULL, NULL, NULL, NULL, 'Hibiscus sabdariffa', 'Sigma > pharma net', 'Tab', 'أقراص', NULL, '1', NULL, NULL, NULL, '6221051810439', 951, '2022-12-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Carlol-v 12.5mg 10 f.c.tab.', 2101, 'كارلول-في 12.5مجم 10 قرص', '8', NULL, 'Antihypertensive.beta blocker.unselective', 'Antihypertensive.beta blocker.unselective', NULL, 'Carvedilol', 'Amoun', 'Tab', 'أقراص', '12.5mg', '1', NULL, NULL, 'about carvedilol beta blocker with alpha- adrenergic blocking activity antihypertensive and anti angina. mechanism of action of carvedilol carvedilol is an adrenergic antagonist capable of blocking alpha-1 beta-1 and beta-2 receptors. it produces vasodila', '6221025019103', 998, '2022-12-03', NULL, 0, 'Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.[L7889,L7892]', 'Carvedilol inhibits exercise induce tachycardia through its inhibition of beta adrenoceptors.[A182306] Carvedilol''s action on alpha-1 adrenergic receptors relaxes smooth muscle in vasculature, leading to reduced peripheral vascular resistance and an overall reduction in blood pressure.[A1929,A182306] At higher doses, calcium channel blocking and antioxidant activity can also be seen.[A1929] The antioxidant activity of carvedilol prevents oxidation of low density lipoprotein and its uptake into coronary circulation.[A1929]', 'Carvedilol reduces tachycardia through beta adrenergic antagonism and lowers blood pressure through alpha-1 adrenergic antagonism.[L7889,L7892] It has a long duration of action as it is generally taken once daily and has a broad therapeutic index as patients generally take 10-80mg daily.[L7889,L7892] Patients taking carvedilol should not abruptly stop taking this medication as this may exacerbate coronary artery disease.[L7889,L7892]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Re-vital hair shampoo 250 ml', 25958, 'ريفيتال شامبو للشعر 250مل', '120', '60', 'Hair care', 'Hair care', NULL, NULL, 'Mash premiere', 'Amp', 'أمبول', '250 ml', '1', NULL, NULL, NULL, '6222001404487', 656, '2024-02-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nifunal 4% susp. 90 ml', 23583, 'نيفيونال 4% معلق 90 مل', '9', NULL, 'Antidiarrheal', 'Antidiarrheal', NULL, 'Nifuroxazide', 'Amriya', 'Susp', 'معلق', '4%', '1', NULL, NULL, NULL, '6221075020784', 905, '2022-12-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Epinor 400mg 14 tab.', 4285, 'ابينور 400مجم 14 قرص', '35', '21.6', 'Antibiotic.quinolone', 'Antibiotic.quinolone', NULL, 'Norfloxacin', 'Eipico', 'Tab', 'أقراص', '400mg', '2', 'مضاد حيوي.', NULL, 'about norfloxacin a synthetic second generation synthetic fluoroquinolone (quinolone) broad spectrum antibiotic. mechanism of action of norfloxacin norfloxacin is a bacteriostatic at low concentration and bactericidal at high concentration. it act by inhi', '6221032112170', 3698, '2025-08-11', NULL, 0, 'For the treatment of urinary tract infection', 'The bactericidal action of Norfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. Norfloxacin is a broad-spectrum antibiotic agent that is shown to be effective against various Gram-positive and Gram-negative bacterial species. The fluorine atom at the 6 position increases potency against gram-negative organisms, and the piperazine moiety at the 7 position is responsible for anti-pseudomonal activity', 'Norfloxacin is a quinolone/fluoroquinolone antibiotic. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Amiprostone 8mcg 20 caps', 13951, 'اميبروستون 8مكجم 20 كبسولة', '90', '66', 'Laxative', 'Laxative', NULL, 'Lubiprostone', 'Andalous pharma', 'Cap', 'كبسولة', '8mcg', '2', NULL, NULL, NULL, '6223004690105', 2481, '2025-01-23', NULL, 0, 'Lubiprostone is indicated for the treatment of adult patients with chronic idiopathic constipation, or opioid-induced constipation in patients with chronic non-cancer pain.[L4421] It is also indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in female patients ≥18 years old.[L4421]', 'Lubiprostone acts by specifically activating ClC-2 chloride channels, which is a normal constituent of the apical membrane of the human intestine, in a protein kinase A action independent fashion. Activation of ClC-2 chloride channels causes an efflux of chloride ions into the lumen, which in turn leads to an efflux of sodium ions through a paracellular pathway to maintain isoelectric neutrality. As a result, water follows sodium into the lumen in order to maintain isotonic equilibrium, thereby increasing intestinal fluid secretion. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby increasing the passage of stool and alleviating symptoms associated with chronic idiopathic constipation. Activation of ClC-2 chloride channels may also stimulate the recovery of muscosal barrier function by restoring tight junction protein complexes in the intestine. Patch clamp cell studies in human cell lines have indicated that the majority of the beneficial biological activity of lubiprostone and its metabolites is observed only on the apical (luminal) portion of the gastrointestinal epithelium.', 'Chronic idiopathic constipation is generally defined by infrequent or difficult passage of stool. The signs and symptoms associated with chronic idiopathic constipation (i.e., abdominal pain or discomfort, bloating, straining, and hard or lumpy stools) may be the result of abnormal colonic motility that can delay the transit of intestinal contents and impede the evacuation of rectal contents. One approach to the treatment of chronic idiopathic constipation is the secretion of fluid into the abdominal lumen through the activation of chloride channels in the apical membrane of the gastrointestinal epithelium. Lubiprostone is a locally acting chloride channel activator that increases intestinal chloride and fluid secretion without altering sodium and potassium concentrations in the serum.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nyolol 0.1% eye gel 5gm', 9104, 'نيولول 0.1% جل للعين 5 جم', '19', NULL, 'Antihypertensive.beta blocker.unselective', 'Antihypertensive.beta blocker.unselective', NULL, 'Timolol', 'Novartis', 'Gel', 'جل', '0.1%', '1', NULL, NULL, NULL, '7680549740778', 844, '2022-12-07', NULL, 0, ' Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure.[L6724,L6727] In certain cases, timolol is used in the prevention of migraine headaches.[A179530,L6742] ', 'Timolol competes with adrenergic neurotransmitters for binding to beta(1)-adrenergic receptors in the heart and the beta(2)-receptors in the vascular and bronchial smooth muscle. This leads to diminished actions of catecholamines, which normally bind to adrenergic receptors and exert sympathetic effects leading to an increase in blood pressure and heart rate.[A179521] Beta(1)-receptor blockade by timolol leads to a decrease in both heart rate and cardiac output during rest and exercise, and a decrease in both systolic and diastolic blood pressure.[A179524,A179527] In addition to this, a reduction in reflex orthostatic hypotension may also occur. The blockade of beta(2) receptors by timolol in the blood vessels leads to a decrease in peripheral vascular resistance, reducing blood pressure.[L6724,L6727,L6733]



The exact mechanism by which timolol reduces ocular pressure is unknown at this time, however, it likely decreases the secretion of aqueous humor in the eye.[L6730] According to one study, the reduction of aqueous humor secretion may occur through the decreased blood supply to the ciliary body resulting from interference with the active transport system or interference with prostaglandin biosynthesis.[A179515]', 'Timolol, when administered by the ophthalmic route, rapidly reduces intraocular pressure. When administered in the tablet form, it reduces blood pressure, heart rate, and cardiac output, and decreases sympathetic activity.[A179506,A179509,A179512,L6727]. This drug has a fast onset of action, usually occurring within 20 minutes of the administration of an ophthalmic dose. Timolol maleate can exert pharmacological actions for as long as 24 hours if given in the 0.5% or 0.25% doses.[L6757]



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Swisslac premium 1 milk 400 gm', 9281, 'سويسلاك بريميوم ايه ار لبن اطفال 400 جم', '330', '315', 'Milk products.anti-regurgitation milk', 'Milk products.anti-regurgitation milk', NULL, 'Milk formula', 'Pharmalys laboratories > eagles international co.', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, 'not to replace mother s milk. for infants from birth to 6 months age. to be used within one month from opening.', '8715845004671', 1155, '2025-07-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ketoked cream 60 gm', 32340, 'كوتيكيد كريم 60 جرام', '55', '48', 'Soothing cream', 'Soothing cream', NULL, 'Zinc oxide+chamomile oil+cod liver oil+panthenol+calendula extract+green tea extract', 'E.c.c > megamed', 'Cream', 'كريم', '60 gm', '1', 'كريم ترطيب وتغذية البشرة غنى بالفيتامينات ومضادات الاكسدة', NULL, NULL, NULL, 950, '2024-02-18', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Defucin h topical cream 60 gm (n/a)', 6946, 'ديفيوسين اتش كريم 60 جم', '51', NULL, 'Glucocorticoid with antibiotic', 'Glucocorticoid with antibiotic', NULL, 'Hydrocortisone+fusidic acid', 'Debeiky', 'Cream', 'كريم', '60 gm', '1', NULL, NULL, NULL, NULL, 697, '2025-08-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Colona 30 f.c.tab', 16659, 'كولونا 30 قرص للقولون', '69', '45', 'Colon.antispasmodic', 'Colon.antispasmodic', NULL, 'Mebeverine+sulpiride', 'Rameda', 'Tab', 'أقراص', NULL, '3', 'علاج اضطرابات القولون وتهيجه.', NULL, NULL, '214403974145', 17792, '2024-06-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mustela vitamin barrier cream 100ml', 23142, 'موستلا كريم مانع بالفيامينات 100 مل', '199', NULL, 'Baby care', 'Baby care', NULL, 'Avocado perseose+alcacea oxeoline+sunflower oil', 'Laboratoires expanscience-france > biotech egypt', 'Cream', 'كريم', '100ml', '1', NULL, NULL, 'fragile and delicate your baby s bottom is exposed to constant stresses and can easily become irritated. after 10 years of research and fundamental discoveries about babies skin mustela has revolutionized skin care for the diaper area with its new 1>2>3 v', NULL, 620, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Levocitrone 5 mg 10 f.c. tab.', 21754, 'ليفوسيترون 5 مجم 10 اقراص', '21', '10.5', 'Antihistamine.non-sedative.third-generation', 'Antihistamine.non-sedative.third-generation', NULL, 'Levocetirizine', 'Egyphar', 'Tab', 'أقراص', '5 mg', '1', 'مضاد للحساسية ويستخدم فى تخفيف اعراض الحساسية مثل دموع العين، وسيلان الأنف، والحكة،', NULL, NULL, '6224001026744', 1902, '2024-05-27', NULL, 0, 'Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria.[L7694] It is also used over the counter for a variety of mild allergy symptoms.[A181748]', 'Levocetirizine selectively inhibits histamine H<sub>1</sub> receptors.[L7694] This action prevents histamine from activating this receptor and causing effects like smooth muscle contraction, increased permeability of vascular endothelium, histidine uptake in basophils, stimulation of cough receptors, and stimulation of flare responses in the nervous system.[A181790]', 'Levocetirizine is a second generation histamine H<sub>1</sub> antagonist used to treat various allergic symptoms.[A181748,A181790,L7694] It has a long duration of action as it is generally taken once daily, and a wide therapeutic window as animal studies show the maximal nonlethal dose is over 100x a normal dose.[L7694] Patients are cautioned to avoid tasks that require complete alertness, avoid alertness, and use caution in patients with factors predisposing urinary retention.[L7694]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Univit for men 14 cap', 11937, 'يونيفيت للرجال 14 كبسولة', '14', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Vitamins', 'Unipharma co.', 'Cap', 'كبسولة', NULL, '2', 'فيتامينات للرجال -- مصدر للطاقة -- مقوي للاعصاب -- مقوي للمناعة -- مضاد للاكسدة', NULL, NULL, NULL, 5254, '2023-02-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Chirocaine 7.5 mg/ml 10 amp.', 16239, 'شيروكائين 7.5 مجم / مل 10 امبول', '399', NULL, 'Local anaesthetic', 'Local anaesthetic', NULL, 'Levobupivacaine', 'Abbvie ltd. > multipharma', 'Amp', 'أمبول', '7.5 mg', '10', NULL, NULL, 'levobupivacaine is a local anaesthetic drug belonging to the amino amide group. it is the s-enantiomer of bupivacaine. compared to bupivacaine levobupivacaine is associated with less vasodilation and has a longer duration of action. it is approximately 13', NULL, 633, '2022-08-03', NULL, 0, 'For the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management', 'Local anesthetics such as Levobupivacaine block the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers. Specifically, the drug binds to the intracellular portion of sodium channels and blocks sodium influx into nerve cells, which prevents depolarization.', 'Levobupivacaine, a local anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Capecitabine-viatris 500 mg 120 tabs.', 30263, 'كابيسيتابين فيتاريس 500مجم 120 قرص', '4,320', '2819', 'Antineoplastic', 'Antineoplastic', NULL, 'Capecitabine', 'Mylan s.a.s > one pharma tech', 'Tab', 'أقراص', '500 mg', '12', NULL, NULL, 'indications: -colorectal cancer. -breast cancer.', NULL, 1970, '2025-02-04', NULL, 0, 'Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer.[L44657] For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy.[L44657] For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease.[L44657] Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.[L44657]', 'Capecitabine is metabolized to 5-fluorouracil in vivo by carboxylesterases, cytidine deaminase, and thymidine phosphorylase/uridine phosphorylase sequentially.[L44657,A256027,A256142,A256147,A32078] 5-fluorouracil is further metabolized through a series of enzymatic reactions into 3 main active metabolites: 5-fluorouridine triphosphate (5-FUTP), 5-fluoro-2’-deoxyuridine monophosphate (5-FdUMP), and 5-fluorodeoxyuridine triphosphate (5-FdUTP).[A256062,A256027,A256077]. These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate (CH<sub>2</sub>THF), bind to thymidylate synthase (TS) to form a covalently bound ternary complex.[L44657] TS is an enzyme that catalyzes the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP).[A256152,A256077] Under normal physiological conditions, dUMP binds to TS first before CH<sub>2</sub>THF, followed by a 1,4 or Michael addition from the pyrimidine C (6)atom to the Cys146 nucleophile.[A256152,A256157] If correctly positioned, dUMP, CH<sub>2</sub>THF, and TS would form a ternary complex to facilitate the donation of the methyl group from CH<sub>2</sub>THF to dUMP.[A256152] However, the substitution of dUMP with FdUMP results in a new time-dependent TS–FdUMP–CH2THF complex. Since the fluorine group prevents dissociation of FdUMP from the pyrimidine ring, the whole complex is rendered irreversibly deactivated, terming this reaction "suicide inhibition".[A256152,A256162] TS inhibition prevents the conversion of dUMP to dTMP, depleting the pool of dTMP that could be phosphorylated into dTTP to be incorporated as DNA nucleotides. This disrupts the nucleotides balance, particularly the the ATP/dTTP ratio, thus impairing DNA synthesis and repair and causing apoptosis.[A256167,A256152] 



5-FdUMP can also be phosphorylated into 5-FdUTP, further increasing the pool of dUTP base to potentially overwhelm the activity of dUTPase.[A256177] Coupled with the decrease in dTTP, 5-FdUMP, and 5-FdUTP increase the probability of mistakenly incorporating a uracil base into DNA strands in place of thymine. Although this mistake can often be resolved by the nucleotide excision repair enzyme uracil-DNA-glycosylase (UDG), the high (F)dUTP/dTTP ratio would result in re-incorporation of uracil into DNA, leading to a futile cycle of misincorporation, excision, and repair.[A256172,A841] Repeated base excision repair can result in abasic sites, which can lead to DNA mutagenesis and thus protein miscoding, replication forks collapse, and DNA fragmentation through single or double strand breaks [A256177,A256182,A256187,A256192] 



However, several reports have found that the incorporation of uracil in genomic DNA does not significantly affect the cytotoxicity of 5-FU, suggesting that the cytotoxic effect of 5-FU is dominated by the perturbation of RNA through 5-FUTP.[A256197,A256202] Similar to 5-dFUTP, 5-FUTP can be mistakenly incorporated into RNA in place of regular UTP and disrupt regular RNA biology through various mechanisms. 5-FUTP can be incorporated into the spliceosomal U2 snRNA at pseudouridylated sites to prevent further pseudouridylation and thus pre-mrNA splicing. 5-FUTP can also change the structure of U4 and U6 snRNA and reduce the turnover rate of U1 snrNA once incorporated.[A256207] For tRNA, 5-FUTP can affect tRNA''s post-transcriptional RNA modifications activity, particularly by inhbiting pseudouridine synthase through formation of covalent complex.[A256212,A256217] Recently, the effect of 5-FUTP on miRNAs and lncRNA was also observed through profound changes in expression, although the precise mechanism is still unknown.[A256222,A256227,A256232]



Although the main mechanism of 5-FU cytotoxicity was thought to be attributed to DNA damages, recent reports have shown that the majority of 5-FU pharmacological action is mediated through RNA, since 5-FU is accumulated ~3000- to 15 000-fold more in RNA compared to that of DNA.[A256237] 

', 'Capecitabine is a fluoropyrimidine carbamate belonging to a group of antineoplastic agents called antimetabolites, which kill cancerous cells by interfering with DNA synthesis.[A256242,A841] It is an orally administered systemic prodrug that has little pharmacologic activity until it is converted to 5-fluorouracil (5-FU) by enzymes that are expressed in higher concentrations in many tumors.[A256247] Capecitabine was designed specifically to overcome the disadvantages of 5-FU and to mimic the infusional pharmacokinetics of 5-FU without the associated complexity and complications of central venous access and infusion pumps.[A256242] Particularly, since the enzymes converting 5-FU into active metabolites exist in the gastrointestinal tract, infusion of 5-FU can have gastrointestinal toxicity while also losing efficacy.[A256252] Since capecitabine can be transported intact across the intestinal mucosa, it can be selectively delivered 5-FU to tumor tissues through enzymatic conversion preferentially inside tumor cells.[A256252]



5-FU exerts its pharmacological action through the inhibition and interference of 3 main targets: thymidylate synthase, DNA, and RNA, leading through protein synthesis disruption and apoptosis.[A841,A256152] Population-based exposure-effect analyses demonstrated a positive association between AUC of 5-FU and grade 3-4 hyperbilirubinemia.[L44657]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Inspago 25 mg 14 f.c.tabs', 6494, 'انسباجو 25 مجم 7 اقراص', '74', NULL, 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Agomelatine', 'Al rowad pharmaceutical industrial co.', 'Tab', 'أقراص', '25 mg', '1', NULL, NULL, NULL, '6224000866280', 1288, '2022-12-06', NULL, 0, 'Agomelatine is indicated to treat major depressive episodes in adults.', 'The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors.', 'Agomelatine resynchronises circadian rhythms in animal models of delayed sleep phase syndrome and other circadian rhythm disruptions. It increases noradrenaline and dopamine release specifically in the frontal cortex and has no influence on the extracellular levels of serotonin. Agomelatine has shown an antidepressant-like effect in animal depression models, (learned helplessness test, despair test, and chronic mild stress) circadian rhythm desynchronisation, and in stress and anxiety models. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset. Controlled studies in humans have shown that agomelatine is as effective as the SSRI antidepressants paroxetine and sertraline in the treatment of major depression', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Verdex sypo clear cleansing gel 200 ml', 29157, 'فيردكس سيبو كلير جل 200مل', '170', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Egoteck srl > macro group pharmaceuticals', 'Gel', 'جل', '200 ml', '1', NULL, NULL, 'soft cleansing gel type with its purifing tooning and soothing action for oily & combination skin', NULL, 673, '2022-07-30', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Maxfan 10 sachets', 22382, 'ماكسفان 10 اكياس', '69', NULL, 'Iron supplement', 'Iron supplement', NULL, 'Lactoferrin+whey protein+milk protein+cocoa powder+sucrose+lecithin+vitamin(a+b1+b2+b6+c+d3+e)+calcium+iron+zinc', 'Dawaa pharma', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, NULL, NULL, 698, '2022-07-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vito care n cream 25 gm', 29536, 'فيتو كير ان كريم 100جم', '40', NULL, 'Moisturizing topicals', 'Moisturizing topicals', NULL, NULL, 'Leader cosmetics > et group (extra tech)', 'Cream', 'كريم', '25 gm', '1', NULL, NULL, 'extra emollient cream for severe cracked skin', NULL, 1063, '2022-07-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Carcemia 400mg 10tabs.', 15834, 'كارسيميا 400مجم 10 اقراص', '942', '723', 'Tyrosine- kinase inhibitor', 'Tyrosine- kinase inhibitor', NULL, 'Imatinib', 'Hikma specialized pharmaceuticals', 'Tab', 'أقراص', '400mg', '1', 'علاج الاورام', NULL, NULL, NULL, 5044, '2025-02-09', NULL, 0, 'Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.[L42080] Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferative diseases, adult aggressive systemic mastocytosis, adult hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), adult dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).[L42080]

', 'Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutively active tyrosine kinase created by the Philadelphia chromosome abnormality in CML.[L42080]Although the function of normal BCR is still unclear, ABL activation is overexpressed in various tumors and is heavily implicated in cancer cells growth and survival.[A249305,A249310] Imatinib inhibits the BCR-ABL protein by binding to the ATP pocket in the active site, thus preventing downstream phosphorylation of target protein.[A249305]



Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor

(SCF), c-Kit, and inhibits PDGF- and SCF-mediated cellular events. In vitro, imatinib inhibits proliferation and induces

apoptosis in GIST cells, which express an activating c-Kit mutation.[L42080]', 'Imatinib is a 2-phenylaminopyrimidine derivative neoplastic agent that belongs to the class of tyrosine kinase inhibitors.[L42080] Although imatinib inhibits a number of tyrosine kinases, it is quite selective toward the BCR-ABL fusion protein that is present in various cancers.[A249305] BCR-ABL pathway controls many downstream pathways that are heavily implicated in neoplastic growth such as the Ras/MapK pathway (cellular proliferation), Src/Pax/Fak/Rac pathway (cellular motility), and PI/PI3K/AKT/BCL-2 pathway (apoptosis pathway).[A249290, A249295, A249300] Therefore, the BCR-ABL pathway is an attractive target for cancer treatment. Although normal cells also depend on these pathways for growth, these cells tend to have redundant tyrosine kinases to continually function in spite of ABL inhibition from imatinib.[A943] Cancer cells, on the other hand, can have a dependence on BCR-ABL, thus more heavily impacted by imatinib.[A943]

 ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Xiloial eye drops 10 ml', 29750, 'زيلويال قطرة عين 10 مل', '235', '206', 'Eye lubricant', 'Eye lubricant', NULL, 'Sodium hyaluronate', 'Farmigea > marcyrl co.', 'Drops', 'نقط', '10 ml', '1', 'مرطب للعين -- تقليل الحساسية والالتهابات بالعين', NULL, 'ï- xiloial is an ophthalmic solution with ts-polysaccharide (tsp) and high-molecular weight sodium hyaluronate obtained by biotechnological synthesis. ï- sodium hyaluronate is a substance that originates mucomimetic solutions with optimal lubricant proper', '8032668871724', 2705, '2024-05-11', NULL, 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rabies vaccine', 25612, 'لقاح السعار', '198', NULL, 'Vaccine', 'Vaccine', NULL, 'Rabies vaccine', 'Vacsera', 'Unknown', 'غير محدد', NULL, '1', 'لقاح السعار', NULL, NULL, '3178048246746', 939, '2022-12-08', NULL, 0, 'Inactivated rabies virus antigen B is indicated for pre- and post-exposure prophylaxis against rabies.[L12795]', NULL, NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Icon hair cream 120 ml', 31835, 'ايكون كريم للشعر 120 مل', '150', NULL, 'Hair care', 'Hair care', NULL, 'Keratin+biotin+caffeine+vitamins(a+c+e)', '> icon cosmetic products', 'Cream', 'كريم', '120 ml', '1', NULL, NULL, NULL, NULL, 368, '2023-03-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Valcyte 450 mg 60 f.c. tab', 28911, 'فالسايت 450 مجم 60 قرص', '22,950', '15800', 'Antiviral', 'Antiviral', NULL, 'Valganciclovir', 'F.hoffman la roche', 'Tab', 'أقراص', '450 mg', '1', 'مضاد للفيروسات', NULL, NULL, NULL, 4743, '2024-07-11', NULL, 0, 'Valganciclovir is an antiviral medication used for the treatment of cytomegalovirus infections.', 'Valganciclovir is a prodrug of ganciclovir that exists as a mixture of two diastereomers. After administration, these diastereomers are rapidly converted to ganciclovir by hepatic and intestinal esterases. In cytomegalovirus (CMV)-infected cells, ganciclovir is initially phosphorylated to the monophosphate form by viral protein kinase, then it is further phosphorylated via cellular kinases to produce the triphosphate form. This triphosphate form is slowly metabolized intracellularly. The phosphorylation is dependent upon the viral kinase and occurs preferentially in virus-infected cells. The virustatic activity of ganciclovir is due to the inhibition of viral DNA synthesis by ganciclovir triphosphate. Ganciclovir triphosphate is incorporated into the DNA strand replacing many of the adenosine bases. This results in the prevention of DNA synthesis, as phosphodiester bridges can longer to be built, destabilizing the strand. Ganciclovir inhibits viral DNA polymerases more effectively than it does cellular polymerase, and chain elongation resumes when ganciclovir is removed.', 'Valganciclovir is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. After this, it (being an analogue of guanosine) gets incorporated into DNA and thus cannot be properly read by DNA polymerase. This results in the termination of the elongation of viral DNA.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vanisca gel 50 gm', 32212, 'فانيسكا جل 50 جم', '475', '450', 'Gel', 'Gel', NULL, 'Cyclopentasiloxane+belsil eg2', 'Smartec > omegamax', 'Gel', 'جل', '50 gm', '1', 'جل مرطب يستخدم فى تحسين الندبات', NULL, NULL, NULL, 2554, '2025-07-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Valobiotin 10000 mcg 30capsules', 31758, 'فالوبيوتين 10000 30 كبسولة', '157', NULL, 'Dietary supplement', 'Dietary supplement', NULL, 'Biotin+zinc+selenium', 'Napco > value', 'Capsule', 'كبسولة', '10000 mcg', '3', 'يدعم مستوى الايض مما يحسن صحة الجسم ومد الجسم بالطاقة', NULL, NULL, NULL, 997, '2023-03-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Coreunity 20 tabs.', 32679, 'كوريونيتى 20 قرص', '78', '58', 'Multivitamins', 'Multivitamins', NULL, 'Selenium+zinc+vitamin c+vitamin d3+vitamin b12', 'Core pharm', 'Tab', 'أقراص', NULL, '2', 'مكمل غذائى مضاد للاكسدة يستخدم لدعم الجهاز العصبى والمناعى', NULL, NULL, NULL, 1740, '2024-07-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Stratamark gel 20 gm', 27552, 'ستراتامارك جل 20جم', '2,402', '1340', 'Firming topical', 'Firming topical', NULL, NULL, 'Stratpharma ag > multipharma', 'Gel', 'جل', '20 gm', '1', NULL, NULL, 'stratamark was specifically developed for treatment and prevention of all types of stretch marks particularly those covering a wide surface area resulting from pregnancy adolescent growth spurts weight gain or bodybuilding. stratamark is easily applied to', NULL, 695, '2024-04-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gentamicin-sigma 40mg/ml 3 amp. for i.m/i.v', 19731, 'جنتاميسين سيجما 40 مجم / مل 3 امبولات', '9', NULL, 'Aminoglycoside antibiotic', 'Aminoglycoside antibiotic', NULL, 'Gentamicin', 'Sigma tec', 'Amp', 'أمبول', '40mg', '3', NULL, NULL, 'about gentamicin aminoglycoside antibiotic. mechanism of action of gentamicin gentamicin exerts its bactericidal action against gram negative organisms & some of gram positive organisms by inhibiting bacterial protein synthesis. the process involves 1. pe', NULL, 984, '2022-07-20', NULL, 0, NULL, 'There are 3 key phases of aminoglycoside entry into cells.[A232294] The first “ionic binding phase” occurs when polycationic aminoglycosides bind electrostatically to negatively charged components of bacterial cell membranes including with lipopolysaccharides and phospholipids within the outer membrane of Gram-negative bacteria and to teichoic acids and phospholipids within the cell membrane of Gram-positive bacteria. This binding results in displacement of divalent cations and increased membrane permeability, allowing for aminoglycoside entry.[A232294, A232304, A232309, A232314]

The second “energy-dependent phase I” of aminoglycoside entry into the cytoplasm relies on the proton-motive force and allows a limited amount of aminoglycoside access to its primary intracellular target - the bacterial 30S ribosome.[A232294, A232314] This ultimately results in the mistranslation of proteins and disruption of the cytoplasmic membrane.[A233320] Finally, in the “energy-dependent phase II” stage, concentration-dependent bacterial killing is observed. Aminoglycoside rapidly accumulates in the cell due to the damaged cytoplasmic membrane, and protein mistranslation and synthesis inhibition is amplified.[A232294, A232314, A232319] The necessity of oxygen-dependent active transport explains why aminoglycosides are ineffective against anaerobic bacteria.[A234130]

Hence, aminoglycosides have both immediate bactericidal effects through membrane disruption and delayed bactericidal effects through impaired protein synthesis; observed experimental data and mathematical modeling support this two-mechanism model.[A232294, A232299]

Inhibition of protein synthesis is a key component of aminoglycoside efficacy. Structural and cell biological studies suggest that aminoglycosides bind to the 16S rRNA in helix 44 (h44), near the A site of the 30S ribosomal subunit, altering interactions between h44 and h45. This binding also displaces two important residues, A1492 and A1493, from h44, mimicking normal conformational changes that occur with successful codon-anticodon pairing in the A site.[A232324, A232329] Overall, aminoglycoside binding has several negative effects including inhibition of translation, initiation, elongation, and ribosome recycling.[A232294, A232334, A232339] Recent evidence suggests that the latter effect is due to a cryptic second binding site situated in h69 of the 23S rRNA of the 50S ribosomal subunit.[A232329, A232339] Also, by stabilizing a conformation that mimics correct codon-anticodon pairing, aminoglycosides promote error-prone translation.[A232344] Mistranslated proteins can incorporate into the cell membrane, inducing the damage discussed above.[A232294, A232319]', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Singukast 5mg 10 chewable tab.', 27039, 'سينجوكاست 5مجم 10 اقراص', '30', NULL, 'Asthma.anti-inflammatory.leukotriene antagonist', 'Asthma.anti-inflammatory.leukotriene antagonist', NULL, 'Montelukast', 'Epci', 'Tab', 'أقراص', '5mg', '1', NULL, NULL, 'about montelukast leukotriene(cyslt1) receptor antagonist antiinflammatory antiasthma. mechanism of action of montelukast montelukast is competitively and selectively antagonizes cyslt1 receptor (leukotrienes receptor) mediated bronchoconstriction.montelu', NULL, 949, '2022-07-13', NULL, 0, 'Montelukast is indicated for:



(a) the prophylaxis and chronic treatment of asthma in adults and pediatric patients who are 12 months of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307] and also include indications for preventing day and night-time symptoms, and the treatment of acetylsalicylic acid-sensitive asthma[L6304];



(b) the prevention of exercise-induced bronchoconstriction (EIB) in patients who are 6 years of age and older[L6301], although other regional health authorities specifically note this indication for adults and adolescents who are 15 years and older[L6304,L6307]; and



(c) the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older[L6301], although other regional health authorities specifically note the relief of seasonal allergic rhinitis symptoms for adults and adolescents who are 15 years and older[L6304,L6307].



Furthermore, some formulations like chewable montelukast tablets may also be specifically indicated by particular regulatory bodies for the prophylaxis and chronic treatment of asthma, including the prevention of day and night-time symptoms, the treatment of acetylsalicylic acid based asthma, and the prevention of exercise-induced bronchoconstriction in adult and pediatric patients aged 2 and older[L6328], between the ages 2 and 5[L6325], or between the ages of 6 and 14 years.[L6331]



Moreover, when employed for such indications montelukast is considered effective as monotherapy or when combined with other medications indicated for the maintenance treatment of chronic asthma.[L6304,L6328] For instance, montelukast and inhaled corticosteroids can be used concomitantly to demonstrate additive effects to control asthma or to decrease the necessary inhaled corticosteroid dose while still maintaining clinical stability.[L6304,L6328]



Additionally, in patients who continue to experience asthma symptoms, montelukast can also be combined with an ''as required'' short-acting beta-agonist, an inhaled corticosteroid, or inhaled corticosteroid paired with a long-acting beta-agonist.[L6304,L6328]', 'Cysteinyl leukotrienes (CysLT) like LTC4, LTD4, and LTE4, among others, are eicosanoids released by a variety of cells like mast cells and eosinophils.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] When such CysLT bind to corresponding CysLT receptors like CysLT type-1 receptors located on respiratory airway smooth muscle cells, airway macrophages, and on various pro-inflammatory cells like eosinophils and some specific myeloid stem cells activities that facilitate the pathophysiology of asthma and allergic rhinitis are stimulated.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, CysLT-mediated airway bronchoconstriction, occluding mucous secretion, vascular permeability, and eosinophil recruitment are all types of effects that facilitate asthma.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Alternatively, in allergic rhinitis, CysLTs are released by the nasal mucosa when exposed to allergens during both early and late phase reactions and participate in eliciting symptoms of allergic rhinitis like a congested nose and airway.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Subsequently, montelukast is a leukotriene receptor antagonist that binds with high affinity and selectivity to the CysLT type 1 receptor, which consequently assists in inhibiting any physiological actions of CysLTs like LTC4, LTD4, and LTE4 at the receptor that may facilitate asthma or allergic rhinitis.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'Montelukast is a leukotriene receptor antagonist that demonstrates a marked affinity and selectivity to the cysteinyl leukotriene receptor type-1 in preference to many other crucial airway receptors like the prostanoid, cholinergic, or beta-adrenergic receptors.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] As a consequence, the agent can elicit substantial blockage of LTD4 leukotriene-mediated bronchoconstriction with doses as low as 5 mg.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Moreover, a placebo-controlled, crossover study (n=12) demonstrated that montelukast is capable of inhibiting early and late phase bronchoconstriction caused by antigen challenge by 75% and 57% respectively.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



In particular, it has been documented that montelukast can cause bronchodilation as soon as within 2 hours of oral administration.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] This action can also be additive to the bronchodilation caused by the concomitant use of a beta agonist.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Nevertheless, clinical investigations performed with adults 15 years of age and older revealed that no additional clinical benefit is obtained when doses of montelukast greater than 10 mg a day are used.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]



Additionally, in clinical trials with adults and pediatric asthmatic patients aged 6 to 14 years, it was also determined that montelukast can reduce mean peripheral blood eosinophils by about 13% to 15% from baseline in comparison to placebo during double-blind treatment periods.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] At the same time, in patients aged 15 years and older who were experiencing seasonal allergic rhinitis, the use of montelukast caused a median reduction of 13% in peripheral blood eosinophil counts when compared to placebo as well.[L6301,L6304,L6307,L6310,L6325,L6328,L6331]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Remo cream 75 ml', 25860, 'ريمو كريم 75 مل', '75', NULL, 'Moisturizing topicals', 'Moisturizing topicals', NULL, 'Shea butter+cocoa butter+vitamin e+d-panthenol+mineral oil+almond oil+gms-se+allantoin+promulgen-d+g', 'Nikim co. > bluebell pharmaceuticals', 'Cream', 'كريم', '75 ml', '1', NULL, NULL, 'adjuvant therapy in very dry skin xerosis eczema and post laser.', NULL, 846, '2022-07-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Botanil cream 50 gm', 15452, 'بوتانيل كريم 50 جم', '39', NULL, 'Anti-acne', 'Anti-acne', NULL, 'Bees wax+petroleum+light liquid paraffin', 'Leader cosmetics > data pharm', 'Cream', 'كريم', '50 gm', '1', 'علاج حب الشباب -- تقليل الالتهاب و الاحمرار -- ترطيب الجلد', NULL, 'acne cream', NULL, 1544, '2022-12-29', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Avene 50+ emulsion 50 ml', 14673, 'افين مستحلب واقي من الشمس 50 مل', '379', '335', 'Sun block', 'Sun block', NULL, NULL, 'Pierre - fabre france > biotech egypt', 'Unknown', 'غير محدد', '50 ml', '1', NULL, NULL, 'very high protection for sensitive skin. effective against all sun radiation (short and long uvb-uva). paraben-free certified uva-compliant very water-resistant. 100% photostable. use: apply evenly to the skin before sun exposure. reapply frequently in ca', NULL, 813, '2023-09-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ermalin 30 chew. pieces', 15728, 'ارمالين 30 قطعة', '45', '45', 'Multivitamin', 'Multivitamin', NULL, 'Iron+lactoferrin+zinc+vitamin c+vitamin b complex', 'Vortex', 'Piece', 'قطعة', NULL, '3', NULL, NULL, NULL, NULL, 908, '2024-07-29', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cipalafil 20mg 4 tablets', 16351, 'سيبالافيل 20مجم 4 قرص', '60', '41', 'Tonic for men', 'Tonic for men', NULL, 'Tadalafil', 'Mash premiere', 'Tablet', 'أقراص', '20mg', '4', 'مقوي للرجال', NULL, NULL, '6224009799053', 21562, '2023-08-10', NULL, 0, 'Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with [finasteride] for the treatment of benign prostatic hypertrophy (BPH).[L39095,L39439] It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with [macitentan] or other endothelin-1 antagonists.[L39100,L39105,L50622]', 'Tadalafil is a selective phosphodiesterase-5 (PDE5) inhibitor that produces several downstream effects with the most common therapeutic effect being smooth muscle relaxation. [L39095] Patients may experience ED due to a variety of causes including psychogenic, neurogenic, vasculogenic, iatrogenic, or endocrine. [A242392] These causes result in dysfunction of penile smooth muscle relaxation through either disrupted neuronal signaling or direct influence on smooth muscle cells. During sexual arousal, non-adrenergic non-cholinergic (NANC) neurons release nitric oxide (NO). Nitric oxide stimulates guanylate cyclase which converts guanosine triphosphate to cyclic guanosine monophosphate (cGMP).[A242287, A242377] cGMP activates the cGMP-dependent kinase (PKG) in a signal cascade which activates K+ channels leading to inhibition of Ca2+ channels, inhibits platelet activation, and inhibits smooth muscle cell proliferation while inducing apoptosis. This signal cascade is attenuated by PDE5 which breaks the phosphodiester bond of cGMP, converting it to GMP. Inhibition of PDE5 by tadalafil increases signaling via the PKG cascade which supports penile smooth muscle relaxation during sexual arousal by decreasing Ca2+ entry into smooth muscle cells. This smooth muscle relaxation allows blood to fill the corpus cavernosum thereby producing an erection.



In PAH, blood pressure in the pulmonary arteries is raised due to a variety of mechanisms stemming from endothelial dysfunction.[A242377] Decreased production of NO and prostacyclin reduce vasodilatory signaling while overproduction of endothelin-1 and thromboxane increase vasoconstriction. Inflammation, thromboses, and hypoxia later contribute to vascular remodeling which further reduces luminal size. The resultant increase in blood pressure reduces the capacity for gas exchange and increases afterload at the right ventricle, producing symptoms of dyspnea, fatigue, and dizziness as well as leading to right-sided heart failure. Tadalafil exerts its therapeutic effect in PAH through boosting NO-cGMP signaling to contribute to smooth muscle relaxation as with ED.



Lastly, tadalafil is used to treat BPH.[L39095] BPH produces urinary dysfunction through hyperproliferation of the epithelial and smooth muscle layers of the prostate.[A242382] The increased size of the prostate blocks urine flow through the urethra resulting in higher residual volumes due to incomplete emptying. Tadalafil does not appear to exert its benefit via smooth muscle relaxation of the prostate. It may instead exert its effect through a mix of increased oxygenation and decreased inflammation, which decreases tissue remodeling, and inhibition of cell proliferation through the cGMP cascade.



The decreased affinity for PDE6 compared to other PDE5 inhibitors may explain the decreased incidence of visual side effects as PDE6 is present in the eye and contributes to color vision.[L39100, L39105, A242287]', 'Tadalafil exerts a therapeutic effect in ED by increasing sexual stimulation-dependant smooth muscle relaxation in the penis, allowing the corpus cavernosum to fill with blood to produce an erection.[A242287, A242377] Smooth muscle relaxation in the pulmonary vasculature helps to produce vasodilation in PAH which reduces blood pressure in the pulmonary arteries.[A242377] In BPH, tadalafil may contribute to decreased smooth muscle cell proliferation which may reduce the size of the prostate and relieve the anatomical obstruction which produces urinary symptoms of BPH.[A242382] The decreased affinity of tadalafil for PDE6 compared to other PDE5 inhibitors may explain the reduced incidence of visual side effects.[L39100, L39105, A242287]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lostapressin 50 mg 21 f.c. tabs.', 22066, 'لوستابريسين 50مجم 21قرص', '33', NULL, 'Antihypertensive.angiotensin blocker', 'Antihypertensive.angiotensin blocker', NULL, 'Losartan potassium', 'Delta pharma', 'Tab', 'أقراص', '50 mg', '3', NULL, NULL, 'about losartan potassium an angiotensin ii receptor antagonist antihypertensive. mechanism of action of losartan potassium it is a competitive antagonist of angiotensin-2 at at-1 receptor. it decreases peripheral resistance and lowers bp in hypertensive i', NULL, 741, '2022-07-25', NULL, 0, 'Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension.[L7423] Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).[L7426,L45663]', 'Losartan reversibly and competitively prevents angiotensin II binding to the AT<sub>1</sub> receptor in tissues like vascular smooth muscle and the adrenal gland.[L7423,L7426] Losartan and its active metabolite bind the AT<sub>1</sub> receptor with 1000 times more affinity than they bind to the AT<sub>2</sub> receptor.[L7423,L7426] The active metabolite of losartan is 10-40 times more potent by weight than unmetabolized losartan as an inhibitor of AT<sub>1</sub> and is a non-competitive inhibitor.[L7423,L7426] Losartan''s prevention of angiotensin II binding causes vascular smooth muscle relaxation, lowering blood pressure.[L7423,L7426]



Angiotensin II would otherwise bind to the AT<sub>1</sub> receptor and induce vasoconstriction, raising blood pressure.[L7423,L7426]', 'Losartan is an angiotensin II receptor blocker used to treat hypertension, diabetic nephropathy, and to reduce the risk of stroke.[A1033,L7423,L7426] Losartan has a long duration of action as it is given once daily.[L7423,L7426] Patients taking losartan should be regularly monitored for hypotension, renal function, and potassium levels.[L7423,L7426]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lc flora 20 caps', 31868, 'ال سي فلورا 20 كبسولة', '190', '90', 'Probiotic', 'Probiotic', NULL, 'Lactobacillus reuteri+zinc', 'Copad egypt > hexa gent drug', 'Cap', 'كبسولة', NULL, '2', NULL, NULL, 'probiotic for adults for healthy git', NULL, 955, '2025-08-16', NULL, 0, NULL, 'Lactobacillus coryniformis has immunomodulatory activity. Administration of a Lc K8 probiotic prior to the influenza vaccine in adults over the age of 65 showed a higher percentage of vaccine responders and a significantly lower incidence of respiratory symptoms associated with respiratory infections.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Valthiazide 80/12.5mg 21 f.c. tabs.', 28949, 'فالثيازيد 80/12.5مجم 21 اقراص', '33', NULL, 'Antihypertensive. combined angiotensin blocker with diuretic', 'Antihypertensive. combined angiotensin blocker with diuretic', NULL, 'Hydrochlorothiazide+valsartan', 'Organopharma', 'Tab', 'أقراص', '12.5mg', '3', NULL, NULL, 'about hydrochlorothiazide thiazide derivatibve diuretic. mechanism of action of hydrochlorothiazide it is thiazide diuretic which exerts its action by acting at site-3(central dilating segment of early distal tubule). it binds to na+cl- symporter and inhi', NULL, 835, '2022-07-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Orangacea 10 sachets', 24212, 'اورانجيسيا 10 اكياس', '14', NULL, 'Immune enhancer', 'Immune enhancer', NULL, 'Echinaceae purpurea+vitamin c', 'Mepaco > riva pharma s.a.e.', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, 'properties and actions: caffeic acid derivatives (mainly chicoric acid) alkamides and polysaccharides are the main effective groups in echinacea the main active constituent of immulone.simmulone contains also vitamin c which supports the integrity of muco', NULL, 815, '2022-07-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hanza cal 30 tabs', 3939, 'هانزا كال 30 قرص', '150', '100', 'Calcium', 'Calcium', NULL, 'Calcium', 'Hanza pharma', 'Tab', 'أقراص', NULL, '1', NULL, NULL, NULL, NULL, 705, '2024-09-26', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Deux cream 50 gm', 3951, 'ديوكس كريم 50 جم', '55', NULL, NULL, NULL, NULL, NULL, 'Brand international', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, NULL, NULL, 1045, '2025-05-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tress hair oil 250 ml', 11612, 'تريس زيت شعر 250 مل', '190', '180', 'Hair care', 'Hair care', NULL, 'Cyclopenta siloxane+matricaria flower extract+badam fruit extract+olive oil+melissa officinalis oily', 'Macro group pharmaceuticals', 'Hair oil', 'زيت شعر', '250 ml', '1', NULL, NULL, 'controls hair damage fall and strengthens it.', '6224000437442', 1303, '2025-03-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hair mix shampoo 250 ml', 20191, 'هير ميكس شامبو 250 مل', '295', '160', 'Hair care', 'Hair care', NULL, 'Caffeine+zinc pyrithione+argan oil+olive oil+panthenol+peg-7 glyceryl cocoate+aloe vera extract', 'Egyptian company for cosmetics > pharmix', 'Amp', 'أمبول', '250 ml', '1', NULL, NULL, 'energizing & anti-dandruff shampoo', NULL, 876, '2024-03-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sekem diarrhoea herbs 10 filter bags', 10275, 'سيكم اعشاب للاسهال 10 فلتر', '8', NULL, 'Drinks', 'Drinks', NULL, 'Achillea+basil+chamomile+chicory+hibiscus+verbascum+vine leaves', 'Atos pharma', 'Unknown', 'غير محدد', NULL, '1', NULL, NULL, NULL, '6223000470527', 820, '2022-12-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Caldin c 30 tabs', 3802, 'كالدين سي 30 قرص', '95', NULL, 'Dietary supplement', 'Dietary supplement', NULL, 'Clacium+vitamin c+vitamin d+mg+zinc', 'Alesraa', 'Tab', 'أقراص', NULL, '3', NULL, NULL, NULL, '6224011605212', 1298, '2022-07-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kemoxetin 18 mg 10 caps.', 21309, 'كيموكسيتين 18مجم 10 كبسولات', '40', NULL, 'Attention-deficit hyperactivity disorder', 'Attention-deficit hyperactivity disorder', NULL, 'Atomoxetine', 'Chemipharm', 'Cap', 'كبسولة', '18 mg', '1', 'علاج لمرض فرط الحركة وتشتت الذهن.', NULL, 'description: atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (adhd). dose: dosing of children and adolescents up to 70 kg body weight initial: the recommended dose is 0.5 mg/kg and increas', NULL, 887, '2022-05-15', NULL, 0, 'Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.', 'Atomoxetine is known to be a potent and selective inhibitor of the norepinephrine transporter (NET),[A175723] which prevents cellular reuptake of norepinephrine throughout the brain, which is thought to improve the symptoms of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT),[A178111] and blocks the N-methyl-d-aspartate (NMDA) receptor,[A18263] indicating a role for the glutamatergic system in the pathophysiology of ADHD. ', 'Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Atomoxetine has been shown to specifically increase norepinephrine and dopamine within the prefrontal cortex, which results in improved ADHD symptoms.[A18262, A18262, F4639]



Due to atomoxetine''s noradrenergic activity, it also has effects on the cardiovascular system such as increased blood pressure and tachycardia.[T244] Sudden deaths, stroke, and myocardial infarction have been reported in patients taking atomoxetine at usual doses for ADHD. Atomoxetine should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. It should not be used in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate. Although the role of atomoxetine in these cases is unknown, consideration should be given to not treating patients with clinically significant cardiac abnormalities. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during atomoxetine treatment should undergo a prompt cardiac evaluation.[F4639]



In general, particular care should be taken in treating ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in patients at risk for bipolar disorder. Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by atomoxetine at usual doses. If such symptoms occur, consideration should be given to a possible causal role of atomoxetine, and discontinuation of treatment should be considered.[F4639]



Atomoxetine capsules increased the risk of suicidal ideation in short-term studies in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). All pediatric patients being treated with atomoxetine  should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.[F4639]



Postmarketing reports indicate that atomoxetine can cause severe liver injury. Although no evidence of liver injury was detected in clinical trials of about 6000 patients, there have been rare cases of clinically significant liver injury that were considered probably or possibly related to atomoxetine use in postmarketing experience. Rare cases of liver failure have also been reported, including a case that resulted in a liver transplant. Atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury, and should not be restarted. Laboratory testing to determine liver enzyme levels should be done upon the first symptom or sign of liver dysfunction (e.g., pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained “flu like” symptoms).[F4639]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kemoxetin 100 mg 10 caps', 21308, 'كيموكستين 100مجم 10 كبسولات', '110', NULL, 'Attention-deficit hyperactivity disorder', 'Attention-deficit hyperactivity disorder', NULL, 'Atomoxetine', 'Chemipharm', 'Cap', 'كبسولة', '100 mg', '1', 'لعلاج حالات فرط الحركة ونقص الانتباه', NULL, NULL, NULL, 1039, '2022-03-25', NULL, 0, 'Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.', 'Atomoxetine is known to be a potent and selective inhibitor of the norepinephrine transporter (NET),[A175723] which prevents cellular reuptake of norepinephrine throughout the brain, which is thought to improve the symptoms of ADHD. More recently, positron emission tomography (PET) imaging studies in rhesus monkeys have shown that atomoxetine also binds to the serotonin transporter (SERT),[A178111] and blocks the N-methyl-d-aspartate (NMDA) receptor,[A18263] indicating a role for the glutamatergic system in the pathophysiology of ADHD. ', 'Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Atomoxetine has been shown to specifically increase norepinephrine and dopamine within the prefrontal cortex, which results in improved ADHD symptoms.[A18262, A18262, F4639]



Due to atomoxetine''s noradrenergic activity, it also has effects on the cardiovascular system such as increased blood pressure and tachycardia.[T244] Sudden deaths, stroke, and myocardial infarction have been reported in patients taking atomoxetine at usual doses for ADHD. Atomoxetine should be used with caution in patients whose underlying medical conditions could be worsened by increases in blood pressure or heart rate such as certain patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease. It should not be used in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experienced clinically important increases in blood pressure or heart rate. Although the role of atomoxetine in these cases is unknown, consideration should be given to not treating patients with clinically significant cardiac abnormalities. Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during atomoxetine treatment should undergo a prompt cardiac evaluation.[F4639]



In general, particular care should be taken in treating ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in patients at risk for bipolar disorder. Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without a prior history of psychotic illness or mania can be caused by atomoxetine at usual doses. If such symptoms occur, consideration should be given to a possible causal role of atomoxetine, and discontinuation of treatment should be considered.[F4639]



Atomoxetine capsules increased the risk of suicidal ideation in short-term studies in children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD). All pediatric patients being treated with atomoxetine  should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.[F4639]



Postmarketing reports indicate that atomoxetine can cause severe liver injury. Although no evidence of liver injury was detected in clinical trials of about 6000 patients, there have been rare cases of clinically significant liver injury that were considered probably or possibly related to atomoxetine use in postmarketing experience. Rare cases of liver failure have also been reported, including a case that resulted in a liver transplant. Atomoxetine should be discontinued in patients with jaundice or laboratory evidence of liver injury, and should not be restarted. Laboratory testing to determine liver enzyme levels should be done upon the first symptom or sign of liver dysfunction (e.g., pruritus, dark urine, jaundice, right upper quadrant tenderness, or unexplained “flu like” symptoms).[F4639]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Trileptal 300mg 50 f.c.tab.', 11669, 'ترايلبتال 300مجم 50 قرص', '356', '223', 'Anti-epileptic.carboxamides', 'Anti-epileptic.carboxamides', NULL, 'Oxcarbazepine', 'Novartis', 'Tab', 'أقراص', '300mg', '5', 'علاج الصرع -- تقليل التشنجات', NULL, NULL, NULL, 9880, '2024-12-08', NULL, 0, 'In the United States, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.[L8627] 



In Canada, oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in patients 6 years of age and older.[L8630]', 'The exact mechanism through which oxcarbazepine and its active metaoblite, MHD, exert their anti-epileptic effects is unclear, but is thought to primarily involve the blockade of voltage-gated sodium channels.[L8627,L8630,L8633,A186104] The opening and closing of sodium channels allows for the propagation of action potentials along neurons - in epilepsy, these action potentials can occur in excess of that required for normal function, and the repetitive and pathological firing of these action potentials leads to seizure activity. Both oxcarbazepine and MHD are thought to inhibit seizure activity by binding to the inactive state of voltage-gated sodium channels, thus prolonging the period in which the receptor is unavailable for action potential propagation.[A186101] This helps to stabilize hyperexcited neuronal membranes, inhibit repetitive neuron firing, and prevent the spread of seizure activity within the CNS without affecting normal neuronal transmission.[L8627,L8630,L8633]



Increased potassium conductance and modulation of voltage-activated calcium channels is also thought to play a role in the anti-seizure activity of oxcarbazepine.[L8627,L8630,L8633] Inhibition of glutamatergic activity was thought to contribute to oxcarbazepine''s activity[A34516], but this effect could not be replicated _in vivo_.[A186104]', 'Oxcarbazepine is an anticonvulsant drug that reduces the incidence of seizures in epilepsy by inhibiting abnormal electrical activity in the brain.[L8627,L8630,L8633]



There have been rare reports of oxcarbazepine resulting in the development of hematologic abnormalities, including agranulocytosis and aplastic anemia. Patients should be undergo frequent laboratory testing and should be monitored closely for signs and symptoms of blood dyscrasias. Oxcarbazepine has also been associated with the development of dermatologic reactions which can progress from a simple rash to potentially fatal reactions such as toxic epidermal necrolysis (TEN) or Stevens-Johnson Syndrome (SJS). Patients with the HLA-A 3101 and/or HLA-B 1502 alleles may be at higher risk of this reaction. Oxcarbazepine should be discontinued at the first sign of a drug-induced skin reaction.[L8627,L8630,L8633]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mefac 20 f.c. tabs', 22455, 'ميفاك 20 اقراص', '46', '23', 'Cold drugs', 'Cold drugs', NULL, 'Chlorpheniramine+dextromethorphan+paracetamol(acetaminophen)+pseudoephedrine', 'Eimc > suecal pharmaceuticals', 'Tab', 'أقراص', NULL, '2', NULL, NULL, 'description a histamine h1 antagonist used in allergic reactions hay fever rhinitis urticaria and asthma. indication for the treatment of rhinitis urticaria allergy common cold asthma and hay fever. pharmacodynamics in allergic reactions an allergen inter', '6225000123984', 1445, '2025-12-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hair stabil hair tonic 100ml', 5883, 'هير ستابيل مقوي للشعر 100 مل', '39', NULL, 'Hair care', 'Hair care', NULL, 'Piroctone olamine+extrapone-5-special', 'Global napi pharmaceuticals > nova pharmaceuticals', 'Tab', 'أقراص', '100ml', '1', NULL, NULL, 'anti-dandruff tonic', NULL, 1216, '2023-04-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Systymycin 500mg 3 caps.', 27836, 'سيستمايسين 500مجم 3 كبسول', '22', NULL, 'Antibiotic.macrolide', 'Antibiotic.macrolide', NULL, 'Azithromycin', 'Egpi > novell pharma', 'Cap', 'كبسولة', '500mg', '1', NULL, NULL, 'description: azithromycin is a semi-synthetic macrolide antibiotic of the azalide class. dose: adult: po- respiratory tract skin and soft tissue infections- 500 mg once daily for 3 days. or 500mg on day 1 followed by 250mg on days 2 to 5. typhoid- 500 mg', NULL, 924, '2022-07-20', NULL, 0, 'Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label].



Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. 



**Adults**:



Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.

Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage.



Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_.



Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.



**Pediatric Patients**



Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy.



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.', 'In order to replicate, bacteria require a specific process of protein synthesis, enabled by ribosomal proteins [A6505]. Azithromycin binds to the 23S rRNA of the bacterial 50S ribosomal subunit. It stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit [FDA label], [A14179]. This results in the control of various bacterial infections [A174193], [FDA label].   The strong affinity of macrolides, including azithromycin, for bacterial ribosomes, is consistent with their broad‐spectrum antibacterial activities [A174193].





Azithromycin is highly stable at a low pH, giving it a longer serum half-life and increasing its concentrations in tissues compared to erythromycin [A174175]. 



', 'Macrolides stop bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections [A174175].

Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose [A174172].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nucore 20 capsules', 4353, 'نوكور 20 كبسولة', '145', NULL, 'Nerve regeneration', 'Nerve regeneration', NULL, 'Uridine-5-triphosphate 3mg+cytidine-monophosphate 5mg', 'Napco pharma', 'Capsule', 'كبسولة', NULL, '2', NULL, NULL, NULL, NULL, 713, '2025-06-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Winzoxib 90mg 20 f.c tab', 2699, 'وينزوكسيب 90 مجم 20 قرص', '136', NULL, 'Nsaid.selective cox-2 inhibitors', 'Nsaid.selective cox-2 inhibitors', NULL, 'Etoricoxib', 'Al esraa pharmaceutical optima', 'Tab', 'أقراص', '90mg', '2', NULL, NULL, NULL, '6223004160844', 1555, '2025-01-28', NULL, 0, 'For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.', 'Like any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2), preventing production of prostaglandins (PGs) from arachidonic acid.', 'Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1).', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Betnovate n ointment 15 gm', 1480, 'بتنوفيت ان مرهم 15 جم', '13', NULL, 'Antibiotic with glucocorticoid', 'Antibiotic with glucocorticoid', NULL, 'Betamethasone+neomycin', 'Smithkline beecham > glaxo smithkline', 'Ointment', 'مرهم', '15 gm', '1', NULL, NULL, 'what is it used for? this cream and ointment are used in short courses to treat inflammatory skin conditions such as those listed below when milder corticosteroids have not been effective and when the condition is either already infected or likely to beco', '6221045000068', 1369, '2022-09-19', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nonem 10 sachet', 23691, 'نونيم 10 أكياس', '69', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Lactoferrin 100 mg+iron+vit b complex+folic acid+zinc+vit c', 'Medcare > top care pharma', 'Sachet', 'أكياس', NULL, '1', 'فيتامينات متعددة', NULL, NULL, NULL, 529, '2022-05-30', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ony 5mg/5ml syrup 100 ml', 6588, 'اوني 5مجم/5مل شراب 100 مل', '39', NULL, NULL, NULL, NULL, NULL, NULL, 'Syrup', 'شراب', '5mg', '1', NULL, NULL, NULL, '6224010990067', 747, '2025-08-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rotahelex 25 mg 30 f.c. tabs.', 26329, 'روتاهيليكس 25مجم 30 قرص', '87', '51', 'Cough drugs', 'Cough drugs', NULL, 'Ivy leaves', 'International drug agency (idi) > egypharma-egypt', 'Tab', 'أقراص', '25 mg', '3', NULL, NULL, NULL, '6224000870324', 1168, '2024-07-26', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hyseac gel nettoyant (cleansing gel) 300ml', 20652, 'هيسياك نيتويانت جل 300 مل', '299', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Uriage dermatological laboratories > biotech egypt', 'Gel', 'جل', '300ml', '1', NULL, NULL, 'cleansing for combination to oily skin. face and/or back. properties hysï-ac gentle cleansing gel eliminates impurities and excess sebum perfectly respecting the epidermis. high rinsability light foaming action in contact with water and its characteristic', NULL, 515, '2022-08-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Alecensa 150 mg 224 caps.', 13650, 'اليسنزا 150مجم 224 كبسولة', '110,000', '80000', '.', '.', NULL, 'Alectinib', 'F.hoffman la roche', 'Cap', 'كبسولة', '150 mg', '4', 'علاج للسرطان.', NULL, 'alecensa is indicated for the treatment of patients with anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc) as detected by an fda-approved test.', NULL, 2573, '2024-01-31', NULL, 0, 'Alectinib is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).[L51008] It is also indicated as an adjuvant treatment in adult patients following tumor resection of ALK-positive non-small cell lung cancer.[L51008]', 'Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability. Both alectinib and its major active metabolite M4 demonstrate similar in vivo and in vitro activity against multiple mutant forms of ALK. ', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zyprexa 5mg 14 coated tab.', 12960, 'زيبريكسا 5مجم 14 اقراص', '284', NULL, 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Olanzapine', 'Eli lilly', 'Tab', 'أقراص', '5mg', '2', NULL, NULL, 'indication for the acute and maintenance treatment of schizophrenia and related psychotic disorders as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. intramuscular olanzapine is indicated for the rapid control of agitated patien', NULL, 1639, '2023-05-03', NULL, 0, 'Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.[A177014] 



Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.[FDA label]



As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.[A177014]



Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.[FDA label]



Schizophrenia is a complex biochemical brain disorder that affects the person''s ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.[L5936]



Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.[L5939]



Olanzapine is also indicated in combination with [samidorphan] for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.[L34359]', 'The activity of olanzapine is achieved by the antagonism of multiple neuronal receptors including the dopamine receptor D1, D2, D3 and D4 in the brain, the serotonin receptors 5HT2A, 5HT2C, 5HT3 and 5HT6, the alpha-1 adrenergic receptor, the histamine receptor H1 and multiple muscarinic receptors.[A176993, A176999]



As abovementioned, olanzapine presents a wide profile of targets, however, its antagonistic effect towards the dopamine D2 receptor in the mesolimbic pathway is key as it blocks dopamine from having a potential action at the post-synaptic receptor. The binding of olanzapine to the dopamine D2 receptors is easily dissociable and hence, it allows for a certain degree of dopamine neurotransmission.[A177014]



On the other hand, olanzapine acts in the serotonin 5HT2A receptors in the frontal cortex in a similar manner than the reported on dopamine D2 receptors. This determined effect allows for a decrease in adverse effects.[A177014]', 'The effect of olanzapine in the D2 receptor is reported to produce the positive effects of this drug such as a decrease in hallucinations, delusions, disorganized speech, disorganized thought, and disorganized behavior. On the other hand, its effect on the serotonin 5HT2A receptor prevents the onset of anhedonia, flat affect, alogia, avolition and poor attention.[A177014] Based on the specific mechanism of action, olanzapine presents a higher affinity for the dopamine D2 receptor when compared to the rest of the dopamine receptor isotypes. This characteristic significantly reduces the presence of side effects.[T554]



Clinical trials for the original use of olanzapine demonstrated significant effectiveness in the treatment of schizophrenia and bipolar disorder in adults and acute manic or mixed episodes associated with bipolar disorder in adolescents.[A177008]



The effect of olanzapine on dopamine and serotonin receptors has been suggested to reduce chemotherapy-induced nausea and vomiting as those receptors are suggested to be involved in this process. For this effect, several clinical trials have been conducted and it has been shown that olanzapine can produce a significant increase in total control of nausea and vomiting.[A176993] In a high-level study of the effect of olanzapine for this condition, a complete response on the delay phase was observed in 84% of the individual and control of emesis of over 80% despite the phase.[A176999]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rotone 20 tabs.', 33551, 'روتون 20 قرص', '110', '99', 'Iron supplement', 'Iron supplement', NULL, 'Iron+zinc+copper+vitamin b1+vitamin b2+vitamin b6+vitamin b12+folic acid+vitamin c', 'Medcare > dawa egypt pharm', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, NULL, 528, '2025-10-29', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Prima-5 syrup 120 ml', 25235, 'بريما 5 شراب 120مل', '25', '14.3', 'Cough drugs', 'Cough drugs', NULL, 'Fennel+guava+neroli+thyme', 'Ibe pharma', 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, 'helps to relieve cough', '6225000181946', 700, '2024-04-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Prote-care hair cream 50 gm', 25411, 'بروت كير كريم 50جم', '60', NULL, 'Hair care', 'Hair care', NULL, 'Panthenol+vitamin e+coconut diethanolamine+edta+sodium lauryl ether sulphate', 'Macro group pharmaceuticals', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, NULL, NULL, 732, '2022-07-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ethyl alcohol spray 70%', 4441, 'كحول ايثيلي سبراي 70 %', '20', NULL, 'Disinfectant', 'Disinfectant', NULL, 'Ethyl alcohol', 'Company', 'Spray', 'بخاخ', '70%', '1', NULL, NULL, NULL, NULL, 948, '2022-12-05', NULL, 0, 'Investigated for use/treatment in burns and burn infections, cardiac surgery, inflammatory disorders (unspecified), ischemic reperfusion injury, and sepsis and septicemia.', 'CTI-01 inhibits the systemic release of cytokines, such as TNF-alpha and HMGB1, which promote the body''s inflammatory response. The over-expression of these cytokines has been linked to diseases that occur in critical care settings, such as severe organ damage following cardiopulmonary bypass (CPB) and post-operative ileus following abdominal surgery.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lidocaine 2% (otsuka) amp. 5 ml', 21804, 'ليدوكايين 2% - اوتوسوكا - امبول 5 مل', '5', NULL, 'Analgesic.local anesthetic', 'Analgesic.local anesthetic', NULL, 'Lidocaine', 'Otsuka', 'Amp', 'أمبول', '2%', '1', NULL, NULL, 'indication for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural tech', '6222010670354', 1163, '2023-06-16', NULL, 0, 'Lidocaine is an anesthetic of the amide group indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks [F4349, L5930].', 'Lidocaine is a local anesthetic of the amide type [F4349, L5930, L5948]. It is used to provide local anesthesia by nerve blockade at various sites in the body [F4349, L5930, L5948]. It does so by stabilizing the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action [F4349, L5930, L5948]. In particular, the lidocaine agent acts on sodium ion channels located on the internal surface of nerve cell membranes [F4349, L5930, L5948]. At these channels, neutral uncharged lidocaine molecules diffuse through neural sheaths into the axoplasm where they are subsequently ionized by joining with hydrogen ions [F4349, L5930, L5948]. The resultant lidocaine cations are then capable of reversibly binding the sodium channels from the inside, keeping them locked in an open state that prevents nerve depolarization [F4349, L5930, L5948]. As a result, with sufficient blockage, the membrane of the postsynaptic neuron will ultimately not depolarize and will thus fail to transmit an action potential [F4349, L5930, L5948]. This facilitates an anesthetic effect by not merely preventing pain signals from propagating to the brain but by aborting their generation in the first place [F4349, L5930, L5948].



In addition to blocking conduction in nerve axons in the peripheral nervous system, lidocaine has important effects on the central nervous system and cardiovascular system [F4349, L5930, L5948]. After absorption, lidocaine may cause stimulation of the CNS followed by depression and in the cardiovascular system, it acts primarily on the myocardium where it may produce decreases in electrical excitability, conduction rate, and force of contraction [F4349, L5930, L5948].', 'Excessive blood levels of lidocaine can cause changes in cardiac output, total peripheral resistance, and mean arterial pressure [F4349, L5930]. With central neural blockade these changes may be attributable to the block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system, and/or the beta-adrenergic receptor stimulating action of epinephrine when present [F4349, L5930]. The net effect is normally a modest hypotension when the recommended dosages are not exceeded [F4349, L5930].



In particular, such cardiac effects are likely associated with the principal effect that lidocaine elicits when it binds and blocks sodium channels, inhibiting the ionic fluxes required for the initiation and conduction of electrical action potential impulses necessary to facilitate muscle contraction [F4349, L5930, L5948]. Subsequently, in cardiac myocytes, lidocaine can potentially block or otherwise slow the rise of cardiac action potentials and their associated cardiac myocyte contractions, resulting in possible effects like hypotension, bradycardia, myocardial depression, cardiac arrhythmias, and perhaps cardiac arrest or circulatory collapse [F4349, L5930, L5948].



Moreover, lidocaine possesses a dissociation constant (pKa) of 7.7 and is considered a weak base [L5948]. As a result, about 25% of lidocaine molecules will be un-ionized and available at the physiological pH of 7.4 to translocate inside nerve cells, which means lidocaine elicits an onset of action more rapidly than other local anesthetics that have higher pKa values [L5948]. This rapid onset of action is demonstrated in about one minute following intravenous injection and fifteen minutes following intramuscular injection [L5930]. The administered lidocaine subsequently spreads rapidly through the surrounding tissues and the anesthetic effect lasts approximately ten to twenty minutes when given intravenously and about sixty to ninety minutes after intramuscular injection [L5930].



Nevertheless, it appears that the efficacy of lidocaine may be minimized in the presence of inflammation [L5948]. This effect could be due to acidosis decreasing the amount of un-ionized lidocaine molecules, a more rapid reduction in lidocaine concentration as a result of increased blood flow, or potentially also because of increased production of inflammatory mediators like peroxynitrite that elicit direct actions on sodium channels [L5948].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ciprofloxacin-amriya 250mg 10 f.c. tab', 16384, 'سيبروفلوكساسين العامرية 250 مجم 10 اقراص', '28', '24.5', 'Antibiotic.quinolone', 'Antibiotic.quinolone', NULL, 'Ciprofloxacin', 'European egyptian pharm. ind.', 'Tab', 'أقراص', '250mg', '1', NULL, NULL, NULL, '6221076010302', 1200, '2023-08-24', NULL, 0, 'Ciprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493]



Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478]



A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493]



A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475]



A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487]', 'Ciprofloxacin acts on bacterial topoisomerase II (DNA gyrase) and topoisomerase IV.[A178885] Ciprofloxacin''s targeting of the alpha subunits of DNA gyrase prevents it from supercoiling the bacterial DNA which prevents DNA replication.[A178876,A178882]', 'Ciprofloxacin is a second generation fluoroquinolone that is active against many Gram negative and Gram positive bacteria.[A178870,L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] It produces its action through inhibition of bacterial DNA gyrase and topoisomerase IV.[A178885] Ciprofloxacin binds to bacterial DNA gyrase with 100 times the affinity of mammalian DNA gyrase.[A178894] There is no cross resistance between fluoroquinolones and other classes of antibiotics, so it may be of clinical value when other antibiotics are no longer effective.[A178894] Ciprofloxain and its derivatives are also being investigated for its action against malaria, cancers, and AIDS.[A178885]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cerederm plaster crown 8cm 10 patches', 16166, 'سيريديرم بلاستر كرون 8 سم 10 لصقات', '1,200', NULL, 'Scar therapy', 'Scar therapy', NULL, 'Reinforced siloxanes', 'Cereplas > biosource', 'Patch', 'لصقة', NULL, '1', NULL, NULL, 'indications / uses treatment & prevention of hypertrophic & keloid scars. contraindications hypersensitivity. open or infected wounds bedsores; weeping or ulcerated wounds burns & mucous membranes.', NULL, 927, '2022-07-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ultra pan cream 50 gm', 28669, 'الترا بان كريم 50جم', '125', '49', 'Moisturizing topicals', 'Moisturizing topicals', NULL, 'Salicylic acid+urea+glycerin+keratin+panthenol+allantoin+dimethicone+bees wax+paraffin oil+cetearyl', 'Hi-care > violine', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, 'moisturizing foot cream', NULL, 972, '2024-02-07', NULL, 0, 'Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts.', 'Salicylic acid directly irreversibly inhibits COX-1 and COX-2 to decrease conversion of arachidonic acid to precursors of prostaglandins and thromboxanes. Salicylate''s use in rheumatic diseases is due to it''s analgesic and anti-inflammatory activity. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. Salicylic acid allows cells of the epidermis to more readily slough off. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid competitively inhibits oxidation of uridine-5-diphosphoglucose (UDPG) with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of the glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to a phenolic acceptor. Inhibition of mucopoly saccharide synthesis is likely responsible for the slowing of wound healing with salicylates.', 'Salicylic acid treats acne by causing skin cells to slough off more readily, preventing pores from clogging up. This effect on skin cells also makes salicylic acid an active ingredient in several shampoos meant to treat dandruff. Use of straight salicylic solution may cause hyperpigmentation on unpretreated skin for those with darker skin types (Fitzpatrick phototypes IV, V, VI), as well as with the lack of use of a broad spectrum sunblock. Subsalicylate in combination with bismuth form the popular stomach relief aid known commonly as Pepto-Bismol. When combined the two key ingredients help control diarrhea, nausea, heartburn, and even gas. It is also very mildly anti-biotic.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ferroject 12.5mg/ml amp. for i.v. inf. or slow i.v. inj.', 18996, 'فيروجيكت 12.5مجم/مل امبول', '9', NULL, 'Anemia.iron supplement', 'Anemia.iron supplement', NULL, 'Iron', 'Adwia', 'Inj', 'حقن', '12.5mg', '1', NULL, NULL, 'description a metallic element found in certain minerals in nearly all soils and in mineral waters. it is an essential constituent of hemoglobin cytochrome and other components of respiratory enzyme systems. its chief functions are in the transport of oxy', NULL, 1075, '2022-10-24', NULL, 0, 'For treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Also used to replenish body iron stores in Non-Dialysis Dependent-Chronic Kidney Disease (NDD-CKD) patients receiving or not receiving erythropoietin and in Hemodialysis Dependent (HDD-CKD) and Peritoneal Dialysis Dependent (PDD-CKD) - Chronic Kidney Disease patients receiving an erythropoietin.', 'After iron dextran is injected, the circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.', 'Iron dextran is a dark brown, slightly viscous sterile liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. It is for treatment of patients with documented iron deficiency in whom oral administration is unsatisfactory or impossible. Iron is essential to the formation of hemoglobin and to the function and formation of other heme and nonheme compounds. Untreated depletion of iron stores leads to iron-deficient erythropoiesis and, in turn, to iron deficiency anemia.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lamictal 100mg 30 tab.', 21560, 'لاميكتال 100مجم 30 قرص', '226', '146.5', 'Anti-epileptic.triazine', 'Anti-epileptic.triazine', NULL, 'Lamotrigine', 'Glaxo smithkline', 'Tab', 'أقراص', '100mg', '3', NULL, NULL, 'about lamotrigine phenyltriazine derivative anticonvulsant mood stabilizer. mechanism of action of lamotrigine lamotrigine prolongs the inactivated state of voltage sensitive neuronal sodium ion channel either by increasing the efflux or decreasing the in', '5900008008280', 4641, '2024-10-22', NULL, 0, 'Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.[L9404]



It is also indicated for the process of conversion to drug monotherapy for those at least 16 years of age or older with partial seizures and currently are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED).[L9404]



In addition to the above, lamotrigine is also indicated for the maintenance treatment of bipolar I disorder, delaying the time to mood episodes (which may include mania, hypomania, depression, mixed episodes) in adults at least 18 years or older, who have been treated for acute mood symptoms with standard therapy.[L9404]



Limitations of use



It is important to note that lamotirigine should not be used in the treatment of acute mood episodes, as efficacy has not been established in this context.[L9404]', 'The exact mechanism of action of lamotrigine is not fully elucidated, as it may exert cellular activities that contribute to its efficacy in a range of conditions. Although chemically unrelated, lamotrigine actions resemble those of phenytoin and carbamazepine, inhibiting voltage-sensitive sodium channels, stabilizing neuronal membranes, thereby modulating the release of presynaptic excitatory neurotransmitters.[A191335,A191350,L9404] 



Lamotrigine likely acts by inhibiting sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate. The mechanism of action of lamotrigine in reducing anticonvulsant activity is likely the same in managing bipolar disorder. Studies on lamotrigine have identified its binding to sodium channels in a fashion similar to local anesthetics, which could explain the demonstrated clinical benefit of lamotrigine in some neuropathic pain states.[T28] 



Lamotrigine displays binding properties to several different receptors. In laboratory binding assays, it demonstrates weak inhibitory effect on the serotonin 5-HT3 receptor. Lamotrigine also weakly binds to Adenosine A1/A2 receptors, α1/α2/β adrenergic receptors, dopamine D1/D2 receptors, GABA A/B receptors, histamine H1 receptors, κ-opioid receptor (KOR), mACh receptors and serotonin 5-HT2 receptors with an IC50>100 µM. Weak inhibitory effects were observed at sigma opioid receptors.[L9404] An in vivo study revealed evidence that lamotrigine inhibits Cav2.3 (R-type) calcium currents, which may also contribute to its anticonvulsant effects.[A31737] ', 'Lamotrigine likely prevents seizures and prevents mood symptoms via stabilizing presynaptic neuronal membranes and preventing the release of excitatory neurotransmitters such as glutamate, which contribute to seizure activity.[A191350,L9404] 



A note on cardiovascular effects



The metabolite of lamotrigine, 2-N-methyl metabolite (formed by glucuronidation), is reported to cause dose-dependent prolongations of the PR interval, widening of the QRS complex, and at higher doses, complete AV block. Although this harmful metabolite is only found in trace amounts in humans, plasma concentrations may increase in conditions that cause decreased drug glucuronidation, such as liver disease.[A191335,L9404,L12183]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Avene after-sun care lotion 200 ml', 14680, 'افين افتر صن كير لوشن 200 مل', '157', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Pierre - fabre france > biotech egypt', 'Lotion', 'لوشن', '200 ml', '1', NULL, NULL, 'light-weight non-greasy lotion restores skin s barrier and prevents moisture loss. soothes calms and cools the skin after sun exposure. ï¿½ light cream-gel formula provides a cooling effect to the skin. ï¿½ lipidic complex biocymentine helps restore skinï', NULL, 796, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ammoniated mercury 5gm/100gm oint.', 13977, 'امونييتد ميركري 5جم/100جم مرهم', '2', NULL, 'White ppt', 'White ppt', NULL, 'Ammoniated mercury', 'Unipharma co.', 'Oint', 'مرهم', '5gm', '1', NULL, NULL, 'mechanism of action/effect: ammoniated mercury has a bacteriostatic action that is probably the result of inhibition of bacterial sulfhydryl enzymes', NULL, 566, '2022-08-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lascar gel 60 gm', 21625, 'لاسكار جل 60 جرام', '450', '290', 'Scar therapy', 'Scar therapy', NULL, 'Silicone oil+onion extract+chamomile oil+aloe vera oil', 'Egyptian co. for cosmetics > infinity pharma for pharmaceuticals', 'Gel', 'جل', '60 gm', '1', 'يستخدم في علاج اثار الجروح والندبات __ يعمل علي تفتيح لون البشرة و اللون الداكن', NULL, 'soothe smooth and soften scar - perfect to improve the appearance of scars - deeply moisturizes the skin - enhance skin tone and texture - non greasy', '6222019602912', 2271, '2025-08-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Immuno flu 20 caps', 6417, 'اميونو فلو 20 كبسولة', '20', NULL, 'Immune enhancer', 'Immune enhancer', NULL, 'Echinacea purpurea+vitamin c+zinc', 'Global napi pharmaceuticals', 'Cap', 'كبسولة', NULL, '2', 'علاج لضعف المناعة.', NULL, NULL, '6223002145683', 5482, '2022-12-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rostevo whitening cream 50 gm', 33544, 'روستيفو كريم تفتيح 100 جم', '125', '100', 'Whitening cream', 'Whitening cream', NULL, 'Licorice extract+kojic acid+zinc oxide+titanium dioxide+vitamin c+vitamin e+glycerin+niacinamide+hyaluronic acid', 'Larose', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, 'rostevo whitening cream 100 gm price 100 le skin whitening cream how to use : put a suitable amount of the cream on the skin the rub gently at evening for external use only', NULL, 935, '2024-03-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Milnavella 12.5 mg 30 f.c. tabs.', 22760, 'مينافيلا 12.5 مجم 30 قرص', '39', '31.5', 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Milnacipran hydrochloride', 'Mash premiere', 'Tab', 'أقراص', '12.5 mg', '3', 'علاج الامراض النفسية', NULL, 'milnacipran is a serotonin-norepinephrine reuptake inhibitor (snri). exactly how milnacipran works to treat fibromyalgia is not known. it may work by restoring the balance of certain natural substances in the brain (serotonin and norepinephrine).', NULL, 1492, '2023-09-08', NULL, 0, 'Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia in patients that are 18 years old or above [F3925]. 



While milnacipran may be used for the treatment of major depressive disorder (MDD), it is only recommended in adult patients who are 18 years old or above [F3922] due to an increased risk for suicidal ideation, thinking, and behavior in children, adolescents, and young adults taking antidepressants for major depressive disorder (MDD) and other psychiatric disorders. Some regional prescribing information notes that the use of the medication is specifically for the short-term symptomatic relief of MDD [F3919]. Nevertheless, it is important to note that the regulatory approval of and/or indications listed here for milnacipran may or may not exist and/or vary greatly between regions and nations [F3928, F3934].', 'The dual ability for milnacipran to inhibit the reuptake of both serotonin (5HT) and norepinephrine (NE) facilitates its treatment of both fibromyalgia and major depressive disorder (MDD).



In particular, it is generally believed that 5HT and NE participate in the modulation of endogenous analgesic mechanisms by way of the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846]. Although the specific mechanism of action remains unclear, some studies have proposed that low levels of 5HT may be associated with increased sensitivity to pain - a condition that could subsequently be improved by milnacipran''s capacity to enhance the presence of 5HT by inhibiting its reuptake via serotonin transporters at synaptic clefts [A175846, F3937, L5659]. Furthermore, in the CNS it is also generally believed that NE released from descending pathways can mitigate pain sensations via eliciting inhibitory effects on alpha-2A-adrenoceptors on central terminals of primary afferent nociceptors, by direct alpha-2-adrenergic action on pain-relay neurons, and by alpha-1-adrenoceptor-mediated activation of inhibitory interneurons [A175843]. Such NE pain mitigation is consequently also enhanced by milnacipran''s ability to enhance the presence of NE by inhibiting its reuptake via norepinephrine transporters at synaptic clefts [F3937].



Concurrently, milnacipran''s capacity to inhibit the reuptake of both 5HT and NE also facilitates its treatment of MDD. Given the monoamine hypothesis'' assertion that decreased 5HT can be associated with anxiety, obsessions, compulsions, and decreased NE can result in lowered alertness, energy, attention, and general interest in life, it is proposed that milnacipran''s basic activities as a serotonin and norepinephrine reuptake inhibitor could assist in treating such symptoms of MDD by increasing the presence of both 5HT and NE in the body by inhibiting their reuptake [A175840]. ', 'When utilized to treat fibromyalgia, the effect of milnacipran on the QTcF interval in patients was measured in a double-blind placebo-and positive-controlled parallel study in 88 healthy subjects using three to six times the recommended therapeutic dose for fibromyalgia at 600 mg/day [F3925]. After baseline and placebo adjustment, the maximum mean QTcF change was 8 ms - an increase that is generally not considered to be clinically significant [F3925].



Conversely, when used for treating major depressive disorder (MDD), non-clinical studies have shown that levomilnacipran binds with high affinity to the norepinephrine (NE) and serotonin (5-HT) transporters (Ki = 71-91 nM and 11 nM respectively at human transporters) [F3919, F3922, F3925]. Levomilnacipran inhibits the uptake of both NE and 5-HT in vitro and in vivo; preferentially inhibiting reuptake of NE over 5-HT by approximately 2-fold [F3919, F3922, F3925]. Levomilnacipran does not directly affect the uptake of dopamine or other neurotransmitters [F3919, F3922, F3925]. Levomilnacipran has no significant affinity for serotonergic (5-HT1-7), α- and β-adrenergic, muscarinic (M1-5), histamine (H1-4), dopamine (D1-5), opiate, benzodiazepine, and γ-aminobutyric acid (GABA) receptors in vitro [F3919, F3922]. Levomilnacipran has no significant affinity for Ca++, K+, Na+, and Cl– channels and does not inhibit the activity of human monoamine oxidases (MAO-A and MAO-B) or acetylcholinesterase [F3919, F3922, F3925].



Moreover, in ECG studies with levomilnacipran used to treat MDD, although no clinically significant changes in QTcF interval (QTcF=QT/RR0.33) were noted, it appears that the agent can cause increases in heart rate and blood pressure [F3919]. In particular, it appears that the maximum therapeutic dose of levomilnacipran at 120 mg/day is capable of causing a maximum mean difference in heart rate from placebo of 20.2 bpm and a mean difference in systolic and diastolic blood pressure from placebo ranging from 3.8 to 7.2 mmHg and 6.1 to 8.1 mmHg, respectively [F3919]. Alternatively, a supratherapeutic dose of 300 mg/day is capable of causing a maximum mean difference in heart rate from placebo of 22.1 bpm and a mean difference in systolic and diastolic blood pressure from placebo ranging from 5.4 to 7.9 mmHg and 7.9 to 10.6 mmHg, respectively [F3919].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mincera powder 14 sachets', 22776, 'مينسيرا بودر 14كيس', '115', NULL, 'Weight loss', 'Weight loss', NULL, 'Psyllium husk powder', 'Ugc > beta pharma-egypt', 'Powder', 'بودرة', NULL, '1', NULL, NULL, 'composition: per 10gm sachet psyllium seed husk powder 7.9 gm + sucralose 20 mg + vitamin c 60 mg + natural pineapple powder 2 gm + pineapple flavor 20 mg use: 1 sachet in a dry water glass then fill it with water (200 ml) and drink immediately once daily', NULL, 875, '2022-07-30', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Axiom melatonin 5 mg 30 tabs.', 7120, 'اكسيوم ميلاتونين 5 مجم 30 قرص', '240', NULL, 'Sleep aid', 'Sleep aid', NULL, 'Melatonin', 'Axiom', 'Tab', 'أقراص', '5 mg', '3', NULL, NULL, NULL, NULL, 972, '2025-08-24', NULL, 0, 'Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders. ', 'Melatonin is a derivative of tryptophan. It binds to melatonin receptor type 1A, which then acts on adenylate cylcase and the inhibition of a cAMP signal transduction pathway. Melatonin not only inhibits adenylate cyclase, but it also activates phosphilpase C. This potentiates the release of arachidonate. By binding to melatonin receptors 1 and 2, the downstream signallling cascades have various effects in the body. The melatonin receptors are G protein-coupled receptors and are expressed in various tissues of the body. There are two subtypes of the receptor in humans, melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2). Melatonin and melatonin receptor agonists, on market or in clinical trials, all bind to and activate both receptor types.The binding of the agonists to the receptors has been investigated for over two decades or since 1986. It is somewhat known, but still not fully understood. When melatonin receptor agonists bind to and activate their receptors it causes numerous physiological processes.

MT1 receptors are expressed in many regions of the central nervous system (CNS): suprachiasmatic nucleus of the hypothalamus (SNC), hippocampus, substantia nigra, cerebellum, central dopaminergic pathways, ventral tegmental area and nucleus accumbens. MT1 is also expressed in the retina, ovary, testis, mammary gland, coronary circulation and aorta, gallbladder, liver, kidney, skin and the immune system. MT2 receptors are expressed mainly in the CNS, also in the lung, cardiac, coronary and aortic tissue, myometrium and granulosa cells, immune cells, duodenum and adipocytes.

The binding of melatonin to melatonin receptors activates a few signaling pathways. MT1 receptor activation inhibits the adenylyl cyclase and its inhibition causes a rippling effect of non activation; starting with decreasing formation of cyclic adenosine monophosphate (cAMP), and then progressing to less protein kinase A (PKA) activity, which in turn hinders the phosphorilation of cAMP responsive element-binding protein (CREB binding protein) into P-CREB. MT1 receptors also activate phospholipase C (PLC), affect ion channels and regulate ion flux inside the cell. The binding of melatonin to MT2 receptors inhibits adenylyl cyclase which decreases the formation of cAMP.[4] As well it hinders guanylyl cyclase and therefore the forming of cyclic guanosine monophosphate (cGMP). Binding to MT2 receptors probably affects PLC which increases protein kinase C (PKC) activity. Activation of the receptor can lead to ion flux inside the cell.', 'Melatonin is a hormone normally produced in the pineal gland and released into the blood. The essential amino acid L-tryptophan is a precursor in the synthesis of melatonin. It helps regulate sleep-wake cycles or the circadian rhythm. Production of melatonin is stimulated by darkness and inhibited by light. High levels of melatonin induce sleep and so consumption of the drug can be used to combat insomnia and jet lag.

MT1 and MT2 receptors may be a target for the treatment of circadian and non circadian sleep disorders because of their differences in pharmacology and function within the SCN. SCN is responsible for maintaining the 24 hour cycle which regulates many different body functions ranging from sleep to immune functions

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ratilya lightening cream 75 gm', 13147, 'راتيليا كريم تفتيح 75 جم', '96', '60', 'Whitening topical', 'Whitening topical', NULL, NULL, 'Debeiky > gold pharm', 'Cream', 'كريم', '75 gm', '1', 'كريم تفتيتح للجلد -- ترطيب الجلد وتنعيمه', NULL, 'whitening cream', NULL, 2329, '2025-08-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Oria deodorant cream 30 gm', 32063, 'اوريا ديودورانت كريم 30 جم', '74', NULL, 'Deodorant cream', 'Deodorant cream', NULL, 'Cetrimide+tea tree oil+jasmine fragrance+glycolic acid+vitamin e+zinc oxide+panthenol+allantoin+olive oil+glycerin', 'Hi-care pharmaceuticals & cosmetics > unimax', 'Cream', 'كريم', '30 gm', '1', NULL, NULL, 'deodorant cream by (antimicrobial antifungal and antiseptic effect controls sweat controls odor anti-inflammatory brightening effect moisturizer effect)', NULL, 667, '2023-03-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Neurocet 20% syrup 120 ml', 23461, 'نيوروسيت 20% شراب 120 مل', '11', NULL, 'Cerebral circulatory inhancer', 'Cerebral circulatory inhancer', NULL, 'Piracetam', 'Misr', 'Syrup', 'شراب', '20%', '1', NULL, NULL, NULL, '6221035003093', 1029, '2022-12-26', NULL, 0, 'Indicated in adult patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies [L1125].', 'Piracetam interacts with the polar heads in the phospholipids membrane and the resulting mobile drug-lipid complexes are thought to reorganize the lipids and influence membrane function and fluidity [A31532]. Such interaction has been reported in a study that investigated the effects of neuronal outgrowth induced by beta amyloid peptides; while amyloid peptides cause lipid disorganization within the cell membranes leading to neuronal death, piracetam demonstrated to decrease the destabilizing effects of amyloid peptide [A31534]. The authors suggest that piracetam induces a positive curvature of the membrane by occupying the polar groups in the phospholipids to counteract the negative curvature induced by amyloid peptides , which in turn would decrease the likelihood of membrane fusion [A31532]. This mechanism of action is thought to improve membrane stability, allowing the membrane and transmembrane proteins to maintain and recover the three-dimensional structure or folding for normal function [L1124] such as membrane transport, chemical secretion, and receptor binding and stimulation [A31532]. 



Through restored membrane fluidity, piracetam promotes restored neurotransmission such as glutamatergic and cholinergic systems, enhances neuroplasticity and mediates neuroprotective and anticonvulsant effects at the neuronal level [A31532]. It is also demonstrated that piracetam also improves the fluidity of platelet membranes. At the vascular level, piracetam decreases adhesion of erythrocytes to cell wall and reduces vasospasm which in turn improves microcirculation including cerebral and renal blood flow [A31532]. ', 'Piracetam is known to mediate various pharmacodynamic actions:



**Neuronal effects**: 



Piracetam modulates the cholinergic, serotonergic, noradrenergic, and glutamatergic neurotransmission although the drug does not display high affinity to any of the associated receptors (Ki >10μM). Instead, piracetam increases the density of postsynaptic receptors and/or restore the function of these receptors through stabilizing the membrane fluidity [A31532]. In the forebrain of aging mice, the density of NMDA receptors was increased by approximately 20% following 14 days of piracetam treatment. Based on the findings of various animal and human studies, the cognitive processses including learning, memory, attention and consciousness were enhanced from piracetam therapy without inducing sedation and psychostimulant effects [L1125]. Piracetam mediate neuroprotective effects against hypoxia-induced damage, intoxication, and electroconvulsive therapy [L1125]. 



In two studies involving alcohol-treated rats with evidences of withdrawal-related neuronal loss, piracetam was shown to reduce the extent of neuronal loss and increase the numbers of synapses in the hippocampus by up to 20% relative to alcohol-treated or alcohol-withdrawn rats [A31532]. This suggests that piracetam is capable in promoting neuroplasticity when recoverable neural circuits are present [A31532]. Although the mechanism of action is not fully understood, administration of piracetam prior to a convulsant stimulus reduces the seizure severity and enhances the anticonvulsant effectiveness of conventional antiepileptics such as carbamazepine and diazepam [A31535]. 



**Vascular effects**: 



Piracetam is shown to increase the deformability of erythrocytes, reduce platelet aggregation in a dose-dependent manner, reduce the adhesion of erythrocytes to vascular endothelium and capillary vasospasm. In healthy volunteers, piracetam mediated a direct stimulant effect on prostacycline synthesis and reduced the plasma levels of fibrinogen and von Willebrand’s factors (VIII: C; VIII R: AG; VIII R: vW) by 30 to 40% [L1125]. Potentiated microcirculation is thought to arise from a combination of effects on erythrocytes, blood vessels and blood coagulation [A31532]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ivymedium 120 ml syrup', 22034, 'ايفي ميديوم 120 مل شراب', '45', NULL, 'Supports respiratory system health', 'Supports respiratory system health', NULL, 'Ivy leaf+licorice root+thyme leaf', 'Remedium pharmaceutical', 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, NULL, '6225000569669', 777, '2022-10-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Phosphoplex iron syrup 120ml', 24891, 'فوسفوبلكس شراب حديد 120مل', '3', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Calcium pantothenate+nicotinamide+vitamin b1+vitamin b2+vitamin b6+iron', 'Kahira', 'Syrup', 'شراب', '120ml', '1', NULL, NULL, NULL, '6221068402887', 902, '2023-01-25', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Caudal scalp & body shampoo 125 ml', 15946, 'كودال شامبو 125 مل', '85', '59', 'Hair care', 'Hair care', NULL, 'Piroctone olamine+chlorhexidine+rosemary+aloe vera+chamomile+thyme+panthenol+olive+eruca+tocopherol', 'Leader industry > farabi', 'Amp', 'أمبول', '125 ml', '1', NULL, NULL, 'application: apply caudal hair shampoo on wet hair leave for 2-3 minutes then rinse. - twice weekly for dandruff and hair falling - once daily for babies cradle cap - once daily for skin fungal infections', '6224007935118', 576, '2024-06-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ilia gel 60 gm', 21532, 'اليا جل 60 جم', '120', '100', 'Anti-acne', 'Anti-acne', NULL, 'Chlorohexidine+chamomile+d-panthenol+aloe vera+tea tree oil+propolis+lemon oil+sodium hydroxide+glycerin+carbomer+hydroxypropyl cellulose', 'Prime pharma', 'Gel', 'جل', '60 gm', '1', NULL, NULL, NULL, '6224011686136', 870, '2025-07-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lepsylief 600 mg 20 tabs.', 21705, 'ليبسيليف 600 مجم 20 قرص', '454', '330', 'Anti-epileptic', 'Anti-epileptic', NULL, 'Eslicarbazepine', 'Horus for pharmaceutical products', 'Tab', 'أقراص', '600 mg', '2', 'يستخدم في حالات الصرع -- يقلل التشنجات الناتجة من الصرع --يقلل عدد نوبات التشنجات', NULL, NULL, '6224009763986', 2422, '2025-08-23', NULL, 0, 'Eslicarbazepine acetate is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.[L4565]', 'Eslicarbazepine acetate is converted to the active metabolite eslicarbazepine which carries out its anticonvulsant activity. The exact mechanism of action is unknown, but it is thought to involve the inhibition of voltage-gated sodium channels. In in vitro electrophysiological studies, eslicarbazepine was shown to inhibit repeated neuronal firing by stabilizing the inactivated state of voltage-gated sodium channels and preventing their return to the activated state. In vitro studies also showed eslicarbazepine inhibiting T-type calcium channels, which likely also has a role in anticonvulsant activity. ', 'Eslicarbazepine acetate is associated with a dose- and concentration-dependant increase in heart rate and prolongation of PR interval.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Eyevit 20 tabs.', 4572, 'اي فيت 20 قرص', '28', NULL, 'Multivitamins', 'Multivitamins', NULL, 'Vitamin a+vitamin e+vitamin c+selenium+zinc+copper', 'Sigma > majestic power', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, NULL, 882, '2022-10-15', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nomassist 5mg 20 tabs', 33287, 'نوماسيست 5 مجم 20 قرص', '150', '86', 'Sleep support', 'Sleep support', NULL, 'Melatonin 5mg + vitamin b6 1.2 mg', 'Zativa pharmaceuticals- phi medical', 'Tab', 'أقراص', '5mg', '2', NULL, NULL, NULL, NULL, 644, '2025-08-03', NULL, 0, 'Used orally for jet lag, insomnia, shift-work disorder, circadian rhythm disorders in the blind (evidence for efficacy), and benzodiazepine and nicotine withdrawal. Evidence indicates that melatonin is likely effective for treating circadian rhythm sleep disorders in blind children and adults. It has received FDA orphan drug status as an oral medication for this use. A number of studies have shown that melatonin may be effective for treating sleep-wake cycle disturbances in children and adolescents with mental retardation, autism, and other central nervous system disorders. It appears to decrease the time to fall asleep in children with developmental disabilities, such as cerebral palsy, autism, and mental retardation. It may also improve secondary insomnia associated with various sleep-wake cycle disturbances. Other possible uses for which there is some evidence for include: benzodiazepine withdrawal, cluster headache, delayed sleep phase syndrome (DSPS), primary insomnia, jet lag, nicotine withdrawal, preoperative anxiety and sedation, prostate cancer, solid tumors (when combined with IL-2 therapy in certain cancers), sunburn prevention (topical use), tardive dyskinesia, thrombocytopenia associated with cancer, chemotherapy and other disorders. ', 'Melatonin is a derivative of tryptophan. It binds to melatonin receptor type 1A, which then acts on adenylate cylcase and the inhibition of a cAMP signal transduction pathway. Melatonin not only inhibits adenylate cyclase, but it also activates phosphilpase C. This potentiates the release of arachidonate. By binding to melatonin receptors 1 and 2, the downstream signallling cascades have various effects in the body. The melatonin receptors are G protein-coupled receptors and are expressed in various tissues of the body. There are two subtypes of the receptor in humans, melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2). Melatonin and melatonin receptor agonists, on market or in clinical trials, all bind to and activate both receptor types.The binding of the agonists to the receptors has been investigated for over two decades or since 1986. It is somewhat known, but still not fully understood. When melatonin receptor agonists bind to and activate their receptors it causes numerous physiological processes.

MT1 receptors are expressed in many regions of the central nervous system (CNS): suprachiasmatic nucleus of the hypothalamus (SNC), hippocampus, substantia nigra, cerebellum, central dopaminergic pathways, ventral tegmental area and nucleus accumbens. MT1 is also expressed in the retina, ovary, testis, mammary gland, coronary circulation and aorta, gallbladder, liver, kidney, skin and the immune system. MT2 receptors are expressed mainly in the CNS, also in the lung, cardiac, coronary and aortic tissue, myometrium and granulosa cells, immune cells, duodenum and adipocytes.

The binding of melatonin to melatonin receptors activates a few signaling pathways. MT1 receptor activation inhibits the adenylyl cyclase and its inhibition causes a rippling effect of non activation; starting with decreasing formation of cyclic adenosine monophosphate (cAMP), and then progressing to less protein kinase A (PKA) activity, which in turn hinders the phosphorilation of cAMP responsive element-binding protein (CREB binding protein) into P-CREB. MT1 receptors also activate phospholipase C (PLC), affect ion channels and regulate ion flux inside the cell. The binding of melatonin to MT2 receptors inhibits adenylyl cyclase which decreases the formation of cAMP.[4] As well it hinders guanylyl cyclase and therefore the forming of cyclic guanosine monophosphate (cGMP). Binding to MT2 receptors probably affects PLC which increases protein kinase C (PKC) activity. Activation of the receptor can lead to ion flux inside the cell.', 'Melatonin is a hormone normally produced in the pineal gland and released into the blood. The essential amino acid L-tryptophan is a precursor in the synthesis of melatonin. It helps regulate sleep-wake cycles or the circadian rhythm. Production of melatonin is stimulated by darkness and inhibited by light. High levels of melatonin induce sleep and so consumption of the drug can be used to combat insomnia and jet lag.

MT1 and MT2 receptors may be a target for the treatment of circadian and non circadian sleep disorders because of their differences in pharmacology and function within the SCN. SCN is responsible for maintaining the 24 hour cycle which regulates many different body functions ranging from sleep to immune functions

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Movelex advance 30 caps.', 33231, 'موفيلكس ادفانس 30 كبسولة', '295', '237', 'Massage', 'Massage', NULL, 'Glucosamine + hydrolyzed marine collagen + chondroitin + msm + bromelain + boswellia + l-methionine', 'Majestic biopharma', 'Cap', 'كبسولة', NULL, '3', 'علاج الام العظام والغضاريف ويساعد على تخفيف الالم والتورم المصاحب لالتهاب المفاصل', NULL, NULL, '6224001455193', 10168, '2024-02-12', NULL, 0, 'Glucosamine is generally used over the counter in the symptomatic treatment of osteoarthritis and joint pain,[A2352] frequently combined with chondroitin sulfate and/or ibuprofen.[L32699]', 'The mechanism of action of glucosamine in joint health is unclear,[A231894] however there are several possible mechanisms that contribute to its therapeutic effects. Because glucosamine is a precursor for glycosaminoglycans, and glycosaminoglycans are a major component of joint cartilage,[A232289] glucosamine supplements may help to rebuild cartilage and treat the symptoms of arthritis.  Some in vitro studies show evidence that glucosamine reduces inflammation via inhibition of interferon gamma[A12619,A12616,A12621]  and Nuclear factor kappa B subunit 65 (NF-κB p65),[A12616,A232284] improving the symptoms of arthritis and joint pain. Clinical relevance is unknown at this time.', 'The administration of glucosamine, in theory, provides a building block towards the synthesis of glycosaminoglycans, slowing the progression of osteoarthritis and relieving symptoms of joint pain. Studies to this date examining the efficacy of glucosamine sulfate have been inconclusive. Glycosaminoglycans contribute to joint cartilage elasticity, strength, and flexibility.[A232144] A systematic review of various studies and guidelines determined that modest improvements were reported for joint pain and function in patients taking glucosamine. A consistent joint space narrowing was observed, but with an unclear clinical significance.[A231894]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Deltacortril 5mg 20 tab', 3395, 'دلتاكورتريل 5مجم 20 قرص', '3', NULL, 'Glucocorticoid', 'Glucocorticoid', NULL, 'Prednisolone', 'Pfizer', 'Tab', 'أقراص', '5mg', '2', 'مضاد للحساسية -- تقليل الالتهابات', NULL, NULL, NULL, 1466, '2023-06-02', NULL, 0, 'Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]', 'The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463]



Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463]



Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463]', 'Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Prednisolone has a short duration of action as the half life is 2.1-3.5 hours.[A187394] Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces.[A187463] Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hycamtin 4mg vial', 20589, 'هيكامتين 4 مجم فيال', '928', NULL, 'Antineoplastic', 'Antineoplastic', NULL, 'Topotecan', 'Smithkline beecham > glaxo smithkline', 'Vial', 'فيال', '4mg', '1', NULL, NULL, NULL, NULL, 1169, '2022-07-15', NULL, 0, 'For the treatment of advanced ovarian cancer in patients with disease that has recurred or progressed following therapy with platinum-based regimens. Also used as a second-line therapy for treatment-sensitive small cell lung cancer, as well as in combination with cisplatin for the treatment of stage IV-B, recurrent, or persistent cervical cancer not amenable to curative treatment with surgery and/or radiation therapy.', 'Topotecan has the same mechanism of action as irinotecan and is believed to exert its cytotoxic effects during the S-phase of DNA synthesis. Topoisomerase I relieves torsional strain in DNA by inducing reversible single strand breaks. Topotecan binds to the topoisomerase I-DNA complex and prevents religation of these single strand breaks. This ternary complex interferes with the moving replication fork, which leads to the induction of replication arrest and lethal double-stranded breaks in DNA. As mammalian cells cannot efficiently repair these double strand breaks, the formation of this ternary complex eventually leads to apoptosis (programmed cell death).



Topotecan mimics a DNA base pair and binds at the site of DNA cleavage by intercalating between the upstream (−1) and downstream (+1) base pairs. Intercalation displaces the downstream DNA, thus preventing religation of the cleaved strand. By specifically binding to the enzyme–substrate complex, Topotecan acts as an uncompetitive inhibitor.', 'Topotecan, a semi-synthetic derivative of camptothecin (a plant alkaloid obtained from the <i>Camptotheca acuminata</i> tree), is an anti-tumor drug with topoisomerase I-inhibitory activity similar to irinotecan. DNA topoisomerases are enzymes in the cell nucleus that regulate DNA topology (3-dimensional conformation) and facilitate nuclear processes such as DNA replication, recombination, and repair. During these processes, DNA topoisomerase I creates reversible single-stranded breaks in double-stranded DNA, allowing intact single DNA strands to pass through the break and relieve the topologic constraints inherent in supercoiled DNA. The 3''-DNA terminus of the broken DNA strand binds covalently with the topoisomerase enzyme to form a catalytic intermediate called a cleavable complex. After DNA is sufficiently relaxed and the strand passage reaction is complete, DNA topoisomerase reattaches the broken DNA strands to form the unaltered topoisomers that allow transcription to proceed. Topotecan interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells can be affected by the medicine, other effects may also occur. Unlike irinotecan, topotecan is found predominantly in the inactive carboxylate form at neutral pH and it is not a prodrug.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Terbin 1% topical spray 30 ml', 28057, 'تيربين 1% سبراي بخاخ 30 مل', '13', NULL, 'Antifungals.allylamines', 'Antifungals.allylamines', NULL, 'Terbinafine', 'Global napi pharmaceuticals', 'Spray', 'بخاخ', '1%', '1', 'مضاد للفطريات في حالات سعفة القدم ، سعفة الجسد ، سعفة الرأس ، سعفة الجلد وداء الفطريات.', NULL, 'about terbinafine a synthetic allylamine derivative antifungal. mechanism of action of terbinafine terbinafine is a fungicidal drug. it interfere the conversion of squalene to ergosterol by inhibiting the enzyme squalene epoxidase.this results in accumula', '6224000821388', 4273, '2022-07-03', NULL, 0, 'Terbinafine hydrochloride is indicated to treat fungal skin and nail infections caused by _Trichophyton_ species, _Microsporum canis_, _Epidermophyton floccosum_,[L9068] and _Tinea_ species.[L9065] Terbinafine hydrochloride also treats yeast infections of the skin caused by _Candida_ species and _Malassezia furfur_.[L9068]', 'Terbinafine inhibits the enzyme squalene monooxygenase (also called squalene epoxidase), preventing the conversion of squalene to 2,3-oxydosqualene, a step in the synthesis of ergosterol.[A1279,A1281,L9068] This inhibition leads to decreased ergosterol, which would normally be incorporated into the cell wall, and accumulation of squalene.[A1281,L9068]



Generation of a large number of squalene containing vesicles in the cytoplasm may leach other lipids away from, and further weaken, the cell wall.[A1281]', 'Terbinafine is an allylamine antifungal that inhibits squalene epoxidase (also known as squalene monooxygenase) to prevent the formation of ergosterol and cause an accumulation of squalene, weakening the cell wall of fungal cells.[A1279,A1281,L9068] Terbinafine distributes into tissues and has a long terminal elimination half life, so the duration of action is long.[A1279] Overdose with terbinafine is rare, even above the therapeutic dose, so the therapeutic index is wide.[L9065,L9068] Patients taking oral terbinafine should have liver function tests performed prior to treatment to reduce the risk of liver injury.[L9065]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pradaxa 75 mg 30 caps.', 25119, 'براداكسا 75مجم 30 كبسول', '560', NULL, 'Anticoagulant.direct thrombin inhibitor', 'Anticoagulant.direct thrombin inhibitor', NULL, 'Dabigatran etexilate', 'Boehringer ingelheim', 'Cap', 'كبسولة', '75 mg', '3', NULL, NULL, 'dabigatran is used for: reducing the risk of stroke and serious blood clots in certain patients with atrial fibrillation. dabigatran is a direct thrombin inhibitor. it works by preventing the formation of a blood clot.', '4048846001627', 902, '2022-12-08', NULL, 0, 'Dabigatran etexilate is available in both oral pellet and capsule form. Dabigatran etexilate pellets are indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients between three months and 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days. They are also indicated in the same age group to reduce the risk of recurrence of VTE in patients who have been previously treated.[L34675]



In capsule form, dabigatran etexilate is indicated in adults to reduce the risk of stroke and systemic embolism associated with non-valvular atrial fibrillation and for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days. It is also indicated in adults to reduce the risk of recurrence of DVT and PE in patients who have been previously treated and for the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery. Lastly, it is indicated in pediatric patients between eight and 18 years of age for the treatment of venous thromboembolic events (VTE) in patients who have been treated with a parenteral anticoagulant for at least 5 days and to reduce the risk of recurrence of VTE in patients who have been previously treated.[L34680]



Dabigatran etexilate is also approved by the EMA to prevent VTE in adult patients. For pediatric patients, Dabigatran etexilate is used to treat TVE and prevent recurrent TVE for patients from birth to less than 18 years of age.[L46856]', 'Hemostasis is a complex process that balances coagulation to prevent excessive thrombus formation or excessive bleeding. Central to the coagulation process is the serine protease thrombin (FIIa), which is synthesized as inactive prothrombin (FII) and subsequently activated by FXa/FVa, leading to a positive feedback loop and the production of large quantities of thrombin; once enough thrombin is formed, it cleaves soluble fibrinogen to form insoluble fibrin fibres that, together with aggregated platelets, form a clot. Although beneficial in wound healing, aberrant thrombus formation can lead to serious health consequences.[A236205]



Dabigatran is a univalent reversible direct thrombin inhibitor (DTI) that competitively inhibits thrombin with a K<sub>i</sub> of 4.5 ± 0.2 nmol/L.[A236200, A236210, L34675, L34680] Furthermore, the reversible nature of the inhibition is believed to allow for some normal physiological thrombin function, which may help alleviate some adverse effects associated with anticoagulation therapy.[A236215] In addition, dabigatran has several glucuronidated metabolites, all of which have been shown to possess _in vitro_ activity similar to the parent compound.[A17924]



In addition to a direct effect on thrombin activity, dabigatran has also been shown to inhibit platelet aggregation, another step in the coagulation pathway. However, the mechanism remains unclear as dabigatran inhibits platelet aggregation stimulated by thrombin and von Willebrand factor (vWF), but not by other pathways such as ADP- or thromboxane A2-induced aggregation.[A236210, A236220, A215227, L34675, L34680]', 'Dabigatran etexilate is a double prodrug that is hydrolyzed to the active [dabigatran] by intestinal and hepatic carboxylesterases.[A236225, A17923, A236195] Dabigatran is a reversible competitive thrombin inhibitor that directly inhibits the conversion by thrombin of fibrinogen to fibrin, impairing the clotting process and acting as an anticoagulant.[A17924, A236200, A236210, L34675, L34680] Dabigatran use prolongs coagulation markers such as the activated partial thromboplastin time (aPTT), ecarin clotting time (ECT), thrombin time (TT), and dilute thrombin time (dTT), but not the international normalized ratio (INR), which cannot be used in this context as it can in [warfarin] monitoring.[L34675, L34680]



As with all anticoagulant therapies, dabigatran carries a risk of bleeding, which may increase with concomitant use of antiplatelet agents, fibrinolytic therapy, heparins, or chronic NSAID use, and should be monitored for. Premature discontinuation of dabigatran, in the absence of an alternative anticoagulant, also carries an increased risk of thromboembolic events. Due to the risk of an epidural or spinal hematoma, dabigatran should generally not be used in the context of neuraxial anesthesia or spinal puncture; if such use is unavoidable, careful monitoring should be employed. Dabigatran should not be used in patients with prosthetic heart valves due to an increased occurrence of major bleeding and thromboembolic events. Dabigatran is a substrate of the P-gp transporter and should generally not be administered together with P-gp inhibitors or inducers, especially in patients with impaired renal function. Lastly, dabigatran or any other direct-acting oral anticoagulant should not be administered in patients with triple-positive antiphospholipid syndrome (APS) due to an increased risk of recurrent thrombotic events. In case of the need for emergency reversal, [idarucizumab] is available for use in adult patients; the safety and efficacy of [idarucizumab] has not been established in pediatric patients yet, for whom reversal may be achieved through hemodialysis, prothrombin complex concentrates, or recombinant FVIIa. However, none of these have been sufficiently evaluated in clinical trials.[L34675, L34680]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Broc 10 sachets', 8078, 'بروك 10 اكياس', '240', '190', 'Anti-rheumatic.osteoarthritis.anabolic agents', 'Anti-rheumatic.osteoarthritis.anabolic agents', NULL, 'Collagen hydrolysate', 'Brother pharma', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, NULL, NULL, 1190, '2024-11-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vulga cream 30 gm', 29613, 'فولجا كريم 30 جرام', '75', '65', 'Anti-acne', 'Anti-acne', NULL, 'Glycolic acid+tea tree oil+vitamin a+aloe vera+liquorice+panthenol+glycerin+emu oil+salicylic acid', 'Hi-care > linkopharm', 'Cream', 'كريم', '30 gm', '1', NULL, NULL, NULL, '6224008585565', 2285, '2025-09-26', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sycocetam 500mg 20 f.c. tabs', 27789, 'سيكوسيتام 500مجم 20 قرص', '124', '93', 'Anti-epileptic.pyrrolidine', 'Anti-epileptic.pyrrolidine', NULL, 'Levetiracetam', 'Marcyrl co.', 'Tab', 'أقراص', '500mg', '2', NULL, NULL, NULL, '6223003570200', 2684, '2024-09-25', NULL, 0, 'Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.[L8606]



Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.[L8609]', 'The exact mechanism through which levetiracetam exerts its anti-epileptic effects is unclear, but is thought to be unique amongst other anti-epileptic medications. Current knowledge suggests that levetiracetam’s binding to synaptic vesicle protein 2A (SV2A) is a key driver of its action. SV2A is a membrane-bound protein that is found on synaptic vesicles and is ubiquitous throughout the CNS[A12546] - it appears to play a role in vesicle exocytosis[L8606,L8615] and in the modulation of synaptic transmission by increasing the available amount of secretory vesicles available for neurotransmission.[A12552] Stimulation of pre-synaptic SV2A by levetiracetam may inhibit neurotransmitter release,[A12551] but this action does not appear to affect normal neurotransmission. This has led to the suggestion that levetiracetam exclusively modulates the function of SV2A only under pathophysiological conditions.[A12546] Levetiracetam and related analogues showed a correlation between affinity for SV2A and anti-epileptic potency, further suggesting that action at this site contributes to the anti-epileptic activity of the drug.[L8606,L8615]



Levetiracetam has also been shown to indirectly affect GABAergic neurotransmission (despite having no direct effect on GABAergic or glutamatergic receptors) and modulate ionic currents.[A12552] Similarly, levetiracetam has been shown in vitro to inhibit N-type calcium channels.[A16562] How, or even if, these actions are implicated in its anti-epileptic action have yet to be elucidated.', 'Levetiracetam appears to prevent seizure activity via the selective inhibition of hypersynchronized epileptiform burst firing without affecting normal neuronal transmission, though the exact mechanism through which this occurs is unclear.[L8606,L8615] The therapeutic index of levetiracetam is wide,[L8615,A185918] making it relatively unique amongst other anti-epileptic medications.



Anti-epileptic drugs, including levetiracetam, may increase the risk of suicidal ideation or behaviour - patients taking levetiracetam should be monitored for the emergence or worsening of depressive symptoms, suicidal ideation, and behavioural abnormalities.[L8606,L8600,L8615]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ringer lactate (compound sodium lactate) (otsuka ateco) i.v. inf. 500 ml (rubber cap)', 26134, 'رينجر لاكتات (صوديوم لاكتات مركب) 500 مل محلول وريدي بغطاء مطاطي', '11', NULL, 'Sterile solution', 'Sterile solution', NULL, 'Calcium chloride+potassium chloride+sodium chloride+sodium lactate', 'Otsuka', 'Cap', 'كبسولة', '500 ml', '1', NULL, NULL, 'descriptions nonpyrogenic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. it contains no antimicrobial agents. the ph may have been adjusted with sodium hydroxide.sindications and usages is indica', NULL, 630, '2022-07-09', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zestoretic 20mg 10 tab', 12816, 'زيستوريتك 20مجم 10 اقراص', '68', '52', 'Antihypertensive.combined ace with diuretic', 'Antihypertensive.combined ace with diuretic', NULL, 'Hydrochlorothiazide+lisinopril', 'Astra zeneca', 'Tab', 'أقراص', '20mg', '1', NULL, NULL, NULL, '6223003270087', 3117, '2024-10-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Parkidopa cr 10 controlled release tab.', 24581, 'باركيدوبا سي ار 10 اقراص', '20', NULL, 'Parkinson s disease.dopamine agonist', 'Parkinson s disease.dopamine agonist', NULL, 'Carbidopa+levodopa', 'Delta pharma > andalous medical', 'Tab', 'أقراص', NULL, '1', NULL, NULL, 'about carbidopa a noncompetitive dopa decarboxylase inhibitor antidyskinetics anti-parkinson`s agent. mechanism of action of carbidopa carbidopa inhibits the peripheral decarboxylation of levodopa and thus slowing its conversion to dopamine in extra cereb', NULL, 761, '2022-07-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bon-one 0.5 mcg 30 tabs.', 1649, 'بون-ون 0.5مكجم 30 قرص', '123', '82.5', 'Vitamin d', 'Vitamin d', NULL, 'Alfacalcidol', 'Mina pharm > teijin limited-japan', 'Tab', 'أقراص', '0.5 mcg', '3', 'علاج نقص فيتامين دال -- التعب و الارهاق -- تحسين امتصاص الكالسيوم', NULL, 'description : alfacalcidol is an active metabolite of vitamin d indication : prescribed for hypocalcaemia hypoparathyroidism hypophosphataemia renal osteodystrophy and osteomalacia. dosage : adult- po- the recommended starting dose is 1mcg/day. maintenanc', '6222003701393', 10556, '2024-10-30', NULL, 0, 'Alfacalcidol is indicated in adult patients with chronic renal failure for the management of hypocalcemia, secondary hyperparathyroidism, or osteodystrophy.[L33284]



Alfacalcidol is indicated in the management of nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic vitamin D resistant rickets and osteomalacia.[L33364,L33369]', 'In conditions like chronic renal failure, renal bone disease, hypoparathyroidism, and vitamin D dependent rickets, the kidneys'' capacity for 1α-hydroxylation is impaired, leading to reduced production of endogenous 1,25-dihydroxyvitamin D and aberrated mineral metabolism. As an active and potent analog of vitamin D, alfacalcidol works to restore the functions and activities of endogenous 1,25-dihydroxyvitamin D.[L33369]', 'Alfacalcidol works to increase serum levels of calcium by stimulating intestinal calcium absorption, reabsorption of calcium from bone, and possibly the renal reabsorption of calcium. It also modestly promotes intestinal phosphorus absorption.[L33284] In patients with renal failure, alfacalcidol increased intestinal calcium and phosphorus absorption in a dose-related manner. This increase in calcium and phosphorus levels occurs within three days following drug administration: this effect was reversed within three days of drug discontinuation. In patients with chronic renal failure, serum calcium levels were elevated while parathyroid hormone and alkaline phosphatase levels returned to normal levels within five days following alfacalcidol administration.[L33369] Since alfacalcidol suppresses parathyroid hormone, a reduction in parathyroid hormone levels is achieved more rapidly in patients on intermittent intravenous therapy, with significant reductions occurring within three months of therapy. In patients receiving daily oral therapy of alfacalcidol, the time it takes alfacalcidol to normalize plasma calcium levels may be up to several months, possibly reflecting calcium being utilized for bone mineralization.[L33284] In patients with nutritional osteomalacia, alfacalcidol increased calcium absorption with six hours of oral administration and the effects peaked at 24 hours.[L33369]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cryptonaz 100mg/5ml susp. 60ml', 16922, 'كريبتوناز 100مجم/5مل معلق 60 مل', '39', '27.50', 'Antihelminthic', 'Antihelminthic', NULL, 'Nitazoxanide', 'Adwia > copad pharma', 'Susp', 'معلق', '100mg', '1', NULL, NULL, 'about nitazoxanide a synthetic nitrothiazolyl-salicylamide derivative antihelminthics in schistosomiasis. mechanism of action of nitazoxanide it excerts its action by blocking anaerobic energy metabolism. the drug interfering with the pyruvate-ferredoxin', '6224000394066', 1268, '2024-08-28', NULL, 0, 'For the treatment of diarrhea in adults and children caused by the protozoa <i>Giardia lamblia</i>,  and for the treatment of diarrhea in children caused by the protozoan,  <i>Cryptosporidium parvum</i> [FDA label].



Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV/immunodeficiency [FDA label, A31973, A31976]. ', 'The most widely accepted mechanism of NTZ is believed to be the disruption of the energy metabolism in anaerobic microbes by inhibition of the pyruvate: ferredoxin/flavodoxin oxidoreductase (PFOR) cycle [A31981]. In parasitic-protozoa, Nitazoxanide also induces lesions in the cell membranes and depolarizes the mitochondrial membrane while inhibiting quinone oxidoreductase NQO1, nitroreductase-1 and protein disulphide isomerase enzymes. In addition, this drug also inhibits the glutathione-S-transferase (a major detoxifying enzyme) and modulates the Avr-14 gene, encoding for the alpha-type subunit of glutamate-gated chloride ion channel present in nematodes. Aside from its well understood non-competitive inhibition of the PFOR in anaerobic bacteria, NTZ also demonstrates various other antibacterial mechanisms. It inhibits pyruvate dehydrogenase in E Coli, disrupts the membrane potential and pH homeostasis in the Mycobacterium tuberculosis, suppresses the chaperone/usher (CU) pathway of the gram-negative bacteria,  and stimulates host macrophage autophagy in tuberculosis patients [A31976]. NTZ also suppresses viral replication by inhibiting the maturation of the viral hemagglutinin and the viral transcription factor immediate early 2 (IE2) as well as by activating the eukaryotic translation initiation factor 2α (an antiviral intracellular protein). Lastly, NTZ exhibits an inhibitory effect on tumor cell progression by altering drug detoxification (glutathione-S-transferase P1), unfolded protein response, autophagy, anti-cytokines activity, and c-Myc inhibition [A31976].', 'The general effect of this medication is the prevention of microbe activity through disruption of important energy pathways for survival and proliferation [FDA label, A31976].  Nitazoxanide exhibits antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, an essential reaction need for anaerobic energy metabolism of various microorganisms.  Sporozoites of Cryptosporidium parvum and trophozoites of Giardia lamblia are therefore inhibited, relieving symptoms of diahrrea [L1425]. Interference with the PFOR enzyme-dependent electron transfer reaction may only be one of the many pathways by which nitazoxanide exhibits antiprotozoal activity [FDA label, A31973, L1425]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cefidime 500mg vial', 16015, 'سيفيديم 500مجم فيال', '24', NULL, 'Antibiotic.cephalosporin.third-generation', 'Antibiotic.cephalosporin.third-generation', NULL, 'Ceftazidime', 'Eipico', 'Vial', 'فيال', '500mg', '1', NULL, NULL, 'about ceftazidime third generation cephalosporin antibiotic parenteral antibiotic. mechanism of action of ceftazidime ceftazidime is a 3rd generation cephalosporin which exerts its bactericidal action against both gram positive & gram negative organisms b', '6221032315908', 773, '2022-07-12', NULL, 0, 'Ceftazidime is indicated for the treatment of lower respiratory tract infections, skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra-abdominal infections (including peritonitis), and central nervous system infections (including meningitis) caused by susceptible bacteria.[L32935]



Ceftazidime is indicated in combination with [avibactam] to treat infections caused by susceptible Gram-negative organisms, including complicated intra-abdominal infections (cIAI), in conjunction with [metronidazole], and complicated urinary tract infections (cUTI), including pyelonephritis, in patients aged three months and older. This combination is also indicated to treat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older.[L45128]



In all cases, to mitigate the risk of bacterial resistance and preserve clinical efficacy, ceftazidime should only be used for infections that are confirmed or strongly suspected to be caused by susceptible bacterial strains.[L32935, L45128]', 'The bacterial cell wall, which is located at the periphery of Gram-positive bacteria and within the periplasm of Gram-negative bacteria, comprises a glycopeptide polymer synthesized through cross-linking of glycans to peptide stems on alternating saccharides, which is known commonly as peptidoglycan.[A232920] Cell wall formation, recycling, and remodelling require numerous enzymes, including a family of enzymes with similar active site character despite distinct and sometimes overlapping roles as carboxypeptidases, endopeptidases, transpeptidases, and transglycosylases, known as "penicillin-binding proteins" (PBPs). The number of PBPs differs between bacteria, in which some are considered essential and others redundant. In general, inhibition of one or more essential PBPs results in impaired cell wall homeostasis, loss of cell integrity, and is ultimately bactericidal.[A232920, A232925, A232930]



Ceftazidime is a semisynthetic third-generation cephalosporin with broad activity against numerous Gram-negative and some Gram-positive bacteria.[L32935] Like other β-lactam antibiotics, ceftazidime exhibits its bactericidal effect primarily through direct inhibition of specific PBPs in susceptible bacteria.[A232935] _In vitro_ experiments in Gram-negative bacteria such as _Escherichia coli_, _Pseudomonas aeruginosa_, _Acinetobacter baumannii_, and _Klebsiella pneumoniae_ suggest that ceftazidime primarily binds to PBP3, with weaker binding to PBP1a/1b and PBP2 as well; although binding to other PBPs, such as PBP4, is detectable, the concentrations required are much greater than those achieved clinically.[A232935, A16721, A232940, A232945, A232950] Similarly, ceftazidime showed binding to _Staphylococcus aureus_ PBP 1, 2, and 3 with a much lower affinity for PBP4.[A16721] Recent data for _Mycobacterium abcessus_ suggest that ceftazidime can inhibit PonA1, PonA2, and PbpA at intermediate concentrations.[A232930]', 'Ceftazidime is a semisynthetic, broad-spectrum, third-generation cephalosporin antibiotic that is bactericidal through inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin-binding protein 3 (PBP3).[L32935] Among cephalosporins, ceftazidime is notable for its resistance to numerous β-lactamases and its broad spectrum of activity against Gram-negative bacteria, including _Pseudomonas aeruginosa_.[A232935] However, it is less active than first- and second-generation cephalosporins against _Staphylococcus aureus_ and other Gram-positive bacteria and also has low activity against anaerobes.[A232935, A233160] Ceftazidime has confirmed activity against clinically relevant Gram-negative bacteria including _Citrobacter_ spp., _Enterobacter_ spp., _Klebsiella_ spp., _Proteus_ spp., _Serratia spp., _Escherichia coli_, _Haemophilus influenzae_, _Neisseria meningitidis_, _Pseudomonas aeruginosa_, and some Gram-positive bacteria including _Staphylococcus_ spp. and _Streptococcus_ spp. There are also _in vitro_ data for ceftazidime efficacy against a wide variety of other bacteria, such as _Acinetobacter baumannii_ and _Neisseria gonorrhoeae_, but no clear clinical studies to support the use of ceftazidime for infections caused by these bacteria.[L32935]



Although β-lactam antibiotics like ceftazidime are generally well tolerated, there remains a risk of serious acute hypersensitivity reactions, which is higher in patients with a known allergy to ceftazidime or any other β-lactam antibiotic. As with all antibiotics, ceftazidime may result in the overgrowth of non-susceptible organisms and potentially serious effects including _Clostridium difficile_-associated diarrhea (CDAD); CDAD should be considered in patients who develop diarrhea and, in confirmed cases, supportive care initiated immediately. Ceftazidime is primarily renally excreted such that high and prolonged serum concentrations can occur in patients with renal insufficiency, leading to seizures, nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia. Treatment may lead to the development or induction of resistance with a risk of treatment failure. Periodic susceptibility testing should be considered, and monotherapy failure may necessitate the addition of another antibiotic such as an aminoglycoside. Cephalosporin use may decrease prothrombin activity, which may be improved by exogenous vitamin K. Inadvertent intra-arterial administration of ceftazidime may result in distal necrosis.[L32935]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Alucal plus 20 chew. tab.', 13858, 'الوكال بلس 20 قرص للمضغ', '5', NULL, 'Antacid', 'Antacid', NULL, 'Dihydroxyaluminum sodium carbonate+simethicone', 'Amriya', 'Tab', 'أقراص', NULL, '2', NULL, NULL, 'treating acid indigestion heartburn and sour stomach. it may also be used for other conditions as determined by your doctor. dihydroxyaluminum sodium chewable tablets is an antacid. it works by neutralizing acid in the stomach.', '6221075010389', 969, '2022-12-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Royal care 20 caps', 10062, 'رويال كير 20 كبسولة', '170', '105', 'Dietary supplement', 'Dietary supplement', NULL, 'Ginseng+royal jelly+wheat germ oil', 'Arab caps > multicare', 'Cap', 'كبسولة', NULL, '2', NULL, NULL, 'active ingredient: royal jelly 1000mg korean ginseng 45mg wheat germ oil 600mg indication dietary supplement to improve body function. dosage one capsule daily or as prescribed by the physician', '6224007326756', 7905, '2023-09-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vixaport 30 f.c. tabs.', 13904, 'فيكسابورت 30 قرص', '150', '78', 'Vitamin b', 'Vitamin b', NULL, 'Benfotiamine+cyanocobalamine+pyridoxine', 'Hikma', 'Tab', 'أقراص', NULL, '3', 'مكمل غذائى يدعم الجهاز العصبى ويمد الجسم بالطاقة', NULL, NULL, '6221000006180', 17625, '2025-06-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hair queen hair nutrients serum 100ml', 32021, 'هير كوين هير سيروم 100 مل', '250', NULL, 'Hair care', 'Hair care', NULL, 'Argan oil+jojoba oil+wheat germ oil+olive oil+rosemary extract+ginseng extract+saw palmetto extract+green tea extract+vitamin e+caffeine+biotin', 'Egyptian co.for cosmetic (ecc) > vida international pharma', 'Serum', 'سيروم', '100ml', '1', NULL, NULL, 'hair nutrients serum', NULL, 910, '2023-03-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dextrose 50% (otsuka) i.v. inf. 25 ml', 17507, 'دكستروز 50% اوتوسوكا محلول وريدي 25 مل', '3', NULL, 'Sterile solution', 'Sterile solution', NULL, 'Glucose (dextrose)', 'Otsuka', 'Unknown', 'غير محدد', '50%', '1', NULL, NULL, NULL, NULL, 669, '2022-07-15', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hyalomark cream 50 gm', 21302, 'هيالومارك كريم 50 جم', '108', '89', 'Healing topical', 'Healing topical', NULL, 'Hyaluronic acid+peanut butter+silicon gel+honey+hydrolyzed wheat protein+olive oil+conezyme a+soybeanoil+l.carnitine+caffeine+green tea extract+aloe vera extract+olive oil+safflower oil+sunflower seed oil+lecithin', 'Mark pharma', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, NULL, NULL, 1363, '2024-07-03', NULL, 0, 'The intra-articular preparations of hyaluronic acid are indicated for knee pain associated with osteoarthritis.[L32228] Hyaluronic acid is used in cosmetic applications to prevent and reduce the appearance of wrinkles on the face, and as a dermal filler to correct facial imperfections or other imperfections on other parts of the body.[L32208,L32223] It is frequently an ingredient in topical applications for wound healing and symptomatic treatment of skin irritation from various causes.[L32198] Hyaluronic acid may also be indicated in ophthalmological preparations or oral capsules to treat discomfort caused by dry eyes or conjunctivitis and for its protective qualities during and before eye surgery.[A230128,L32213] Finally, hyaluronic acid can be used off-label to coat the bladder for relief of interstitial cystitis symptoms.[A230533]', 'General principles and hyaluronic acid receptor binding 



Hyaluronic acid works by two basic mechanisms: serving as a passive structural molecule or serving as signaling molecule, depending on the molecule size. The physicochemical properties of high molecular weight HA contribute to passive structural effects, demonstrating hygroscopicity and viscoelasticity and improving hydration, water balance, and structural integrity. As a signalling  molecule interacting with proteins, HA causes several opposing effects based on molecular weight: pro- or anti-inflammatory effects, promotion or inhibition of cell migration, and activating or inhibiting cell division.[A230133] 



Hyaluronic acid exerts its therapeutic effects through binding to three primary types of cell surface receptors: CD44 (a membrane glycoprotein), the receptor for hyaluronate-mediated motility (RHAMM), and the Intercellular Adhesion Molecule 1 (ICAM-1). CD44 is considered the most widely distributed receptor for hyaluronic acid, demonstrating cellular interactions with osteopontin, collagen, and matrix metalloproteinases (MMPs).  High and low molecular weight hyaluronic acids demonstrate differing molecular and cellular mechanisms in their interaction with CD44 receptors. Some examples of these effects include modification of chondrocyte survival pathways in addition to alteration of apoptosis pathways.  Lymphatic vessel endothelial hyaluronan receptor (LYVE-1), and hyaluronic acid receptor for endocytosis (HARE), (also known as Stabilin-2) also bind to hyaluronic acid.[A230128] 



Hyaluronic acid for skin conditions and cosmetics



Hyaluronic acid''s anionic proprieties cause it to attract water and induce swelling, increasing tissue volume and skin structural integrity. The aging process is associated with reduced production of skin hyaluronic acid and collagen, causing the appearance of wrinkles and the loss of facial volume. Dermal fillers of hyaluronic acid replace lost tissue volume, imparting a full and youthful appearance to skin that has lost its elasticity. Hyaluronic acid fillers contain cross-linked hyaluronic acid particles, rendering a concentrated substance with resistance to various forms of physical and chemical breakdown. The cosmetic benefits of hyaluronic acid filler may last up to 6 months, depending on the brand and technique used for injection.[L32193] Additionally, dermal hyaluronic acid fillers are known to increase the production of fibroblasts[L32193], supporting wound healing and offering relief from irritating and inflammatory skin conditions.[A230118]





Hyaluronic acid for joint pain



Most cells in the human body are capable of synthesizing HA. It is a primary component of the extracellular matrix (ECM) and can be found in bone marrow, cartilage, and synovial fluid in joints.[A230128] In osteoarthritis, the concentration of naturally occurring hyaluronic acid gradually decreases, lowering the viscosity of synovial fluid that protects joints from excess friction. Administration of intra-articular hyaluronic acid increases viscosity of synovial joint fluid, reducing friction and subsequently relieving painful arthritic symptoms.[L32193]





Hyaluronic acid for ophthalmic conditions and ophthalmological procedures



Solutions of hyaluronic acid with a concentration greater than 0.1% moisturize the surface of the eyes to treat symptoms of dry eye while improving the stabilization of tear film, replenishing deficiencies of HA, reducing friction, and preventing binding of foreign substances to the ocular tissue.[A230128,L32193] Hyaluronic acid is frequently used during and after ophthalmological surgeries and plays important roles by virtue of its moisturizing, viscoelastic, and protective properties. It promotes tissue healing of the corneal epithelium and other parts of the eye following ophthalmological surgery, minimizing the risk of adhesions and free radical formation.[A230128]

', 'HA has long-acting lubricant, shock absorbing, joint stabilizing, and water balancing properties.[A230128,L32193] It is similar to the naturally occurring glycosaminoglycan (GAG) in joints. Hyaluronic acid works by acting as a lubricant and shock absorber, facilitating joint mobility and thereby reducing osteoarthritic pain.  Hyaluronic acid has antioxidative, anti-inflammatory, and analgesic effects.[A230128] The water-balancing properties and viscoelasticity of hyaluronic acid are beneficial in cosmetic injections, imparting volume and reducing the appearance of imperfections and wrinkles.[L32193] Due to the abovementioned properties, HA has a protective effect on the eyes and cornea.[A230133]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Virecta 100 mg 12 f.c.tabs.', 29398, 'فايركتا 100مجم 12 قرص', '132', '51', 'Tonic for men', 'Tonic for men', NULL, 'Sildenafil', 'Eva pharma', 'Tab', 'أقراص', '100 mg', '12', 'مقوي للرجال', NULL, 'about sildenafil citrate phosphodiesterase-5 enzyme inhibitor anti-erectile dysfunction agent.smechanism of action of sildenafil citratessildenafil is a phosphodiesterase enzyme (pde5) inhibitor. this enzyme is responsible for the degradation cyclic guano', '6224011817943', 13950, '2022-08-19', NULL, 0, 'Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:



(1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and



(2) treatment of pulmonary hypertension, where:

a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850];



b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and



c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].', 'Sildenafil is an oral therapy for erectile dysfunction [A175582, F3853, F3856, F3886, L5611]. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis [A175582, F3853, F3856, F3886, L5611].



The physiological mechanism responsible for the erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation [A175582, F3853, F3856, F3886, L5611]. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood [A175582, F3853, F3856, F3886, L5611].



Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP [A175582, F3853, F3856, F3886, L5611]. Sildenafil has a peripheral site of action on erections [A175582, F3853, F3856, F3886, L5611]. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue [A175582, F3853, F3856, F3886, L5611]. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP [A175582, F3853, F3856, F3886, L5611]. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects [A175582, F3853, F3856, F3886, L5611].



Moreover, apart from the presence of PDE5 in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature [A175579, F3850, F3859, F3883, L5614]. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation [A175579, F3850, F3859, F3883, L5614]. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation [A175579, F3850, F3859, F3883, L5614].', 'In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Its effect is more potent on PDE5 than on other known phosphodiesterases [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. There is an 80-times selectivity over PDE1, and over 700-times over PDE 2, 3, 4, 7, 8, 9, 10 and 11 [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg)[F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614] . At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Mean pulmonary systolic blood pressure decreased by 9% [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nasonex 0.05% nasal spray 120 doses', 8587, 'نازونكس 0.05% بخاخ للانف 120 جرعة', '157', '104', 'Anti-inflammatory.glucocorticoid.', 'Anti-inflammatory.glucocorticoid.', NULL, 'Mometasone furoate', 'Msd > merck sharp & dohme scientific office', 'Spray', 'بخاخ', '0.05%', '1', 'الوقاية وعلاج حساسية الانف الموسمية -- علاج احتقان وحكة وسيلان الانف', NULL, 'about mometasone a glucocorticoid steroid anti psoriatic anti asthma anti inflammatory. mechanism of action of mometasone mometasone is a topical medium potency glucocorticoid. the drug exerts its pharmacological action by penetrating and binding to cytop', '32001487', 20349, '2024-08-20', NULL, 0, 'The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.', 'Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A<sub>2</sub> inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.', 'Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tantum rosa 0.5g powder for vaginal solution', 11171, 'تانتم وردي بودرة 10 جم 5 اكياس', '19', '13', 'Vaginal wash', 'Vaginal wash', NULL, 'Benzydamine', 'Eipico > angliny', 'Solution', 'محلول', NULL, '1', NULL, NULL, NULL, '6221032160546', 2067, '2024-11-08', NULL, 0, 'Available predominantly as a liquid mouthwash, oromucosal spray, or topical cream, benzydamine is most frequently employed as a locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions. 



When formulated as a mouthwash or spray, benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a naso-gastric tube, inflammatory conditions like pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy, dentistry operations and procedures, or more general conditions like sore throat, sore tongue, sore gums, mouth ulcers, or discomfort caused by dentures. [L1121] 



When used as a topical cream, benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscolo-skeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains, strains, bruises, sore muscles, stiff joints, or even the after-effects of fractures. [ L1123]', 'Despite being categorized as a non-steroidal anti-inflammatory drug (NSAID), benzydamine demonstrates various mechanisms of action that differ from those of traditional aspirin-like NSAIDs. In particular, benzydamine predominantly acts by inhibiting the synthesis of pro inflammatory cytokines like tumour necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β) without largely affecting other pro inflammatory cytokines (ie. such as IL-6 and IL-8) or anti-inflammatory cytokines (ie. like IL-10 or IL-1 receptor antagonist). [A31528, L1120]



Moreover, benzydamine is largely a weak inhibitor of prostaglandin synthesis as it has been shown to effectively inhibit cyclooxygenase (COX) and lipoxygenase enzyme activity only at concentrations of 1mM or greater. Considering most contemporary usages of benzydamine are topical applications that are generally not well absorbed through the skin and/or non-specialized mucosae, benzydamine does not often achieve the kind of absorption or blood concentrations necessary to cause any extraneous distant systemic effects or COX inhibition, allowing it to localize its action. [A31528, L1120]



Additionally, it is also hypothesized that benzydamine is capable of inhibiting the oxidative burst of neutrophils and membrane stabilization. These actions are exhibited by the substance’s ability to inhibit the release of granules from neutrophils and to stabilize lysosomes. [A31528, L1120]



Furthermore, benzydamine is capable of a local anaesthetic effect that may be related to its capability for inhibiting the release of inflammatory mediators like substance P and calcitonin gene related peptide from sensory nerve endings. Since substance P is capable of causing the release of histamine from mast cells, benzydamine’s prevention of substance P release further contributes to an anti-inflammatory effect. [A31528, L1120]



Benzydamine also demonstrates a non-specific antibacterial activity against various bacterial strains that are resistant to broad-spectrum antibiotics such as ampicillin, chloramphenicol, and tetracycline at concentrations of about 3 mmol/L. Combinatorial use of benzydamine and other antibiotics like tetracycline and chloramphenicol are also synergistic against antibiotic resistant strains of *Staphylococcus aureus* and *Pseudomonas aeruginosa*. [A31528]', 'Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) designed to elicit local anesthetic and analgesic effects mainly for the mouth and throat. It specifically acts on the local mechanisms of inflammation such as pain, oedema, or granuloma. Typically applied topically, the drug demonstrates anti-inflammatory activity reducing oedema as well as exudate and granuloma formation. Moreover, benzydamine exhibits analgesic properties and local anaesthetic activity if pain is caused by an inflammatory condition. Benzydamine can be absorbed into the oral mucosa and intact skin. Once absorbed in the local area of pain or inflammation, benzydamine binds selectively to local inflamed tissues, usually allowing it to act with few adverse systemic effects. On average a period of 2 to 4 hours is necessary for the substance to reach peak plasma concentration. [L1120]

 

Benzydamine can be synthesized with the reaction of the N-benzyl derivative from methyl anthranilate with nitrous acid to give N-nitoso derivative. This is next reduced by sodium thiosulfate to give transient hydrazine. This hydrazine can then undergo spontaneous internal hydrazide formation. Treating this resultant enolate with 3-chloro-1-dimethylamkino propane ultimately yields benzydamine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Declophen fast 50mg gr. for oral susp. 10 sachets', 3360, 'ديكلوفين فاست 50مجم حبيبات لعمل معلق 10 اكياس', '34', '23.5', 'Nsaid.acetic acid derivatives', 'Nsaid.acetic acid derivatives', NULL, 'Diclofenac potassium', 'Pharco', 'Susp', 'معلق', '50mg', '1', NULL, NULL, 'about diclofenac potassium nsaid anti-inflammatory antipyretic and analgesic. mechanism of action of diclofenac potassium diclofenac possess analgesic anti-inflammatory and antipyretic action. it inhibits the enzyme cyclo-oxygenase and there by inhibits t', '6221151454168', 2414, '2024-11-11', NULL, 0, 'Diclofenac is indicated for use in the treatment of pain and inflammation from varying sources including inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as injury-related inflammation due to surgery and physical trauma. It is often used in combination with [misoprostol] as a gastro-protective agent in patients with high risk of developing NSAID-induced ulcers.', 'Diclofenac inhibits cyclooxygenase-1 and -2, the enzymes responsible for production of prostaglandin (PG) G<sub>2</sub> which is the precursor to other PGs.[label,T116] These molecules have broad activity in pain and inflammation and the inhibition of their production is the common mechanism linking each effect of diclofenac.



PGE<sub>2</sub> is the primary PG involved in modulation of nociception.[A179023] It mediates peripheral sensitization through a variety of effects.[T116,A179023] PGE<sub>2</sub> activates the G<sub>q</sub>-coupled EP<sub>1</sub> receptor leading to increased activity of the inositol trisphosphate/phospholipase C pathway. Activation of this pathway releases intracellular stores of calcium which directly reduces action potential threshold and activates protein kinase C (PKC) which contributes to several indirect mechanisms. PGE<sub>2</sub> also activates the EP<sub>4</sub> receptor, coupled to G<sub>s</sub>, which activates the adenylyl cyclase/protein kinase A (AC/PKA) signaling pathway. PKA and PKC both contribute to the potentiation of transient receptor potential cation channel subfamily V member 1 (TRPV1) potentiation, which increases sensitivity to heat stimuli. They also activate tetrodotoxin-resistant sodium channels and inhibit inward potassium currents. PKA further contributes to the activation of the P2X3 purine receptor and sensitization of T-type calcium channels. The activation and sensitization of depolarizing ion channels and inhibition of inward potassium currents serve to reduce the intensity of stimulus necessary to generate action potentials in nociceptive sensory afferents. PGE<sub>2</sub> act via EP<sub>3</sub> to increase sensitivity to bradykinin and via EP<sub>2</sub> to further increase heat sensitivity. Central sensitization occurs in the dorsal horn of the spinal cord and is mediated by the EP<sub>2</sub> receptor which couples to G<sub>s</sub>. Pre-synaptically, this receptor increases the release of pro-nociceptive neurotransmitters glutamate, CGRP, and substance P. Post-synaptically it increases the activity of AMPA and NMDA receptors and produces inhibition of inhibitory glycinergic neurons. Together these lead to a reduced threshold of activating, allowing low intensity stimuli to generate pain signals. PGI<sub>2</sub> is known to play a role via its G<sub>s</sub>-coupled IP receptor although the magnitude of its contribution varies. It has been proposed to be of greater importance in painful inflammatory conditions such as arthritis. By limiting sensitization, both peripheral and central, via these pathways NSAIDs can effectively reduce inflammatory pain.



PGI<sub>2</sub> and PGE<sub>2</sub> contribute to acute inflammation via their IP and EP<sub>2</sub> receptors.[T116,A179044] Similarly to β adrenergic receptors these are G<sub>s</sub>-coupled and mediate vasodilation through the AC/PKA pathway. PGE<sub>2</sub> also contributes by increasing leukocyte adhesion to the endothelium and attracts the cells to the site of injury.[T116] PGD<sub>2</sub> plays a role in the activation of endothelial cell release of cytokines through its DP<sub>1</sub> receptor.[A179044] PGI<sub>2</sub> and PGE<sub>2</sub> modulate T-helper cell activation and differentiation through IP, EP<sub>2</sub>, and EP<sub>4</sub> receptors which is believed to be an important activity in the pathology of arthritic conditions. By limiting the production of these PGs at the site of injury, NSAIDs can reduce inflammation.



PGE<sub>2</sub> can cross the blood-brain barrier and act on excitatory G<sub>q</sub> EP<sub>3</sub> receptors on thermoregulatory neurons in the hypothalamus.[T116] This activation triggers an increase in heat-generation and a reduction in heat-loss to produce a fever. NSAIDs prevent the generation of PGE<sub>2</sub> thereby reducing the activity of these neurons.

', 'Diclofenac reduces inflammation and by extension reduces nociceptive pain and combats fever.[label,T116] It also increases the risk of developing a gastrointestinal ulcer by inhibiting the production of protective mucus in the stomach.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fractin 20 caps', 32870, 'فراكتين 20 كبسولة', '90', '80', 'Multivitamin', 'Multivitamin', NULL, 'Iron+folic acid+vitamin', 'Health point pharma', 'Cap', 'كبسولة', NULL, '2', NULL, NULL, NULL, NULL, 1457, '2024-05-28', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Agera acne facial cleanser 150 ml', 30088, 'اجيرا غسول للحبوب 150 مل', '249', '229', 'Skin care', 'Skin care', NULL, NULL, 'Leader cosmetics > beauty & beyond international', 'Cleanser', 'منظف', '150 ml', '1', NULL, NULL, NULL, NULL, 1000, '2025-11-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sanidox gel 60 gm', 26501, 'سانيدوكس جل 60 جرام', '65', '38', 'Topical massage', 'Topical massage', NULL, 'Camphor+menthol crystal+clove extract+eucalyptus oil+fatty acids', 'Smartic > sanitas', 'Gel', 'جل', '60 gm', '1', 'جل مساج للشد العضلي -- مسكن للالام العضلية -- استرخاء العضلات', NULL, 'topical massage', NULL, 1949, '2025-12-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Appegreek syrup 100 ml', 346, 'ابيجرييك شراب 100 مل', '120', '100', 'Multivitamins', 'Multivitamins', NULL, 'Iron(ferrous bisglycinate)+l lysine+vitamin c+vitamen e+vitamin d3+ vitamin(b1+b2+b3+b6+b12)+vitamin a+pantothenic acid+biotin+ folic acid+zinc+magnesium+manganese+iodine', 'ElsebaeyPharma', 'Syrup', 'شراب', '100 ml', '1', 'مميزات الابيجرييك شراب', NULL, NULL, '6225000481510', 4974, '2025-11-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mulone syrup 60 ml', 8425, 'ميولون شراب 60مل', '17', NULL, 'Immune enhancer', 'Immune enhancer', NULL, 'Echinacea purpurea extract', 'Atos pharma', 'Syrup', 'شراب', '60 ml', '1', NULL, NULL, 'properties and actions: caffeic acid derivatives (mainly chicoric acid) alkamides and polysaccharides are the main active constituent in echinacea the main of mulone extract. it stimulates the immune response by enhancing phagocytosis by macrophages and a', '6223000471579', 932, '2022-12-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Erectalis 20 mg 2 f.c. tab', 4341, 'اريكتاليس 20مجم 2 قرص', '74', '50', 'Tonic for men', 'Tonic for men', NULL, 'Tadalafil', 'Penta pharma-egypt', 'Tab', 'أقراص', '20 mg', '2', 'مقوي للرجال', NULL, NULL, '6224007738191', 11359, '2025-02-18', NULL, 0, 'Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with [finasteride] for the treatment of benign prostatic hypertrophy (BPH).[L39095,L39439] It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with [macitentan] or other endothelin-1 antagonists.[L39100,L39105,L50622]', 'Tadalafil is a selective phosphodiesterase-5 (PDE5) inhibitor that produces several downstream effects with the most common therapeutic effect being smooth muscle relaxation. [L39095] Patients may experience ED due to a variety of causes including psychogenic, neurogenic, vasculogenic, iatrogenic, or endocrine. [A242392] These causes result in dysfunction of penile smooth muscle relaxation through either disrupted neuronal signaling or direct influence on smooth muscle cells. During sexual arousal, non-adrenergic non-cholinergic (NANC) neurons release nitric oxide (NO). Nitric oxide stimulates guanylate cyclase which converts guanosine triphosphate to cyclic guanosine monophosphate (cGMP).[A242287, A242377] cGMP activates the cGMP-dependent kinase (PKG) in a signal cascade which activates K+ channels leading to inhibition of Ca2+ channels, inhibits platelet activation, and inhibits smooth muscle cell proliferation while inducing apoptosis. This signal cascade is attenuated by PDE5 which breaks the phosphodiester bond of cGMP, converting it to GMP. Inhibition of PDE5 by tadalafil increases signaling via the PKG cascade which supports penile smooth muscle relaxation during sexual arousal by decreasing Ca2+ entry into smooth muscle cells. This smooth muscle relaxation allows blood to fill the corpus cavernosum thereby producing an erection.



In PAH, blood pressure in the pulmonary arteries is raised due to a variety of mechanisms stemming from endothelial dysfunction.[A242377] Decreased production of NO and prostacyclin reduce vasodilatory signaling while overproduction of endothelin-1 and thromboxane increase vasoconstriction. Inflammation, thromboses, and hypoxia later contribute to vascular remodeling which further reduces luminal size. The resultant increase in blood pressure reduces the capacity for gas exchange and increases afterload at the right ventricle, producing symptoms of dyspnea, fatigue, and dizziness as well as leading to right-sided heart failure. Tadalafil exerts its therapeutic effect in PAH through boosting NO-cGMP signaling to contribute to smooth muscle relaxation as with ED.



Lastly, tadalafil is used to treat BPH.[L39095] BPH produces urinary dysfunction through hyperproliferation of the epithelial and smooth muscle layers of the prostate.[A242382] The increased size of the prostate blocks urine flow through the urethra resulting in higher residual volumes due to incomplete emptying. Tadalafil does not appear to exert its benefit via smooth muscle relaxation of the prostate. It may instead exert its effect through a mix of increased oxygenation and decreased inflammation, which decreases tissue remodeling, and inhibition of cell proliferation through the cGMP cascade.



The decreased affinity for PDE6 compared to other PDE5 inhibitors may explain the decreased incidence of visual side effects as PDE6 is present in the eye and contributes to color vision.[L39100, L39105, A242287]', 'Tadalafil exerts a therapeutic effect in ED by increasing sexual stimulation-dependant smooth muscle relaxation in the penis, allowing the corpus cavernosum to fill with blood to produce an erection.[A242287, A242377] Smooth muscle relaxation in the pulmonary vasculature helps to produce vasodilation in PAH which reduces blood pressure in the pulmonary arteries.[A242377] In BPH, tadalafil may contribute to decreased smooth muscle cell proliferation which may reduce the size of the prostate and relieve the anatomical obstruction which produces urinary symptoms of BPH.[A242382] The decreased affinity of tadalafil for PDE6 compared to other PDE5 inhibitors may explain the reduced incidence of visual side effects.[L39100, L39105, A242287]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dextrose 10% & sodium chloride 0.9% (otsuka) i.v. inf. 1000 ml (n/a)', 17466, 'دكستروز 10% و صوديوم كلوريد 0.9% اوتوسوكا 1000 مل', '6', NULL, 'Sterile solution', 'Sterile solution', NULL, 'Glucose (dextrose)+sodium chloride', 'Otsuka', 'Unknown', 'غير محدد', '10%', '1', NULL, NULL, NULL, NULL, 801, '2022-07-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nerhasilda 75 mg 8 orodispersible films', 23420, 'نيرهاسيلدا 75مجم 8 افلام ذائبة بالفم', '88', '64', 'Tonic for men', 'Tonic for men', NULL, 'Sildenafil', 'Nerhadou international co.', 'Film', 'فيلم', '75 mg', '8', 'مقوي للرجال', NULL, NULL, '6224011153065', 9957, '2024-07-12', NULL, 0, 'Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor that is predominantly employed for two primary indications:



(1) the treatment of erectile dysfunction [A175582, L5611, F3853, F3856, F3886]; and



(2) treatment of pulmonary hypertension, where:

a) the US FDA specifically indicates sildenafil for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening [F3850]. The delay in clinical worsening was demonstrated when sildenafil was added to background epoprostenol therapy [F3850]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%) [F3850];



b) the Canadian product monograph specifically indicates sildenafil for the treatment of primary pulmonary arterial hypertension (PPH) or pulmonary hypertension secondary to connective tissue disease (CTD) in adult patients with WHO functional class II or III who have not responded to conventional therapy [F3859]. In addition, improvement in exercise ability and delay in clinical worsening was demonstrated in adult patients who were already stabilized on background epoprostenol therapy [F3859]; and



c) the EMA product information specifically indicates sildenafil for the treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity [F3883]. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease [F3883]. The EMA label also indicates sildenafil for the treatment of pediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension [F3883]. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease [F3883].', 'Sildenafil is an oral therapy for erectile dysfunction [A175582, F3853, F3856, F3886, L5611]. In the natural setting, i.e. with sexual stimulation, it restores impaired erectile function by increasing blood flow to the penis [A175582, F3853, F3856, F3886, L5611].



The physiological mechanism responsible for the erection of the penis involves the release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation [A175582, F3853, F3856, F3886, L5611]. Nitric oxide then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood [A175582, F3853, F3856, F3886, L5611].



Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum, where PDE5 is responsible for degradation of cGMP [A175582, F3853, F3856, F3886, L5611]. Sildenafil has a peripheral site of action on erections [A175582, F3853, F3856, F3886, L5611]. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum but potently enhances the relaxant effect of NO on this tissue [A175582, F3853, F3856, F3886, L5611]. When the NO/cGMP pathway is activated, as occurs with sexual stimulation, inhibition of PDE5 by sildenafil results in increased corpus cavernosum levels of cGMP [A175582, F3853, F3856, F3886, L5611]. Therefore sexual stimulation is required in order for sildenafil to produce its intended beneficial pharmacological effects [A175582, F3853, F3856, F3886, L5611].



Moreover, apart from the presence of PDE5 in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature [A175579, F3850, F3859, F3883, L5614]. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation [A175579, F3850, F3859, F3883, L5614]. In patients with pulmonary arterial hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemic circulation [A175579, F3850, F3859, F3883, L5614].', 'In vitro studies have shown that sildenafil is selective for phosphodiesterase-5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Its effect is more potent on PDE5 than on other known phosphodiesterases [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. In particular, there is a 10-times selectivity over PDE6 which is involved in the phototransduction pathway in the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. There is an 80-times selectivity over PDE1, and over 700-times over PDE 2, 3, 4, 7, 8, 9, 10 and 11 [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. And finally, sildenafil has greater than 4,000-times selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In eight double-blind, placebo-controlled crossover studies of patients with either organic or psychogenic erectile dysfunction, sexual stimulation resulted in improved erections, as assessed by an objective measurement of hardness and duration of erections (via the use of RigiScan®), after sildenafil administration compared with placebo [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Most studies assessed the efficacy of sildenafil approximately 60 minutes post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The erectile response, as assessed by RigiScan®, generally increased with increasing sildenafil dose and plasma concentration [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The time course of effect was examined in one study, showing an effect for up to 4 hours but the response was diminished compared to 2 hours [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Sildenafil causes mild and transient decreases in systemic blood pressure which, in the majority of cases, do not translate into clinical effects [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with systemic hypertension the mean change from baseline in systolic and diastolic blood pressure was a decrease of 9.4 mmHg and 9.1 mmHg respectively [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg, three times a day to patients with pulmonary arterial hypertension lesser effects in blood pressure reduction were observed (a reduction in both systolic and diastolic pressure of 2 mmHg)[F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614] . At the recommended dose of 20 mg three times a day no reductions in systolic or diastolic pressure were seen [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. After chronic dosing of 80 mg three times a day to patients with pulmonary arterial hypertension no clinically relevant effects on the ECG were reported either [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) (> 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Mean pulmonary systolic blood pressure decreased by 9% [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil showed no effect on cardiac output and did not impair blood flow through the stenosed coronary arteries [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].



Mild and transient differences in color discrimination (blue/green) were detected in some subjects using the Farnsworth-Munsell 100 hue test at 1 hour following a 100 mg dose, with no effects evident after 2 hours post-dose [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The postulated mechanism for this change in color discrimination is related to inhibition of PDE6, which is involved in the phototransduction cascade of the retina [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Sildenafil has no effect on visual acuity or contrast sensitivity. In a small size placebo-controlled study of patients with documented early age-related macular degeneration (n = 9), sildenafil (single dose, 100 mg) demonstrated no significant changes in visual tests conducted (which included visual acuity, Amsler grid, color discrimination simulated traffic light, and the Humphrey perimeter and photostress test) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fuci-top 2% oint. 15 gm', 5192, 'فيوسي توب 2% مرهم 15 جم', '15', NULL, 'Antibiotic', 'Antibiotic', NULL, 'Fusidic acid', 'Hikma pharma', 'Oint', 'مرهم', '2%', '1', NULL, NULL, 'about fusidic acid a bacteriostatic steroid antibiotic systemic antibacterial anti-infective. mechanism of action of fusidic acid fusidic acid is a bactericidal or bacteriostatic drug depending upon the concentration. it inhibits the transfer of aminoacid', NULL, 985, '2022-08-26', NULL, 0, 'For the treatment of bacterial infections.', 'Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.', 'Fusidic acid is a bacteriostatic antibiotic and helps prevent bacterial growth while the immune system clears the infection.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Borsens spray 60 ml', 15447, 'بورسينس بخاخ 60 مل', '25', NULL, 'Antiseptic', 'Antiseptic', NULL, 'Cholorohexidine+ alcohol+tea tree oil+zinc oxide', 'Dreams el-haboba > sms pharmaceuticals', 'Spray', 'بخاخ', '60 ml', '1', NULL, NULL, 'alcohol spray with soothing agents', NULL, 997, '2022-07-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Orasan mouth wash 125 ml', 9347, 'اورازان مضمضة 125 مل', '45', '35', 'Oral care', 'Oral care', NULL, 'Clove oil+menthol', 'Hi-care > pixel pharmaceutical company', 'Mouth wash', 'غسول للفم', '125 ml', '1', NULL, NULL, NULL, '6224001202322', 1143, '2024-04-20', NULL, 0, 'Clove oil is primarily indicated in conditions like colic, flatulence, and toothache [L2849].', 'The chief constituent present in clove oil is the phenol "_eugenol_" which is present in amounts up to 85%. Clove oil acts as a germicide [L2849] to Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa [A24841]. 



Clove oil is thought to inhibit prostaglandin synthesis, thereby reducing painful symptoms [A33145].



Eugenol, the main constituent of clove oil is purported to have anticancer action. In one study, eugenol-treated HL-60 cells showed features of apoptosis including DNA fragmentation and formation of DNA ladders in agarose gel electrophoresis. It was observed that eugenol transduced the apoptotic signal via reactive oxygen species (ROS) generation, inducing mitochondrial permeability transition (MPT), decreasing anti-apoptotic protein _bcl-2_ level, inducing _cytochrome c_ release to the cytosol, and subsequent apoptotic cell death. When taken together, the study showed that ROS plays a critical role in eugenol-induced apoptosis in _HL-60_, and this is the first report on the mechanism of the anticancer effect of eugenol [A33146].', 'Clove (Eugenia caryophyllata Thunb. [Myrtaceae]) essential oil (CEO) has been demonstrated to possess antimicrobial, antifungal, antiviral, antioxidant, anti-inflammatory, anti-histamine, and anticancer properties. However, few studies have focused on its topical use [A33133], [L2850].



Clove essential oil, used as an antiseptic in oral infections, inhibits gram-negative and gram-positive bacteria as well as yeast [A24841].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Floxia osmosia - deep moisturizing fluid 125ml', 19172, 'فلوكسيا اسموزيا - سائل ترطيب عميق 125 مل', '134', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Floxia international sarl > bio-earth egypt', 'Unknown', 'غير محدد', '125ml', '1', NULL, NULL, 'osmosia improves and regulates daily moisturization reinforces natural defenses (skin barrier) and contributes unifying skin complexion. is is specifically formulated to soothe chronically dry skin and lighten skin complexion. allergen free paraben-free a', NULL, 780, '2022-07-21', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Skin mix cream 60 gm', 27071, 'سكين مكس كريم 60جم', '150', NULL, 'Whitening topical', 'Whitening topical', NULL, 'Liquorice+titanium dioxide+vitamin c', 'Egyptian company for cosmetics > pharmix', 'Cream', 'كريم', '60 gm', '1', NULL, NULL, 'whitening & lightening cream skin-refining cream to enhance radiance & improve texture', NULL, 756, '2022-07-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Quella laser cream gel 100 gm', 25535, 'كويلا ليزر كريم جل 100 جم', '150', NULL, 'Healing topical', 'Healing topical', NULL, 'Panthenol+soybean oil+seasame oil+aloe vera+chamomile+calendula+dimethicone+jojoba+allantoin+liquorice+shea butter', 'Macro group pharmaceuticals', 'Cream', 'كريم', '100 gm', '1', 'كريم جل لتسريع التئام الجلد', NULL, 'post laser skin soothing and moisturizing.', NULL, 5089, '2023-02-02', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vota gel 15 gm', 12574, 'فوتا جل 15 جم', '38', NULL, 'Delay action', 'Delay action', NULL, 'Vitamin e+menthol crystals+l-arginine+methyl nicotinate', 'Al esraa pharmaceutical optima', 'Gel', 'جل', '15 gm', '1', 'يستخدم في حالات التأخير عند الرجال', NULL, 'used for premature ejaculation', '6223004160233', 2489, '2022-04-09', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Arabzinc 50 mg 30 tabs.', 5748, 'اراب زنك 50مجم 30 قرص', '45', NULL, 'Zinc supplement', 'Zinc supplement', NULL, 'Zinc', 'Kmt pharma', 'Tab', 'أقراص', '50 mg', '3', NULL, NULL, NULL, NULL, 1157, '2024-05-29', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Flubenzole 2% oral susp. 30ml', 19192, 'فلوبنزول 2% معلق 30 مل', '4', NULL, 'Anthelmintic', 'Anthelmintic', NULL, 'Flubendazole', 'Marcyrl co. > alfacure pharmaceuticals', 'Susp', 'معلق', '2%', '1', NULL, NULL, 'indication: flubendazol is used in the treatment of single or mixed infections caused by: enterobiasis ascariasis hookworm and trichuriasis contraindications: hypersensitivity to the drug pregnancy and lactation side effects: flubendazol is well tolerated', NULL, 870, '2022-07-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Legando preg 30 film coated tablets', 15944, 'ليجاندو بريج 30 قرص', '180', '135', '14 multivitamins & minerals', '14 multivitamins & minerals', NULL, 'Zinc+iron+iodine+folicacid', 'Unitrade pharma', 'Tablet', 'أقراص', NULL, '3', NULL, NULL, NULL, '796554975344', 1597, '2025-08-09', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Abstain sr 150 mg 20 tab.', 13290, 'ابستين اس ار 150مجم 20 قرص', '20', NULL, 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Bupropion', 'Adwia', 'Tab', 'أقراص', '150 mg', '2', 'يعمل العلاج على تحسين المزاج و الثقة بالنفس لمرضى الاكتئاب', NULL, 'about bupropion norepinephrine and dopamine reuptake inhibitor nicotinic antagonist aminoketone derivative atypical antidepressant smoking cessation aid. mechanism of action of bupropion bupropion blocks the re-uptake of neurotransmitter dopamine and noradrenaline from the synapse in to the presynaptic nerve terminal in the cns. it has only a less activity in blocking the reuptake of serotonin. bupropion potentiates the noradrenergic and dopaminergic activity and produces antidepressant activity. smoking cessation action: bupropion is a competitive antagonist of nicotine. indications for bupropion 1. depression 2. smoking cessation treatment', NULL, 2468, '2022-06-18', NULL, 0, 'Bupropion is indicated for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation. 



When used in combination with [naltrexone] as the marketed product ContraveⓇ, bupropion is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m^2 or greater (obese) or 27 kg/m^2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).



Bupropion is also used off-label as a first-line treatment in patients with ADHD and comorbid bipolar disorder when used as an adjunct to mood stabilizers.[F4624]', 'Bupropion is a norepinephrine/dopamine-reuptake inhibitor (NDRI) that exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] 



Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,[A178798,A178804] bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.[A6399,A178840] Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.[A178804,A178807]



When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor (AChR), thereby blunting the effects of nicotine.[A178825,A1966,A16508] Furthermore, the stimulatory effects produced by bupropion in the central nervous system are similar to nicotine''s effects, making low doses of bupropion a suitable option as a nicotine substitute.[A179062]  



When used in combination with [naltrexone] in the marketed product ContraveⓇ for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways.[L6562] Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.[L6562,A179038,A179050] This combination was also found to reduce food intake when injected directly into the ventral tegmental area of the mesolimbic circuit in mice, which is an area associated with the regulation of reward pathways.[L6562]', 'Bupropion is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitors, or other known antidepressant agents. Compared to classical tricyclic antidepressants, Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine. In addition, Bupropion does not inhibit monoamine oxidase. Bupropion has been found to be essentially inactive at the serotonin transporter (SERT)(IC50 >10 000 nM),[A178810] however both bupropion and its primary metabolite hydroxybupropion have been found to block the function of cation-selective serotonin type 3A receptors (5-HT3ARs). 



Bupropion produces dose-related central nervous system (CNS) stimulant effects in animals, as evidenced by increased locomotor activity, increased rates of responding in various schedule-controlled operant behaviour tasks, and, at high doses, induction of mild stereotyped behaviour [FDA Label]. Due to these stimulant effects and selective activity at dopamine and norepinephrine receptors, bupropion has been identified as having an abuse potential.[FDA Label,A178846] Bupropion has a similar structure to the controlled substance [DB01560], and has been identified as having mild amphetamine-like activity, particularly when inhaled or injected.[A178846]



Bupropion is also known to lower the seizure threshold, making any pre-existing seizure conditions a contraindication to its use. This risk is exacerbated when bupropion is combined with other drugs or substances that lower the seizure threshold, such as [cocaine], or in clinical situations that would increase the risk of a seizure such as abrupt alcohol or benzodiazepine withdrawal.[FDA Label] As norepinephrine has been shown to have anticonvulsant properties, bupropion''s inhibitory effects on NET are thought to contribute to its pro-convulsant activity.[A178846]



Bupropion has been shown to increase blood pressure and pose a risk for exacerbation of unmanaged or pre-existing hypertension,[A178852,FDA Label] however, clinical trials of bupropion in smokers with CVD have not identified an increased incidence of CV events including stroke or heart attack.[A178855] In clinical trials, the mean increase in systolic blood pressure associated with the use of bupropion was found to be 1.3 mmHg.[FDA Label]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Foleses b 30 sublingual tablets', 12155, 'فوليسيس بي 30 قرص تحت اللسان', '90', NULL, 'Vitamin b complex', 'Vitamin b complex', NULL, 'Vitamin b12+vitamin b6+folic acid', 'Be healthy medicine - bhm', 'Tablet', 'أقراص', NULL, '3', NULL, NULL, NULL, NULL, 1094, '2024-06-15', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Argento eye contour cream 30 gm', 14378, 'ارجنتو كريم 30 جم', '195', '189', 'Eye contour', 'Eye contour', NULL, 'Royal jelly+collagen+green tea ext+liquorice ext+wheat germ oil+almond oil+chamomile ext+allantoin', 'Hi-care > alba pharma', 'Cream', 'كريم', '30 gm', '1', NULL, NULL, 'moisturizing - minimize wrinkles - minimize dark circles. ** ingredients: royal jelly + collagen + green tea extract + liquorice extract + wheat germ oil + almond oil + chamomile extract + allantoin + panthenol + dimethicone + caffeine ** how to use: plac', '6224010520028', 873, '2024-04-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Spaniela mr 35mg 30 f.c. tab.', 27317, 'سبانيلا ام ار 35مجم 30 قرص', '54', '39', 'Anti-ischemic', 'Anti-ischemic', NULL, 'Trimetazidine', 'Marcyrl co.', 'Tab', 'أقراص', '35mg', '3', 'علاج قصور الدورة الدموية — تنشيط الدورة الدموية للمخ — علاج مساعد في حالات الذبحة الصدرية', NULL, 'about trimetazidine cytoprotective vasodilator anti-ischemic (anti-anginal) agent. mechanism of action of trimetazidine it is a cytoprotective drug which reduces anginal attacks and improves exercise tolerance by nonhaemodynamic mechanisms. it improves ce', '6223003579418', 10537, '2025-05-27', NULL, 0, 'Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.[L33015]', 'During myocardial ischemia, anaerobic metabolism takes over, increasing levels of lactic acid.[A233215] The decreased intracellular pH and increased concentration of protons activates sodium-hydrogen and sodium-calcium antiport systems, raising intracellular calcium concentrations, finally leading to decreased contractility.[A233215]



This injury to the myocardium raises concentrations of catecholamines, which activate hormone sensitive lipase, and increasing fatty acid concentrations in plasma.[A233215] When the myocardium is repurfused, fatty acid oxidation becomes the dominant form of ATP production, maintaining an acidic pH, and further exacerbating the injury.[A233215]



The mechanism of action of trimetazidine is not fully understood.[A233215] Trimetazidine may inhibit mitochondrial 3-ketoacyl coenzyme A thiolase, decreasing long chain fatty acid β-oxidation but not glycolysis in the myocardium.[A7688,L33020] The decreased long chain fatty acid β-oxidation is compensated for by increased use of glucose, preventing a lowered myocardial pH, and further decreases in contractility.[A7688,L33020] However, another study suggests that 3-ketoacyl coenzyme A thiolase may not be trimetazidine''s target, and that this mechanism may be incorrect.[A233215]', 'Trimetazidine is indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies.[L33015] Patients should be counselled regarding the risk of use with reduced renal or hepatic function, worsening of extrapyramidal symptoms or other movement disorders, and risk of falls.[L33020]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Forgenap 5/160/12.5mg 10 f.c. tab.', 19330, 'فورجيناب 5/160/12.5مجم 10 قرص', '32', NULL, 'Antihypertensive. combined angiotensin blocker with calcium channel blocker', 'Antihypertensive. combined angiotensin blocker with calcium channel blocker', NULL, 'Amlodipine+hydrochlorothiazide+valsartan', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '12.5mg', '1', 'علاج ارتفاع ضغط الدم', NULL, 'valsartan is a nonpeptide orally active and specific angiotensin ii antagonist acting on the at1 receptor subtype. (amlodipine and valsartan) is indicated for the treatment of hypertension to lower blood pressure. lowering blood pressure reduces the risk', NULL, 993, '2022-07-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nonemia 20 capsules', 5809, 'نونيميا 20 كبسولة', '110', NULL, 'Anemia', 'Anemia', NULL, 'Iron+folic acid+vitamin c', 'Advanced care pharma', 'Capsule', 'كبسولة', NULL, '2', NULL, NULL, NULL, NULL, 1222, '2025-07-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rivotril 0.5mg 50 tab.', 26216, 'ريفوتريل 0.5مجم 50 اقراص', '16', NULL, 'Anti-epileptic.benzodiazepines', 'Anti-epileptic.benzodiazepines', NULL, 'Clonazepam', 'F.hoffman la roche > egyptian pharmaceutical trading company', 'Tab', 'أقراص', '0.5mg', '5', NULL, NULL, NULL, NULL, 1037, '2022-07-27', NULL, 0, 'Clonazepam is indicated as monotherapy or as an adjunct in the treatment of Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures.[FDA Label][F3787] Furthermore, clonazepam may also be of some value in patients with absence spells (petit mal) who have failed to respond to succinimides.[FDA Label][F3787] Additionally, clonazepam is also indicated for the treatment of panic disorder, with or without agoraphobia, as defined in the DSM-V.[FDA Label]



Alternatively, some regional prescribing information note that clonazepam is indicated for all clinical forms of epileptic disease and seizures in adults, especially absence seizures (petit mal) including atypical absence; primary or secondarily generalised tonic-clonic (grand mal), tonic or clonic seizures; partial (focal) seizures with elementary or complex symptomatology; various forms of myoclonic seizures, myoclonus and associated abnormal movements.[L5572,F3796] Such regional label data also has clonazepam indicated for most types of epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalized epilepsy or to secondary generalization of partial epilepsy.[F3796]                                                                                                                                                                 ', 'Gamma-Aminobutyric acid (GABA) is considered the principal inhibitory neurotransmitter in the human body [A175423, A175438, A175441]. When GABA binds to GABA(a) receptors found in neuron synapses, chloride ions are conducted across neuron cell membranes via an ion channel in the receptors [A175423, A175438, A175441, F3787]. With enough chloride ions conducted, the local, associated neuron membrane potentials are hyperpolarized - making it more difficult or less likely for action potentials to fire, ultimately resulting in less excitation of the neurons [A175423, A175438, A175441, F3787]. 



Subsequently, benzodiazepines like clonazepam can bind to benzodiazepine receptors that are components of various varieties of GABA(a) receptors [A175423, A175438, A175441, F3787, L5572, F3763]. This binding acts to enhance the effects of GABA by increasing GABA affinity for the GABA(a) receptor, which ultimately enhances GABA ligand binding at the receptors [A175423, A175438, A175441, F3787, L5572, F3763]. This enhanced ligand binding of the inhibitory neurotransmitter GABA to the receptors increases the aforementioned chloride ion conduction (perhaps reportedly via an increase in the frequency of the chloride channel opening), resulting in a hyperpolarized cell membrane that prevents further excitation of the associated neuron cells [A175423, A175438, A175441, F3787, L5572, F3763]. Combined with the notion that such benzodiazepine receptor associated GABA(a) receptors exist both peripherally and in the CNS, this activity consequently facilitates various effects like sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175423, A175438, A175441, F3787, L5572, F3763].



In particular, when out of the ordinary rapid and repetitive electrical signals are released in the CNS, it is proposed that the brain can become over-stimulated and ordinary functions are disrupted - resulting in seizure activity [A175441]. By enhancing the neuro-inhibitory activity of GABA, it is believed that clonazepam can facilitate in decreasing any excessive electrical nerve activity in the CNS that might be contributing to seizures [A175441]. Concurrently, it is also believed that clonazepam''s actions in enhancing GABA effects may inhibit neuronal activity proposed to occur in amygdala-centered fear circuits - therefore assisting in the management of anxiety or panic [A175438].', 'The pharmacodynamic properties of clonazepam are common among benzodiazepines and include anticonvulsive, sedative, muscle relaxing and anxiolytic effects [A175423, L5572, F3763, F3787]. Animal data and electroencephalographic investigations in man have shown that clonazepam rapidly suppresses many types of paroxysmal activity including the spike and wave discharge in absence seizures (petit mal), slow spike wave, generalized spike wave, spikes with temporal or other locations, as well as irregular spikes and waves [FDA Label] [A175423, L5572, F3763, F3787]. Moreover, the agent can also decrease the frequency, amplitude, duration, and spread of discharge in minor motor seizures [FDA Label] [F3763].



Generalized EEG abnormalities are more readily suppressed by clonazepam than are focal EEG abnormalities such as focal spikes [L5572]. Clonazepam has beneficial effects in generalized and focal epilepsies [L5572].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vitamount for women 15 s.g. caps', 12504, 'فيتاماونت للسيدات 15 كبسولة', '120', '90', 'Multivitamins', 'Multivitamins', NULL, 'Minerals+vitamins', 'Amoun', 'Cap', 'كبسولة', NULL, '3', 'فيتامينات للسيدات', NULL, NULL, '6221025030832', 13898, '2025-11-19', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sinuc 0.9% syrup 100 ml', 27055, 'سينوك 0.9% شراب 100 مل', '16', NULL, 'Cough drugs', 'Cough drugs', NULL, 'Ivy leaves', 'Novartis', 'Syrup', 'شراب', '0.9%', '1', NULL, NULL, 'due to their broncholytic and secretolic properties ivy leaf dried extract has long provided its worth in practice. their efficacy has been demonstrated in numerous scientific studies. according to a pharmacological investigation its constituent appears t', '6223002642304', 1032, '2022-07-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Muvista massage gel 50 gm', 23144, 'موفيستا مساج جل 50 جم', '90', '50', 'Massage', 'Massage', NULL, 'Camphor+menthol', 'Chemica > nova pharma', 'Gel', 'جل', '50 gm', '1', NULL, NULL, NULL, '6223002143634', 1387, '2023-08-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Simulect 20 mg powder vial for i.v. infusion', 27009, 'سيميوليكت 20مجم باودر فيال للتسريب الوريدي', '13,854', '6441', 'Immunosuppressants', 'Immunosuppressants', NULL, 'Basiliximab', 'Novartis', 'Vial', 'فيال', '20 mg', '1', 'مثبط للمناعة', NULL, NULL, NULL, 1415, '2025-08-16', NULL, 0, 'For prophylactic treatment of kidney transplant rejection', 'Basiliximab binds with high-affinity to the alpha-subunit (CD25) of the high-affinity IL-2 receptor. This inhibits IL-2 binding, which inhibits T-cell activation and prevents the body from mounting an immune response against the foreign kidney.', 'Basiliximab functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Centropax advance 20 tabs', 8551, 'سنتروباكس ادفانس 20 قرص', '118', '85', 'Multivitamin', 'Multivitamin', NULL, NULL, 'Paxal pharmaceutical', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, '6224011120166', 1775, '2025-08-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Verdapiotal 10mg 30 f.c.tablets', 29143, 'فيردابيوتال 10مجم 30 قرص', '140', '63', 'Psychiatric.antidepressants', 'Psychiatric.antidepressants', NULL, 'Escitalopram', 'Global napi pharmaceuticals > global advanced pharmaceutical (gap)', 'Tablet', 'أقراص', '10mg', '3', 'مضاد اكتئاب', NULL, NULL, '6223005940179', 6376, '2023-12-03', NULL, 0, 'Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older.[L8513,L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]', 'Escitalopram, like other selective serotonin re-uptake inhibitors, enhances serotonergic activity by binding to the orthosteric (i.e. primary) binding site on the serotonin transporter (SERT), the same site to which endogenous 5-HT binds, and thus prevents the re-uptake of serotonin into the presynaptic neuron.[A185420,A39738,A185726] Escitalopram, along with [paroxetine], is also considered an allosteric serotonin re-uptake inhibitor - it binds to a secondary allosteric site on the SERT molecule to more strongly inhibit 5-HT re-uptake. Its combination of orthosteric and allosteric activity on SERT allows for greater extracellular 5-HT levels, a faster onset of action, and greater efficacy as compared to other SSRIs. [A185825,A185726] The sustained elevation of synaptic 5-HT eventually causes desensitization of 5-HT<sub>1A</sub> auto-receptors, which normally shut down endogenous 5-HT release in the presence of excess 5-HT - this desensitization may be necessary for the full clinical effect of SSRIs and may be responsible for their typically prolonged onset of action.[A185828,A185726]



Escitalopram has shown little-to-no binding affinity at a number of other receptors, such as histamine and muscarinic receptors, and minor activity at these off-targets may explain some of its adverse effects.[L8513,L8516,L8522,A185726]', 'Escitalopram belongs to a class of medications called selective serotonin re-uptake inhibitors (SSRIs). These agents cause an increase in serotonin levels in neuronal synapses by preventing the re-uptake of serotonin (5-HT) into the presynaptic terminals of serotonergic neurons.[A185420,A39738,L8513,L8516] As compared to other SSRIs, it appears to have a relatively quick onset of effect due to its potency.[A185819,A185822]



SSRIs as a class have been associated with abnormal bleeding, particularly in patients receiving concomitant therapy with other medications affecting hemostasis, and with the development of serotonin syndrome. Use escitalopram with caution in patients with a higher-than-baseline risk of bleeding and in patients receiving concomitant therapy with other serotonergic drugs. Escitalopram may also cause a discontinuation syndrome with abrupt removal of the drug, and should be slowly tapered if discontinuation of therapy is warranted.[L8513,L8516,L8522]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Psychoton dragee 0.12 %', 25474, 'سايكوتون دراجي 0.12%', '10', NULL, NULL, NULL, NULL, 'Hypericin', 'Kahira > sekem', 'Unknown', 'غير محدد', '0.12 %', '1', NULL, NULL, NULL, NULL, 714, '2022-07-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gynomonix 0.8% vag. cream 30 gm', 20113, 'جينومونيكس 0.8% كريم مهبلي 30 جرام', '50', '34.5', 'Antifungals.triazoles', 'Antifungals.triazoles', NULL, 'Terconazole', 'Medizen pharmaceutical industries', 'Cream', 'كريم', '0.8%', '1', NULL, NULL, 'indication for the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina. mechanism of action terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. terconazole and other triazole a', '6222012400744', 1592, '2024-10-28', NULL, 0, 'For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.', 'Terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. Terconazole and other triazole antifungal agents inhibit cytochrome P450 14-alpha-demethylase in susceptible fungi, which leads to the accumulation of lanosterol and other methylated sterols and a decrease in ergosterol concentration. Depletion of ergosterol in the membrane disrupts the structure and function of the fungal cell leading to a decrease or inhibition of fungal growth.', 'Terconazole is a triazole antifungal agent available for intravaginal use. It is structurally related to imidazole-derivative antifungal agents, although terconazole and other triazoles have 3 nitrogens in the azole ring. By inhibiting the 14-alpha-demethylase (lanosterol 14-alpha-demethylase), Terconazole inhibits ergosterol synthesis. Depletion of ergosterol in fungal membrane disrupts the structure and many functions of fungal membrane leading to inhibition of fungal growth.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lessuric 100mg 20 tab.', 21719, 'ليسيوريك 100 مجم 20 قرص', '6', NULL, 'Antigout.xanthine oxidase inhibitor', 'Antigout.xanthine oxidase inhibitor', NULL, 'Allopurinol', 'Alexandria', 'Tab', 'أقراص', '100mg', '2', NULL, NULL, 'description xanthine oxidase inhibitor in hyperuricemia in gout or during cancer chemotherapy. mechanism of action of allopurinol it inhibits an enzyme xanthine oxidase that is necessary to form uric acid (the enzyme catalyzing the conversion of hypoxanth', '6223000170571', 973, '2022-12-06', NULL, 0, 'Allopurinol is indicated in [FDA label]:



1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).



2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present.



3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.', 'Allopurinol is a structural analog of the natural purine base, hypoxanthine.  After ingestion, allopurinol is metabolized to its active metabolite, oxypurinol (_alloxanthine_) in the liver [T508], which acts as an inhibitor of xanthine oxidase enzyme [FDA label]. 



Allopurinol and its active metabolite inhibit xanthine oxidase, the enzyme that converts hypoxanthine to xanthine and xanthine to uric acid. Inhibition of this enzyme is responsible for the effects of allopurinol. This drug increases the reutilization of hypoxanthine and xanthine for nucleotide and nucleic acid synthesis by a process that involves the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase).  This process results in an increased nucleotide concentration, which causes feedback inhibition of de novo purine synthesis. The end result is decreased urine and serum uric acid concentrations [F3988], which decreases the incidence of gout symptoms. 



Accompanying the reduction of serum uric acid by allopurinol is an increase in the serum and urine concentrations of hypoxanthine and xanthine (due to inhibition of xanthine oxidase).  In the absence of allopurinol, regular urinary excretion of oxypurines almost entirely occurs in the form of uric acid. After the ingestion of allopurinol, the contents of excreted urine are hypoxanthine, xanthine, and uric acid. Because each substance has its own individual solubility, the concentration of uric acid in plasma is decreased without exposing the renal tissues to a high load of uric acid, thereby decreasing the risk of crystalluria. By lowering the uric acid concentration in the plasma below its limits of solubility, allopurinol encourages the dissolution of gout tophi. Although the levels of hypoxanthine and xanthine are found to be increased after allopurinol ingestion, the risk of deposition in renal tissues is less than that of uric acid, as they become more soluble and are rapidly excreted by the kidney [F3988]. ', '

Allopurinol decreases the production of uric acid by stopping the biochemical reactions that precede its formation [FDA label].  This process decreases urate and relieves the symptoms of gout, which may include painful tophi, joint pain, inflammation, redness, decreased range of motion, and swelling [A665].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Beesline deo whitening hair delaying roll-on 50 ml', 14998, 'بيزلين رول اون لتفتيح وتبييض الشعر 50 مل', '295', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Beesline > pharma cruise medical', 'Unknown', 'غير محدد', '50 ml', '1', NULL, NULL, 'active ingredients alum rock lumiskin teflose lactic acid wheatgerm oil sodium lactate ginger aloe vera soybean parsley olive leaf & propolis. an innovative safe & highly effective 48hr antiperspirant deodorant that works to fight body odour adsorb moistu', NULL, 695, '2022-07-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ivydex syrup 120 ml', 6062, 'ايفيدكس شراب 120 مل', '45', NULL, 'Cough product', 'Cough product', NULL, 'Ivy extract+thyme', 'Organix - c-med pharma', 'Syrup', 'شراب', '120 ml', '1', NULL, NULL, NULL, '6780200388125', 887, '2025-07-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Meburide 2.5/500mg 20 f.c. tab.', 22429, 'مبيورايد 2.5/500مجم 20 قرص', '8', NULL, 'Anti-diabetic.combined secretagogues+sensitizers', 'Anti-diabetic.combined secretagogues+sensitizers', NULL, 'Glibenclamide(glyburide)+metformin', 'European egyptian pharm. ind. > technopharm', 'Tab', 'أقراص', '500mg', '2', NULL, NULL, 'about metformin biguanide derivative oral anti-diabetic. mechanism of action of metformin it is a biguanide which exerts antidiabetic action. the drug suppresses gluconeogenesis in liver and thus suppresses hepatic glucose output. it enhance insulin media', '6221076010937', 787, '2022-12-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Liblab leaves 100 ml syrup', 8034, 'لبلاب ليفز شراب 100 مل', '59', NULL, 'Anti-tussive,anti-couch , mucolytic.', 'Anti-tussive,anti-couch , mucolytic.', NULL, 'Ivy leaves extract', 'Tripoli pharmaceutical company', 'Syrup', 'شراب', '100 ml', '1', NULL, NULL, NULL, NULL, 787, '2025-11-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sedotazole 100 mg 10 tab.', 26692, 'سيدوتازول 100مجم 10 اقراص', '30', NULL, 'Antiplatelet.phosphodiesterase 3 inhibitor', 'Antiplatelet.phosphodiesterase 3 inhibitor', NULL, 'Cilostazol', 'Sedico', 'Tab', 'أقراص', '100 mg', '1', NULL, NULL, 'description cilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. it is manufactured by otsuka pharmaceutical co. under the trade name pletal. although drugs similar', NULL, 826, '2022-07-15', NULL, 0, 'Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).', 'Cilostazol and several of its metabolites are cyclic AMP (cAMP) phosphodiesterase III inhibitors (PDE III inhibitors), inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.', 'Cilostazol reduces the symptoms of intermittent claudication, as indicated by an increased walking distance. Intermittent claudication is pain in the legs that occurs with walking and disappears with rest. The pain occurs due to reduced blood flow to the legs.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Empagliform xr 10/1000 mg 30 f.c. tabs.', 30475, 'ايمباجليفورم اكس ار 10/1000مجم 30 قرص', '312', '236.25', 'Anti-diabetic.secretagogues.sglt2 inhibitors', 'Anti-diabetic.secretagogues.sglt2 inhibitors', NULL, 'Empagliflozin+metformin', 'Hikma pharma', 'Tab', 'أقراص', '1000 mg', '3', NULL, NULL, 'it is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes alone or along with other antidiabetic medicines and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who hav', NULL, 1406, '2025-02-10', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Epimate 200 mg 10 caps.', 18428, 'ابيمات 200 مجم 10 كبسولات', '24', NULL, 'Anti-epileptic.fructose derivative', 'Anti-epileptic.fructose derivative', NULL, 'Topiramate', 'Sedico', 'Cap', 'كبسولة', '200 mg', '1', NULL, NULL, 'about topiramate a sulfamate-substituted monosaccharide carbonic anhydrase inhibitor anticonvulsant antimigraine. mechanism of action of topiramate topiramate acts on the motor cortex where it stabilizes neuronal membrane and inhibits the spread of seizur', NULL, 766, '2022-07-30', NULL, 0, 'Topiramate is indicated  for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients above 2 years of age 4)Prophylaxis of migraine in children 12 years of age and older and adults.[L10544]



Topiramate is also used off-label as an adjunct therapy for weight management[L10550] and for mood disorders.[A188312]', 'A seizure is an abnormal and unregulated electrical discharge occurring in the brain. This leads to transient interruption in brain function, manifested by reduced alertness, abnormal sensations, and focal involuntary movements or convulsions. Several types of seizures exist, with common types including tonic-clonic seizures and partial onset seizures.[L5548]



The exact mechanisms by which topiramate exerts pharmacological actions on seizures and migraines are currently not fully characterized.[A188336,L10544]  Several properties of this drug, however, are likely to contribute to its therapeutic effects. Topiramate has been observed to exert actions on voltage-dependent sodium channels, GABA receptors, and glutamate receptors.[A175249,L10544] 



Topiramate stimulates GABA-A receptor activity at brain non-benzodiazepine receptor sites and reduces glutamate activity at both AMPA and kainate receptors. Normally, GABA-A receptors are inhibitory and glutaminergic receptors are stimulatory for neuronal activity.[A175243,T752] By increasing GABA activity and inhibiting glutamate activity, topiramate blocks neuronal excitability, preventing seizures and migraines.[A188333,A188309,L10544] Additionally, it blocks the voltage-dependent sodium channels, further blocking seizure activity.[A175243] Topiramate has been shown to inhibit various carbonic anhydrase isozymes, but the clinical significance of this is unknown at this time.[A10342,A10348,A20066,L10544]



', 'Topiramate prevents the occurrence of seizures and prevents migraine symptoms by reducing neural pathway excitability.[A188330,L10544] It is important to note that this drug may cause metabolic acidosis, mood changes, suicidal thoughts and attempts, as well as kidney stones. When topiramate is combined with [valproic acid], it is known to cause hypothermia.[L10544]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Unizithrin 200mg/5ml susp. 30ml', 11939, 'يونيزيثرين 200مجم/5مل معلق 30 مل', '63', '37', 'Antibiotic.macrolide', 'Antibiotic.macrolide', NULL, 'Azithromycin', 'Unipharma co.', 'Susp', 'معلق', '200mg', '1', NULL, NULL, NULL, '6224008676850', 943, '2024-08-08', NULL, 0, 'Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label].



Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. 



**Adults**:



Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.

Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage.



Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_.



Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.



**Pediatric Patients**



Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy.



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.', 'In order to replicate, bacteria require a specific process of protein synthesis, enabled by ribosomal proteins [A6505]. Azithromycin binds to the 23S rRNA of the bacterial 50S ribosomal subunit. It stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit [FDA label], [A14179]. This results in the control of various bacterial infections [A174193], [FDA label].   The strong affinity of macrolides, including azithromycin, for bacterial ribosomes, is consistent with their broad‐spectrum antibacterial activities [A174193].





Azithromycin is highly stable at a low pH, giving it a longer serum half-life and increasing its concentrations in tissues compared to erythromycin [A174175]. 



', 'Macrolides stop bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections [A174175].

Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose [A174172].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bobai sunscreen hydrocare gel spf 50 - 60 gm', 6428, 'بوباي صنسكرين هيدروكير اس بي اف 50 جل 60 جم', '325', NULL, 'Sun block', 'Sun block', NULL, 'Sun protection formula', 'Parkville', 'Gel', 'جل', '60 gm', '1', NULL, NULL, NULL, NULL, 547, '2025-08-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hostapred syrup 100 ml', 3446, 'هوستابريد شراب 100 مل', '15', NULL, 'Glucocorticoid', 'Glucocorticoid', NULL, 'Prednisolone', 'Pharco', 'Syrup', 'شراب', '100 ml', '1', NULL, NULL, NULL, '6221151015611', 1751, '2024-06-01', NULL, 0, 'Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]', 'The short term effects of corticosteroids are decreased vasodilation and permeability of capillaries, as well as decreased leukocyte migration to sites of inflammation.[A187463] Corticosteroids binding to the glucocorticoid receptor mediates changes in gene expression that lead to multiple downstream effects over hours to days.[A187463]



Glucocorticoids inhibit neutrophil apoptosis and demargination; they inhibit phospholipase A2, which decreases the formation of arachidonic acid derivatives; they inhibit NF-Kappa B and other inflammatory transcription factors; they promote anti-inflammatory genes like interleukin-10.[A187463]



Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.[A187463] High doses of glucocorticoids for an extended period bind to the mineralocorticoid receptor, raising sodium levels and decreasing potassium levels.[A187463]', 'Corticosteroids bind to the glucocorticoid receptor, inhibiting pro-inflammatory signals, and promoting anti-inflammatory signals.[A187463] Prednisolone has a short duration of action as the half life is 2.1-3.5 hours.[A187394] Corticosteroids have a wide therapeutic window as patients make require doses that are multiples of what the body naturally produces.[A187463] Patients taking corticosteroids should be counselled regarding the risk of hypothalamic-pituitary-adrenal axis suppression and increased susceptibility to infections.[A187463]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Genepregna fertility 30 tabs.', 31951, 'جينبريجنا فيرتليتلى 30 قرص', '180', NULL, 'Multivitamin', 'Multivitamin', NULL, NULL, 'Copad egypt > genesis pharma', 'Tab', 'أقراص', NULL, '3', NULL, NULL, 'l-arginine 100mg inositol 50mg n-acetylcysteine 50mg beta-carotene 3mg vit d3 15mcg vit e 4mg vit c 90mg thiamine 8mg riboflavin 5mg niacin 20mg vit b6 10mg folic acid 400mcg vit b12 20mcg biotin 150mcg pantothenic acid 6mg magnesium 60mg iron 14mg zinc 1', NULL, 581, '2023-03-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Minro 10 sachets', 22804, 'مينرو 10 اكياس', '60', NULL, 'Iron supplement', 'Iron supplement', NULL, 'Ferrous fumarate+lactoferrin+folic acid+vitamin b1+vitamin b6+ vitamin b12+vitamin c', 'Medcare > ultra pharma plus', 'Sachet', 'أكياس', NULL, '1', 'مكمل غذائى مضاد للاكسدة وغنى بالحديد لعلاج الانيميا ودعم الجهاز العصبى والمناعى', NULL, NULL, NULL, 2300, '2022-06-24', NULL, 0, 'Ferrous sulfate is used for the prevention and treatment of iron deficiency anemia in adults and children.[A190804,L2240,L11800]

', 'Iron is required to maintain optimal health, particularly for helping to form red blood cells (RBC) that carry oxygen around the body. A deficiency in iron indicates that the body cannot produce enough normal red blood cells.[A32514,L11800] Iron deficiency anemia occurs when body stores of iron decrease to very low levels, and the stored iron is insufficient to support normal red blood cell (RBC) production. Insufficient dietary iron, impaired iron absorption, bleeding, pregnancy, or loss of iron through the urine can lead to iron deficiency.[A32514,L11794]  Symptoms of iron deficiency anemia include fatigue, breathlessness, palpitations, dizziness, and headache.



Taking iron in supplement form, such as ferrous sulfate, allows for more rapid increases in iron levels when dietary supply and stores are not sufficient.[L2175] Iron is transported by the divalent metal transporter 1 (DMT1) across the endolysosomal membrane to enter the macrophage. It can then can be incorporated into ferritin and be stored in the macrophage or carried of the macrophage by ferroportin. This exported iron is  oxidized by the enzyme to ceruloplasmin to Fe3+, followed by sequestration by transferrin for transport in the serum to various sites, including the bone marrow for hemoglobin synthesis or into the liver.[A32524] Iron combines with porphyrin and globin chains to form hemoglobin, which is critical for oxygen delivery from the lungs to other tissues.[L2263]', 'Ferrous sulfate replenishes iron, an essential component in hemoglobin, myoglobin, and various enzymes. It replaces the iron that is usually found in hemoglobin and myoglobin. Iron participates in oxygen transport and storage, electron transport and energy metabolism, antioxidant and beneficial pro-oxidant functions, oxygen sensing, tissue proliferation and growth, as well as DNA replication and repair.[A32524,A32514]



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Revita hair stimulating shampoo 180 ml', 25954, 'ريفيتا شامبو 180مل', '425', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Ds laboratories > multitrade', 'Amp', 'أمبول', '180 ml', '1', NULL, NULL, 'revita hair stimulating shampoo is a cutting-edge shampoo designed to stimulate hair while protecting existing hair from falling/thinning.ssideal for men and women this revitalizing hair treatment nourishes the hair and scalp with amino acids strengthenin', NULL, 739, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pedia topical lotion 120 ml', 24622, 'بيديا لوسيون 120 مل', '25', NULL, 'Skin care', 'Skin care', NULL, 'Aloe vera+panthenol+chamomile+bee propolis+tea tree oil+glycerin', 'Hi-care > pedia pharma', 'Lotion', 'لوشن', '120 ml', '1', 'كريم ترطيب وتجديد البشرة غنى بالفيتامينات ومضادات الاكسدة ويحارب علامات تقدم العمر', NULL, NULL, NULL, 1237, '2022-07-08', NULL, 0, 'Indicated for use as a topical agent to soothe sensitive skin and to relieve symptoms of various skin conditions, including contact or atopic dermatitis, eczema, dermatitis and acne urticata, first- and second-degree burns, radiation dermatitis, and sunburn. ', 'It is suggested that aloe polysaccharides mediate skin-protectant effects in damaged skin, induced by internal or other external factors such as radiation, via inhibiting apoptosis of normal cell lines _in vitro_ and thrombocytes _in vivo_ [A32473]. Following irradiation, aloe polysaccharides block the upregulation of pro-apoptotic p53, Bax, and Bad while blocking downregulating anti-apoptotic Bcl-2 [A32473]. _In vivo_, aloe polysaccharides may act as a scavenger for oxygen free radicals including DPPH, alkyl radicals, superoxides, and singlet oxygen and hydroxyl radicals that may also be generated by superoxides [A32470, A32476]. Hydrogen peroxide, which is a weak initiate lipid peroxidation, may also be effectively scavenged by aloe polysaccharides [A32476]. In a Fenton reaction system, aloe polysaccharides demonstrated a concentration-dependent scavenging activity against hydroxyl radical that were generated during the reaction [A32476]. Aloe polysaccharides may also compete with oxygen to react with nitric oxide (NO), thereby inhibiting the generation of nitrite and peroxynitrite anions that act as free radicals [A32476]. 



Findings from a study investigating the effects of aloe polysaccharides on doxorubicin-induced oxidative stress suggest that aloe polysaccharides mediate potent antioxidant actions _in vivo_ [A32476]. Doxorubicin, known to generate reactive oxygen species such as superoxide and hydroxy radicals, was administered to albino rats. This led to myocardial oxidative stress and cardiac injury accompanied by leakage of LDH and CPK from cardiac myocytes and to serum due to lipid peroxidation of cardiac membranes, reduced levels of antioxidant coenzyme GSH, and increased levels of SOD from a compensatory and combative mechanism of oxidative stress [A32476]. Treatment with aloe polysaccharides resulted in a significant decrease in serum LDH and CPK levels, indicating that aloe polysaccharides are capable in stabilizing cardiac membranes from peroxidative damage. Restored levels of endogenous GSH and SOD in a dose-dependent manner were also observed with the treatment of aloe polysaccharides, suggesting that aloe polysaccharides exhibit potent antioxidant properties [A32476].



In a study of rats with open cutaneous back wounds, treatment with aloe polysaccharides decreased the levels of matrix metalloproteinase-3 (MMP-3) and induced tissue inhibitors of matrix metalloproteinase-2 (TIMP-2) during the early stage of wound repair, resulting in decreased collagen breakdown and increased preservation of collagen content in the injured area [A32471]. A study proposes that acemannan, a common aloe polysaccharide, stimulates BMSC proliferation, ALPase activity, expression of VEGF, BMP-2, OPN, BSP, and mineralization leading to osteoblast differentiation and bone formation during socket healing [A32475]. ', 'Aloe polysaccharides mediate antioxidant and anti-inflammatory actions, as well as immunoregulatory activities. Various studies indicate that aloe polysaccharides possess effective free radical scavenging activity _in vitro_, and produce potent antioxidant potential during oxidative stress _in vivo_ [A32476]. According to the findings of studies _in vitro_ and _in vivo_, aloe polysaccharides exhibit radioprotective activity. Treatment with acemmanan, which is a common aloe polysaccharide, on CH3 mice with radiation-induced skin reactions resulted in reduced signs of those reactions [A32473]. Studies suggest that aloe polysaccharides may evidently attenuate tumor growth in mice [A32473]. Treatment of aloe polysaccharides in Vero cells as well as in the in vivo zebrafish model led to protective effects against AAPH-indued oxidative stress resulting from accumulation of free radical species and improved cell viability [A32470]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Calcitron 20 caps.', 30251, 'كالسيترون 20 كبسولة', '96', NULL, 'Calcium supplement', 'Calcium supplement', NULL, 'Amino acids chelated minerals with vitamins', 'Nerhadou international co.', 'Cap', 'كبسولة', NULL, '2', NULL, NULL, 'calcium supplement', '6224008097105', 2053, '2024-12-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Concor amlo 5/5 mg 30 tabs', 16716, 'كونكور املو 5/5 مجم 30 قرص', '210', '160', 'Beta blocking agents with calcium channel blocker', 'Beta blocking agents with calcium channel blocker', NULL, 'Bisoprolol fumarate+amlodipine', 'Merck > amoun', 'Tab', 'أقراص', '5 mg', '3', 'لعلاج مرضى ارتفاع ضغط الدم', NULL, NULL, '429999730727', 8838, '2024-08-08', NULL, 0, 'Bisoprolol is indicated for the treatment of mild to moderate hypertension.[L7219] It may be used off-label to treat heart failure, atrial fibrillation, and angina pectoris.[A180460,A180463]', 'Though the mechanism of action of bisoprolol has not been fully elucidated in hypertension, it is thought that therapeutic effects are achieved through the antagonism of β-1adrenoceptors to result in lower cardiac output. Bisoprolol is a competitive, cardioselective β1-adrenergic antagonist. When β1-receptors (located mainly in the heart)[T640] are activated by adrenergic neurotransmitters such as epinephrine, both the blood pressure and heart rate increase, leading to greater cardiovascular work, increasing the demand for oxygen.  Bisoprolol reduces cardiac workload by decreasing contractility and the need for oxygen through competitive inhibition of β1-adrenergic receptors.[A180502,T640]



Bisoprolol is also thought to reduce the output of renin in the kidneys, which normally increases blood pressure. Additionally, some central nervous system effects of bisoprolol may include diminishing sympathetic nervous system output from the brain, decreasing blood pressure and heart rate.[L7219]', 'Bisoprolol decreases heart rate (chronotropy), decreases contractility (inotropy), and reduces blood pressure.[T640,L7219] The results of various clinical studies indicate that bisoprolol reduces cardiovascular mortality and all-cause mortality in patients with heart failure and decreased cardiac ejection fraction (EF).[A180466,A180505] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Neomycin and polymyxin b sulfate 40ml topical spray', 23382, 'نيومايسين وبوليميكسن بي سلفات سبراي 40 مل', '11', NULL, 'Antibiotic topical', 'Antibiotic topical', NULL, 'Neomycin+polymyxin', 'European egyptian pharm. ind.', 'Spray', 'بخاخ', '40ml', '1', 'بخاخ مضاد حيوي موضعي', NULL, 'about neomycin an aminoglycoside antibiotic ammonium detoxicant. mechanism of action of neomycin this aminoglycoside cause protein synthesis inhibition by irreversibly bind to specific 30s-subunit proteins and 16s rrna. specifically neomycin binds to four', '6221076160199', 2082, '2023-04-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ambroxol 75mg s.r 10 caps.', 13901, 'امبروكسول ممتد المفعول 75 10 كبسولة', '9', NULL, 'Mucolytic', 'Mucolytic', NULL, 'Ambroxol', 'Glaxo smithkline', 'Cap', 'كبسولة', '75mg', '1', NULL, NULL, '(indications): this medication is a mucolytic agent prescribed for various respiratory diseases such as emphysema with bronchitis pneumoconiosis chronic inflammatory pulmonary conditions tracheobronchitis (respiratory tract inflammation) bronchiectasis br', '6221045001492', 1182, '2022-07-07', NULL, 0, 'Ambroxol is indicated for secretolytic therapy in bronchoplmonary disease with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient''s breathing.', 'Ambroxol is a mucolytic agent. Excessive Nitric oxide (NO) is associated with inflammatory and some other disturbances of airways function. NO enhances the activation of soluble guanylate cyclase and cGMP accumulation. Ambroxol has been shown to inhibit the NO-dependent activation of soluble guanylate cyclase. It is also possible that the inhibition of NO-dependent activation of soluble guanylate cyclase can suppress the excessive mucus secretion, therefore it lowers the phlegm viscosity and improves the mucociliary transport of bronchial secretions.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cisplatin-ebewe 25mg/50ml vial(n/a)', 2668, 'سيسبلاتين ايبوي 25مجم فيال', '30', NULL, 'Antineoplastic', 'Antineoplastic', NULL, 'Cisplatin', 'Hospira inc.-uk > pfizer scientific office', 'Vial', 'فيال', '25mg', '1', NULL, NULL, 'description cisplatin cisplatinum or cis-diamminedichloroplatinum(ii) (cddp) is a platinum-based chemotherapy drug used to treat various types of cancers including sarcomas some carcinomas (e.g. small cell lung cancer and ovarian cancer) lymphomas and ger', NULL, 814, '2022-09-22', NULL, 0, 'For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.', 'Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.', 'Cisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mirablad xr 25 mg 10 f.c. tabs.', 22818, 'ميرابلاد اكس ار 25مجم 10 اقراص', '64', NULL, 'Overactive bladder', 'Overactive bladder', NULL, 'Mirabegron', 'Rameda', 'Tab', 'أقراص', '25 mg', '1', 'علاج حالات فرط نشاط المثانة', NULL, 'uses: overactive bladder management of overactive bladder for relief of symptoms associated with voiding (e.g. urge urinary incontinence urgency frequency). how to manage your overactive bladder may be an appropriate alternative in patients with overactiv', NULL, 1754, '2022-05-19', NULL, 0, 'Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with [solifenacin].[L32853] It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.[L32853]', 'Mirabegron is a potent and selective agonist of beta-3 adrenergic receptors. The activation of beta-3 receptors relaxes detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle, which increases the bladder''s storage capacity thereby alleviating feelings of urgency and frequency.[L32853]', 'Mirabegron exerts its pharmacologic effects by forcing bladder smooth muscle to relax, thereby expanding its capacity and relieving urgency. Mirabegron does not appear to adversely affect the mean maximum flow rate or mean detrusor pressure at maximum flow rate in patients with lower urinary tract symptoms and bladder outlet obstruction (BOO), but should be used with in patients with BOO due to reports of significant urinary retention. Furthermore, mirabegron increases both blood pressure and heart rate in a dose-dependent manner and should therefore be used with caution in patients with severely uncontrolled hypertension or others for whom these increases may prove dangerous.[L32853]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Flunzapine 12/50 mg 20 capsules', 19229, 'فلونزابين 12/50 مجم 20 كبسولة', '200', '152', 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Fluoxetine+olanzapine', 'Delta pharma', 'Capsule', 'كبسولة', '50 mg', '2', 'امراض نفسية - مضاد للذهان', NULL, NULL, NULL, 2379, '2025-01-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sulpepta 25 mg 30 tabs.', 6281, 'سولبيبتا 25مجم 30 قرص', '54', NULL, 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Levosulpride', 'Averroes pharma', 'Tab', 'أقراص', '25 mg', '3', 'يستخدم فى و عسر الهضم و الإرتجاع المريئي', NULL, NULL, '6224008179917', 13237, '2024-07-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hydrensa lip balm 5 gm', 18785, 'هيدرنسا مرطب شفاه 5 جم', '90', '85', 'Skin care', 'Skin care', NULL, 'Hyaluronic acid+shea butter+vitamin e+cocoa butter', 'Bio stream', 'Unknown', 'غير محدد', '5 gm', '1', NULL, NULL, NULL, NULL, 732, '2024-12-01', NULL, 0, 'The intra-articular preparations of hyaluronic acid are indicated for knee pain associated with osteoarthritis.[L32228] Hyaluronic acid is used in cosmetic applications to prevent and reduce the appearance of wrinkles on the face, and as a dermal filler to correct facial imperfections or other imperfections on other parts of the body.[L32208,L32223] It is frequently an ingredient in topical applications for wound healing and symptomatic treatment of skin irritation from various causes.[L32198] Hyaluronic acid may also be indicated in ophthalmological preparations or oral capsules to treat discomfort caused by dry eyes or conjunctivitis and for its protective qualities during and before eye surgery.[A230128,L32213] Finally, hyaluronic acid can be used off-label to coat the bladder for relief of interstitial cystitis symptoms.[A230533]', 'General principles and hyaluronic acid receptor binding 



Hyaluronic acid works by two basic mechanisms: serving as a passive structural molecule or serving as signaling molecule, depending on the molecule size. The physicochemical properties of high molecular weight HA contribute to passive structural effects, demonstrating hygroscopicity and viscoelasticity and improving hydration, water balance, and structural integrity. As a signalling  molecule interacting with proteins, HA causes several opposing effects based on molecular weight: pro- or anti-inflammatory effects, promotion or inhibition of cell migration, and activating or inhibiting cell division.[A230133] 



Hyaluronic acid exerts its therapeutic effects through binding to three primary types of cell surface receptors: CD44 (a membrane glycoprotein), the receptor for hyaluronate-mediated motility (RHAMM), and the Intercellular Adhesion Molecule 1 (ICAM-1). CD44 is considered the most widely distributed receptor for hyaluronic acid, demonstrating cellular interactions with osteopontin, collagen, and matrix metalloproteinases (MMPs).  High and low molecular weight hyaluronic acids demonstrate differing molecular and cellular mechanisms in their interaction with CD44 receptors. Some examples of these effects include modification of chondrocyte survival pathways in addition to alteration of apoptosis pathways.  Lymphatic vessel endothelial hyaluronan receptor (LYVE-1), and hyaluronic acid receptor for endocytosis (HARE), (also known as Stabilin-2) also bind to hyaluronic acid.[A230128] 



Hyaluronic acid for skin conditions and cosmetics



Hyaluronic acid''s anionic proprieties cause it to attract water and induce swelling, increasing tissue volume and skin structural integrity. The aging process is associated with reduced production of skin hyaluronic acid and collagen, causing the appearance of wrinkles and the loss of facial volume. Dermal fillers of hyaluronic acid replace lost tissue volume, imparting a full and youthful appearance to skin that has lost its elasticity. Hyaluronic acid fillers contain cross-linked hyaluronic acid particles, rendering a concentrated substance with resistance to various forms of physical and chemical breakdown. The cosmetic benefits of hyaluronic acid filler may last up to 6 months, depending on the brand and technique used for injection.[L32193] Additionally, dermal hyaluronic acid fillers are known to increase the production of fibroblasts[L32193], supporting wound healing and offering relief from irritating and inflammatory skin conditions.[A230118]





Hyaluronic acid for joint pain



Most cells in the human body are capable of synthesizing HA. It is a primary component of the extracellular matrix (ECM) and can be found in bone marrow, cartilage, and synovial fluid in joints.[A230128] In osteoarthritis, the concentration of naturally occurring hyaluronic acid gradually decreases, lowering the viscosity of synovial fluid that protects joints from excess friction. Administration of intra-articular hyaluronic acid increases viscosity of synovial joint fluid, reducing friction and subsequently relieving painful arthritic symptoms.[L32193]





Hyaluronic acid for ophthalmic conditions and ophthalmological procedures



Solutions of hyaluronic acid with a concentration greater than 0.1% moisturize the surface of the eyes to treat symptoms of dry eye while improving the stabilization of tear film, replenishing deficiencies of HA, reducing friction, and preventing binding of foreign substances to the ocular tissue.[A230128,L32193] Hyaluronic acid is frequently used during and after ophthalmological surgeries and plays important roles by virtue of its moisturizing, viscoelastic, and protective properties. It promotes tissue healing of the corneal epithelium and other parts of the eye following ophthalmological surgery, minimizing the risk of adhesions and free radical formation.[A230128]

', 'HA has long-acting lubricant, shock absorbing, joint stabilizing, and water balancing properties.[A230128,L32193] It is similar to the naturally occurring glycosaminoglycan (GAG) in joints. Hyaluronic acid works by acting as a lubricant and shock absorber, facilitating joint mobility and thereby reducing osteoarthritic pain.  Hyaluronic acid has antioxidative, anti-inflammatory, and analgesic effects.[A230128] The water-balancing properties and viscoelasticity of hyaluronic acid are beneficial in cosmetic injections, imparting volume and reducing the appearance of imperfections and wrinkles.[L32193] Due to the abovementioned properties, HA has a protective effect on the eyes and cornea.[A230133]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Amofluxin 1 gm 20 f.c. tabs.', 611, 'اموفلوكسين 1جم 20 قرص', '45', NULL, 'Penicillins.penicillin with b-lactamase inhibitor', 'Penicillins.penicillin with b-lactamase inhibitor', NULL, 'Amoxicillin+flucloxacillin', 'Rameda', 'Tab', 'أقراص', '1 gm', '2', 'مضاد حيوي', NULL, 'amoxycillin and flucloxacillin ï¿½ generally exhibit an additive effect against sensitive bacteria and bacteria that are sensitive to amoxycillin or to flucloxacillin remain sensitive to the combination showing that antagonism does not occur when the two', '6223003970451', 2855, '2022-12-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('M.p.cold & flu 10 sachet.', 22158, 'ام بي كولد&فلو 10 اكياس', '6', NULL, 'Cold drugs', 'Cold drugs', NULL, 'Paracetamol(acetaminophen)+phenylephrine + sodium ascorbate', 'Alexandria > millenium pharma-egypt', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, 'about paracetamol acetanilide derivative non narcotic analgesic antipyretic. mechanism of action of paracetamol paracetamol has analgesic and antipyretic action. it is more active on cyclo-oxygenase enzyme in brain. peripherally it is a poor inhibitor of', '6223004245480', 1011, '2022-07-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Glucose 10% (el nasr) i.v. inf. 500 ml', 5621, 'جلوكوز 10% 500 مل', '11', NULL, 'Antihypoglycemic', 'Antihypoglycemic', NULL, 'Glucose (dextrose)', 'El nasr > ultimate pharma', 'Unknown', 'غير محدد', '10%', '1', NULL, NULL, 'dextrose 10% in water (d10w) is an hypertonic iv solution used in the treatment of ketosis of starvation and provides calories (380 kcal/l) free water and no electrolytes. it should be administered using a central line if possible and should not be infuse', '6224011830010', 1786, '2024-12-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Advagraf 0.5 mg 100 prolonged r. caps.', 13514, 'ادفاجراف 0.5 مجم 100 كبسولات', '1,440', NULL, 'Immunosuppressants', 'Immunosuppressants', NULL, 'Tacrolimus', 'Astellas > egyptian pharmaceutical trading company', 'Cap', 'كبسولة', '0.5 mg', '1', NULL, NULL, 'about tacrolimus calcineurin inhibitor a macrolide immunosuppressant for prevention of graft rejection. mechanism of action of tacrolimus it binds to specific receptors on t cells. it reduces peptidyl-prolyl isomerase activity by forming a complex with im', NULL, 1235, '2022-07-15', NULL, 0, 'Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants.[L8162] Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving kidney transplants, in combination with other immunosuppressants,[L20034,L41005] and may be used in patients converted from immediate-release formulations.[L41005]



Topical tacrolimus ointment is indicated as second-line therapy for short-term and non-continuous treatment of moderate-to-severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical treatments or for whom alternative treatments are not advisable.[L3935] Both available strengths are indicated in adult patients, while only the lower strength (0.03%) formulation is indicated in pediatric patients between 2 and 15 years of age.[L3935]', 'The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells.', 'Tacrolimus acts by reducing peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This inhibits both T-lymphocyte signal transduction and IL-2 transcription. Tacrolimus has similar activity to cyclosporine but rates of rejection are lower with tacrolimus. Tacrolimus has also been shown to be effective in the topical treatment of eczema, particularly atopic eczema. It suppresses inflammation in a similar way to steroids, but is not as powerful. An important dermatological advantage of tacrolimus is that it can be used directly on the face; topical steroids cannot be used on the face, as they thin the skin dramatically there. On other parts of the body, topical steroid are generally a better treatment.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Selvin firming cream 120 gm', 26758, 'سيلفن كريم 120جم', '149', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Egyptian co. for cosmetics > tig pharma', 'Cream', 'كريم', '120 gm', '1', 'كريم لعلاج علامات التمدد', NULL, NULL, NULL, 909, '2022-07-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Farcotilium 10mg 10 eff. sachets', 18825, 'فاركوتيليوم 10مجم 10 اكياس فوار', '13', '7', 'Antiemetic', 'Antiemetic', NULL, 'Domperidone', 'Pharco', 'Sachet', 'أكياس', '10mg', '1', NULL, NULL, NULL, NULL, 977, '2025-04-08', NULL, 0, 'For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.', 'Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of domperidone are related to its peripheral dopamine receptor blocking properties. Domperidone facilitates gastric emptying and decreases small bowel transit time by increasing esophageal and gastric peristalsis and by lowering esophageal sphincter pressure. Antiemetic: The antiemetic properties of domperidone are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level. It has strong affinities for the D2 and D3 dopamine receptors, which are found in the chemoreceptor trigger zone, located just outside the blood brain barrier, which - among others - regulates nausea and vomiting', 'Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hisatrup 10 mg 30 f.c. tabs.', 20506, 'هيساتروب 10مجم 30 قرص', '68', '45.75', 'Antihistamine.second-generation', 'Antihistamine.second-generation', NULL, 'Rupatadine', 'Mash premiere', 'Tab', 'أقراص', '10 mg', '3', 'مضاد للحساسية -- يخفف اعراض الرشح والتهاب الانف', NULL, 'rupatadine fumarate has been approved for the treatment of allergic rhinitis and chronic urticaria in adults and children over 12 years. the defined daily dose (ddd) is 10 mg orally.', '6222001401882', 4067, '2024-02-08', NULL, 0, 'For the symptomatic relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and perennial allergic rhinitis in patients 2 years of age and older [FDA Label]. Also used for the symptomatic relief of chronic spontaneous urticaria in patients 2 years of age and older.', 'Rupatadine is a dual histamine H1 receptor and platelet activating (PAF) receptor antagonist [A19779] [FDA Label]. During allergic response mast cells undergo degranulation, releasing histamine and other substances [A19780]. Histamine acts on H1 receptors to produce symptoms of nasal blockage, rhinorhea, itching, and swelling. PAF is produced from phospholipids cleaved by phospholipase A2. It acts to produce vascular leakage which contributes to rhinorhea and nasal blockage. By blocking both the H1 receptor and PAF receptor, rupatidine prevents these mediators from exerting their effects and so reduces the severity of allergic symptoms.', 'Rupatadine is an anti allergenic and acts to reduce allergic symptoms like urticaria, rhinorrhea, sneezing and itching [FDA Label].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Faslodex 250mg/5ml i.m. 2 prefilled syringe', 18842, 'فاسلودكس 250 مجم / 5 مل 2 حقن مملؤة مسبقاً', '10,330', '7600', 'Antineoplastic', 'Antineoplastic', NULL, 'Fulvestrant', 'Astra zeneca', 'Syringe', 'حقنة', '250mg', '2', NULL, NULL, NULL, NULL, 1727, '2025-08-12', NULL, 0, 'For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.', 'Fulvestrant competitively and reversibly binds to estrogen receptors present in cancer cells and achieves its anti-estrogen effects through two separate mechanisms. First, fulvestrant binds to the receptors and downregulates them so that estrogen is no longer able to bind to these receptors. Second, fulvestrant degrades the estrogen receptors to which it is bound. Both of these mechanisms inhibit the growth of tamoxifen-resistant as well as estrogen-sensitive human breast cancer cell lines.', 'Fulvestrant for intramuscular administration is an estrogen receptor antagonist without known agonist effects.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dand rast anti-dandruff shampoo 125 gm', 17084, 'داند رست شامبو مضاد للقشرة 125 مل', '69', NULL, 'Hair care', 'Hair care', NULL, 'Zinc pyrithione+piroctone olamine+keratin+soyabean oil+salicylic acid', 'Cosmopack for cosmetics > x med', 'Amp', 'أمبول', '125 gm', '1', NULL, NULL, 'anti-dandruff shampoo with salicylic acid provides these following advantages: *eliminates moderate to heavy dandruff problems. *eliminates flakes and itchy scalp. *can be used regularly to prevent the recurrence of dandruff. application: applied on a wet', NULL, 887, '2022-07-30', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Infinity facial wash 200 ml', 6393, 'انفينيتي غسول وجه 200 مل', '130', NULL, 'Skin care.moisturizing', 'Skin care.moisturizing', NULL, 'Rosemary+honey+olive oil+dimethicone+d-panthenol+magnesium ascorbyl phosphate+citric acid+glycerin', 'Infinity pharm', 'Facial wash', 'غسول للوجه', '200 ml', '1', NULL, NULL, NULL, NULL, 735, '2022-12-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Maxanagen hair lotion', 31715, 'ماكساناجين لوشن للشعر', '168', NULL, 'Hair booster lotion', 'Hair booster lotion', NULL, 'Salicylic acid+caffeine+biotin+vitamin e+panthenol+coconut oil', 'Smartec for pharmaceuticals and cosmetics > vaxil for pharmaceutical industries', 'Lotion', 'لوشن', NULL, '1', NULL, NULL, 'maxanagen hair lotion slows down hair loss due to its properties which stimulate hair growth strengthens the hair roots and increases the thickness and density of hair. it also ensures optimal hair anchorage in the hair bulb. hair loss prevention nourishi', NULL, 748, '2023-03-06', NULL, 0, 'Key additive in many skin-care products for the treatment of acne, psoriasis, callouses, corns, keratosis pilaris and warts.', 'Salicylic acid directly irreversibly inhibits COX-1 and COX-2 to decrease conversion of arachidonic acid to precursors of prostaglandins and thromboxanes. Salicylate''s use in rheumatic diseases is due to it''s analgesic and anti-inflammatory activity. Salicylic acid is a key ingredient in many skin-care products for the treatment of acne, psoriasis, calluses, corns, keratosis pilaris, and warts. Salicylic acid allows cells of the epidermis to more readily slough off. Because of its effect on skin cells, salicylic acid is used in several shampoos used to treat dandruff. Salicylic acid is also used as an active ingredient in gels which remove verrucas (plantar warts). Salicylic acid competitively inhibits oxidation of uridine-5-diphosphoglucose (UDPG) with nicotinamide adenosine dinucleotide (NAD) and noncompetitively with UDPG. It also competitively inhibits the transferring of the glucuronyl group of uridine-5-phosphoglucuronic acid (UDPGA) to a phenolic acceptor. Inhibition of mucopoly saccharide synthesis is likely responsible for the slowing of wound healing with salicylates.', 'Salicylic acid treats acne by causing skin cells to slough off more readily, preventing pores from clogging up. This effect on skin cells also makes salicylic acid an active ingredient in several shampoos meant to treat dandruff. Use of straight salicylic solution may cause hyperpigmentation on unpretreated skin for those with darker skin types (Fitzpatrick phototypes IV, V, VI), as well as with the lack of use of a broad spectrum sunblock. Subsalicylate in combination with bismuth form the popular stomach relief aid known commonly as Pepto-Bismol. When combined the two key ingredients help control diarrhea, nausea, heartburn, and even gas. It is also very mildly anti-biotic.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('X-tension plus 300/12.5mg 28 scored tab.', 29783, 'اكستنشن بلس 300/12.5مجم 28 قرص', '148', '108', 'Antihypertensive.angiotensin blocker', 'Antihypertensive.angiotensin blocker', NULL, 'Hydrochlorothiazide+irbesartan', 'Marcyrl co. > rameda', 'Tab', 'أقراص', '12.5mg', '4', NULL, NULL, 'about hydrochlorothiazide thiazide derivatibve diuretic. mechanism of action of hydrochlorothiazide it is thiazide diuretic which exerts its action by acting at site-3(central dilating segment of early distal tubule). it binds to na+cl- symporter and inhi', '6223003973841', 3252, '2024-10-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sitagliform 50/500mg 30 f.c. tabs.', 2104, 'سيتاجليفورم 50/500مجم 30 قرص', '207', NULL, 'Anti-diabetic.combined secretagogues+sensitizers', 'Anti-diabetic.combined secretagogues+sensitizers', NULL, 'Metformin+sitagliptin', 'P & c labs', 'Tab', 'أقراص', '500mg', '3', NULL, NULL, NULL, NULL, 970, '2022-09-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aripiprazole 30mg 20 f.c tab', 948, 'اريبيبرازول 30 مجم 20 قرص', '152', '114', 'Psychiatric antipsychotics', 'Psychiatric antipsychotics', NULL, 'Aripiprazole', 'El- Obour', 'Tab', 'أقراص', '30mg', '2', 'حالات الامراض النفسية -- علاج الاكتئاب -- علاج الانفصام الشخصية -- يؤخذ تحت اشراف طبي', NULL, NULL, '6224000866037', 4032, '2024-05-26', NULL, 0, 'Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette''s disorder.[L45859] It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania.[L45859] Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.[L46203]', 'The antipsychotic action of aripiprazole is likely due to its partial agonist activity on D2 and 5-HT<sub>1A</sub> receptors as well as its antagonist activity at 5-HT<sub>2A</sub> receptors; however, the exact mechanism has not been fully elucidated.[A4393,L45859,L4620] One of the mechanisms that have been proposed is that aripiprazole both stimulates and inhibits dopamine as it engages the D2 receptor. It lowers dopamine neuronal firing at high dopamine concentrations and increases dopamine firing at low concentrations. Its partial agonist activity gives aripiprazole an intermediate level of dopaminergic neuronal tone between full agonist and antagonist of the D2 receptor.[A258699] In addition, some adverse effects may be due to action on other receptors.[L4620] For example, orthostatic hypotension may be explained by antagonism of the adrenergic alpha-1 receptors.[L4620,A4393]', 'Aripiprazole exhibits high affinity for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5-HT<sub>1a</sub> and 5-HT<sub>2a</sub> receptors (Ki values of 0.34 nM, 0.8 nM, 1.7 nM, and 3.4 nM, respectively), moderate affinity for dopamine D<sub>4</sub>, serotonin 5-HT<sub>2c</sub> and 5-HT<sub>7</sub>, alpha<sub>1</sub>-adrenergic and histamine H<sub>1</sub> receptors (Ki values of 44 nM, 15 nM, 39 nM, 57 nM, and 61 nM, respectively), and moderate affinity for the serotonin reuptake site (Ki=98 nM). Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors (IC<sub>50</sub>>1000 nM).[L45859]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Genove genocutan biosulphur shampoo 250ml', 19700, 'جينوفي جينوكيوتان شامبو 250 مل', '159', NULL, 'Hair care', 'Hair care', NULL, 'Biosulphur+tea tree oil', 'Laboratorio genove s.a.', 'Amp', 'أمبول', '250ml', '1', NULL, NULL, 'genocuta n biosulfur shampoo has a 2% content of biosulfur which makes of it an ideal treatment for excessively oily hair. together with biolsulfur melaleuca alternifolio and hydrolized keratin help control oil and remove the excess of secretions. biosulf', NULL, 979, '2022-07-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zurcal 40mg powder for i.v. inf. vial', 12943, 'زوركال 40مجم فيال حقن وريدي', '84', '65', 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Pantoprazole', 'Marcyrl co. > aug pharma', 'Vial', 'فيال', '40mg', '1', 'حرقان المعدة والصدر بسبب الحموضة.', NULL, 'about pantoprazole a proton pump inhibitor benzimidazole derivative anti ulcer. mechanism of action of pantoprazole pantoprazole is a proton pump inhibitor. it is a prodrug. after administration it diffuses in to the parietal cell of the stomach and accum', '6223005460561', 5852, '2024-11-12', NULL, 0, '

**Pantoprazole Injection**:



**Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis**



Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. _Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time_.[FDA label]



**Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome**



Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions.[FDA label]



**Pantoprazole delayed-release oral suspension**:



**Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD)**



Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined.[F3202]



**Maintenance of healing of erosive esophagitis**



Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD.[F3202]



**Pathological hypersecretory conditions including Zollinger-Ellison syndrome**



Indicated for the long-term treatment of the above conditions.[F3202]', 'Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K(+)-ATPase of the proton pump, expressed in high quantities by the parietal cells of the stomach.[A174295] ATPase is an enzyme on the parietal cell membrane that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid). 



Proton pump inhibitors such as pantoprazole are substituted _benzimidazole_ derivatives, weak bases, which accumulate in the acidic space of the parietal cell before being converted in the _canaliculi_  (small canal) of the gastric parietal cell, an acidic environment, to active _sulfenamide_ derivatives. This active form then makes disulfide bonds with important cysteines on the gastric acid pump, inhibiting its function.[A174247] Specifically, pantoprazole binds to the _sulfhydryl group_ of H+, K+-ATPase, which is an enzyme implicated in accelerating the final step in the acid secretion pathway. The enzyme is inactivated, inhibiting gastric acid secretion.[A174253] The inhibition of gastric acid secretion is stronger with proton pump inhibitors such as pantoprazole and lasts longer than with the H(2) antagonists.[A174295] ', 'This drug acts to decrease gastric acid secretion, which reduces stomach acidity. Pantoprazole administration leads to long-lasting inhibition of gastric acid secretion.[F3193]



**General Effects**



Pantoprazole has been shown to reduce acid reflux-related symptoms, heal inflammation of the esophagus, and improve patient quality of life more effectively than histamine-2 receptor antagonists (H2 blockers). This drug has an excellent safety profile and a low incidence of drug interactions. It can be used safely in various high-risk patient populations, including the elderly and those with renal failure or moderate hepatic dysfunction.[A174226]



Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as pantoprazole have been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.[A177571]



PPIs such as pantoprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes [A177577, A177580]. 



**A note on laboratory testing abnormalities**



During treatment with antisecretory medicinal products such as pantoprazole, serum gastrin (a peptide hormone that stimulates secretion of gastric acid) increases in response to the decreased acid secretion caused by proton pump inhibition. The increased gastrin level may interfere with investigations for neuroendocrine tumors. Published evidence suggests that proton pump inhibitors should be stopped 14 days before chromogranin A (CgA) measurements. This permits chromogranin A levels, that might be falsely elevated after proton pump inhibitor treatment, to return to the normal reference range.[F3217] 



Reports have been made of false-positive results in urine screening tests for tetrahydrocannabinol (THC) in patients receiving the majority of proton pump inhibitors, including pantoprazole. A confirmatory method should be used.[F3217]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rexomair 20 gm gel', 29755, 'ريكسومير جل 20 جم', '45', NULL, 'Nasal gel', 'Nasal gel', NULL, 'Hylaronic acid+allantoin+glycerin+panthenol+aloe vera gel', 'Rixos bharma', 'Gel', 'جل', '20 gm', '1', NULL, NULL, NULL, '6225000604124', 1004, '2022-10-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dermofix 2% cream 15 gm', 3493, 'ديرموفكس 2% كريم 15 جم', '51', '34', 'Antifungals.imidazoles', 'Antifungals.imidazoles', NULL, 'Sertaconazole', 'Sigma > ferrer international sa -spain', 'Cream', 'كريم', '2%', '1', 'كريم مضاد للفطريات -- تقليل الالتهابات -- تقليل الحكة والالحمرار -- علاج الجروح', NULL, 'indication for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older caused by trichophyton rubrum trichophyton mentagrophytes and epidermophyton floccosum. mechanism of action sertaconazole interacts with', '6224009165025', 2246, '2025-01-12', NULL, 0, 'For the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by <i>Trichophyton rubrum</i>, <i>Trichophyton mentagrophytes</i>, and <i>Epidermophyton floccosum</i>.', 'Sertaconazole interacts with 14-&alpha; demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Sertaconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.', 'Sertaconazole is an imidazole/triazole type antifungal agent. Sertaconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 &alpha;-demethylation via the inhibition of the enzyme cytochrome P450 14&alpha;-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 &alpha;-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Sertaconazole exhibits <i>in vitro</i> activity against <i>Cryptococcus neoformans</i> and <i>Candida spp.</i> Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to <i>Cryptococcus neoformans</i> and for systemic infections due to Candida albicans.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pharmabilast 20 mg 20 tabs.', 31097, 'فارمابيلاست 20مجم 20 قرص', '92', '62', 'Anti-histamine.second-generation', 'Anti-histamine.second-generation', NULL, 'Bilastine', 'Pharma cure pharmaceuticals', 'Tab', 'أقراص', '20 mg', '2', NULL, NULL, 'bilastine is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives). it exerts its effect as a selective histamine h1 receptor antagonist and has a effectiveness similar to cetirizine fexofenadine an', NULL, 1163, '2025-09-03', NULL, 0, 'For symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older [FDA Label].', 'Bilastine is a selective histamine H1 receptor antagonist (Ki = 64nM) [FDA Label]. During allergic response mast cells undergo degranulation which releases histamine and other subastances. By binding to and preventing activation of the H1 receptor, bilastine reduces the development of allergic symptoms due to the release of histamine from mast cells.', 'Bilastine is an antiallergenic and acts to reduce allergic symptoms such as nasal congestion and urticaria [FDA Label].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kombiglyza xr 5/1000 mg 30 tablets', 21478, 'كومبيجليز اكس ار 2.5 / 1000 مجم 60 قرص', '270', NULL, 'Anti-diabetic.secretagogues.dpp-4 inhibitors', 'Anti-diabetic.secretagogues.dpp-4 inhibitors', NULL, 'Saxagliptin+metformin', 'Bristol-myers squibb > united pharma international-egypt', 'Tablet', 'أقراص', '1000 mg', '3', NULL, NULL, NULL, NULL, 1116, '2022-07-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Conventin 800mg 30 tabs.', 16775, 'كونفنتين 800مجم 30 قرص', '171', '127.5', 'Anti-epileptic.gaba analogs', 'Anti-epileptic.gaba analogs', NULL, 'Gabapentin', 'Eva pharma', 'Tab', 'أقراص', '800mg', '3', NULL, NULL, NULL, '6223007355117', 5374, '2024-05-29', NULL, 0, 'In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older.[L8717] In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.[L8732]', 'The precise mechanism through which gabapentin exerts its therapeutic effects is unclear.[L8717,L8720] The primary mode of action appears to be at the auxillary α2δ-1 subunit of voltage-gated calcium channels (though a low affinity for the α2δ-2 subunit has also been reported).[A186179,A14097,A186277] The major function of these subunits is to facilitate the movement of pore-forming α1 subunits of calcium channels from the endoplasmic reticulum to the cell membrane of pre-synaptic neurons.[A186179] There is evidence that chronic pain states can cause an increase in the expression of α2δ subunits and that these changes correlate with hyperalgesia.[A14097] Gabapentin appears to inhibit the action of α2δ-1 subunits, thus decreasing the density of pre-synaptic voltage-gated calcium channels and subsequent release of excitatory neurotransmitters.[A186179] It is likely that this inhibition is also responsible for the anti-epileptic action of gabapentin.[A186277]



There is some evidence that gabapentin also acts on adenosine receptors[A11009, A186209] and voltage-gated potassium channels,[A186212] though the clinical relevance of its action at these sites is unclear.', 'Gabapentin is an anti-convulsant medication that inhibits the release of excitatory neurotransmitters, allowing for its use against pathologic neurotransmission such as that seen in neuropathic pain and seizure disorders.[L8717,L8732] It has a wide therapeutic index, with doses in excess of 8000 mg/kg failing to cause a fatal reaction in rats.[L8765]



Gabapentin is ineffective in absence seizures and should be used in caution in patients with mixed seizure disorders involving absence seizures. Gabapentin has been associated with drug reaction with eosinophilia and systemic symptoms (DRESS), otherwise known as multi-organ hypersensitivity. This reaction can prove fatal and early symptoms such as fever, lymphadenopathy, and rash should be promptly investigated.[L8717,L8720,L8732]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aripiprazole 10mg 20 f.c. tab.', 14394, 'اريبيبرازول 10مجم 20 قرص', '99', '87', 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Aripiprazole', 'El-obour', 'Tab', 'أقراص', '10mg', '2', NULL, NULL, NULL, '6224000866006', 1407, '2024-07-20', NULL, 0, 'Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette''s disorder.[L45859] It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania.[L45859] Finally, an extended-release, bimonthly injection formulation of aripiprazole is indicated for the treatment of adult schizophrenia and maintenance therapy for adult bipolar I disorder.[L46203]', 'The antipsychotic action of aripiprazole is likely due to its partial agonist activity on D2 and 5-HT<sub>1A</sub> receptors as well as its antagonist activity at 5-HT<sub>2A</sub> receptors; however, the exact mechanism has not been fully elucidated.[A4393,L45859,L4620] One of the mechanisms that have been proposed is that aripiprazole both stimulates and inhibits dopamine as it engages the D2 receptor. It lowers dopamine neuronal firing at high dopamine concentrations and increases dopamine firing at low concentrations. Its partial agonist activity gives aripiprazole an intermediate level of dopaminergic neuronal tone between full agonist and antagonist of the D2 receptor.[A258699] In addition, some adverse effects may be due to action on other receptors.[L4620] For example, orthostatic hypotension may be explained by antagonism of the adrenergic alpha-1 receptors.[L4620,A4393]', 'Aripiprazole exhibits high affinity for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5-HT<sub>1a</sub> and 5-HT<sub>2a</sub> receptors (Ki values of 0.34 nM, 0.8 nM, 1.7 nM, and 3.4 nM, respectively), moderate affinity for dopamine D<sub>4</sub>, serotonin 5-HT<sub>2c</sub> and 5-HT<sub>7</sub>, alpha<sub>1</sub>-adrenergic and histamine H<sub>1</sub> receptors (Ki values of 44 nM, 15 nM, 39 nM, 57 nM, and 61 nM, respectively), and moderate affinity for the serotonin reuptake site (Ki=98 nM). Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors (IC<sub>50</sub>>1000 nM).[L45859]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Pyrazide 500mg 10 tab.', 25515, 'بيرازيد 500مجم 10 اقراص', '3', NULL, 'Antitubercular', 'Antitubercular', NULL, 'Pyrazinamide', 'El nasr', 'Tab', 'أقراص', '500mg', '1', NULL, NULL, 'about pyrazinamide niacinamide derivative antitubercular. mechanism of action of pyrazinamide pyrazinamide is a bactericidal or bacteriostatic drug depending on the drug concentration at the infection site and the susceptibility of organism. pyrazinamide', NULL, 734, '2022-07-25', NULL, 0, 'For the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents.', 'Pyrazinamide diffuses into active _M. tuberculosis_ that express pyrazinamidase enzyme that converts pyrazinamide to the active form pyrazinoic acid. Pyrazinoic acid can leak out under acidic conditions to be converted to the protonated conjugate acid, which is readily diffused back into the bacilli and accumulate intracellularly. The net effect is that more pyrazinoic acid accumulates inside the bacillus at acid pH than at neutral pH. Pyrazinoic acid was thought to inhibit the enzyme fatty acid synthase (FAS) I, which is required by the bacterium to synthesise fatty acids. However, this theory was thought to have been discounted.[A512] However, further studies reproduced the results of FAS I inhibition as the putative mechanism first in whole cell assay of replicating M. tuberculosis bacilli which have shown that pyrazinoic acid and its ester inhibit the synthesis of fatty acids.[A513] This study was followed by in vitro assay of tuberculous FAS I enzyme that tested the activity with pyrazinamide, pyrazinoic acid and several classes of pyrazinamide analogs. Pyrazinamide and its analogs inhibited the activity of purified FAS I.[A514] 



It has also been suggested that the accumulation of pyrazinoic acid disrupts membrane potential and interferes with energy production, necessary for survival of M. tuberculosis at an acidic site of infection. Pyrazinoic acid has also been shown to bind to the ribosomal protein S1 (RpsA) and inhibit trans-translation. This may explain the ability of the drug to kill dormant mycobacteria.[A515]', 'Pyrazinamide kills or stops the growth of certain bacteria that cause tuberculosis (TB). It is used with other drugs to treat tuberculosis. It is a highly specific agent and is active only against <i>Mycobacterium tuberculosis</i>. In vitro and in vivo, the drug is active only at a slightly acid pH. Pyrazinamie gets activated to Pyrazinoic acid in the bacilli where it interferes with fatty acid synthase FAS I. This interferes with the bacteriums ability to synthesize new fatty acids, required for growth and replication.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Coumadin 5 mg 28 tablets (illegal import)', 16859, 'كومادين 5 مجم 28 قرص مستورد', '0', NULL, 'Anticoagulant.clotting factors activation inhibitors', 'Anticoagulant.clotting factors activation inhibitors', NULL, 'Warfarin', 'Zentiva >', 'Tablet', 'أقراص', '5 mg', '4', NULL, NULL, 'about warfarin synthetic coumarin derivative vitamin k antagonist anticoagulant. mechanism of action of warfarin it exerts it`s pharmacological action by inhibiting regeneration of active hydroquinone from vitamin k and also behaves as a competitive antag', '300560172750', 1150, '2022-07-09', NULL, 0, '**Indicated** for:[label,L6616]



1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.



2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.



3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.



4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.



**Off-label** uses include:



1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.[A179182]', 'Warfarin is a [vitamin K] antagonist which acts to inhibit the production of vitamin K by vitamin K epoxide reductase.[label,A179221,T116] The reduced form of vitamin K, vitamin KH<sub>2</sub> is a cofactor used in the γ-carboxylation of coagulation factors VII, IX, X, and thrombin. Carboxylation induces a conformational change allowing the factors to bind Ca<sup>2+</sup> and to phospholipid surfaces. Uncarboxylated factors VII, IX, X, and thrombin are biologically inactive and therefore serve to interrupt the coagulation cascade. The endogenous anticoagulation proteins C and S also require  γ-carboxylation to function. This is particularly true in the case of thrombin which must be activated in order to form a thrombus. vitamin KH<sub>2</sub> is converted to vitamin K epoxide as part of the γ-carboxylation reaction catalyzed by γ-glutamyl carboxylase. Vitamin K epoxide is then converted to vitamin K<sub>1</sub> by vitamin K epoxide reductase then back to vitamin KH<sub>2</sub> by vitamin K reductase. Warfarin binds to vitamin K epoxide reductase complex subunit 1 and irreversibly inhibits the enzyme thereby stopping the recycling of vitamin K by preventing the conversion of vitamin K epoxide to vitamin K<sub>1</sub>. This process creates a hypercoagulable state for a short time as proteins C and S degrade first with half lives of 8 and 24 hours, with the exception of factor VII which has a half life of 6 hours.[A179221] Factors IX, X, and finally thrombin degrade later with half lives of 24, 36, and 50 hours resulting in a dominant anticoagulation effect.[A179221] In order to reverse this anticoagulation vitamin K must be supplied, either exogenously or by removal of the vitamin K epoxide reductase inhibition, and time allowed for new coagulation factors to be synthesized.[label,A179221,T116] It takes approximately 2 days for new coagulation factors to be synthesized in the liver. Vitamin K<sub>2</sub>, functionally identical to vitamin K<sub>1</sub>, is synthesized by gut bacteria leading to interactions with antibiotics as elimination of these bacteria can reduce vitamin K<sub>2</sub supply and result in a greater anticoagulation effect.[T116]', 'Warfarin is an anticoagulant, as such it disrupts the coagulation cascade to reduce frequency and extent of thrombus formation.[label,L6616] In patients with deep vein thrombosis or atrial fibrillation there is an increased risk of thrombus formation due to the reduced movement of blood.[T622] For patients with cardiac valve disease or valve replacements this increased coagulability is due to tissue damage. Thrombi due to venous thrombosis can travel to the lungs and become pulmonary emboli, blocking circulation to a portion of lung tissue. Thrombi which form in the heart can travel to the brain and cause ischemic strokes. Prevention of these events is the primary goal of warfarin therapy.



Limitation of thrombus formation is also a source of adverse effects. In patients with atheroscelotic plaques rupture typically results in thrombus formation.[A179212] When these patients are anticoagulated plaque rupture can allow the escape of cholesterol from the lipid core in the form of atheroemboli or cholesterol microemboli. These emboli are smaller than thrombi and block smaller vessels, usually less than 200 μm in diameter. The consequences of this are varied and depend on the location of the blockage. Effects include visual disturbances, acute kidney injury or worsening of chronic kidney disease, central nervous system ischemia, and purple or blue toe syndrome.[label,A179212] Blue toe syndrome can be reversed if it has not progressed to tissue necrosis but the other effects of microemboli are often permanent.



Antocoagulation appears to mediate warfarin-related nephropathy, a seemingly spontaneous kidney injury or worsening of chronic kidney disease associated with warfarin therapy.[A179215] Nephropathy in this case appears to be due to increased passage of red blood cells through the glomerulus and subsequent blockage of renal tubules with red blood cell casts. This is worsened or possibly triggered by pre-existing kidney damage. Increased risk of warfarin-related nephropathy occurs at INRs over 3.0 but risk does not increase as a function of INR beyond this point.



Warfarin has been linked to the development of calciphylaxis.[label] This is thought to be due to warfarin''s inhibition of [vitamin K](VKA) recycling as VKA is needed for the carboxylation of matrix Gla protein.[A179218] This protein is an anti-calcification factor and its inhibition through preventing the carboxylation step in its production leads to a shift in calcification balance in favor of calciphylaxis. 



Tissue necrosis can occur early on in warfarin therapy.[label] This is attributable to half lives of the clotting factors impacted by inhibition of vitamin K recycling.[label,A179221] Proteins C and S are anticoagulation factors with half lives of 8 and 24 hours respectively. The coagulation factors IX, X, VII, and thrombin (factor II) have half lives of 24, 36, 6, and 50 hours respectively. This means proteins C and S are inactivated sooner than pro-coagulation proteins, with the exception of factor VII, resulting in a pro-thrombotic state for the first few days of therapy. Thrombi which form in this time period can occlude arterioles in various locations, blocking blood flow and causing tissue necrosis due to ischemia.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Wessol 10 sachets', 8848, 'ويسول 10 اكياس', '200', NULL, 'Collagen supplement', 'Collagen supplement', NULL, 'Collagen+calcium+vitamin c', 'Nutra pharm', 'Sol', 'محلول', NULL, '1', NULL, NULL, NULL, NULL, 687, '2024-08-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gytrocetam 400 mg 20 f.c. tabs.', 5782, 'جيتروسيتام 400مجم 20 قرص', '32', '16', 'Cerebral circulatory inhancer', 'Cerebral circulatory inhancer', NULL, 'Piracetam', 'Gypto pharma', 'Tab', 'أقراص', '400 mg', '2', NULL, NULL, NULL, '6224008874218', 2551, '2025-08-11', NULL, 0, 'Indicated in adult patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies [L1125].', 'Piracetam interacts with the polar heads in the phospholipids membrane and the resulting mobile drug-lipid complexes are thought to reorganize the lipids and influence membrane function and fluidity [A31532]. Such interaction has been reported in a study that investigated the effects of neuronal outgrowth induced by beta amyloid peptides; while amyloid peptides cause lipid disorganization within the cell membranes leading to neuronal death, piracetam demonstrated to decrease the destabilizing effects of amyloid peptide [A31534]. The authors suggest that piracetam induces a positive curvature of the membrane by occupying the polar groups in the phospholipids to counteract the negative curvature induced by amyloid peptides , which in turn would decrease the likelihood of membrane fusion [A31532]. This mechanism of action is thought to improve membrane stability, allowing the membrane and transmembrane proteins to maintain and recover the three-dimensional structure or folding for normal function [L1124] such as membrane transport, chemical secretion, and receptor binding and stimulation [A31532]. 



Through restored membrane fluidity, piracetam promotes restored neurotransmission such as glutamatergic and cholinergic systems, enhances neuroplasticity and mediates neuroprotective and anticonvulsant effects at the neuronal level [A31532]. It is also demonstrated that piracetam also improves the fluidity of platelet membranes. At the vascular level, piracetam decreases adhesion of erythrocytes to cell wall and reduces vasospasm which in turn improves microcirculation including cerebral and renal blood flow [A31532]. ', 'Piracetam is known to mediate various pharmacodynamic actions:



**Neuronal effects**: 



Piracetam modulates the cholinergic, serotonergic, noradrenergic, and glutamatergic neurotransmission although the drug does not display high affinity to any of the associated receptors (Ki >10μM). Instead, piracetam increases the density of postsynaptic receptors and/or restore the function of these receptors through stabilizing the membrane fluidity [A31532]. In the forebrain of aging mice, the density of NMDA receptors was increased by approximately 20% following 14 days of piracetam treatment. Based on the findings of various animal and human studies, the cognitive processses including learning, memory, attention and consciousness were enhanced from piracetam therapy without inducing sedation and psychostimulant effects [L1125]. Piracetam mediate neuroprotective effects against hypoxia-induced damage, intoxication, and electroconvulsive therapy [L1125]. 



In two studies involving alcohol-treated rats with evidences of withdrawal-related neuronal loss, piracetam was shown to reduce the extent of neuronal loss and increase the numbers of synapses in the hippocampus by up to 20% relative to alcohol-treated or alcohol-withdrawn rats [A31532]. This suggests that piracetam is capable in promoting neuroplasticity when recoverable neural circuits are present [A31532]. Although the mechanism of action is not fully understood, administration of piracetam prior to a convulsant stimulus reduces the seizure severity and enhances the anticonvulsant effectiveness of conventional antiepileptics such as carbamazepine and diazepam [A31535]. 



**Vascular effects**: 



Piracetam is shown to increase the deformability of erythrocytes, reduce platelet aggregation in a dose-dependent manner, reduce the adhesion of erythrocytes to vascular endothelium and capillary vasospasm. In healthy volunteers, piracetam mediated a direct stimulant effect on prostacycline synthesis and reduced the plasma levels of fibrinogen and von Willebrand’s factors (VIII: C; VIII R: AG; VIII R: vW) by 30 to 40% [L1125]. Potentiated microcirculation is thought to arise from a combination of effects on erythrocytes, blood vessels and blood coagulation [A31532]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Medivarum10 ml drops', 13114, 'ميديفارم نقط فم 10 مل', '60', NULL, 'Multivitamin', 'Multivitamin', NULL, 'Vitamin d3+vitamin k2', 'Medi drug pharma', 'Drops', 'نقط', '10 ml', '1', NULL, NULL, NULL, NULL, 1036, '2022-09-22', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Xyrkux 60 mg 20 tabs', 7484, 'زيركوكس 60مجم 20 قرص', '188', '130', 'Non steroid anti-inflammatory drugs', 'Non steroid anti-inflammatory drugs', NULL, 'Etoricoxib', 'Liptis usa', 'Tab', 'أقراص', '60 mg', '2', NULL, NULL, NULL, NULL, 1916, '2025-08-11', NULL, 0, 'For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.', 'Like any other COX-2 selective inhibitor Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2), preventing production of prostaglandins (PGs) from arachidonic acid.', 'Etoricoxib is a COX-2 selective inhibitor (approximately 106 times more selective for COX-2 inhibition over COX-1).', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Innohep anti-xa 10000 i.u./0.5ml (0.5ml)*2 prefilled syringe', 20848, 'اينوهيب انتي اكسا 10000 وحدة دولية / 0.5 مل (0.5مل) 2 سرنجة مملؤة', '140', NULL, 'Anticoagulant.low mwt heparin', 'Anticoagulant.low mwt heparin', NULL, 'Tinzaparin sodium', 'Leo pharmaceutical products', 'Syringe', 'حقنة', '0.5ml', '2', 'مضاد للتجلطات --يحافظ علي سيولة الدورة الدموية -- حالات الجلطات', NULL, 'about tinzaparin low molecular weight heparin anticoagulant. mechanism of action of tinzaparin tinzaparin is an anticoagulant. it is a low molecular weight heparin that binds to and accelerate the activity of antithrombin iii.this produces inactivation of', '5702191005530', 882, '2022-12-06', NULL, 0, 'Tinzaparin is used for the prevention of postoperative venous thromboembolism in patients undergoing orthopedic surgery and in patients undergoing general surgery who are at high risk of developing postoperative venous thromboembolism. It is also used for the treatment of deep vein thrombosis and/or pulmonary embolism. It is indicated for use in preventing clot formation in indwelling intravenous lines for hemodialysis.', 'Tinzaparin binds to the plasma protein antithrombin III, forming a complex with then accelerates the inhibition of factor Xa. Its affinity for factor Xa is 2-4 times greater than that of unbound ATIII. The inactivation of factor Xa in turn will exponentially generation of thrombin (factor IIa) molecules, which is needed to activate fibrinogen to fibrin. The coagulation cascade is inhibited because fibrin cannot be formed in the presence of tinzaparin. Like all LMWH, it cannot be given intramuscularly due to increased risk of hematoma.', 'Tinzaparin, like other LMWHs, have a higher anti-Xa activity  than anti-IIa activity. The anti-Xa activity of tinzaparin is 2.0 +/- 0.5 times greater than its to anti-IIa activity. Heparin exhibits approximately equal inhibitory activity against Xa and IIa. Tinzaparin is an anticoagulant that blocks the formation of thrombi. Like all LMWHs, tinzaparin only causes activated partial thromboplastin time (aPTT) prolongation at higher doses and routine monitoring is not recommended. However, anti-factor Xa levels may be monitored in some conditions such as pregnancy and renal dysfunction. Its use should be avoided in patients with a creatinine clearance less than 20 mL/min. In these patients, unfractionated heparin should be used. Tinzaparin can be used in patients who have a creatinine clearance between 20-30 mL/min, giving it the highest safety threshold for use in renal failure patients compared to all the LMWHs.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hertraz 440 mg vial (pd for injection)', 20432, 'هيرتراز 440 مجم فيال', '15,014', '11000', 'Antineoplastic', 'Antineoplastic', NULL, 'Trastuzumab', 'Mylan laboratories limited > ramco', 'Injection', 'حقن', '440 mg', '1', NULL, NULL, NULL, NULL, 1408, '2024-11-06', NULL, 0, 'For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based therapy.[L14015]



Trastuzumab is indicated as a first-line treatment, in combination with paclitaxel, for metastatic HER2-overexpressing breast cancer, and as monotherapy in patients who have previously received one or more chemotherapy regimens in the metastatic setting.[L14015] In Europe, trastuzumab can also be used in combination with paclitaxel or docetaxel for the treatment of metastatic HER2-positive breast cancer in adult patients and with an aromatase inhibitor in postmenopausal patients.[L49324]



For HER2-positive early breast cancer, the EMA approved trastuzumab as monotherapy following surgery, chemotherapy (neoadjuvant or adjuvant), and radiation or following adjuvant chemotherapy with doxorubicin and cyclophosphamide in combination with paclitaxel or docetaxel. It can also be used in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin or with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy for locally advanced (including inflammatory) disease or tumors > 2 cm in diameter.[L49324]



Trastuzumab is also indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease by the FDA and EMA.[L14015]



Trastuzumab is indicated for subcutaneous administration - in combination with either [hyaluronidase][L14132] or both hyaluronidase and [pertuzumab][L14510] - for the treatment of adults with HER2-positive breast cancers.', 'Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the HER-2 receptor, a member of the epidermal growth factor receptors which is a photo-oncogene. Over-expressed in breast tumour cells, HER-2 overamplifies the signal provided by other receptors of the HER family by forming heterodimers [A121]. The HER-2 receptor is a transmembrane tyrosine kinase receptor that consists of an extracellular ligand-binding domain, a transmembrane region, and an intracellular or cytoplasmic tyrosine kinase domain. It is activated by the formation of homodimers or heterodimers with other EGFR proteins, leading to dimerization and autophosphorylation and/or transphosphorylation of specific tyrosine residues in EGFR intracellular domains [A121]. Further downstream molecular signaling cascades are activated, such as the Ras/Raf/mitogen-activated protein kinase (MAPK), the phosphoinositide 3-kinase/Akt, and the phospholipase Cγ (PLCγ)/protein kinase C (PKC) pathways that promote cell growth and survival and cell cycle progression [A121]. Due to upregulation of HER-2 in tumour cells, hyperactivation of these signaling pathways and abnormal cell proliferation is observed. Trastuzumab binds to the extracellular ligand-binding domain and blocks the cleavage of the extracellular domain of HER-2 to induce its antibody-induced receptor downmodulation [A121], and subsequently inhibits HER-2-mediated intracellular signaling cascades. Inhibition of MAPK and PI3K/Akt pathways lead to an increase in cell cycle arrest, and the suppression of cell growth and proliferation [A121]. Trastuzumab also mediates the activation of antibody-dependent cell-mediated cytotoxicity (ADCC) [A40276] by attracting the immune cells, such as natural killer (NK) cells, to tumor sites that overexpress HER-2 [A121]. While the drug alone has a minimal potential to induce complement-dependent cytotoxicity (CDC),[A201902] one study demonstrated increased therapeutic effectiveness and a synergistic effect on uterine serous carcinoma cells _in vitro_ when used in combination with [pertuzumab], which also has minor effects on CDC alone. This study showed that only the combination of both cell-bound antibodies would be sufficient to bind and activate the complement component 1q (C1q) required to initiate the complement cascade reaction.[A201896]



Intrinsic trastuzumab resistance has been noted for some patients with HER-2 positive breast cancer. Mechanisms involving trastuzumab resistance include deficiency of phosphatase and tensin homologue and activation of phosphoinositide 3-kinase, and the overexpression of other surface receptors, such as insulin-like growth factor [A40276].', 'Trastuzumab exerts an antitumour activity and is used in the treatment of HER2-positive breast cancer. HER2 protein overexpression is observed in 20%-30% of primary breast cancers [A40277] thus HER2 presents as a useful therapeutic target for the treatment of breast cancers. Trastuzumab has been shown, in both _in vitro_ assays and in animals, to inhibit the proliferation of human tumour cells that overexpress HER2. It works as a mediator of antibody-dependent cellular cytotoxicity, where it binds as an antibody to cells over-expressing HER2, leading to preferential cell death. Trastuzumab was also shown to inhibit angiogenesis of tumor cells _in vivo_ [A121]. Higher doses and longer dosing intervals show no significant benefit over standard dose schedules [A40276]. In patients with HER2 positive solid tumours, trastuzumab did not exert any clinically significant QTc interval duration.[L14015]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Teddy go 60 gummies', 27969, 'تيدي جو 60 قرص للمضغ', '250', '200', 'Multivitamins', 'Multivitamins', NULL, 'Vitamin(a+e+b12+c)+calcium+phosphorus+iodine+magnesium+zinc+folic acid', 'Copad pharma', 'Unknown', 'غير محدد', NULL, '1', 'فيتامينات', NULL, NULL, NULL, 1788, '2025-10-21', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gazik eye contour cream 60 gm', 19627, 'جازيك كريم كونتور العين 60 جم', '130', NULL, 'Eye contour', 'Eye contour', NULL, 'Kojic acid+hyaluoronic acid+glycerin+vitamin a+elastin+collagen+liquorice', 'Hi-care > pure pharmaceuticals', 'Cream', 'كريم', '60 gm', '1', NULL, NULL, 'eye contour cream to reduce dark circles and puffiness under the eye.', NULL, 774, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Doxorubicin stada 2mg/ml vial 10mg', 17883, 'دوكسوروبيسين ستادا 2 مجم/ مل 10 مجم فيال', '55', NULL, 'Antineoplastic', 'Antineoplastic', NULL, 'Doxorubicin', 'Cell pharm gmbh-germany > germa pharm', 'Vial', 'فيال', '2mg', '1', NULL, NULL, 'about doxorubicin anthracycline antibiotic antineoplastic agent. mechanism of action of doxorubicin this anthracycline antibiotic intercalates the dna which directly affects the transcription and replication of dna. it forms a tripartite complex with topo', NULL, 722, '2022-07-12', NULL, 0, 'Doxorubicin is indicated for the treatment of neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin and non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue and bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, and metastatic bronchogenic carcinoma.[L45231] Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.[L45231] For the liposomal formulation, doxorubicin is indicated for the treatment of ovarian cancer that has progressed or recurred after platinum-based chemotherapy, AIDS-Related Kaposi''s Sarcoma after the failure of prior systemic chemotherapy or intolerance to such therapy, and multiple myeloma in combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy.[L45226]', 'Generally, doxorubicin is thought to exert its antineoplastic activity through 2 primary mechanisms: intercalation into DNA and disrupt topoisomerase-mediated repairs and free radicals-mediated cellular damages.[A257614]



Doxorubicin can intercalate into DNA through the anthraquinone ring, which stabilizes the complex by forming hydrogen bonds with DNA bases.[A257659] Intercalation of doxorubicin can introduce torsional stress into the polynucleotide structure, thus destabilizing nucleosome structures and leading to nucleosome eviction and replacement.[A257664,A18538] Additionally, the doxorubicin-DNA complex can interfere with topoisomerase II enzyme activity by preventing relegation of topoisomerase-mediated DNA breaks, thus inhibiting replication and transcription and inducing apoptosis.[A257669,A257674] 



Moreover, doxorubicin can be metabolized by microsomal NADPH-cytochrome P-450 reductase into a semiquinone radical, which can be reoxidized in the presence of oxygen to form oxygen radicals.[A1579,A257584] Reactive oxygen species have been known to cause cellular damage through various mechanisms, including lipid peroxidation and membrane damage, DNA damage, oxidative stress, and apoptosis.[A257634] Although free radicals generated from this pathway can be deactivated by catalase and superoxide dismutase, tumor and myocardial cells tend to lack these enzymes, thus explaining doxorubicin''s effectiveness against cancer cells and tendency to cause cardiotoxicity.[A1579,A257584,A1578]

', 'Doxorubicin is a cytotoxic, cell-cycle non-specific anthracycline antibiotic.[A1574,A257674] It is generally thought to exert its antitumor effect by destabilizing DNA structures through intercalation, thus introducing DNA strand breakages and damages.[A257664,A18538,A257674] Not only does it alter the transcriptomes of the cells, failure in repairing DNA structures can also initiate the apoptotic pathways.[A257674,A257679] Additionally, doxorubicin intercalation can also interfere with vital enzyme activity, such as topoisomerase II, DNA polymerase, and RNA polymerase, leading to cell cycle arrests.[A257674] Finally, doxorubicin can also generate cytotoxic reactive oxygen species to exert cellular damages.[A257584]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Healthylase 90 ml', 4629, 'هيلثيلاز شراب 90 مل', '59', NULL, 'Anti inflammatory', 'Anti inflammatory', NULL, 'Alpha -amylase', 'Healthy med pharam', 'Unknown', 'غير محدد', '90 ml', '1', NULL, NULL, NULL, NULL, 1873, '2025-06-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rotapyretic 1 gm/100ml vial for i.v. inf.', 26334, 'روتابيريتيك 1جم/100مل فيال', '67', '35.5', 'Antipyretic', 'Antipyretic', NULL, 'Paracetamol(acetaminophen)', 'Grand pharma > biocapital pharma', 'Vial', 'فيال', '1 gm', '1', NULL, NULL, 'about paracetamol acetanilide derivative non narcotic analgesic antipyretic. mechanism of action of paracetamol paracetamol has analgesic and antipyretic action. it is more active on cyclo-oxygenase enzyme in brain. peripherally it is a poor inhibitor of', '6224009667215', 5010, '2024-06-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Green-viii inj. 250 i.u. / vial.', 20067, 'جرين 250 وحدة دولية فيال', '480', NULL, 'Blood-coagulation factor', 'Blood-coagulation factor', NULL, 'Blood-coagulation factor viii', 'Koria green cross > eimc', 'Inj', 'حقن', NULL, '1', NULL, NULL, NULL, NULL, 688, '2023-05-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sodium chloride 2.7% (el nasr) i.v. inf. 500 ml (rubber cap)', 10620, 'صوديوم كلورايد 2.7% النصر محلول ملح وريدي 500 مل بغطاء مطاطي', '6', NULL, 'Sterile solution', 'Sterile solution', NULL, 'Sodium chloride', 'El nasr', 'Cap', 'كبسولة', '2.7%', '1', 'يعمل على زيادة القلوية', NULL, NULL, NULL, 1062, '2022-05-20', NULL, 0, 'This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. Also, designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. ', 'Sodium and chloride — major electrolytes of the fluid compartment outside of cells (i.e., extracellular) — work together to control extracellular volume and blood pressure. Disturbances in sodium concentrations in the extracellular fluid are associated with disorders of water balance.', 'Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.

Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Leservo syrup 100 ml', 7834, 'ليسيرفو شراب 100 مل', '100', NULL, 'Support brain function and normal vision', 'Support brain function and normal vision', NULL, 'Dha+epa+omega 3', 'Company', 'Syrup', 'شراب', '100 ml', '1', NULL, NULL, NULL, NULL, 958, '2024-09-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Micort 10mg 10 tab.', 8146, 'ميكورت 10مجم 10 قرص', '7', NULL, 'Glucocorticoid', 'Glucocorticoid', NULL, 'Hydrocortisone acetate', 'Misr', 'Tab', 'أقراص', '10mg', '1', 'مضاد للالتهاب.', NULL, NULL, '6221035008081', 8838, '2023-02-04', NULL, 0, 'For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn''s disease.', 'Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.', 'Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Semabella syrup 125 ml', 33612, 'سيمابيلا شراب 125 مل', '95', '60', 'Multivitamin', 'Multivitamin', NULL, 'Calcium + magnesium + vit c + zinc + vit d3 + manganese', 'Semaf pharma', 'Syrup', 'شراب', '125 ml', '1', NULL, NULL, NULL, NULL, 716, '2025-07-29', NULL, 0, 'Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.', 'Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.', 'Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Apexidone 4mg 30 f.c.tab.', 847, 'ابيكسيدون 4مجم 30 قرص', '126', NULL, 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Risperidone', 'Multi-apex', 'Tab', 'أقراص', '4mg', '3', NULL, NULL, 'about risperidone second-generation antipsychotic benzisoxazole derivative antimanic atypical antipsychotic. mechanism of action of risperidone risperidone exerts its antipsychotic activity by blocking dopamine and serotonin (5ht2) receptors. the drug has', '6223003200909', 2124, '2022-12-02', NULL, 0, 'Risperidone is indicated for the treatment of schizophrenia [L12885,L44692,L46297] and irritability associated with autistic disorder.[L12885] It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.[L12885,L44692]



Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.[L12906]



Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.[A177226]', 'Though its precise mechanism of action is not fully understood, current focus is on the ability of risperidone to inhibit the D2 dopaminergic receptors and 5-HT2A serotonergic receptors in the brain. Schizophrenia is thought to result from an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively.[A1115, A1116, A1117]



D2 dopaminergic receptors are transiently inhibited by risperidone, reducing dopaminergic neurotransmission, therefore decreasing positive symptoms of schizophrenia, such as delusions and hallucinations.[A251765] Risperidone binds transiently and with loose affinity to the dopaminergic D2 receptor, with an ideal receptor occupancy of 60-70% for optimal effect.[A1119,A31773] Rapid dissociation of risperidone from the D2 receptors contributes to decreased risk of extrapyramidal symptoms (EPS), which occur with permanent and high occupancy blockade of D2 dopaminergic receptors.[A1118,A1119] Low-affinity binding and rapid dissociation from the D2 receptor distinguish risperidone from the traditional antipsychotic drugs. A higher occupancy rate of D2 receptors is said to increase the risk of extrapyramidal symptoms and is therefore to be avoided.[A1118,A1119,A31771] 

 

Increased serotonergic mesocortical activity in schizophrenia results in negative symptoms, such as depression and decreased motivation. The high-affinity binding of risperidone to 5-HT2A receptors leads to a decrease in serotonergic activity. In addition, 5-HT2A receptor blockade results in decreased risk of extrapyramidal symptoms, likely by increasing dopamine release from the frontal cortex, and not the nigrostriatal tract. Dopamine level is therefore not completely inhibited.[A1117,A1119] Through the above mechanisms, both serotonergic and D2 blockade by risperidone are thought to synergistically work to decrease the risk of extrapyramidal symptoms. 

 

Risperidone has also been said to be an antagonist of alpha-1 (α1), alpha-2 (α2), and histamine (H1) receptors.[A37034] Blockade of these receptors is thought to improve symptoms of schizophrenia, however the exact mechanism of action on these receptors is not fully understood at this time.[L12885]', 'The primary action of risperidone is to decrease dopaminergic and serotonergic pathway activity in the brain, therefore decreasing symptoms of schizophrenia and mood disorders.[A1115,A1116]



Risperidone has a high binding affinity for serotonergic 5-HT2A receptors when compared to dopaminergic D2 receptors in the brain.[A1114,A1115] Risperidone binds to D2 receptors with a lower affinity than first-generation antipsychotic drugs, which bind with very high affinity. A reduction in extrapyramidal symptoms with risperidone, when compared to its predecessors, is likely a result of its moderate affinity for dopaminergic D2 receptors.[A1119,A1117]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Depiwhite eye contour gel 15 ml', 17283, 'ديبي وايت جل لمحيط العين 15 مل', '379', '215', 'Whitening topical', 'Whitening topical', NULL, NULL, 'Acm dermatological laboratories > biotech egypt', 'Gel', 'جل', '15 ml', '1', NULL, NULL, 'properties depiwhite gel acts on the main factors responsible for causing dark circles and bags under the eyes. it reduces the bags under the eyes lightens and limits dark circles resulting in a refreshed appearance. directions for use apply depiwhite ey', '3760095250205', 657, '2025-08-11', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('France lait 1 to 3 milk 400 gm', 19382, 'فرانس ليه من 1-3 حليب 400 جرام', '75', NULL, 'Milk products.third stage (age 1-3 years)', 'Milk products.third stage (age 1-3 years)', NULL, 'Milk formula stage 3', 'Regilait > eva pharma', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, 'not to replace mother s milk. for infants from 1 to 3 years age. to be used within one month from opening.', '3043932161316', 758, '2022-07-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Egycusate plus 30 f.c. tabs', 18114, 'ايجيكيوسات بلس 30 قرص', '48', '30', 'Laxative', 'Laxative', NULL, 'Docusate sodium+sennosides', 'Egpi', 'Tab', 'أقراص', NULL, '3', 'ملين -- علاج حالات الامساك الشديد -- تقليل الانتفاخات والغازات', NULL, NULL, '6223003932107', 9407, '2024-10-09', NULL, 0, 'Indicated for the treatment of constipation associated with dry, hard stools or opioid induced constipation[A176984]. Though recently, pressure has been building to end the use of docusate over concerns of efficacy[A176972,A176987,L5912].', 'Recent studies suggest that docusate''s mechanism of action is due largely to it''s surfactant effect in the intestines, which allow fat and water into the feces to soften the stool[A176984].



Docusate’s mechanism of action was investigated in 1985 on healthy patients.[A32201] Docusate was added directly to the jejunum based on calculated concentrations of docusate in the jejunum.[A32201] At this concentration, there was an increase in secretion of water, sodium, chloride, and potassium as well as a decrease in absorption of glucose and bicarbonate[A32201]. Based on in vitro data, the authors suggested this effect was due to an increase in intracellular cyclic AMP either directly through docusate or E series prostaglandins.[A32201]', 'Docusate sodium is a laxative and an anionic detergent that supposedly promotes incorporation of water and fats into stool through a reduction in surface tension, resulting in softer fecal mass [L1801,A176984]. Docusate''s onset of action is 6-72 hours orally and 2-15 minutes rectally [L1801, L1804]. The effects of docusate are thought to be exerted locally in the jejunum[A32201]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Salicortiderm oint. 15 gm', 26473, 'ساليكورتيديرم مرهم 15جم', '15', '10', 'Glucocorticoid with keratolytic', 'Glucocorticoid with keratolytic', NULL, 'Flumethasone+salicylic acid', 'Medizen pharmaceutical industries', 'Oint', 'مرهم', '15 gm', '1', 'مضاد للالتهابات ويستخدم لعلاج الإلتهابات الجلدية منها الصدفية و الأكزيما.', NULL, 'about flumethasone topical steroids anti inflammatory and antipruritic drugs mechanism of action of flumethasone its mechanism of action is to inhibit arachidonic acids role in the biosynthesis of prostaglandins and leukotrienes. flumethasone is active wh', NULL, 5612, '2024-02-27', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sebaferro 30 tabs.', 4186, 'سيبافيرو 30 قرص', '250', '140', 'Iron.anemia', 'Iron.anemia', NULL, 'Liposomal iron+vitamin c+vitamen e+vitamin d3+ vitamin(b1+b2+b3+b6+b12)+beta-carotene+pantothenic acid+biotin+ folic acid+zinc+magnesium+manganese+iodine+chromium+copper+ selenium+molybdenum', 'Elsebaeypharma', 'Tab', 'أقراص', NULL, '3', 'أحدث تكنولوجيا لامتصاص الحديد قل وداعا لكل مشاكل امتصاص الحديد', NULL, NULL, '6225000481527', 14741, '2025-11-02', NULL, 0, 'Investigated for use/treatment in neuropathy (diabetic) and peripheral vascular disease.', 'The encapsulated formulation (Liprostin) has been shown to improve the therapeutic index of PGE-1, positively impacting many areas of treatment, such as heart attacks, occlusive disease, ischemic ulcers, critical limb salvage, claudicants, and arthritis.', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Era d3 400 iu oral drops 10ml', 8010, 'ايرا د3 - 400 وحدة دولية 10 مل', '45', NULL, 'Vitamin d3', 'Vitamin d3', NULL, 'Cholecalciferol 10 mcg (vitamin d3 400 iu)', 'Era egypt pharma', 'Drops', 'نقط', '400 iu', '1', NULL, NULL, NULL, NULL, 779, '2025-11-17', NULL, 0, 'Cholecalciferol use is indicated for the treatment of specific medical conditions like refractory rickets (or vitamin D resistant rickets), hypoparathyroidism, and familial hypophosphatemia [F4027, F4042].



Concurrently, as one of the most commonly utilized forms of vitamin D, cholecalciferol is also very frequently used as a supplement in individuals to maintain sufficient vitamin d levels in the body or to treat vitamin D deficiency, as well as various medical conditions that can be associated directly or indirectly with vitamin d insufficiency like osteoporosis and chronic kidney disease, among others [A176041, A176044, F4051].', 'Most individuals naturally generate adequate amounts of vitamin D through ordinary dietary intake of vitamin D (in some foods like eggs, fish, and cheese) and natural photochemical conversion of the vitamin D3 precursor 7-dehydrocholesterol in the skin via exposure to sunlight [L5689, F4027, F4042, F4048].



Conversely, vitamin D deficiency can often occur from a combination of insufficient exposure to sunlight, inadequate dietary intake of vitamin D, genetic defects with endogenous vitamin D receptor, or even severe liver or kidney disease [A243]. Such deficiency is known for resulting in conditions like rickets or osteomalacia, all of which reflect inadequate mineralization of bone, enhanced compensatory skeletal demineralization, resultant decreased calcium ion blood concentrations, and increases in the production and secretion of parathyroid hormone [A223]. Increases in parathyroid hormone stimulate the mobilization of skeletal calcium and the renal excretion of phosphorus [A223]. This enhanced mobilization of skeletal calcium leads towards porotic bone conditions [A223].



Ordinarily, while vitamin D3 is made naturally via photochemical processes in the skin, both itself and vitamin D2 can be found in various food and pharmaceutical sources as dietary supplements. The principal biological function of vitamin D is the maintenance of normal levels of serum calcium and phosphorus in the bloodstream by enhancing the efficacy of the small intestine to absorb these minerals from the diet [A223]. At the liver, vitamin D3 or D2 is hydroxylated to 25-hydroxyvitamin D and then finally to the primary active metabolite 1,25-dihydroxyvitamin D in the kidney via further hydroxylation [A223, A243]. This final metabolite binds to endogenous vitamin d receptors, which results in a variety of regulatory roles - including maintaining  calcium balance, the regulation of parathyroid hormone, the promotion of the renal reabsorption of calcium, increased intestinal absorption of calcium and phosphorus, and increased calcium and phosphorus mobilization of calcium and phosphorus from bone to plasma to maintain balanced levels of each in bone and the plasma [A223, A243].



In particular, calcitriol interacts with vitamin D receptors in the small intestine to enhance the efficiency of intestinal calcium and phosphorous absorption from about 10-15% to 30-40% and 60% increased to 80%, respectively [L5689]. Furthermore, calcitriol binds with vitamin D receptors in osteoblasts to stimulate a receptor activator of nuclear factor kB ligand (or RANKL) which subsequently interacts with receptor activator of nuclear factor kB (NFkB) on immature preosteoclasts, causing them to become mature bone-resorbing osteoclasts [L5689]. Such mature osteoclasts ultimately function in removing calcium and phosphorus from bone to maintain blood calcium and phosphorus levels [L5689]. Moreover, calcitriol also stimulates calcium reabsorption from the glomerular filtrate in the kidneys [L5689].



Additionally, it is believed that when calcitriol binds with nuclear vitamin D receptors, that this bound complex itself binds to retinoic acid X receptor (RXR) to generate a heterodimeric complex that consequently binds to specific nucleotide sequences in the DNA called vitamin D response elements [L5689]. When bound, various transcription factors attach to this complex, resulting in either up or down-regulation of the associated gene''s activity. It is thought that there may be as much as 200 to 2000 genes that possess vitamin D response elements or that are influenced indirectly to control a multitude of genes across the genome [L5689].  It is in this way that cholecalciferol is believed to function in regulating gene transcription associated with cancer risk, autoimmune disorders, and cardiovascular disease linked to vitamin D deficiency [L5689]. In fact, there has been some research to suggest calcitriol may also be able to prevent malignancies by inducing cellular maturation and inducing apoptosis and inhibiting angiogenesis, exhibit anti-inflammatory effects by inhibiting foam cell formation and promoting angiogenesis in endothelial colony-forming cells in vitro, inhibit immune reactions by enhancing the transcription of endogenous antibiotics like cathelicidin and regulate the activity and differentiation of CD4+ T cells, amongst a variety of other proposed actions [L5689].   ', 'The in vivo synthesis of the predominant two biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of vitamin D3 cholecalciferol (or D2) occurs in the liver to yield 25-hydroxyvitamin D while the second hydroxylation happens in the kidneys to give 1, 25-dihydroxyvitamin D [F4027, F4042, F4048]. These vitamin D metabolites subsequently facilitate the active absorption of calcium and phosphorus in the small intestine, serving to increase serum calcium and phosphate levels sufficiently to allow bone mineralization [F4027, F4042, F4048]. Conversely, these vitamin D metabolites also assist in mobilizing calcium and phosphate from bone and likely increase the reabsorption of calcium and perhaps also of phosphate via the renal tubules [F4027, F4042, F4048]. There exists a period of 10 to 24 hours between the administration of cholecalciferol and the initiation of its action in the body due to the necessity of synthesis of the active vitamin D metabolites in the liver and kidneys [F4027, F4042, F4048]. It is parathyroid hormone that is responsible for the regulation of such metabolism at the level of the kidneys [F4027, F4042, F4048].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Amriflucan 150 mg 2 caps.', 682, 'امريفلوكان 150مجم 2كبسولة', '11', NULL, 'Antifungals.triazoles', 'Antifungals.triazoles', NULL, 'Fluconazole', 'Amriya', 'Cap', 'كبسولة', '150 mg', '1', 'مضاد للفطريات -- تقليل الالتهابات -- تقليل العدوي الفطرية', NULL, 'about fluconazolesa triazole derivative a board range antifungal.ssmechanism of action of fluconazolesfluconazole is fungicidal or fungistatic depending on the drug concentrations. i t inhibits the conversion of lanosterol to 14 demethyl lanosterol by inh', '6221075021019', 2191, '2022-12-02', NULL, 0, 'Fluconazole can be administered in the treatment of the following fungal infections[L11043]:



 1) Vaginal yeast infections caused by Candida

 2) Systemic Candida infections

 3) Both esophageal and oropharyngeal candidiasis 

 4) Cryptococcal meningitis

 5) UTI (urinary tract infection) by Candida

 6) Peritonitis (inflammation of the peritoneum) caused by Candida



**A note on fungal infection prophylaxis**



Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.[L11043]



**A note on laboratory testing**



Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.[L11043]

', 'Fluconazole is a very selective inhibitor of fungal cytochrome P450 dependent enzyme _lanosterol 14-α-demethylase_. This enzyme normally works to convert _lanosterol_ to _ergosterol_, which is necessary for fungal cell wall synthesis.  The free nitrogen atom located on the azole ring of fluconazole binds with a single iron atom located in the heme group of lanosterol 14-α-demethylase.[A178774] This prevents oxygen activation and, as a result, inhibits the demethylation of lanosterol, halting the process of ergosterol biosynthesis.[A178777]  Methylated sterols are then found to accumulate in the fungal cellular membrane, leading to an arrest of fungal growth.[A178774] These accumulated sterols negatively affect the structure and function of the fungal cell plasma membrane.[A16632]



Fluconazole resistance may arise from an alteration in the amount or function of the target enzyme (lanosterol 14-α-demethylase), altered access to this enzyme, or a combination of the above.[A16632] Other mechanisms may also be implicated, and studies are ongoing.[A178783]', 'Fluconazole has been demonstrated to show fungistatic activity against the majority of strains of the following microorganisms, curing fungal infections[L11043]:



_Candida albicans, Candida glabrata (Many strains are intermediately susceptible), Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans_



This is achieved through steroidal inhibition in fungal cells, interfering with cell wall synthesis and growth as well as cell adhesion, thereby treating fungal infections and their symptoms.[L11043,A174325,A174343]



The fungistatic activity of fluconazole has also been shown in normal and immunocompromised animal models with both systemic and intracranial fungal infections caused by _Cryptococcus neoformans_ and for systemic infections caused by Candida albicans.[L11043]  It is important to note that resistant organisms have been found against various strains of organisms treated with fluconazole.[A178759,A178762,A178765] This further substantiates the need to perform susceptibility testing when fluconazole is considered as an antifungal therapy.[A178768,A178786] 





**A note on steroidal effects of fluconazole**



There has been some concern that fluconazole may interfere with and inactivate human steroids/hormones due to the inhibition of hepatic cytochrome enzymes.[L11034]  Fluconazole has demonstrated to be more selective for _fungal_ cytochrome P-450 enzymes than for a variety of mammalian cytochrome P-450 enzymes. Fluconazole 50 mg administered daily for up to 28 days in individuals of reproductive age has been show to have no effect on testosterone plasma concentrations of males and plasma concentrations of steroids in females. A 200-400 mg dose of fluconazole showed no clinically relevant effect on steroid levels or on ACTH-stimulated steroid response in healthy males, in one clinical study mentioned on the European Medicines Agency label.[L11034] Other studies have shown no significant effects of fluconazole on steroid levels, further confirming these data.[A174358,A178780]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mikids hair lotion 110 ml', 4143, 'مايكيدز لوشن للشعر110 مل', '175', NULL, 'Hair lotion _hair tonic _reduce hair loss_increaes hair density for kids', 'Hair lotion _hair tonic _reduce hair loss_increaes hair density for kids', NULL, NULL, NULL, 'Lotion', 'لوشن', '110 ml', '1', 'يستخدم ميكيدز لوشون', NULL, NULL, NULL, 659, '2025-06-13', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bebeto 4gm/100 ml oral drops 30 ml', 14961, 'بيبيتو 4 جم/100 مل نقط 30 مل', '2', NULL, 'Antiflatulent', 'Antiflatulent', NULL, 'Dimethicone', 'Alfacure pharmaceuticals', 'Drops', 'نقط', '4gm', '1', 'مضاد للانتفاخ وطارد للغازات', NULL, NULL, NULL, 1111, '2023-02-03', NULL, 0, 'Dimethicone is a colorless liquid with both cosmetic and therapeutic uses. It is used in topical creams and ointments to help distribute the active ingredients. Dimethicone is used as an anti-foaming agent, a hair and skin conditioner, and in the treatment of head lice and, as an anti-bloating/anti-flatulence agent [L1765], [L1772].', 'When applied topically, dimethicone forms a layer to delay the evaporation of water [L1773].

In the treatment of head lice dimethicone 100, the respiratory systems of head lice are targeted.  NYDA works by suffocating the lice, nymphs and the embryos. The physical properties of this drug, including the viscosity and spreading property of the solution allow it to easily flow into the respiratory system of all developmental stages of the insect,  causing suffocation and death of the organisms. It diffuses through the stigmata (spiracles) of the lice, into the tracheae of the head lice as well as through the aeropyles of the egg operculum. The solution then displaces oxygen. The low viscosity, volatile dimethicone enables the NYDA head lice solution to penetrate into the breathing system. Its evaporation causes the thickening of the NYDA solution. The remaining high viscosity dimethicone ultimately encloses the respiratory system and thus leading to suffocation of all stages of head lice (adult lice, larvae and eggs). This mode of action prevents the development of lice resistance by preventing the formation of new progency [L1774].



Studies performed using house crickets and lice suggest a close correlation between the death of the lice and the influx of the solution into the insect head tracheae. These data strongly suggest that the total filling of the head tracheae immediately blocks the oxygen supply to the insect central nervous system. Death, following numerous stages of disability after the entrance of dimethicones into the abdominal tracheal system, demonstrates the sequence of oxygen deprivation. NYDA was applied directly to the head and mouth of the organism, and was found to have no effect when applied solely to the outside of the head/mouth [L1774].', 'This drug acts as a skin protectant by helping to treat and prevent minor skin irritation due to diaper rash and seals out moisture from the diaper area. This drug temporarily protects and helps prevent chafed, chapped, cracked or windburned skin.  [L1772].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rexsol ultra whitening alpha arbutin cream 56 gm', 26002, 'ريكسول كريم تفتيح الترا 56جم', '410', NULL, 'Whitening topical', 'Whitening topical', NULL, NULL, 'Rexsol usa > global health', 'Cream', 'كريم', '56 gm', '1', NULL, NULL, 'ultra whitening alpha arbutin cream removes the appearance of all types of skin discolorations including melasma dark spots hyperpigmentation and more. faster and safer approach to promoting skin-whitening and an even skin tone. for all skin types method', NULL, 978, '2022-08-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Actolind gel 50 ml', 13435, 'اكتوليند جل 50 مل', '359', NULL, 'Healing topical', 'Healing topical', NULL, '0 1% polyhexanide (phmb)+poloxamer+auxiliary substances', 'Acto gmbh > biosource', 'Gel', 'جل', '50 ml', '1', 'جل يعمل علي ترطيب و تلطيف الجلد -- علاج الجروح والندبات', NULL, 'actolindï¿½ w gel is a ready-to-use clear colorless and odorless gel. it is ready to use. it contains polyhexanide as active substance and poloxamer as auxiliary substance. actolindï¿½ w gel is used for the mechanical cleaning and moisturizing of chronic', NULL, 1373, '2022-04-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fluroquinomox 0.5% ophthalmic sol. 5 ml', 5033, 'فلوروكينوموكس 0.5% قطرة 5 مل', '66', '45', 'Antibiotic.quinolone', 'Antibiotic.quinolone', NULL, 'Moxifloxacin', 'Sigma tec > concord pharmaceutical industries', 'Sol', 'محلول', '0.5%', '1', NULL, NULL, 'about moxifloxacin a third generation synthetic fluoroquinolone antibiotic a broad spectrum antibiotic. mechanism of action of moxifloxacin moxifloxacin acts by inhibiting the enzyme dna gyrase (topoisomerase 2) and topoisomerase 4.dna gyrase helps in the', '6221172200058', 1270, '2025-06-12', NULL, 0, 'For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).', 'The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.', 'Moxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin can be used to treat infections caused by the following bacteria: Aerobic Gram-positive microorganisms: _Corynebacterium_ species, _Micrococcus luteus_, _Staphylococcus aureus_, _Staphylococcus epidermidis_, _Staphylococcus haemolyticus_, _Staphylococcus hominis_, _Staphylococcus warneri_, _Streptococcus pneumoniae_, and _Streptococcus viridans_ group. Aerobic Gram-negative microorganisms: _Acinetobacter lwoffii_, _Haemophilus influenzae_, and _Haemophilus parainfluenzae_. Other microorganisms: _Chlamydia trachomatis_. Moxifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Andogonium syrup 100 ml', 30134, 'اندوجونيوم شراب 100 مل', '33', NULL, 'Cold products', 'Cold products', NULL, 'Pelargonium', 'Copad egypt > andalous pharma', 'Syrup', 'شراب', '100 ml', '1', 'مكمل غذائى يستخدم لدعم الجهاز المناعي ويساعد على تخفيف أعراض التهابات الجهاز التنفسي العلوي مثل نزلات البرد', NULL, 'it supports immunity system against respiratory tract infections. dose: adult and children above 12 years: 7.5 ml / 3 times daily. children 6-12 years: 5 ml / 3 times daily.', '6223004691362', 1477, '2023-05-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tribulus terrestris 250 mg 90 caps. (puritans pride)', 28484, 'تريبولوس تريستريس 250مجم 90 كبسولة', '725', NULL, NULL, NULL, NULL, 'Tribulus terrestris', 'Puritans pride', 'Cap', 'كبسولة', '250 mg', '1', NULL, NULL, 'ribulus terrestris can be found throughout asia where it has long been popular with bodybuilders. tribulus terrestris is lab-tested for 40% saponins per serving one of the highest standardized levels available on the market today! as an herb traditionally', NULL, 800, '2022-07-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Eupitrexed 100 mg pwd. for i.v. inf. vial', 32818, 'اوبيتركسيد 100 مجم فيال', '2,477', '1564', 'Antineoplastic', 'Antineoplastic', NULL, 'Pemetrexed', 'Hikma specialized pharmaceuticals', 'Vial', 'فيال', '100 mg', '1', NULL, NULL, 'it is approved by the fda in combination with cisplatin (another chemotherapy drug) for the initial treatment of advanced nonsquamous non-small cell lung cancer (nsclc) a specific type of nsclc. it is not indicated for patients who have a different type o', NULL, 572, '2024-12-04', NULL, 0, 'Pemetrexed is indicated for the treatment of the following conditions:



**Non-squamous non-small cell lung cancer (NSCLC)**



- in combination with [pembrolizumab] and platinum-based chemotherapy as initial treatment in metastatic disease where no EGFR or ALK genomic tumour aberrations exist [L40943]

- in combination with [cisplatin] as initial treatment for locally advanced or metastatic disease [L40943,L44883]

- as maintenance treatment for locally advanced or metastatic disease that has not progressed following four cycles of platinum-based chemotherapy [L40943,L44883]

- recurrent metastatic disease following prior chemotherapy [L40943]

- as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer [L44883]



**Malignant pleural mesothelioma**



- in combination with [cisplatin] for the initial treatment of patients with malignant pleural mesothelioma.[L40943,L44883] In the US, it is reserved for patients whose disease is unresectable or otherwise not candidates for curative surgery.[L40943]', 'Pemetrexed is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.[A973,A974,A975,A976,A253907,L40943]', 'Pemetrexed inhibited the in vitro growth of mesothelioma cell lines (MSTO-211H, NCI-H2052) and showed synergistic

effects when combined with cisplatin. Based on population pharmacodynamic analyses, the depth of the absolute neutrophil counts (ANC) nadir correlates with systemic exposure to pemetrexed and supplementation with folic acid and vitamin B12. There is no cumulative effect of pemetrexed exposure on ANC nadir over multiple treatment cycles.[L40943] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Royal jelly 1500 mg 60 veg. caps. (now)', 33558, 'رويال جيلى 1500 مجم 60 كبسولة', '2,100', '1800', 'Multivitamins', 'Multivitamins', NULL, 'Royal jelly', 'Soficopharm', 'Cap', 'كبسولة', '1500 mg', '1', NULL, NULL, 'royal jelly is a natural honeybee product that is used in the nutrition of immature and adult queen bees. royal jelly has a complex nutritional profile that includes nucleotides polyphenols and unique organic acids. it has been used traditionally since an', NULL, 1000, '2025-09-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Viscoplus 1% (20mg/2ml) intra-articular prefilled syringe', 29428, 'فيسكوبلس 1% (20مجم/2مل) سرنجة معبأة للحقن بالمفصل', '2,000', '850', 'Analgesic anti-inflammatory.eye surgery.tissue lubricant', 'Analgesic anti-inflammatory.eye surgery.tissue lubricant', NULL, 'Sodium hyaluronate', 'Biomedical b. baumann gmbh > pharmacon', 'Syringe', 'حقنة', '1%', '1', 'مسكن ومضاد للالتهابات ومرطب للعين', NULL, 'about sodium hyaluronate a visco-elastic polymer(glycosaminoglycan) a tissue lubricant(prevent vaginal dryness) in osteoarthritis. mechanism of action of sodium hyaluronate sodium hyaluronate is a sterile nonpyrogenic highly purified noninflammatory high', NULL, 1823, '2024-02-14', NULL, 0, 'For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.', 'Sodium tetradecyl sulfate is a potent toxin for endothelial cells in that brief exposure to even low concentrations are effective in stripping endothelium over a considerable distance and exposing highly thrombogenic endothelium in the process. Diluted sodium tetradecyl sulfate is also able to induce a hypercoagulable state, possibly by selective inhibition of protein C, and can also promote platelet aggregation.', 'Sodium tetradecyl sulfate is an anionic surfactant which occurs as a white, waxy solid. It is used as a sclerosing agent in sclerotherapy. Sclerotherapy is an injection of a sclerosing agent directly through the skin into a lesion and is used primarily for slow-flow vascular anomalies, particularly for venous malformation and lymphatic malformation. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may or may not be permanent.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Perdofenex 267mg 30 caps', 7009, 'بيردوفينيكس 267مجم 30 كبسولة', '767', '588', 'Antifibrotic', 'Antifibrotic', NULL, 'Pirfenidone', 'Multicare', 'Cap', 'كبسولة', '267mg', '3', NULL, NULL, NULL, '6224007326992', 2389, '2024-09-28', NULL, 0, 'Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).[L26801,L26816,L42555] In Canada and Europe, it is approved in adults only.[L26816,L42555]', 'The exact mechanism of action of pirfenidone is not fully understood.[L26801] It is suggested that the antioxidant effects of pirfenidone contribute to its anti-inflammatory effects, leading to antifibrotic effects.[A251370] 



Pirfenidone attenuates the production of transforming growth factor-β1 (TGF-β1), a key profibrotic and pro-inflammatory cytokine implicated in idiopathic pulmonary fibrosis (IPF). By suppressing TGF-β1, pirfenidone inhibits TGF-β1-induced differentiation of human lung fibroblasts into myofibroblasts, thereby preventing excess collagen synthesis and extracellular matrix production.[A225556,A225571,A225576,A225581,A251365]



Some evidence suggests that pirfenidone downregulates pro-inflammatory cytokines, including TNF-α, interleukin-1 (IL-1), IL-6, interferon-gamma (IFN-γ),[A225556,A225576,A251365] and platelet-derived growth factor (PDGF).[A251365] Animal models demonstrated that pirfenidone promotes the production of anti-inflammatory IL-10 and prevents the accumulation of various inflammatory cells, including lymphocytes, macrophages and neutrophils.[A251365] In animal models, pirfenidone inhibited the influx of inflammatory cells and ameliorated bleomycin-induced pulmonary vascular permeability.[A225556] Several _in vitro_ studies show that pirfenidone mediates antioxidant actions by scavenging reactive oxygen species (ROS) and inhibiting lipid peroxidation, thereby reducing cellular injury in IPF.[A251365] ', 'Pirfenidone is a novel agent with anti-inflammatory, antioxidant, and antifibrotic properties. It may improve lung function and reduce the number of acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF).[L26801]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sugarlo plus 50/500mg 30 f.c. tabs', 27611, 'شوجارلو بلس 5/500مجم 30 قرص', '132', '99', 'Anti-diabetic.combined secretagogues+sensitizers', 'Anti-diabetic.combined secretagogues+sensitizers', NULL, 'Metformin hydrochloride+vildagliptin', 'Al esraa pharmaceutical optima', 'Tab', 'أقراص', '500mg', '3', 'لمرضى السكر', NULL, NULL, '6223004161216', 10801, '2024-08-01', NULL, 0, '**Metformin immediate-release formulations**

 

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.[L40243]



**Metformin extended-release tablet (XR)**



The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.[L12207]



**Metformin combination products**



Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263] in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729] or in combination with [pioglitazone].[L11419]', 'Metformin''s mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.[L12207] It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.[A36534, A36557]   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.



After ingestion, the organic cation transporter-1 (OCT1) is responsible for the uptake of metformin into hepatocytes (liver cells). As this drug is positively charged, it accumulates in cells and in the mitochondria because of the membrane potentials across the plasma membrane as well as the mitochondrial inner membrane. Metformin inhibits mitochondrial complex I, preventing the production of mitochondrial ATP leading to increased cytoplasmic ADP:ATP and AMP:ATP ratios.[A36534] These changes activate AMP-activated protein kinase (AMPK), an enzyme that plays an important role in the regulation of glucose metabolism.[A176348] Aside from this mechanism, AMPK can be activated by a lysosomal mechanism involving other activators.  Following this process, increases in AMP:ATP ratio also inhibit _fructose-1,6-bisphosphatase_ enzyme, resulting in the inhibition of gluconeogenesis, while also inhibiting _adenylate cyclase_ and decreasing the production of cyclic adenosine monophosphate (cAMP),[A36534] a derivative of ATP used for cell signaling [A176351]. Activated AMPK phosphorylates two isoforms of acetyl-CoA carboxylase enzyme, thereby inhibiting fat synthesis and leading to fat oxidation, reducing hepatic lipid stores and increasing liver sensitivity to insulin.[A36534] 



In the intestines, metformin increases anaerobic glucose metabolism in enterocytes (intestinal cells), leading to reduced net glucose uptake and increased delivery of lactate to the liver. Recent studies have also implicated the gut as a primary site of action of metformin and suggest that the liver may not be as important for metformin action in patients with type 2 diabetes. Some of the ways metformin may play a role on the intestines is by promoting the metabolism of glucose by increasing glucagon-like peptide I (GLP-1) as well as increasing gut utilization of glucose.[A36534] 



In addition to the above pathway, the mechanism of action of metformin may be explained by other ways, and its exact mechanism of action has been under extensive study in recent years.[A36535, A36554, A36555, A36557]', '**General effects**



Insulin is an important hormone that regulates blood glucose levels.[T514] Type II diabetes is characterized by a decrease in sensitivity to insulin, resulting in elevations in blood glucose when the pancreas can no longer compensate. In patients diagnosed with type 2 diabetes, insulin is unable to exert adequate effects on tissues and cells (i.e. insulin resistance)[T514] and insulin deficiency may also be present.[L5753]



Metformin reduces hepatic production of glucose, decreases the intestinal absorption of glucose, and enhances insulin sensitivity by increasing both peripheral glucose uptake and utilization. In contrast with drugs of the sulfonylurea class, which lead to hyperinsulinemia, the secretion of insulin is unchanged with metformin use.[L12207]



**Effect on fasting plasma glucose (FPG) and Glycosylated hemoglobin (HbA1c)**



HbA1c is an important periodic measure of glycemic control used to monitor diabetic patients. Fasting plasma glucose is also a useful and important measure of glycemic control. In a 29-week clinical trial of subjects diagnosed with type II diabetes, metformin decreased the fasting plasma glucose levels by an average of 59 mg/dL from baseline, compared to an average increase of 6.3 mg/dL from baseline in subjects taking a placebo.[L12207]  Glycosylated hemoglobin (HbA1c) was decreased by about 1.4% in subjects receiving metformin, and increased by 0.4% in subjects receiving placebo only.[L12207]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Savanna 2gm 10 sachets', 26560, 'سافانا 2جم 10 اكياس', '23', NULL, 'Weight loss', 'Weight loss', NULL, 'Green tea+ginger+marjoram', 'Nutrixia > falcon group', 'Sachet', 'أكياس', '2gm', '1', NULL, NULL, 'help in weight loss.', '6224000696610', 1021, '2022-12-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aphthtab 2mg 20 buccal bioadhesive tab.', 851, 'افثتاب 2مجم 20 قرص لاصق بالفم', '46', NULL, 'Mouth ulcer.antiallergic.anti-inflammatory', 'Mouth ulcer.antiallergic.anti-inflammatory', NULL, 'Amlexanox', 'Eva pharma', 'Tab', 'أقراص', '2mg', '2', NULL, NULL, 'description : amlexanox is an antiallergic drug clinically effective for atopic diseases especially allergic asthma and rhinitis. amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. recurrent aphthous ulcer (rau) is th', '6223002451876', 1316, '2022-12-02', NULL, 0, 'Used as a paste in the mouth to treat aphthous ulcers (canker sores). ', 'As a benzopyrano-bipyridine carboxylic acid derivative, amlexanox has anti-inflammatory and antiallergic properties. It inhibits chemical mediatory release of the slow-reacting substance of anaphylaxis (SRS-A) and may have antagonistic effects on interleukin-3. When cells are under stress, they release an inactive form of human fibroblast growth factor 1 (FGF-1), a potent mitogen (entity that causes mitosis). Amlexanox binds to FGF1, increasing its conformational stability, sterically blocking Cu(2+) induced oxidation which normally leads to activation of FGF-1.  ', 'Amlexanox is a mucoadhesive oral paste which has been clinically proven to abort the onset, accelerate healing and resolve the pain of aphthous ulcers (canker sores). It decreases the time ulcers take to heal. Because amlexanox decreases the healing time, it also decreases the pain you feel. Recent studies have also shown that the majority of ulcers can be prevented by application of the paste during the prodromal (pre-ulcerative) phase of the disease. Recurrent Aphthous Ulcers (RAU) also known as Recurrent Aphthous Stomatitis (RAS) is recognized as the most common oral mucosal disease known to man. Estimates suggest that 20% - 25% of the general population suffer at least one incidence of aphthous ulcers each year. Amlexanox is also being investigated for its anti-allergenic and anti-inflammatory properties.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Occuplus 0.6 ml eye liquid gel', 14959, 'اوكيوبلس جل سائل للعين 0.6 مل', '300', '275', 'Lubricant solution', 'Lubricant solution', NULL, 'Carbomer', 'Rx healthcare', 'Gel', 'جل', '0.6 ml', '1', NULL, NULL, NULL, '8033959760307', 1461, '2025-03-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Coenzyme q10 forte 100 mg 20 caps.', 16611, 'كوانزيم كيو10 فورت 100مجم 20 كبسولة', '60', NULL, 'Antioxidant', 'Antioxidant', NULL, 'Coenzyme q-10', 'Mepaco', 'Cap', 'كبسولة', '100 mg', '2', 'مضاد للاكسدة -- مصدر للطاقة -- الحفاظ علي اعضاء الجسم -- يحسن التركيز والذاكرة ولاالنتباه', NULL, 'coenzyme q10 (coq10) is a substance that is naturally present in the human body with the highest levels in the heart liver kidneys and pancreas. it is sold in the united states as a dietary supplement. because coq10 has important functions in the body and', '6223002219506', 9339, '2023-02-19', NULL, 0, 'Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.[A18572]', 'A metabolite called acrolein is produced when ifosfamide and cyclophosphamide are metabolized. This metabolite concentrates in the bladder and causes cell death via upregulation of reactive oxygen species (ROS), and activates inducible nitric oxide synthase (iNOS) which leads to production of nitric oxide (NO). Both ROS and NO produce products which are detrimental to lipids, proteins and DNA strands. Furthermore, ROS stimulate gene expression of pro-inflammatory cytokines such as TNF-α AND IL-1β. Acrolein may also lead to ulceration of the bladder urothelium. Mesna protects against cyclophosphamide and ifosfamide induced hemorrhagic cystitis by binding to their toxic metabolites. Mesna is metabolized to dimesna and excreted by the kidneys. Glutathione dihydrogenase acts on the reabsorbed portion and produces free sulfhydryl groups. These free sulfhydryl  groups bind acrolein in the bladder, allowing effective excretion and prevention  of toxic effects.[A18570] In addition, Mesna binds to and detoxifies a urotoxic ifosfamide metabolite called 4-hydroxy-ifosfamide.', 'Mesna binds to and inactivates acrolein there by preventing or reducing bladder problems', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Tramundin 200mg s.r. 10 tab.', 11580, 'تراموندين 200مجم اس.ار . 10 اقراص', '19', NULL, 'Analgesics.narcotic opioid', 'Analgesics.narcotic opioid', NULL, 'Tramadol', 'Mup > mundipharma', 'Tab', 'أقراص', '200mg', '1', 'مسكن قوي للالام -- يستخدم في العمليات الجراحية -- يؤخذ تحت اشراف طبي', NULL, NULL, '6221508017411', 3959, '2023-02-05', NULL, 0, 'Tramadol is approved for the management of moderate to severe pain in adults.[L9257,F4679]



Tramadol is also used off-label in the treatment of premature ejaculation.[A173986]', 'Tramadol is a centrally acting μ-opioid receptor agonist and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Tramadol binds weakly to κ- and δ-opioid receptors and to the μ-opioid receptor with 6000-fold less affinity than morphine.[A182300]



Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol''s ability to modulate the perception of and response to pain.[A4269] 



In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in μ-opioid binding.[L9257] 



Tramadol has also been shown to affect a number of pain modulators including alpha2-adrenoreceptors, neurokinin 1 receptors, the voltage-gated sodium channel type II alpha subunit[A183728], transient receptor potential cation channel subfamily V member 1 (TRPV1 - also known as the capsaicin receptor)[A183734], muscarinic receptors (M1 and M3), N-methyl-D-aspartate receptor (also known as the NMDA receptor or glutamate receptor)[A17158], Adenosine A1 receptors[A183761], and nicotinic acetylcholine receptor.[A17159] 



In addition to the above neuronal targets, tramadol has a number of effects on inflammatory and immune mediators involved in the pain response. This includes inhibitory effects on cytokines, prostaglandin E2 (PGE2), nuclear factor-κB, and glial cells as well as a change in the polarization state of M1 macrophages.[A182300]', 'Tramadol modulates the descending pain pathways within the central nervous system through the binding of parent and M1 metabolite to μ-opioid receptors and the weak inhibition of the reuptake of norepinephrine and serotonin.[A173983,A173980] 



Apart from analgesia, tramadol may produce a constellation of symptoms (including dizziness, somnolence, nausea, constipation, sweating and pruritus) similar to that of other opioids. 



**Central Nervous System**



In contrast to [morphine], tramadol has not been shown to cause histamine release. At therapeutic doses, tramadol has no effect on heart rate, left-ventricular function or cardiac index. Orthostatic hypotension has been observed.[L9257]



Tramadol produces respiratory depression by direct action on brain stem respiratory centres. The respiratory depression involves both a reduction in the responsiveness of the brain stem centres to increases in CO2 tension and to electrical stimulation. 



Tramadol depresses the cough reflex by a direct effect on the cough centre in the medulla. Antitussive effects may occur with doses lower than those usually required for analgesia.



Tramadol causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid overdose but

are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce

similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in the setting of

oxycodone overdose.[F4679]



Seizures have been reported in patients receiving tramadol within the recommended dosage range. Spontaneous post-marketing reports indicate that seizure risk is increased with doses of tramadol above the recommended range. Risk of convulsions may also increase in patients with epilepsy, those with a history of seizures

or in patients with a recognized risk for seizure (such as head trauma, metabolic disorders,

alcohol and drug withdrawal, CNS infections), or with concomitant use of other drugs known to reduce the seizure threshold.[F4679]



Tramadol can cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs (e.g., anti-depressants, migraine medications). Treatment with the serotoninergic drug should be discontinued if such events (characterized by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated. Tramadol should not be used in combination with MAO inhibitors or serotonin-precursors (such as L-tryptophan, oxitriptan) and should be used with caution in combination with other serotonergic drugs (triptans, certain tricyclic antidepressants, lithium, St. John’s Wort) due to the risk of serotonin syndrome.[F4679]



**Gastrointestinal Tract and Other Smooth Muscle**



Tramadol causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, while tone may be increased to the point of spasm resulting in constipation. Other opioid-induced effects may include a reduction in gastric, biliary and pancreatic secretions, spasm of the sphincter of Oddi, and transient elevations in serum amylase.[F4679]



**Endocrine System**



Opioids may influence the hypothalamic-pituitary-adrenal or -gonadal axes. Some changes that can be seen include an increase in serum prolactin and decreases in plasma cortisol and testosterone. Clinical signs and symptoms may be manifest from these hormonal changes.[F4679]



Hyponatremia has been reported very rarely with the use of tramadol, usually in patients with predisposing risk factors, such as elderly patients and/or patients using concomitant medications that may cause hyponatremia (e.g., antidepressants, benzodiazepines, diuretics). In some reports, hyponatremia appeared to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and resolved with discontinuation of tramadol and appropriate treatment (e.g., fluid restriction). During tramadol treatment, monitoring for signs and symptoms of hyponatremia is recommended for patients with predisposing risk factors.[F4679]



**Cardiovascular**



Tramadol administration may result in severe hypotension in patients whose ability to maintain adequate blood pressure is compromised by reduced blood volume, or concurrent administration of drugs such as phenothiazines and other tranquillizers, sedative/hypnotics, tricyclic antidepressants or general anesthetics. These patients should be monitored for signs of hypotension after initiating or titrating the dose of tramadol.[F4679]



**QTc-Interval Prolongation**



The maximum placebo-adjusted mean change from baseline in the QTcF interval was 5.5 ms in the 400 mg/day treatment arm and 6.5 ms in the 600 mg/day mg treatment arm, both occurring at the 8h time point. Both treatment groups were within the 10 ms threshold for QT prolongation. Post-marketing experience with the use of tramadol containing products included rare reports of QT prolongation reported with an overdose. Particular care should be exercised when administering tramadol to patients who are suspected to be at an increased risk of experiencing torsade de pointes during treatment with a QTc-prolonging drug.[F4679]



**Abuse and Misuse**



Like all opioids, tramadol has the potential for abuse and misuse, which can lead to overdose and death. Therefore, tramadol should be prescribed and handled with caution.[F4679]



**Dependence/Tolerance**



Physical dependence and tolerance reflect the neuroadaptation of the opioid receptors to chronic exposure to an opioid and are separate and distinct from abuse and addiction. Tolerance, as well as physical dependence, may develop upon repeated administration of opioids, and are not by themselves evidence of an addictive disorder or abuse. Patients on prolonged therapy should be tapered gradually from the drug if it is no longer required for pain control. Withdrawal symptoms may occur following abrupt discontinuation of therapy or upon administration of an opioid antagonist. Some of the symptoms that may be associated with abrupt withdrawal of an opioid analgesic include body aches, diarrhea, gooseflesh, loss of appetite, nausea, nervousness or restlessness, anxiety, runny nose, sneezing, tremors or shivering, stomach cramps, tachycardia, trouble with sleeping, unusual increase in sweating, palpitations, unexplained fever, weakness and yawning.[F4679]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Todiphi 10 ml oral drops', 3158, 'توديفى 10 مل نقط بالفم', '79', NULL, 'Anti colic probiotics', 'Anti colic probiotics', NULL, 'Probiotic l.reuteri+vitamin d3 400iu per 5 drops', 'Phi pharma', 'Drops', 'نقط', '10 ml', '1', NULL, NULL, NULL, NULL, 1712, '2025-02-25', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Serigabtin 150mg 20 caps.', 26832, 'سيريجابتين 150مجم 20 كبسولة', '63', NULL, 'Anti-epileptic.gaba analogs', 'Anti-epileptic.gaba analogs', NULL, 'Pregabalin', 'Sedico > serio pharm-egypt', 'Cap', 'كبسولة', '150mg', '2', NULL, NULL, 'about pregabalin a gaba agonist anticonvulsant. mechanism of action of pregabalin pregabalin is a gaba neurotransmitter analog. it produces its action by modulating calcium channels and also reduces the release of neurotransmitters such as glutamate norep', '6225000092129', 715, '2022-12-08', NULL, 0, 'Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.[L7066]', 'Although the mechanism of action has not been fully elucidated, studies involving structurally related drugs suggest that presynaptic binding of pregabalin to voltage-gated calcium channels is key to the antiseizure and antinociceptive effects observed in animal models.[L7066]  



By binding presynaptically to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, pregabalin modulates the release of several excitatory neurotransmitters including glutamate, substance-P, norepinephrine, and calcitonin gene related peptide.[A31163] In addition, pregabalin prevents the alpha2-delta subunit from being trafficked from the dorsal root ganglia to the spinal dorsal horn, which may also contribute to the mechanism of action.[A36628] 



Although pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA or benzodiazepine receptors.[A31165]  ', 'Although the structure of pregabalin is similar to gamma-aminobutyric acid (GABA), it does not bind to GABA receptors.[A31163,A187190] Instead, it binds the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system.[A31163,A187190] Pregabalin does not modulate dopamine receptors, serotonin receptors, opiate receptors, sodium channels or cyclooxygenase activity.[A187190] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sebium hydra 40 ml', 26650, 'سيبيوم هيدرا 40مل', '375', '299', 'Skin care', 'Skin care', NULL, NULL, 'Bioderma dermatological laboratories > biotech egypt', 'Unknown', 'غير محدد', '40 ml', '1', NULL, NULL, '*a moisturising and soothing compensating treatment for skin that has been weakened dried and/or irritated by dermatological treatments. *indication: acne-prone skin weakened by drying treatments. instructions for use morning and/or evening - 7 days a wee', NULL, 433, '2023-09-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cefozon 500mg i.m./i.v. vial', 16052, 'سيفوزون 500مجم فيال', '28', '18.5', 'Antibiotic.cephalosporin.third-generation', 'Antibiotic.cephalosporin.third-generation', NULL, 'Cefoperazone', 'Eipico', 'Vial', 'فيال', '500mg', '1', NULL, NULL, NULL, '6221032312341', 859, '2024-09-18', NULL, 0, 'Indicated for the treatment of following infections caused by susceptible bacteria:[label]



1) Respiratory tract infections caused by _S. pneumoniae_, _H. influenzae_, _S. aureus_ (penicillinase and non-penicillinase producing strains), _S. pyogenes_ (Group A beta-hemolytic streptococci), _P. aeruginosa_, _Klebsiella pneumoniae_, _E. coli_, _Proteus mirabilis_, and Enterobacter species.



2) Peritonitis and other intra-abdominal infections caused by _E. coli_, _P. aeruginosa_, and anaerobic gram-negative bacilli (including _Bacteroides fragilis_).



3) Bacterial septicemia caused by _S. pneumoniae_, _S. agalactiae_, _S. aureus_, _Pseudomonas aeruginosa_, _E. coli_, _Klebsiella_ spp., _Klebsiella pneumoniae_, Proteus species (indole-positive and indole-negative), _Clostridium_ spp. and anaerobic gram-positive cocci.



4) Infections of the skin and skin structures caused by S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes, and P. aeruginosa.



5) Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract caused by N. gonorrhoeae, S. epidermidis, S. agalactiae, E. coli, Clostridium spp., Bacteroides species (including Bacteroides fragilis), and anaerobic gram-positive cocci.



6) Urinary tract infections caused by Escherichia coli and Pseudomonas aeruginosa.



7) Enterococcal Infections. Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility, and are moderately resistant to cefoperazone. However, _in vitro_ susceptibility testing may not correlate directly with _in vivo_ results. Despite this, cefoperazone therapy has resulted in clinical cures of enterococcal infections, chiefly in polymicrobial infections. Cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone.', 'Like all beta-lactam antibiotics, cefoperazone binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.', 'Cefoperazone is a third generation cephalosporin antibiotic. Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Eucavan massage spray 120ml', 32817, 'ايوكافان مساج سبراى 120 مل', '139', '119', 'Massage spray', 'Massage spray', NULL, 'Thyme+eucalyptus oil+camphor oil+pepprmint oil+menthol+almond oil+clove oil+glycerine', 'Egy heart', 'Spray', 'بخاخ', '120ml', '1', 'مساج سبراي، يستخدم في تقليل الألم وعلاج الالتهابات الناتجة عن المجهود العنيف او ممارسة الرياضة', NULL, NULL, NULL, 1746, '2025-10-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Resis cream 50 gm', 24736, 'ريسيس كريم 50 جم', '85', '70', 'Soothing agent.emollient', 'Soothing agent.emollient', NULL, NULL, 'Aspire', 'Cream', 'كريم', '50 gm', '1', NULL, NULL, NULL, NULL, 3081, '2025-08-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Prexo topical lotion 60 ml', 25224, 'بريكسو لوشن 60 مل', '84', '70', 'Anti-acne', 'Anti-acne', NULL, 'Allantoin+glycolic acid+salicylic acid+triclosan+phmg+zinc oxide+olive leaves extract+aloe vera extr', 'Hi-care > roventis pharma', 'Lotion', 'لوشن', '60 ml', '1', NULL, NULL, '*** indications ï- treatment of all types of acne. ï- repair acne damaged skin. ï- with other acne treatments to restore vitality and hydration to the skin. ***direction for use apply on the affected areas and rub gently until completely absorbed 2-3 dail', '6224000201746', 1992, '2024-05-03', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sevelto 10mg 10 sachets', 26719, 'سيفيلتو 10مجم 10 اكياس', '180', NULL, 'Weight loss', 'Weight loss', NULL, 'Psyllium husk powder+chromium picolinate+pineapple powder', 'Zeta bio', 'Sachet', 'أكياس', '10mg', '1', NULL, NULL, NULL, NULL, 696, '2022-08-31', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sulfozinc 20mg/5ml syrup 80ml', 10976, 'سلفوزنك 20مجم 80 مل شراب', '24', '15.5', 'Zinc supplement', 'Zinc supplement', NULL, 'Zinc sulphate', 'Cid', 'Syrup', 'شراب', '20mg', '1', NULL, NULL, 'about zinc sulphate zinc compound an astringent adjunctive treatment of wilson?s disease.', '6221043013015', 3432, '2025-12-10', NULL, 0, 'Zinc can be used for the treatment and prevention of zinc deficiency/its consequences, including stunted growth and acute diarrhea in children, and slowed wound healing. It is also utilized for boosting the immune system, treating the common cold and recurrent ear infections, as well as preventing lower respiratory tract infections [L2172].  



', '**Zinc has three primary biological roles**: _catalytic_, _structural_, and _regulatory_. The catalytic and structural role of zinc is well established, and there are various noteworthy reviews on these functions. For example, zinc is a structural constituent in numerous proteins, inclusive of growth factors, cytokines, receptors, enzymes, and transcription factors for different cellular signaling pathways. It is implicated in numerous cellular processes as a cofactor for approximately 3000 human proteins including enzymes, nuclear factors, and hormones [L2096].



Zinc promotes resistance to epithelial apoptosis through cell protection (cytoprotection) against reactive oxygen species and bacterial toxins, likely through the antioxidant activity of the cysteine-rich metallothioneins [A32419].



In HL-60 cells (promyelocytic leukemia cell line), zinc enhances the up-regulation of A20 mRNA, which, via TRAF pathway, decreases NF-kappaB activation, leading to decreased gene expression and generation of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-8 [A32418].



There are several mechanisms of action of zinc on acute diarrhea. Various mechanisms are specific to the gastrointestinal system: zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens, and has a direct effect on ion channels, acting as a potassium channel blocker of adenosine 3-5-cyclic monophosphate-mediated chlorine secretion. Cochrane researchers examined the evidence available up to 30 September 2016 [L2106].



Zinc deficiency in humans decreases the activity of serum _thymulin_ (a hormone of the thymus), which is necessary for the maturation of T-helper cells. T-helper 1 (Th(1)) cytokines are decreased but T-helper 2 (Th(2)) cytokines are not affected by zinc deficiency in humans [A32417].



The change of _Th(1)_ to _Th(2)_ function leads to cell-mediated immune dysfunction. Because IL-2 production (Th(1) cytokine) is decreased, this causes decreased activity of natural-killer-cell (NK cell) and T cytolytic cells, normally involved in killing viruses, bacteria, and malignant cells [A32424]. 



In humans, zinc deficiency may lead to the generation of new CD4+ T cells, produced in the thymus. In cell culture studies (HUT-78, a Th(0) human malignant lymphoblastoid cell line), as a result of zinc deficiency, nuclear factor-kappaB (NF-kappaB) activation, phosphorylation of IkappaB, and binding of NF-kappaB to DNA are decreased and this results in decreased Th(1) cytokine production [A32417].



In another study, zinc supplementation in human subjects suppressed the gene expression and production of pro-inflammatory cytokines and decreased oxidative stress markers [A32424]. In HL-60 cells (a human pro-myelocytic leukemia cell line), zinc deficiency increased the levels of TNF-alpha, IL-1beta, and IL-8 cytokines and mRNA. In such cells, zinc was found to induce A20, a zinc finger protein that inhibited NF-kappaB activation by the tumor necrosis factor receptor-associated factor pathway. This process decreased gene expression of pro-inflammatory cytokines and oxidative stress markers [A32417].



The exact mechanism of zinc in acne treatment is poorly understood. However, zinc is considered to act directly on microbial inflammatory equilibrium and facilitate antibiotic absorption when used in combination with other agents. Topical zinc alone as well as in combination with other agents may be efficacious because of its anti-inflammatory activity and ability to reduce P. acnes bacteria by the inhibition of P. acnes lipases and free fatty acid levels [L2102].', 'Zinc is involved in various aspects of cellular metabolism. It has been estimated that approximately 10% of human proteins may bind zinc, in addition to hundreds of proteins that transport and traffic zinc. It is required for the catalytic activity of more than 200 enzymes, and it plays a role in immune function wound healing, protein synthesis, DNA synthesis, and cell division. Zinc is an essential element for a proper sense of taste and smell and supports normal growth and development during pregnancy, childhood, and adolescence. It is thought to have antioxidant properties, which may be protective against accelerated aging and helps to speed up the healing process after an injury; however, studies differ as to its effectiveness. Zinc ions are effective antimicrobial agents even if administered in low concentrations [L2211].



Studies on oral zinc for specific conditions shows the following evidence in various conditions [L2095]:



**Colds:** Evidence suggests that if zinc lozenges or syrup are taken within 24 hours after cold symptoms start, the supplement may shorten the length of colds. The use intranasal zinc has been associated with the loss of the sense of smell, in some cases long-term or permanently [L2095].



**Wound healing:** Patients with skin ulcers and decreased levels of zinc may benefit from oral zinc supplements [L2095]. 



**Diahrrea**: Oral zinc supplements can reduce the symptoms of diarrhea in children with low levels of zinc, especially in cases of malnutrition [L2095].

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ricoxitibe 90mg 20 tabs', 8056, 'ريكوكسيتايب 90 مجم 20 قرص', '228', NULL, NULL, NULL, NULL, NULL, NULL, 'Tab', 'أقراص', '90mg', '2', NULL, NULL, NULL, NULL, 782, '2025-11-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cludinetech 0.5mg 10 h.g.cap', 16572, 'كلودين تك 0.5 مجم 10 كبسولات', '391', '271.5', 'Antiviral.nucleoside', 'Antiviral.nucleoside', NULL, 'Entecavir', 'European egyptian pharm. ind. > pharma-tech', 'Cap', 'كبسولة', '0.5mg', '1', 'مضاد للفيروسات يستخدم لعلاج التهاب الكبد الوبائي بي المزمن عند البالغين', NULL, 'about entecavir nucleoside analog reverse transcriptase inhibitor oral antiviral drug used in the treatment of hepatitis b infection. mechanism of action of entecavir by competing with the natural substrate deoxyguanosine triphosphate entecavir functional', '6225000069312', 1826, '2025-04-13', NULL, 0, 'For the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.', 'By competing with the natural substrate deoxyguanosine triphosphate, entecavir functionally inhibits all three activities of the HBV polymerase (reverse transcriptase, rt): (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA. Upon activation by kinases, the drug can be incorporated into the DNA which has the ultimate effect of inhibiting the HBV polymerase activity.', 'Entecavir is a guanosine nucleoside analogue with selective activity against hepatitis B virus (HBV). It is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process. Entecavir is more efficient than an older Hepatitis B drug, lamivudine.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vertod 10000 vitamin d 20 tab', 4899, 'فيرتود 1000 فيتامين دال 20 قرص', '80', NULL, 'Vitamin d', 'Vitamin d', NULL, 'Vitamin d 10000', 'Stay green', 'Tab', 'أقراص', NULL, '2', NULL, NULL, NULL, NULL, 1123, '2022-12-07', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Perroxy 6.5% ear drops 15 ml', 24772, 'بيروكسي 6.5% نقط للاذن 15 مل', '7', NULL, 'Ear wax remover', 'Ear wax remover', NULL, 'Carbamide peroxide', 'Pharopharma', 'Drops', 'نقط', '6.5%', '1', NULL, NULL, 'this medication is used to treat earwax buildup. it helps to soften loosen and remove the earwax. too much earwax can block the ear canal and reduce hearing. this medication releases oxygen and starts to foam when it comes in contact with the skin. the fo', NULL, 1087, '2022-08-01', NULL, 0, 'Indicated as a dental bleaching agent. 



Indicated as an oral wound healing agent in oral mucosal injuries.



Indicated as an aid in the removal of hardened ear wax.', 'Carbamide peroxide release hydrogen peroxide upon contact with teeth, which is a strong oxidizing and bleaching agent. It also release free radicals such as H+ or H3O+ [A32336]. Hydrogen peroxide also acts as an antiseptic, especially in sites with relative anaerobiosis. Following otic administration, carbamide peroxide complex releases hydrogen peroxide that breaks up the hardened wax. The hydrogen peroxide component, which further breaks down into water, is also a cerumenolytic that hydrates the desquamated sheets of corneocytes, which are the major constituent of cerumen plugs [A32340]. The glycerol and urea facilitates softening of the cerumen, either with or without syringing [L1974]. Both hydrogen peroxide and urea mildly induce keratolysis with disintegration of the ear wax to help reduce the keratin-load in the ear debris and allow other active components to reach the skin under the debris [A32340, L1974]. ', 'Carbamide peroxide releases hydrogen peroxide and free radicals upon contact with water or outer surfaces of ear and tooth. Hydrogen peroxide exerts cerumenolytic, enamel-bleaching and antiseptic actions. _In vitro_, the chemical stability of ceramics against bleaching agents was observed after treatment with 15% carbamide peroxide for 56 h, 16% carbamide peroxide for 126 h, 10% or 15% carbamide peroxide and 38% hydrogen peroxide for 30 minutes or 45 minutes, respectively [A32336]. According to _in vitro_ studies, high (37%) or low (10 or 16%) concentrated carbamide peroxide agents were similarly effective as oral bleaching agents [A32337]. Treatment with carbamide peroxide may lead to demineralization which involves decreased mineral content of enamel calcium, phosphate, and fluoride, and alteration of the chemical, structural, and mechanical properties [A32339]. Carbamide peroxide may affect the organic components of the enamel and lead to increased susceptibility to erosion, fracture stability or decreased abrasion resistance of the treated area [A32339].', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vetobactisone cream 15 gm', 8016, 'فيتو باكتيزون كريم 15 جم', '7', NULL, 'Glucocorticoid with antibiotic', 'Glucocorticoid with antibiotic', NULL, 'Betamethasone+neomycin', 'VETOPHARM-EGYPT', 'Cream', 'كريم', '15 gm', '1', NULL, NULL, NULL, NULL, 824, '2023-05-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Antidiazox 500mg 12 f.c.tab.', 793, 'انتي ديازوكس 500مجم 12 قرص', '43', NULL, 'Antihelminthic', 'Antihelminthic', NULL, 'Nitazoxanide', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '500mg', '2', NULL, NULL, 'about nitazoxanide a synthetic nitrothiazolyl-salicylamide derivative antihelminthics in schistosomiasis. mechanism of action of nitazoxanide it excerts its action by blocking anaerobic energy metabolism. the drug interfering with the pyruvate-ferredoxin', '6223002143122', 1629, '2023-02-06', NULL, 0, 'For the treatment of diarrhea in adults and children caused by the protozoa <i>Giardia lamblia</i>,  and for the treatment of diarrhea in children caused by the protozoan,  <i>Cryptosporidium parvum</i> [FDA label].



Nitazoxanide has not been shown to be superior to placebo medication for the management of diarrhea caused by Cryptosporidium parvum in patients with HIV/immunodeficiency [FDA label, A31973, A31976]. ', 'The most widely accepted mechanism of NTZ is believed to be the disruption of the energy metabolism in anaerobic microbes by inhibition of the pyruvate: ferredoxin/flavodoxin oxidoreductase (PFOR) cycle [A31981]. In parasitic-protozoa, Nitazoxanide also induces lesions in the cell membranes and depolarizes the mitochondrial membrane while inhibiting quinone oxidoreductase NQO1, nitroreductase-1 and protein disulphide isomerase enzymes. In addition, this drug also inhibits the glutathione-S-transferase (a major detoxifying enzyme) and modulates the Avr-14 gene, encoding for the alpha-type subunit of glutamate-gated chloride ion channel present in nematodes. Aside from its well understood non-competitive inhibition of the PFOR in anaerobic bacteria, NTZ also demonstrates various other antibacterial mechanisms. It inhibits pyruvate dehydrogenase in E Coli, disrupts the membrane potential and pH homeostasis in the Mycobacterium tuberculosis, suppresses the chaperone/usher (CU) pathway of the gram-negative bacteria,  and stimulates host macrophage autophagy in tuberculosis patients [A31976]. NTZ also suppresses viral replication by inhibiting the maturation of the viral hemagglutinin and the viral transcription factor immediate early 2 (IE2) as well as by activating the eukaryotic translation initiation factor 2α (an antiviral intracellular protein). Lastly, NTZ exhibits an inhibitory effect on tumor cell progression by altering drug detoxification (glutathione-S-transferase P1), unfolded protein response, autophagy, anti-cytokines activity, and c-Myc inhibition [A31976].', 'The general effect of this medication is the prevention of microbe activity through disruption of important energy pathways for survival and proliferation [FDA label, A31976].  Nitazoxanide exhibits antiprotozoal activity by interfering with the pyruvate ferredoxin/flavodoxin oxidoreductase dependent electron transfer reaction, an essential reaction need for anaerobic energy metabolism of various microorganisms.  Sporozoites of Cryptosporidium parvum and trophozoites of Giardia lamblia are therefore inhibited, relieving symptoms of diahrrea [L1425]. Interference with the PFOR enzyme-dependent electron transfer reaction may only be one of the many pathways by which nitazoxanide exhibits antiprotozoal activity [FDA label, A31973, L1425]. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Rametalina xr 5/1000 mg 30 ext. rel. f.c. tabs.', 4557, 'راميتالينا اكس ار 5/1000 مجم 30 قرص', '300', NULL, 'Anti-diabetic.secretagogues.sglt2 inhibitors', 'Anti-diabetic.secretagogues.sglt2 inhibitors', NULL, 'Empagliflozin+metformin', 'Rameda', 'Tab', 'أقراص', '1000 mg', '3', NULL, NULL, NULL, NULL, 876, '2025-06-17', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Faulcurium 10mg/ml 5 amp. i.v.* 2.5 ml', 18876, 'فولكوريوم 10 مجم / مل 5 امبول* 2.5 مل', '61', NULL, 'Skeletal muscle relaxant', 'Skeletal muscle relaxant', NULL, 'Atracurium besylate', 'Sedico', 'Amp', 'أمبول', '10mg', '5', NULL, NULL, 'indication for use as an adjunct to general anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. pharmacodynamics atracurium is a nondepolarizing skeletal muscle relaxant. atr', NULL, 1320, '2022-07-11', NULL, 0, 'For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.', 'Atracurium antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.', 'Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Exelon 9 mg 5 cm 4.6mg/24h 30 transdermal patches', 4534, 'اكسيلون 9مجم 5 سم 4.5مجم/24 ساعة 30 لصقة', '1,069', '822', 'Anticholinesterase', 'Anticholinesterase', NULL, 'Rivastigmine', 'Lts lohman', 'Patch', 'لصقة', '9 mg', '1', 'يستخدم العلاج في بعض حالات الخرف الخفيفة إلى المتوسطة المترافقة مع داء الزهايمر أو داء باركينسون.', NULL, 'about rivastigmine a central reversible non competitive anticholinesterase antidementia. mechanism of action of rivastigmine alzheimer`s disease may result from a deficiency in neurotransmitters used by nerves in the brain to communicate with one another.', NULL, 1401, '2024-12-28', NULL, 0, 'For the treatment of mild to moderate dementia associated with Parkinson''s disease or of the Alzheimer''s type.', 'Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.', 'Rivastigmine is a parasympathomimetic and a reversible cholinesterase inhibitor. An early pathophysiological feature of Alzheimer''s disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. While the precise mechanism of rivastigmine''s action is unknown, it is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase. If this proposed mechanism is correct, rivastigmine''s effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vitix regulating gel 50 ml', 29534, 'فيتيكس ريجيوليتنج جل 50 مل', '525', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Acm dermatological laboratories > biotech egypt', 'Gel', 'جل', '50 ml', '1', NULL, NULL, 'vitix gel is intended to promote epidermal repigmentation and its activity has been confirmed by numerous clinical studies. properties vitixï- gel has a totally innovative mode of action through its ability to re-establish the physiological balance of fre', NULL, 639, '2022-06-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Glucolight xr 1000mg 30 ex. rel .f.c. tab.', 5600, 'جلوكولايت اكس ار 1000مجم 30 قرص', '54', '54', 'Anti-diabetic.sensitizers.biguanide', 'Anti-diabetic.sensitizers.biguanide', NULL, 'Metformin hydrochloride', 'Al rowad pharmaceutical industrial co.', 'Tab', 'أقراص', '1000mg', '3', 'لعلاج مرض السكري', NULL, 'about metformin biguanide derivative oral anti-diabetic. mechanism of action of metformin it is a biguanide which exerts antidiabetic action. the drug suppresses gluconeogenesis in liver and thus suppresses hepatic glucose output. it enhance insulin media', '6224000915131', 2805, '2025-03-10', NULL, 0, '**Metformin immediate-release formulations**

 

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.[L40243]



**Metformin extended-release tablet (XR)**



The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.[L12207]



**Metformin combination products**



Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors ([sitagliptin], [linagliptin], [alogliptin], or [saxagliptin]),[L11479,L40248,L40253,L40258,L40263] in combination with SGLT2 inhibitors ([canagliflozin], [empagliflozin], [ertugliflozin], or [dapagliflozin]),[L11479,L30503,L1134,L13679,L38729] or in combination with [pioglitazone].[L11419]', 'Metformin''s mechanisms of action are unique from other classes of oral antihyperglycemic drugs. Metformin decreases blood glucose levels by decreasing hepatic glucose production (also called gluconeogenesis), decreasing the intestinal absorption of glucose, and increasing insulin sensitivity by increasing peripheral glucose uptake and utilization.[L12207] It is well established that metformin inhibits mitochondrial complex I activity, and it has since been generally postulated that its potent antidiabetic effects occur through this mechanism.[A36534, A36557]   The above processes lead to a decrease in blood glucose, managing type II diabetes and exerting positive effects on glycemic control.



After ingestion, the organic cation transporter-1 (OCT1) is responsible for the uptake of metformin into hepatocytes (liver cells). As this drug is positively charged, it accumulates in cells and in the mitochondria because of the membrane potentials across the plasma membrane as well as the mitochondrial inner membrane. Metformin inhibits mitochondrial complex I, preventing the production of mitochondrial ATP leading to increased cytoplasmic ADP:ATP and AMP:ATP ratios.[A36534] These changes activate AMP-activated protein kinase (AMPK), an enzyme that plays an important role in the regulation of glucose metabolism.[A176348] Aside from this mechanism, AMPK can be activated by a lysosomal mechanism involving other activators.  Following this process, increases in AMP:ATP ratio also inhibit _fructose-1,6-bisphosphatase_ enzyme, resulting in the inhibition of gluconeogenesis, while also inhibiting _adenylate cyclase_ and decreasing the production of cyclic adenosine monophosphate (cAMP),[A36534] a derivative of ATP used for cell signaling [A176351]. Activated AMPK phosphorylates two isoforms of acetyl-CoA carboxylase enzyme, thereby inhibiting fat synthesis and leading to fat oxidation, reducing hepatic lipid stores and increasing liver sensitivity to insulin.[A36534] 



In the intestines, metformin increases anaerobic glucose metabolism in enterocytes (intestinal cells), leading to reduced net glucose uptake and increased delivery of lactate to the liver. Recent studies have also implicated the gut as a primary site of action of metformin and suggest that the liver may not be as important for metformin action in patients with type 2 diabetes. Some of the ways metformin may play a role on the intestines is by promoting the metabolism of glucose by increasing glucagon-like peptide I (GLP-1) as well as increasing gut utilization of glucose.[A36534] 



In addition to the above pathway, the mechanism of action of metformin may be explained by other ways, and its exact mechanism of action has been under extensive study in recent years.[A36535, A36554, A36555, A36557]', '**General effects**



Insulin is an important hormone that regulates blood glucose levels.[T514] Type II diabetes is characterized by a decrease in sensitivity to insulin, resulting in elevations in blood glucose when the pancreas can no longer compensate. In patients diagnosed with type 2 diabetes, insulin is unable to exert adequate effects on tissues and cells (i.e. insulin resistance)[T514] and insulin deficiency may also be present.[L5753]



Metformin reduces hepatic production of glucose, decreases the intestinal absorption of glucose, and enhances insulin sensitivity by increasing both peripheral glucose uptake and utilization. In contrast with drugs of the sulfonylurea class, which lead to hyperinsulinemia, the secretion of insulin is unchanged with metformin use.[L12207]



**Effect on fasting plasma glucose (FPG) and Glycosylated hemoglobin (HbA1c)**



HbA1c is an important periodic measure of glycemic control used to monitor diabetic patients. Fasting plasma glucose is also a useful and important measure of glycemic control. In a 29-week clinical trial of subjects diagnosed with type II diabetes, metformin decreased the fasting plasma glucose levels by an average of 59 mg/dL from baseline, compared to an average increase of 6.3 mg/dL from baseline in subjects taking a placebo.[L12207]  Glycosylated hemoglobin (HbA1c) was decreased by about 1.4% in subjects receiving metformin, and increased by 0.4% in subjects receiving placebo only.[L12207]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Terramycin top. oint. 14 gm', 28074, 'تيراميسين مرهم جلد انبوبة 14 جم', '14', NULL, 'Antibiotic topical', 'Antibiotic topical', NULL, 'Oxytetracycline+polymyxin', 'Pfizer', 'Oint', 'مرهم', '14 gm', '1', NULL, NULL, 'about oxytetracycline tetracycline derivative a broad spectrum antibiotic. mechanism of action of oxytetracycline oxytetracycline is a broad spectrum antibiotic which has action against both gram positive organisms & gram negative organisms. it exerts its', '6221180000015', 987, '2023-02-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Dextrose in 5% & 0.9 % sodium cloride (500ml) (rom) i.v.infusion', 17487, 'دكستروز 5%و 0.9%صوديوم كولوريد 500مل محلول', '11', NULL, 'Sterile solution', 'Sterile solution', NULL, 'Glucose (dextrose)+sodium chloride', 'Allmed middle east', 'Unknown', 'غير محدد', '5%', '1', NULL, NULL, NULL, NULL, 1086, '2022-07-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Entresto 100 mg (49/51 mg) 28 f.c. tabs.', 18348, 'انترستو 100مجم 28 قرص', '1,700', '1369', 'Angiotensin receptor blockers & neprilysin inhibitors', 'Angiotensin receptor blockers & neprilysin inhibitors', NULL, 'Sacubitril+valsartan', 'Novartis', 'Tab', 'أقراص', '100 mg', '2', 'علاج ارتفاع ضغط الدم -- علاج الفشل القلبي', NULL, NULL, '300780777209', 11757, '2024-09-29', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Olmesab 20 mg 20 f.c. tabs.', 24022, 'اولميساب 20مجم 20 اقراص', '25', NULL, 'Antihypertensive.angiotensin blocker', 'Antihypertensive.angiotensin blocker', NULL, 'Olmesartan', 'Sabaa > activa therapeutics', 'Tab', 'أقراص', '20 mg', '2', NULL, NULL, 'about olmesartan an angiotensin ii receptor antagonist imidazole derivative antihypertensive. mechanism of action of olmesartan olmesartan is a competitive antagonist of angiotensin-ii at at-1 receptor. it decreases peripheral resistance and lowers bp in', NULL, 714, '2022-07-26', NULL, 0, 'Olmesartan is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents.[F4709,F4712,A173869] 



Olmesartan is also used off-label for the management Type 2 Diabetes-associated nephropathy, heart failure, and post-myocardial infarction, particularly in patients who are unable to tolerate ACE inhibitors.[A178153,A185912,A185915] ARBs such as olmesartan have been shown in a number of large-scale clinical outcomes trials to improve cardiovascular outcomes including reducing risk of myocardial infarction, stroke, the progression of heart failure, and hospitalization.[A174124,A178153,A173869,A185324,A185327,A185333,A185342,A185345] Like other ARBs, olmesartan blockade of RAAS slows the progression of diabetic nephropathy due to its renoprotective effects.[A185906,A185909,A185912] ', 'Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects. As the principal pressor agent of the renin-angiotensin system, Angiotensin II causes vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Its action is, therefore, independent of the pathways for angiotensin II synthesis.[F4709] Overall, olmesartan''s physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. 



Olmesartan also effects on the renin-angiotensin aldosterone system (RAAS) plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via  AT1 receptor blockade inhibits negative regulatory feedback within RAAS, which is a contributing factor to the pathogenesis and progression of cardiovascular disease, heart failure, and renal disease. In particular, heart failure is associated with chronic activation of RAAS, leading to inappropriate fluid retention, vasoconstriction, and ultimately a further decline in left ventricular function. ARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling.[A174154] ', 'Overall, olmesartan''s physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. 





**Hypotension in Volume- or Salt-Depleted Patients**



In patients with an activated renin-angiotensin aldosterone system, such as volume-and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with olmesartan. Initiate treatment under close medical supervision. If hypotension does occur, place the patient in the supine position and, if necessary, give an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized.[F4709,F4712]



Valvular Stenosis: there is concern on theoretical grounds that patients with aortic stenosis might be at a particular risk of decreased coronary perfusion, because they do not develop as much afterload reduction.[F4712]





**Impaired Renal Function**



As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals treated with olmesartan. In patients whose renal function may depend upon the activity of the renin-angiotensin- aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists has been associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death. Similar results may be anticipated in patients treated with olmesartan.



In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. There has been no long-term use of olmesartan medoxomil in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected.[F4709,F4712]





**Sprue-like Enteropathy**



Severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan months to years after drug initiation. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, exclude other etiologies. Consider discontinuation of olmesartan medoxomil in cases where no other etiology is identified.[F4709,F4712]





**Electrolyte Imbalances**



Olmesartan medoxomil contains olmesartan, a drug that inhibits the renin-angiotensin system (RAS). Drugs that inhibit the RAS can cause hyperkalemia. Monitor serum electrolytes periodically.[F4709,F4712]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vitrovage 12% 3 tube*10 ml', 29548, 'فيتروفيج 12% 3 انبوبة 10مل', '75', NULL, 'Vaginal care', 'Vaginal care', NULL, NULL, 'Vitro-bio > al ansar for marketing', 'Unknown', 'غير محدد', '12%', '1', NULL, NULL, NULL, NULL, 782, '2022-07-19', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Zithropro 500 mg 3 caps.', 31653, 'زيثروبرو 500مجم 3 كبسولة', '52', '21.5', 'Antibiotic.macrolide', 'Antibiotic.macrolide', NULL, 'Azithromycin', 'Eva pharma', 'Cap', 'كبسولة', '500 mg', '1', NULL, NULL, 'description: azithromycin is a semi-synthetic macrolide antibiotic of the azalide class. dose: adult: po- respiratory tract skin and soft tissue infections- 500 mg once daily for 3 days. or 500mg on day 1 followed by 250mg on days 2 to 5. typhoid- 500 mg', NULL, 2703, '2025-10-02', NULL, 0, 'Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label].



Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. 



**Adults**:



Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.

Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage.



Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_.



Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.



**Pediatric Patients**



Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy.



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.', 'In order to replicate, bacteria require a specific process of protein synthesis, enabled by ribosomal proteins [A6505]. Azithromycin binds to the 23S rRNA of the bacterial 50S ribosomal subunit. It stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit [FDA label], [A14179]. This results in the control of various bacterial infections [A174193], [FDA label].   The strong affinity of macrolides, including azithromycin, for bacterial ribosomes, is consistent with their broad‐spectrum antibacterial activities [A174193].





Azithromycin is highly stable at a low pH, giving it a longer serum half-life and increasing its concentrations in tissues compared to erythromycin [A174175]. 



', 'Macrolides stop bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections [A174175].

Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose [A174172].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Candalkan 8mg 14 f.c. tab.', 15742, 'كاندلكان 8 مجم 14 قرص', '48', '34', 'Antihypertensive.arbs', 'Antihypertensive.arbs', NULL, 'Candesartan cilexetil', 'Global napi pharmaceuticals > future pharmaceutical industries (fpi)', 'Tab', 'أقراص', '8mg', '2', NULL, NULL, NULL, '6223004190056', 3203, '2024-06-29', NULL, 0, 'May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.', 'Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.', 'Candesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Moonshine facial cleanser liquid 250 ml', 30938, 'مون شاين غسول للوجه 250 مل', '145', '119', 'Skin care', 'Skin care', NULL, 'Vit.c+bit.b3+lactic acid+salicylic acid+allantoin+chamomile extract+tea tree oil+calendula extract', 'Dreams elhaboba > united pyramids', 'Cleanser', 'منظف', '250 ml', '1', 'غسول لتفتيح وترطيب البشرة ومنع التصبغات وازالة الكلف', NULL, 'facial cleanser liquid', NULL, 7950, '2025-08-12', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Serderm cream 25 gm', 26818, 'سيرديرم كريم 25مجم', '20', NULL, 'Moisturizing cream', 'Moisturizing cream', NULL, 'Lanolin+petrolatum+panthenol+cetyl stearyl alcohol+vitamin e+vitamin b6', 'Leader cosmetics > pharmaserve medical', 'Cream', 'كريم', '25 gm', '1', NULL, NULL, 'skin moisturizer', NULL, 685, '2022-08-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Irbesartan 150mg 20 tab.', 6568, 'اربيسارتان 150مجم 20 قرص', '26', NULL, 'Antihypertensive.angiotensin blocker', 'Antihypertensive.angiotensin blocker', NULL, 'Irbesartan', 'Debeiky', 'Tab', 'أقراص', '150mg', '2', NULL, NULL, 'about irbesartan angiotensin ii receptor blocker a non-peptide compound antihypertensive. mechanism of action of irbesartan it is a competitive antagonist of angiotensin-2 at at-1 receptor. it decreases peripheral resistance and lowers bp in hypertensive', NULL, 1775, '2023-02-06', NULL, 0, 'Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria.[L7456] A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled with monotherapy.[L7459]', 'Irbesartan prevents angiotensin II binding to the AT<sub>1</sub> receptor in tissues like vascular smooth muscle and the adrenal gland.[L7456,L7459] Irbesartan and its active metabolite bind the AT<sub>1</sub> receptor with 8500 times more affinity than they bind to the AT<sub>2</sub> receptor.[L7456,L7459] Irbesartan''s prevention of angiotensin II binding causes vascular smooth muscle relaxation and prevents the secretion of aldosterone, lowering blood pressure.[L7456,L7459]



Angiotensin II would otherwise bind to the AT<sub>1</sub> receptor, inducing vasoconstriction and aldosterone secretion, raising blood pressure.[L7456,L7459]', 'Irbesartan is an angiotensin receptor blocker used to treat hypertension and diabetic nephropathy.[L7456,L7459] It has a long duration of action as it is usually taken once daily and a wide therapeutic index as doses may be as low as 150mg daily but doses of 900mg/day were well tolerated in healthy human subjects.[L7456,L7459,A181165]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Esogerdazole 40 mg 14 dr. caps', 18564, 'ايزوجيردازول 40 مجم 14 كبسولة', '72', NULL, 'Peptic ulcer.proton pump inhibitor', 'Peptic ulcer.proton pump inhibitor', NULL, 'Esomeprazole', 'Al rowad pharmaceutical industrial co.', 'Cap', 'كبسولة', '40 mg', '2', NULL, NULL, NULL, '6224000915193', 1440, '2022-07-24', NULL, 0, 'Esomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome. ', 'Esomeprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cells. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of esomeprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, esomeprazole''s duration of antisecretory effect that persists longer than 24 hours.[FDA Label]

', 'Esomeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and <i>H. pylori</i> eradication to reduce the risk of duodenal ulcer recurrence. Esomeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H<sup>+</sup>/K<sup>+</sup> ATPase at the secretory surface of the gastric parietal cell. By doing so, it inhibits acid secretion into the gsatric lumen. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.



Esomeprazole is the s-isomer of [DB00338], which is a racemate of the S- and R-enantiomer. Esomeprazole has been shown to inhibit acid secretion to a similar extent as [DB00338], without any significant differences between the two compounds _in vitro_. 



PPIs such as esomeprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.[A177577, A177580]



Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as esomeprazole has been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life.[A177571]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mandara hair growth oil 120 ml', 32326, 'ماندارا زيت لنمو الشعر 120 مل', '350', NULL, 'Hair care', 'Hair care', NULL, 'Rosmary+tea tree+sage oil+cedar oil+seed oil+soy milk+caffeine+keratin', 'Nile factory for cosmetics > she organic', 'Oil', 'زيت', '120 ml', '1', NULL, NULL, NULL, NULL, 443, '2023-04-24', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Kidrolase 10000 i.u.vial (n/a)', 21415, 'كيدروليز 10000 وحدة دولية فيال', '240', NULL, NULL, NULL, NULL, 'Asparaginase(l-asparaginase)', 'Opi-france > medico pharma', 'Vial', 'فيال', NULL, '1', NULL, NULL, NULL, NULL, 708, '2022-08-04', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Unitone reveal cream 30ml', 11924, 'يونيتون ريفيل كريم 30 مل', '139', NULL, 'Skin care', 'Skin care', NULL, NULL, 'Isis pharma > biotech egypt', 'Cream', 'كريم', '30ml', '1', NULL, NULL, '*indications pigmentation spots revealing cream *use apply unitone reveal on the morning to the areas to be treated. *properties colour spots intensity is visibly reduced and skin recovers its lightness and fairness thanks to alpha-arbutin which inhibits', NULL, 755, '2022-08-14', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Thiotacid 300mg 5 i.v. amp 10 ml', 28134, 'ثيوتاسيد 300مجم 5 امبول 10مل', '47', NULL, 'Antioxidant', 'Antioxidant', NULL, 'Thioctic acid(alpha lipoic acid)', 'Eva pharma', 'Amp', 'أمبول', '300mg', '1', NULL, NULL, NULL, NULL, 1528, '2022-07-08', NULL, 0, 'Investigated for use/treatment in diabetes mellitus type 2, neuropathy (diabetic), and vascular diseases.', NULL, NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Anivagene ampoules man 14*2.5ml', 14188, 'انيفاجين امبول رجالي 14 * 2.5 مل', '499', NULL, 'Hair care', 'Hair care', NULL, NULL, 'Aniva international s.a. > biotech egypt', 'Ampoule', 'أمبول', '2.5ml', '14', NULL, NULL, 'helps to reduce hair loss in men. improves the health of the scalp. strengthens hair fiber. iridixinaï¿½ ï¿½ t is a proprietary mixture of low molecular weight oligosaccharides which regulates the life cycle of the hair: prolongs the duration ofï¿½the hai', NULL, 550, '2022-08-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Daktacort cream 15 gm', 3287, 'دكتاكورت كريم 15 جم', '48', '10', 'Antifungal with glucocorticoid', 'Antifungal with glucocorticoid', NULL, 'Hydrocortisone+miconazole', 'Mina pharm > janssen cilag', 'Cream', 'كريم', '15 gm', '1', 'مضاد للالتهابات ومضيق للأوعية. ومضاد للحكة أيضًا. و يستخدم للمنطقة الحساسة وذلك لعلاج بعض أنواع الفطريات أو الالتهابات.', NULL, 'about hydrocortisone systemic synthetic glucocorticoid anti-inflammatory indications for hydrocortisone periarticular or soft tissue injections: 1. bursitis 2. synovitis 3. tendinitis 4. taenosinovitis 5. cystic tumors of tendon or aponeurosis 6. epicondy', '3574661806990', 14603, '2024-01-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Lipanthyl 300mg 30 capsules', 7338, 'ليبانتيل 300 مجم 30 كبسولة', '126', '96', 'Antihyperlipidemic.fibrates', 'Antihyperlipidemic.fibrates', NULL, 'Fenofibrate', 'Mina pharm', 'Capsule', 'كبسولة', '300mg', '3', 'خافض للكوليسترول والدهون في الدم', NULL, NULL, '6222003701942', 13132, '2024-07-24', NULL, 0, 'Fenofibrate is indicated as adjunctive therapy to diet:[L51464]



- To reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL)

- To reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when the use of recommended LDL-C lowering therapy is not possible', 'Fenofibrate activates peroxisome proliferator activated receptor alpha (PPARα), increasing lipolysis, activating lipoprotein lipase, and reducing apoprotein C-III.[A186002,L8588,L8591] PPARα is a nuclear receptor and its activation alters lipid, glucose, and amino acid homeostasis.[A186002] Activation of PPARα activates transcription of gene transcription and translation that generates peroxisomes filled with hydrogen peroxide, reactive oxygen species, and hydroxyl radicals that also participate in lipolysis.[A186005] This mechanism of increased lipid metabolism is also associated with increased oxidative stress on the liver.[A186005] In rare cases this stress can lead to cirrhosis and chronic active hepatitis.[A186002,L8588,L8591]', 'Fenofibrate is a fibrate that activates peroxisome proliferator activated receptor alpha (PPARα) to alter lipid metabolism and treat primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia.[A186002,L8588,L8591] Fenofibrate requires once daily dosing and has a half life of 19-27 hours so its duration of action is long.[A36366,L8588,L8591] Fenofibrate capsules are given at a dose of 50-150mg daily so the therapeutic index is wide.[L8591] Patients should be counselled about the risk of rhabdomyolysis, myopathy, and cholelithiasis when taking fibrates.[L8588,L8591]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Straline emollient cream 500 ml', 31411, 'سترالين كريم مرطب 500 مل', '587', '510', 'Skin care.moisturizing', 'Skin care.moisturizing', NULL, NULL, 'Egyptian company for cosmetics > hayah lab.', 'Cream', 'كريم', '500 ml', '1', NULL, NULL, 'nourishes and restores the skin s hydration level for face and body.', NULL, 769, '2025-04-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Follidanza 30 film coated tablets', 15741, 'فوليدانزا 30 قرص', '395', NULL, 'Multivitamin', 'Multivitamin', NULL, 'D-chiro inositol (dci)+n-acetyl cystein (nac)+d - biotin+r-lipoic acid+choline bitartrate+docosahexaenoic acid+myo-inositol (mi)+ascorbic acid+calcium carbonate+magnesium oxide+zinc+manganese carbonate+selenium+cholecalciferol', 'Hoechst pharmaceutical industries', 'Tablet', 'أقراص', NULL, '3', NULL, NULL, NULL, NULL, 1698, '2024-06-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Fucidin 2% 10x30cm intertulle', 19444, 'فيوسيدين 2% 10*30 سم شاش معقم', '3', NULL, 'Antibiotic', 'Antibiotic', NULL, 'Fusidic acid', 'Mina pharm > leo pharmaceutical products', 'Unknown', 'غير محدد', '2%', '1', NULL, NULL, 'about fusidic acid a bacteriostatic steroid antibiotic systemic antibacterial anti-infective. mechanism of action of fusidic acid fusidic acid is a bactericidal or bacteriostatic drug depending upon the concentration. it inhibits the transfer of aminoacid', NULL, 933, '2022-06-21', NULL, 0, 'For the treatment of bacterial infections.', 'Fusidic acid works by interfering with bacterial protein synthesis, specifically by preventing the translocation of the elongation factor G (EF-G) from the ribosome. It also can inhibit chloramphenicol acetyltransferase enzymes.', 'Fusidic acid is a bacteriostatic antibiotic and helps prevent bacterial growth while the immune system clears the infection.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mapodose 10 000iu 20 capsules', 9266, 'مابودوز 10000وحدة دولية 20 كبسولة', '80', NULL, 'Therapeutic vitamin', 'Therapeutic vitamin', NULL, 'Cholecalciferol(vit d3)', 'Mapco', 'Capsule', 'كبسولة', '000iu', '1', NULL, NULL, NULL, NULL, 650, '2023-02-06', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Mannitol 20% (el nasr) i.v. inf. 500 ml', 22269, 'مانيتول 20% النصر محلول وريدي 500 مل', '17', NULL, 'Osmotic diuretic', 'Osmotic diuretic', NULL, 'Mannitol', 'El nasr', 'Unknown', 'غير محدد', '20%', '1', NULL, NULL, 'about mannitol a polyol (sugar alcohol) low molecular weight non electrolyte osmotic diuretic. mechanism of action of mannitol 10% it is a non electrolyte of low molecular weight which limit the tubular water and electrolyte reabsorption in a variety of w', NULL, 632, '2022-08-04', NULL, 0, 'Used for the promotion of diuresis before irreversible renal failure becomes established, the reduction of intracranial pressure, the treatment of cerebral edema, and the promotion of urinary excretion of toxic substances.



Mannitol is also indicated as add-on maintenance therapy for improving pulmonary function in cystic fibrosis patients aged 18 and over who have passed the BRONCHITOL tolerance test (BTT). It is recommended that patients take an orally inhaled short-acting bronchodilator 5-15 minutes prior to every inhaled mannitol dose.[L20024]', 'Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitol elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. As a diurectic mannitol induces diuresis because it is not reabsorbed in the renal tubule, thereby increasing the osmolality of the glomerular filtrate, facilitating excretion of water, and inhibiting the renal tubular reabsorption of sodium, chloride, and other solutes. Mannitol promotes the urinary excretion of toxic materials and protects against nephrotoxicity by preventing the concentration of toxic substances in the tubular fluid. As an Antiglaucoma agent mannitol levates blood plasma osmolarity, resulting in enhanced flow of water from the eye into plasma and a consequent reduction in intraocular pressure. As a renal function diagnostic aid mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption. Therefore, its urinary excretion rate may serve as a measurement of glomerular filtration rate (GFR).



The exact mechanism of action of inhaled mannitol in the symptomatic maintenance treatment of cystic fibrosis remains unclear.[A223199, L20024] It is hypothesized that mannitol produces an osmotic gradient across the airway epithelium that draws fluid into the extracellular space and alters the properties of the airway surface mucus layer, allowing easier mucociliary clearance.[A223199]', 'Chemically, mannitol is an alcohol and a sugar, or a polyol; it is similar to xylitol or sorbitol. However, mannitol has a tendency to lose a hydrogen ion in aqueous solutions, which causes the solution to become acidic. For this reason, it is not uncommon to add a substance to adjust its pH, such as sodium bicarbonate. Mannitol is commonly used to increase urine production (diuretic). It is also used to treat or prevent medical conditions that are caused by an increase in body fluids/water (e.g., cerebral edema, glaucoma, kidney failure). Mannitol is frequently given along with other diuretics (e.g., furosemide, chlorothiazide) and/or IV fluid replacement.



Inhaled mannitol has the possibility to cause bronchospasm and hemoptysis; the occurrence of either should lead to discontinuation of inhaled mannitol.[L20024]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Xerexomair 100mg/5ml pd. for oral susp. 30ml', 29743, 'زيريكسومير 100مجم/5مل شراب معلق 30 مل', '37', '24', 'Antibiotic.macrolide', 'Antibiotic.macrolide', NULL, 'Azithromycin', 'Organopharma', 'Susp', 'معلق', '100mg', '1', NULL, NULL, 'description: azithromycin is a semi-synthetic macrolide antibiotic of the azalide class. dose: adult: po- respiratory tract skin and soft tissue infections- 500 mg once daily for 3 days. or 500mg on day 1 followed by 250mg on days 2 to 5. typhoid- 500 mg', '6224000908041', 1070, '2025-01-07', NULL, 0, 'Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label].



Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. 



**Adults**:



Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.

Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage.



Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_.



Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established.



**Pediatric Patients**



Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_



Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy.



Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy.', 'In order to replicate, bacteria require a specific process of protein synthesis, enabled by ribosomal proteins [A6505]. Azithromycin binds to the 23S rRNA of the bacterial 50S ribosomal subunit. It stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit [FDA label], [A14179]. This results in the control of various bacterial infections [A174193], [FDA label].   The strong affinity of macrolides, including azithromycin, for bacterial ribosomes, is consistent with their broad‐spectrum antibacterial activities [A174193].





Azithromycin is highly stable at a low pH, giving it a longer serum half-life and increasing its concentrations in tissues compared to erythromycin [A174175]. 



', 'Macrolides stop bacterial growth by inhibiting protein synthesis and translation, treating bacterial infections [A174175].

Azithromycin has additional immunomodulatory effects and has been used in chronic respiratory inflammatory diseases for this purpose [A174172].



', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Savapran 5 mg 20 f.c. tabs.', 26561, 'سافابران 5مجم 20 قرص', '99', NULL, 'Anti-ischemic', 'Anti-ischemic', NULL, 'Ivabradine', 'Horus for pharmaceutical products > eva pharma', 'Tab', 'أقراص', '5 mg', '2', NULL, NULL, 'about ivabradine antianginal drug smechanism of action of ivabradine ivabradine is a heart rate lowering agent that works through selective and specific inhibition of the cardiac pacemaker if current. if current controls the spontaneous diastolic depolari', NULL, 1335, '2022-07-08', NULL, 0, 'Ivabradine is indicated by the FDA to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use. It is also indicated for treatment of stable symptomatic heart failure as a result of dilated cardiomyopathy for pediatric patients 6 months of age or more[FDA Label].', 'Ivabradine lowers heart rate by selectively inhibiting If channels ("funny channels") in the heart in a concentration-dependent manner without affecting any other cardiac ionic channels (including calcium or potassium). Ivabradine binds by entering and attaching to a site on the channel pore from the intracellular side and disrupts If ion current flow, which prolongs diastolic depolarization, lowering heart rate. The If currents are located in the sinoatrial node and are the home of all cardiac pacemaker activity. Ivabradine therefore lowers the pacemaker firing rate, consequently lowering heart rate and reducing myocardial oxygen demand. This allows for an improved oxygen supply and therefore mitigation of ischemia, allowing for a higher exercise capacity and reduction in angina episodes. ', 'The funny channels (If) open during repolarization and close during depolarization, making ivabradine''s activity dependent on heart rate or the closing and opening of the channels. Therefore ivabradine exhibits use-dependence and is more pharmacologically active at higher heart rates. Ivabradine exhibits a linear dose-dependent heart-rate lowering activity (bradycardic effect) until a maximum dose of 30-40mg. At higher doses, the concentration of ivabradine tends to plateau, reducing risk of serious sinus bradycardia.  It has been shown that the metabolite of ivabradine lowers heart rate as well, contributing to ivabradine''s overall effect. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cona-adione 10mg 100 chewable tablets', 2967, 'كونا-اديون 10مجم 100 قرص للمضغ', '83', NULL, 'Vitamin k. bleeding', 'Vitamin k. bleeding', NULL, 'Vitamin k1', 'T3a pharma', 'Tablet', 'أقراص', '10mg', '1', 'فيتامين ك لعلاج النزيف', NULL, NULL, '6222003456156', 1347, '2022-12-04', NULL, 0, 'For the treatment of vitamin A deficiency.', 'Vision:Vitamin A (all-<i>trans</i> retinol) is converted in the retina to the 11-<i>cis</i>-isomer of retinaldehyde or 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal functions in the retina in the transduction of light into the neural signals necessary for vision. 11-<i>cis</i>-retinal, while attached to opsin in rhodopsin is isomerized to all-<i>trans</i>-retinal by light. This is the event that triggers the nerve impulse to the brain which allows for the perception of light. All-<i>trans</i>-retinal is then released from opsin and reduced to all-<i>trans</i>-retinol. All-<i>trans</i>-retinol is isomerized to 11-<i>cis</i>-retinol in the dark, and then oxidized to 11-<i>cis</i>-retinal. 11-<i>cis</i>-retinal recombines with opsin to re-form rhodopsin. Night blindness or defective vision at low illumination results from a failure to re-synthesize 11-<i>cis</i> retinal rapidly. Epithelial differentiation: The role of Vitamin A in epithelial differentiation, as well as in other physiological processes, involves the binding of Vitamin A to two families of nuclear retinoid receptors (retinoic acid receptors, RARs; and retinoid-X receptors, RXRs). These receptors function as ligand-activated transcription factors that modulate gene transcription. When there is not enough Vitamin A to bind these receptors, natural cell differentiation and growth are interrupted.', 'Vitamin A is effective for the treatment of Vitamin A deficiency. Vitamin A refers to a group of fat-soluble substances that are structurally related to and possess the biological activity of the parent substance of the group called all-<i>trans</i> retinol or retinol. Vitamin A plays vital roles in vision, epithelial differentiation, growth, reproduction, pattern formation during embryogenesis, bone development, hematopoiesis and brain development. It is also important for the maintenance of the proper functioning of the immune system.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Co-dilatrol 30 tab.', 2865, 'كو-ديلاترول 30قرص', '75', '52.5', 'Antihypertensive', 'Antihypertensive', NULL, 'Carvedilol+hydrochlorothiazide', 'Chemipharm', 'Tab', 'أقراص', NULL, '3', NULL, NULL, 'about hydrochlorothiazide thiazide derivatibve diuretic. mechanism of action of hydrochlorothiazide it is thiazide diuretic which exerts its action by acting at site-3(central dilating segment of early distal tubule). it binds to na+cl- symporter and inhi', '6222006500245', 1662, '2025-01-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Acne-stop facial wash 200 ml', 80, 'اكني ستوب غسول وجه لحب الشباب 200 مل', '120', '74', 'Skin care.anti-acne', 'Skin care.anti-acne', NULL, 'Oleanolic acid+ndga (nordihydroguaiaretic acid)+propolis+osmotic gel', 'Mash premiere', 'Facial wash', 'غسول للوجه', '200 ml', '1', 'غسول وجه لحب الشباب', NULL, 'effective cleanser for acne treatment', '6222001409499', 5782, '2024-02-08', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Vagizole 2% vaginal cream 15 gm+3 applicators', 28909, 'فاجيزول 2% كريم مهبلي', '123', '76.5', 'Antifungal', 'Antifungal', NULL, 'Butoconazole', 'Biopharm egypt > saja pharmaceuticals', 'Cream', 'كريم', '2%', '1', NULL, NULL, 'indication: vulvo-vaginal candidiasis use: only one dose of one tube intravaginally.', '6221126000338', 1347, '2024-10-21', NULL, 0, 'For the local treatment of vulvovaginal candidiasis (infections caused by Candida)', 'The exact mechanism of the antifungal action of butoconazole is unknown, however, it is presumed to function as other imidazole derivatives via inhibition of steroid synthesis. Imidazoles generally inhibit the conversion of lanosterol to ergosterol via the inhibition of the enzyme cytochrome P450 14&alpha;-demethylase, resulting in a change in fungal cell membrane lipid composition. This structural change alters cell permeability and, ultimately, results in the osmotic disruption or growth inhibition of the fungal cell.', 'Butoconazole is an imidazole derivative that has fungicidal activity <i>in vitro</i> against <i>Candida</i> spp. and has been demonstrated to be clinically effective against vaginal infections due to <i>Candida albicans</i>. <i>Candida albicans</i> has been identified as the predominant species responsible for vulvovaginal candidasis.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Restolam 0.25mg 20 tab.', 9830, 'رستولام 0.25مجم 20 قرص', '20', '10', 'Psychiatric.anxiolytics-hypnotics.narcotic', 'Psychiatric.anxiolytics-hypnotics.narcotic', NULL, 'Alprazolam', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '0.25mg', '2', NULL, NULL, NULL, '6223002141609', 1233, '2024-11-06', NULL, 0, 'Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults.[L34783] Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.[L34783, L34788]



Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.[A177973]', 'Neurotransmission relies on excitatory and inhibitory signalling. γ-aminobutyric acid (GABA) type-A receptors (GABA<sub>A</sub>Rs) are members of the pentameric ligand-gated ion channel (PLGIC) superfamily located synaptically and perisynaptically to mediate phasic inhibition and extrasynaptically to mediate tonic inhibition. GABA<sub>A</sub>Rs comprise a variety of subunits from a homologous family whose members are named based on sequence identity as one of α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3. Each subunit possesses an extracellular (ECD), transmembrane (TMD), and intracellular (ICD) domain; inter-subunit interfaces are the primary points of neurotransmitter and modulator binding, described by coordination of the principal (+) and complementary (-) sites in each subunit. Binding of GABA to GABA<sub>A</sub>Rs induces pore opening, rapid flow of chloride ions, and synaptic hyperpolarization, which in turn manifests as an inhibitory signal.[A236793, A236798]



The most prevalent GABA<sub>A</sub>Rs _in vivo_ are the α1β2γ2 receptors, which contain both GABA (β+/α-) and benzodiazepine (BZD, α+/γ-) binding sites in the intersubunit interfaces of the relevant subunits.[A236793, A236798, A236828] In general, any receptors containing an α<sub>x</sub>/γ<sub>z</sub> interface, where x = 1-3,5 and z = 1-3, have potential high-affinity BZD binding sites, although small sequence differences between subunits may alter binding affinity to individual molecules. The α4 and α6 subunits, in which an otherwise conserved histidine is replaced by arginine, do not bind traditional BZD ligands such as diazepam and hence are considered "diazepam-insensitive".[A236793, A236798, A236828] GABA binding results in a series of conformational changes in the ECDs of GABA<sub>A</sub>R β subunits, "locking" each to its neighbouring α- interface. The binding of alprazolam in the high-affinity BZD site stabilizes the α+/γ- interface and facilitates the conformational changes that lead to pore opening, hence functioning as a positive allosteric modulator.[A236833]



The exact manner in which GABA<sub>A</sub>R allosteric modulation mediates the therapeutic and unwanted effects of benzodiazepines remains unclear.[A177973, A18125] Earlier studies suggested that the primary factor was the α subunit composition, with α1-containing receptors mediating the sedative effects, α2/3-containing receptors the anxiolytic effects, and α5-containing receptors the memory effects of benzodiazepines.[A236838] More recent studies suggest a more complex set of factors including subunit composition, physiological location, neuronal circuit, and nerve cell type.[A236843] To further complicate matters, there may be up to five distinct BZD binding sites on GABA<sub>A</sub>Rs, with site 1 corresponding to the classical high-affinity α+/γ- interface. The effects of binding at sites 2-4 are not fully understood and likely impart greater complexity to benzodiazepine pharmacological action.[A236798, A236828]', 'Alprazolam is a benzodiazepine that binds γ-aminobutyric acid (GABA) type-A receptors (GABA<sub>A</sub>Rs) to enhance their inhibitory effect on neurotransmission, specifically in the brain.[L34783, L34788] Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death; patients taking benzodiazepines and opioids concurrently may require lower doses of one or both medications, depending on their clinical situation. Patients with pre-existing impaired respiratory function are at increased risk of adverse effects including death during treatment with benzodiazepines. In addition, due to its CNS depressant effects, patients taking alprazolam should avoid operating heavy machinery or driving and should avoid other CNS depressants such as alcohol. As with other benzodiazepines, alprazolam carries a risk of abuse, misuse, and addiction, which is higher in predisposed individuals and may require strict monitoring. Cessation of therapy may result in acute or protracted withdrawal symptoms, which may be life-threatening; the patient dose should be gradually tapered whenever discontinuation or reduced dosage are necessary. Newborns born to mothers using alprazolam later in pregnancy may suffer from sedation and withdrawal symptoms. As CYP3A is required for the initial step in alprazolam metabolism, alprazolam is contraindicated in patients taking strong CYP3A inhibitors, such as ketoconazole and itraconazole; milder CYP3A inhibitors still necessitate alprazolam dosage adjustments. Lastly, benzodiazepines may have negative effects, such as panic disorders, increased suicide incidence, and episodes of mania/hypomania, in patients suffering from depression.[A18125, A236788, L34783, L34788]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Erastapex co 10/40mg 30 f.c. tabs.', 4328, 'ايراستابكس كو 10/40مجم 30 قرص', '165', '124.5', 'Antihypertensive', 'Antihypertensive', NULL, 'Olmesartan+amlodipine', 'Multi-apex', 'Tab', 'أقراص', '40mg', '3', 'علاج ضغط الدم المرتفع', NULL, NULL, '6223003205669', 8305, '2024-08-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gantolief 50mg 30 f.c.tab.', 5318, 'جانتوليف 50 مجم 30 قرص', '60', '37.5', 'Motility stimulant', 'Motility stimulant', NULL, 'Itopride', 'Global napi pharmaceuticals', 'Tab', 'أقراص', '50mg', '3', NULL, NULL, NULL, '6223002142552', 2548, '2024-10-26', NULL, 0, 'Investigated for use/treatment in gastrointestinal diseases and disorders (miscellaneous).', 'Itopride has anticholinesterase (AchE) activity as well as dopamine D2 receptor antagonistic activity. It is well established that M3 receptors exist on the smooth muscle layer throughout the gut and acetylcholine (ACh) released from enteric nerve endings stimulates the contraction of smooth muscle through M3 receptors. The enzyme AChE hydrolyses the released ACh, inactivates it and thus inhibits the gastric motility leading to various digestive disorders. Besides ACh, dopamine is present in significant amounts in the gastrointestinal tract and has several inhibitory effects on gastrointestinal motility, including reduction of lower esophageal sphincter and intragastric pressure. These effects appear to result from suppression of ACh release from the myenteric motor neurons and are mediated by the D2 subtype of dopamine receptors. Itopride, by virtue of its dopamine D2 receptor antagonism, removes the inhibitory effects on Ach release. It also inhibits the enzyme AchE which prevents the degradation of ACh. The net effect is an increase in ACh concentration, which in turn, promotes gastric motility, increases the lower esophageal sphincter pressure, accelerates gastric emptying and improves gastro-duodenal coordination. This dual mode of action of Itopride is unique and different from the actions of other prokinetic agents available in the market.

', NULL, 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Hi-forte gel 60 gm', 6121, 'هاي فورت مساج جل 60 جرام', '65', '44.95', 'Massage', 'Massage', NULL, 'Menthol+camphor+clove oil+panthenol', 'Egyptian company for cosmetics > pearla pharm co.', 'Gel', 'جل', '60 gm', '1', NULL, NULL, 'indication: muscular spasm rheumatic pain neck and back pain tired feet and sprains.', NULL, 946, '2023-12-23', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Clexane 80 mg/0.8ml 2 prefilled syringe.', 16507, 'كليكسان 80 مجم / 0.8 مل 2 سرنجة معباة', '417', '289', 'Anticoagulant.low mwt heparin', 'Anticoagulant.low mwt heparin', NULL, 'Enoxaparin sodium', 'Sanofi', 'Syringe', 'حقنة', '80 mg', '2', 'مضاد للتجلط', NULL, NULL, '3664798053333', 15820, '2024-08-27', NULL, 0, 'Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.[L31393]



Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.[L31393]', 'Enoxaparin binds to antithrombin III, a serine protease inhibitor, forming a complex that irreversibly inactivates factor Xa, which is frequently used to monitor anticoagulation in the clinical setting.[A228318] Following factor Xa inactivation, enoxaparin is released and binds to other anti-thrombin molecules. Factor IIa (thrombin) is directly inhibited by enoxaparin, however with less potency than unfractionated heparin (UFH). [A188051] Due to the cascade of effects resulting from enoxaparin binding, thrombin is unable to convert fibrinogen to fibrin and form a clot, preventing thromboembolic events. 

 

', 'This drug has an immediate onset of action.[L31468] Enoxaparin increases Thrombin Time (TT) and activated partial thromboplastin time (aPTT), preventing and reducing thromboembolic complications such as DVT, pulmonary embolism, and ischemic cardiac complications.[A228128] Administered at 1.5 mg/kg subcutaneously in a pharmacodynamic study, enoxaparin led to a higher ratio of anti-Factor Xa to anti-Factor IIa activity (mean ±SD, 14.0±3.1) (based on areas under anti-Factor activity versus time curves) when compared to that of heparin (mean ±SD, 1.22±0.13). Increases in the TT and aPTT were 1.8 times those of the control group.[L31393]  Enoxaparin at 1 mg/kg subcutaneously every 12 hours led to aPTT values of 45 seconds or less in most patients. Average aPTT prolongation time on Day 1 was approximately 16% higher than on Day 4 of enoxaparin therapy.[L31393]



Caution is advised during treatment with enoxaparin - the risk of hemorrhage and thrombocytopenia is increased. In pregnant women with prosthetic mechanic heart valves, the risk of thromboembolism is increased.[L31393] 

', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Sermion 10mg 50 tab', 10355, 'سيرميون 10مجم 50 قرص', '32', NULL, 'Cerebral vasodilator', 'Cerebral vasodilator', NULL, 'Nicergoline', 'Pfizer', 'Tab', 'أقراص', '10mg', '5', 'يحسن التدفق الدموي -- علاج الزهايمر', NULL, NULL, NULL, 912, '2022-05-19', NULL, 0, 'For the treatment of senile dementia, migraines of vascular origin, transient ischemia, platelet hyper-aggregability, and macular degeneration.', 'Nicergoline acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. Therefore the mechanism of Nicergoline is to increase vascular circulation in the brain, thereby enhancing the transmission of nerve signals across the nerve fibres, which secrete acetylcholine as a neural transmitter.', 'Nicergoline is a potent vasodilator (improves brain blood flow). On the cerebral level it prompts a lowering of vascular resistance, an increase in arterial flow and stimulates the use of oxygen and glucose. Nicergoline also improves blood circulation in the lungs and limbs and has been shown to inhibit blood platelet aggregation.', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Capecitagit 500mg 120 tabs', 15782, 'كابيسيتاجيت 500مجم 120 قرص', '4,320', '2825', 'Antineoplastic', 'Antineoplastic', NULL, 'Capecitabine', 'Hikma specialized pharmaceuticals', 'Tab', 'أقراص', '500mg', '12', 'لعلاج الاورام', NULL, NULL, '6223003840808', 18720, '2024-05-27', NULL, 0, 'Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer.[L44657] For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy.[L44657] For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease.[L44657] Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.[L44657]', 'Capecitabine is metabolized to 5-fluorouracil in vivo by carboxylesterases, cytidine deaminase, and thymidine phosphorylase/uridine phosphorylase sequentially.[L44657,A256027,A256142,A256147,A32078] 5-fluorouracil is further metabolized through a series of enzymatic reactions into 3 main active metabolites: 5-fluorouridine triphosphate (5-FUTP), 5-fluoro-2’-deoxyuridine monophosphate (5-FdUMP), and 5-fluorodeoxyuridine triphosphate (5-FdUTP).[A256062,A256027,A256077]. These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate (CH<sub>2</sub>THF), bind to thymidylate synthase (TS) to form a covalently bound ternary complex.[L44657] TS is an enzyme that catalyzes the methylation of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP).[A256152,A256077] Under normal physiological conditions, dUMP binds to TS first before CH<sub>2</sub>THF, followed by a 1,4 or Michael addition from the pyrimidine C (6)atom to the Cys146 nucleophile.[A256152,A256157] If correctly positioned, dUMP, CH<sub>2</sub>THF, and TS would form a ternary complex to facilitate the donation of the methyl group from CH<sub>2</sub>THF to dUMP.[A256152] However, the substitution of dUMP with FdUMP results in a new time-dependent TS–FdUMP–CH2THF complex. Since the fluorine group prevents dissociation of FdUMP from the pyrimidine ring, the whole complex is rendered irreversibly deactivated, terming this reaction "suicide inhibition".[A256152,A256162] TS inhibition prevents the conversion of dUMP to dTMP, depleting the pool of dTMP that could be phosphorylated into dTTP to be incorporated as DNA nucleotides. This disrupts the nucleotides balance, particularly the the ATP/dTTP ratio, thus impairing DNA synthesis and repair and causing apoptosis.[A256167,A256152] 



5-FdUMP can also be phosphorylated into 5-FdUTP, further increasing the pool of dUTP base to potentially overwhelm the activity of dUTPase.[A256177] Coupled with the decrease in dTTP, 5-FdUMP, and 5-FdUTP increase the probability of mistakenly incorporating a uracil base into DNA strands in place of thymine. Although this mistake can often be resolved by the nucleotide excision repair enzyme uracil-DNA-glycosylase (UDG), the high (F)dUTP/dTTP ratio would result in re-incorporation of uracil into DNA, leading to a futile cycle of misincorporation, excision, and repair.[A256172,A841] Repeated base excision repair can result in abasic sites, which can lead to DNA mutagenesis and thus protein miscoding, replication forks collapse, and DNA fragmentation through single or double strand breaks [A256177,A256182,A256187,A256192] 



However, several reports have found that the incorporation of uracil in genomic DNA does not significantly affect the cytotoxicity of 5-FU, suggesting that the cytotoxic effect of 5-FU is dominated by the perturbation of RNA through 5-FUTP.[A256197,A256202] Similar to 5-dFUTP, 5-FUTP can be mistakenly incorporated into RNA in place of regular UTP and disrupt regular RNA biology through various mechanisms. 5-FUTP can be incorporated into the spliceosomal U2 snRNA at pseudouridylated sites to prevent further pseudouridylation and thus pre-mrNA splicing. 5-FUTP can also change the structure of U4 and U6 snRNA and reduce the turnover rate of U1 snrNA once incorporated.[A256207] For tRNA, 5-FUTP can affect tRNA''s post-transcriptional RNA modifications activity, particularly by inhbiting pseudouridine synthase through formation of covalent complex.[A256212,A256217] Recently, the effect of 5-FUTP on miRNAs and lncRNA was also observed through profound changes in expression, although the precise mechanism is still unknown.[A256222,A256227,A256232]



Although the main mechanism of 5-FU cytotoxicity was thought to be attributed to DNA damages, recent reports have shown that the majority of 5-FU pharmacological action is mediated through RNA, since 5-FU is accumulated ~3000- to 15 000-fold more in RNA compared to that of DNA.[A256237] 

', 'Capecitabine is a fluoropyrimidine carbamate belonging to a group of antineoplastic agents called antimetabolites, which kill cancerous cells by interfering with DNA synthesis.[A256242,A841] It is an orally administered systemic prodrug that has little pharmacologic activity until it is converted to 5-fluorouracil (5-FU) by enzymes that are expressed in higher concentrations in many tumors.[A256247] Capecitabine was designed specifically to overcome the disadvantages of 5-FU and to mimic the infusional pharmacokinetics of 5-FU without the associated complexity and complications of central venous access and infusion pumps.[A256242] Particularly, since the enzymes converting 5-FU into active metabolites exist in the gastrointestinal tract, infusion of 5-FU can have gastrointestinal toxicity while also losing efficacy.[A256252] Since capecitabine can be transported intact across the intestinal mucosa, it can be selectively delivered 5-FU to tumor tissues through enzymatic conversion preferentially inside tumor cells.[A256252]



5-FU exerts its pharmacological action through the inhibition and interference of 3 main targets: thymidylate synthase, DNA, and RNA, leading through protein synthesis disruption and apoptosis.[A841,A256152] Population-based exposure-effect analyses demonstrated a positive association between AUC of 5-FU and grade 3-4 hyperbilirubinemia.[L44657]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Bienadol 30 tab.', 15188, 'بينادول 30 قرص', '29', '18', 'Analgesic.antipyretic', 'Analgesic.antipyretic', NULL, 'Caffeine+paracetamol(acetaminophen)', 'El nile.', 'Tab', 'أقراص', NULL, '3', NULL, NULL, 'mechanism: it is thought paracetamol reduces fever by affecting an area of the brain that regulates our body temperature (the hypothalamic heat-regulating center). paracetamol is about as effective as aspirin or ibuprofen at relieving mild to moderate pai', '2749313881712', 1444, '2023-12-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Histaseric 8mg 30 tab.', 20515, 'هيستاسريك 8 مجم 30 قرص', '16', NULL, 'Diamine oxidase inhibitor.anti vertigo', 'Diamine oxidase inhibitor.anti vertigo', NULL, 'Betahistine', 'Arab drug company.', 'Tab', 'أقراص', '8mg', '3', NULL, NULL, 'about betahistine h1 selective histamine analogue diamine oxidase inhibitor anti vertigo and in meniere s syndrome. mechanism of action of betahistine betahistine is a histamine substitute. it produces vasodilatation and improves blood flow to the labyrin', NULL, 901, '2022-07-22', NULL, 0, 'Betahistine is indicated for the reduction of recurrent vertigo episodes associated with Ménière''s disease in patients 18 years old and above.[L16388]', 'Vertigo is a disturbing sensation of movement caused by dysfunction of the labyrinth (inner ear), vestibular nerve, cerebellum, brainstem, or Central Nervous System (CNS). Vestibular forms of vertigo are often accompanied by auditory dysfunctions such as hyperacusis, hearing loss, and tinnitus.[A220328] In most cases, adaptive mechanisms of the CNS lead to functional recovery after episodes of vertigo, however, syndromes such as Ménière''s disease tend to cause the recurrence of vertigo symptoms. This significantly impacts the quality of life and the ability to carry out daily activities.[A220318] 



**H1-receptor activity**



The mechanism of action of betahistine is multifactorial. Ménière''s disease is thought to result from a disruption of endolymphatic fluid homeostasis in the ear.[A220438] Betahistine mainly acts as a histamine H1-receptor agonist. The stimulation of H1-receptors in the inner ear causes a vasodilatory effect leading to increased permeability of blood vessels and a reduction in endolymphatic pressure; this action prevents the rupture of the labyrinth, which can contribute to the hearing loss associated with  Ménière''s disease. Betahistine is also purported to act by reducing the asymmetrical functioning of sensory vestibular organs and increasing vestibulocochlear blood flow, relieving symptoms of vertigo.[A220433]



**H3-receptor activity**



In addition to the above mechanisms, betahistine also acts as a histamine H3-receptor antagonist, increasing the turnover of histamine from postsynaptic histaminergic nerve receptors, subsequently leading to an increase in H1-agonist activity. H3-receptor antagonism elevates levels of neurotransmitters including serotonin in the brainstem, inhibiting the activity of vestibular nuclei, thus restoring proper balance and decreasing vertigo symptoms.[A220328]', 'Through its actions on the histamine receptors, betahistine provides relief from vertigo associated with Ménière''s disease.[A220328,A220433,L16388] ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Nuxe merveillance expert serum 30 ml', 23874, 'نوكس سيرم 30مل', '710', '690', 'Skin care', 'Skin care', NULL, NULL, 'Nuxe laboratory > biotech egypt', 'Serum', 'سيروم', '30 ml', '1', NULL, NULL, 'this anti-wrinkle serum with daylily olï-oactifï- combats deep wrinkles and loss of tone. this serum immediately smooths the skin the visible lifting effect lasts for 8 hours. day after day deep wrinkles are reversed and tone is restored. use apply mervei', NULL, 602, '2023-09-05', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Romix cream 100 gm', 9970, 'روميكس كريم 100 جم', '280', '235', 'Whitening topical', 'Whitening topical', NULL, 'Amino acids+soya protein+lecithin+retinol & tocopherol+licorice+vitamin c+lavender extract', 'Leader cosmetics > original pharma group', 'Cream', 'كريم', '100 gm', '1', 'كريم تفتيح', NULL, 'whitening cream', NULL, 1220, '2025-01-18', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Caffeinospire 10mg/ml sterile oral soln. 3 ml', 1841, 'كافينوسبير 10مجم /مل محلول معقم بالفم 3 مل', '45', '30', 'Cns.stimulant.methylxanthines', 'Cns.stimulant.methylxanthines', NULL, 'Caffeine', 'Memphis > inspire pharmaceutical company', 'Sol', 'محلول', '10mg', '1', 'علاج الصداع النصفي -- الوقاية من الصداع بعد الجراحة -- يعالج صداع التوتر', NULL, 'about caffeine xanthine alkaloid central stimulant and metabolic stimulant. mechanism of action of caffeine because caffeine is both water-soluble and lipid-soluble it readily crosses the blood?brain barrier .caffeine stimulates medullary vagal vasomotor', '6224000866105', 1723, '2025-06-09', NULL, 0, 'Caffeine is indicated for the short term treatment of apnea of prematurity in infants and off label for the prevention and treatment of bronchopulmonary dysplasia caused by premature birth.[T716,L9851] In addition, it is indicated in combination with sodium benzoate to treat respiratory depression resulting from an overdose with CNS depressant drugs.[L9899] Caffeine has a broad range of over the counter uses, and is found in energy supplements, athletic enhancement products, pain relief products, as well as cosmetic products.[T716,L9854,L9872]', 'The mechanism of action of caffeine is complex, as it impacts several body systems, which are listed below. The effects as they relate to various body systems are described as follows:



**General and cellular actions**



Caffeine exerts several actions on cells, but the clinical relevance is poorly understood. One probable mechanism is the inhibition of nucleotide phosphodiesterase enzymes, adenosine receptors, regulation of calcium handling in cells, and participates in adenosine receptor antagonism.[A187721,L9857] Phosphodiesterase enzymes regulate cell function via actions on second messengers cAMP and cGMP.[A187724] This causes lipolysis through activation of hormone-sensitive lipases, releasing fatty acids and glycerol.[T722]



**Respiratory**



The exact mechanism of action of caffeine in treating apnea related to prematurity is unknown, however, there are several proposed mechanisms, including respiratory center stimulation in the central nervous system, a reduced threshold to hypercapnia with increased response, and increased consumption of oxygen, among others.[L9851] The blocking of the adenosine receptors enhances respiratory drive via an increase in brain medullary response to carbon dioxide, stimulating ventilation and respiratory drive, while increasing contractility of the diaphragm.[T716]



**Central nervous system**



Caffeine demonstrates antagonism of all 4 adenosine receptor subtypes (A1, A2a, A2b, A3) in the central nervous system.[T716,L9851] Caffeine''s effects on alertness and combatting drowsiness are specifically related to the antagonism of the A2a receptor.[T716]



**Renal system**



Caffeine has diuretic effects due to is stimulatory effects on renal blood flow, increase in glomerular filtration, and increase in sodium excretion.[T716]



**Cardiovascular system**



Adenosine receptor antagonism at the A1 receptor by caffeine stimulates inotropic effects in the heart. Blocking of adenosine receptors promotes catecholamine release, leading to stimulatory effects occurring in the heart and the rest of the body.  In the blood vessels, caffeine exerts direct antagonism of adenosine receptors, causing vasodilation. It stimulates the endothelial cells in the blood vessel wall to release nitric oxide, potentiating blood vessel relaxation. Catecholamine release, however, antagonizes this and exerts inotropic and chronotropic effects on the heart, ultimately leading to vasoconstriction. Finally, caffeine is shown to raise systolic blood pressure measurements by 5 to 10 mmHg when it is not taken regularly, versus no effect in those who consume it regularly.[T716] The vasoconstricting effects of caffeine are beneficial in migraines and other types of headache, which are normally caused by vasodilation in the brain.[A187709,L9872]', 'Caffeine stimulates the central nervous system (CNS), heightening alertness, and sometimes causing restlessness and agitation. It relaxes smooth muscle, stimulates the contraction of cardiac muscle, and enhances athletic performance.[A298,T716,L9857] Caffeine promotes gastric acid secretion and increases gastrointestinal motility. It is often combined in products with analgesics and ergot alkaloids, relieving the symptoms of migraine and other types of headaches. Finally, caffeine acts as a mild diuretic.[T716]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Apexidone 1mg 20 f.c.tab.', 842, 'ابيكسيدون 1مجم 20 قرص', '54', NULL, 'Psychiatric.antipsychotics', 'Psychiatric.antipsychotics', NULL, 'Risperidone', 'Multi-apex', 'Tab', 'أقراص', '1mg', '2', NULL, NULL, 'about risperidone second-generation antipsychotic benzisoxazole derivative antimanic atypical antipsychotic. mechanism of action of risperidone risperidone exerts its antipsychotic activity by blocking dopamine and serotonin (5ht2) receptors. the drug has', '6223003200596', 3618, '2022-12-02', NULL, 0, 'Risperidone is indicated for the treatment of schizophrenia [L12885,L44692,L46297] and irritability associated with autistic disorder.[L12885] It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.[L12885,L44692]



Risperidone is additionally indicated in Canada for the short-term symptomatic management of aggression or psychotic symptoms in patients with severe dementia of the Alzheimer type unresponsive to nonpharmacological approaches.[L12906]



Risperidone is also used off-label for a number of conditions including as an adjunct to antidepressants in treatment-resistant depression.[A177226]', 'Though its precise mechanism of action is not fully understood, current focus is on the ability of risperidone to inhibit the D2 dopaminergic receptors and 5-HT2A serotonergic receptors in the brain. Schizophrenia is thought to result from an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively.[A1115, A1116, A1117]



D2 dopaminergic receptors are transiently inhibited by risperidone, reducing dopaminergic neurotransmission, therefore decreasing positive symptoms of schizophrenia, such as delusions and hallucinations.[A251765] Risperidone binds transiently and with loose affinity to the dopaminergic D2 receptor, with an ideal receptor occupancy of 60-70% for optimal effect.[A1119,A31773] Rapid dissociation of risperidone from the D2 receptors contributes to decreased risk of extrapyramidal symptoms (EPS), which occur with permanent and high occupancy blockade of D2 dopaminergic receptors.[A1118,A1119] Low-affinity binding and rapid dissociation from the D2 receptor distinguish risperidone from the traditional antipsychotic drugs. A higher occupancy rate of D2 receptors is said to increase the risk of extrapyramidal symptoms and is therefore to be avoided.[A1118,A1119,A31771] 

 

Increased serotonergic mesocortical activity in schizophrenia results in negative symptoms, such as depression and decreased motivation. The high-affinity binding of risperidone to 5-HT2A receptors leads to a decrease in serotonergic activity. In addition, 5-HT2A receptor blockade results in decreased risk of extrapyramidal symptoms, likely by increasing dopamine release from the frontal cortex, and not the nigrostriatal tract. Dopamine level is therefore not completely inhibited.[A1117,A1119] Through the above mechanisms, both serotonergic and D2 blockade by risperidone are thought to synergistically work to decrease the risk of extrapyramidal symptoms. 

 

Risperidone has also been said to be an antagonist of alpha-1 (α1), alpha-2 (α2), and histamine (H1) receptors.[A37034] Blockade of these receptors is thought to improve symptoms of schizophrenia, however the exact mechanism of action on these receptors is not fully understood at this time.[L12885]', 'The primary action of risperidone is to decrease dopaminergic and serotonergic pathway activity in the brain, therefore decreasing symptoms of schizophrenia and mood disorders.[A1115,A1116]



Risperidone has a high binding affinity for serotonergic 5-HT2A receptors when compared to dopaminergic D2 receptors in the brain.[A1114,A1115] Risperidone binds to D2 receptors with a lower affinity than first-generation antipsychotic drugs, which bind with very high affinity. A reduction in extrapyramidal symptoms with risperidone, when compared to its predecessors, is likely a result of its moderate affinity for dopaminergic D2 receptors.[A1119,A1117]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Gemcitabine actavis 200mg i.v.vial(n/a)', 19644, 'جيمسيتابين اكتافيس 200 مجم فيال', '154', NULL, 'Antineoplastic', 'Antineoplastic', NULL, 'Gemcitabine', 'Actavis > multipharma', 'Tab', 'أقراص', '200mg', '1', NULL, NULL, NULL, NULL, 668, '2022-07-30', NULL, 0, 'Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents. 



In combination with [carboplatin], it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.[L32950]



Gemcitabine in combination with [paclitaxel] is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated.[L32950]



In combination with [cisplatin], gemcitabine is indicated for the first-line treatment of patients with inoperable, locally advanced (Stage IIIA or IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC).[L32950] Dual therapy with cisplatin is also used to treat patients with Stage IV (locally advanced or metastatic) transitional cell carcinoma (TCC) of the bladder.[L32955]



Gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine is indicated for patients previously treated with [fluorouracil].[L32950]', 'Gemcitabine is a potent and specific deoxycytidine analog. After uptake into malignant cells, gemcitabine is phosphorylated by deoxycytidine kinase to form gemcitabine monophosphate, which is then converted to the active compounds, gemcitabine diphosphate (dFdCDP) and gemcitabine triphosphate (dFdCTP). These active metabolites are nucleosides that mediate antitumour effects. dFdCTP competes with deoxycytidine triphosphate (dCTP) for incorporation into DNA, thereby competitively inhibiting DNA chain elongation. The non-terminal position of dFdCTP in the DNA chain prevents detection of dFdCTP in the chain and repair by proof-reading 3′5′-exonuclease: this process is referred to as "masked DNA chain termination." Incorporation of dFdCTP into the DNA chain ultimately leads to chain termination, DNA fragmentation, and apoptotic cell death of malignant cells.[A233140,A233145,L32950]



Gemcitabine has self-potentiating pharmacological actions that can increase the probability of successful incorporation of gemcitabine triphosphate into the DNA chain: dFdCDP inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate dCTP for DNA synthesis. Since dFdCDP reduces the levels of dCTP, there is less competition for gemcitabine triphosphate for incorporation into DNA.[A233140,L32950] Gemcitabine can also reduce metabolism and elimination of active metabolites from the target ce1l, prolonging high intracellular concentrations of the active metabolites. Such self-potentiating effects are not present with [cytarabine].[A233140]', 'Gemcitabine is a nucleoside analog that mediates its antitumour effects by promoting apoptosis of malignant cells undergoing DNA synthesis. More specifically, it blocks the progression of cells through the G1/S-phase boundary.[L32950] Gemcitabine demonstrated cytotoxic effects against a broad range of cancer cell lines _in vitro_. It displayed schedule-dependent antitumour activity in various animal models and xenografts from human non-small cell lung cancer (NSCLC) and pancreatic cancer.[A233140] Therefore, the antineoplastic effects of gemcitabine are enhanced through prolonged infusion time rather than higher dosage.[A233140] Gemcitabine inhibited the growth of human xenografts from carcinoma of the lung, pancreas, ovaries, head and neck, and breast. In mice, gemcitabine inhibited the growth of human tumour xenografts from the breast, colon, lung or pancreas by 69 to 99%. In clinical trials of advanced NSCLC, gemcitabine monotherapy produced objective response rates ranging from 18 to 26%, with a median duration of response ranging from 3.3 to 12.7 months. Overall median survival time was 6.2 to 12.3 months. The combined use of cisplatin and gemcitabine produced better objective response rates compared to monotherapy. In patients with advanced pancreatic cancer, objective response rates in patients ranged from 5.to 12%, with a median survival duration of 3.9 to 6.3 months.[A233145] In Phase II trials involving patients with metastatic breast cancer, treatment with gemcitabine alone or with adjuvant chemotherapies resulted in response rate ranging from 13 to 42% and median survival duration ranging from 11.5 to 17.8 months. In metastatic bladder cancer, gemcitabine has a response rate 20 to 28%. In Phase II trials of advanced ovarian cancer, patients treated with gemcitabine had response rate of 57.1%, with progression free survival of 13.4 months and median survival of 24 months.[A233140]



Gemcitabine causes dose-limiting myelosuppression, such as anemia, leukopenia, neutropenia, and thrombocytopenia; however, events leading to discontinuation tend to occur less than 1% of the patients. Gemcitabine can elevate ALT, AST and alkaline phosphatase levels.[A233145]', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Aptamil 2 advance premium+ milk 400 gm', 889, 'ابتاميل 2 ادفانس بريميوم+ لبن اطفال 400 جم', '380', '370', 'Milk products.second stage (age 6-12 months)', 'Milk products.second stage (age 6-12 months)', NULL, 'Milk formula stage 2', 'Nutricia cuijk b.v. > united partners company', 'Unknown', 'غير محدد', '400 gm', '1', NULL, NULL, 'not to replace mother s milk. for infants from 0-6 months age. to be used within one month from opening.', NULL, 1011, '2025-06-01', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Liki panthenol cream 30gm', 33101, 'ليكي بانثينول كريم 30 جم', '30', '19.75', 'Moisturizing cream', 'Moisturizing cream', NULL, 'Panthenol 2%', 'Liki for cosmetics', 'Cream', 'كريم', '30gm', '1', NULL, NULL, NULL, NULL, 960, '2025-08-04', NULL, 0, 'Panthenol (containing a racemic mixture of dexpanthenol and levopanthenol) is not currently available in any FDA-approved products and therefore does not have an indication.



Please see [DB09357] for FDA-approved uses of the dextrorotatory form of Panthenol. ', 'Panthenol is an alcohol derivative of pantothenic acid, a component of the B complex vitamins and an essential component of a normally functioning epithelium. Dexpanthenol, the active form of panthenol, is enzymatically cleaved to form pantothenic acid (Vitamin B5), which is an essential component of Coenzyme A that acts as a cofactor in many enzymatic reactions that are important for protein metabolism in the epithelium [A32373].



Dermatological effects of the topical use of dexpanthenol include increased fibroblast proliferation and accelerated re-epithelialization in wound healing. Furthermore, it acts as a topical protectant, moisturizer, and has demonstrated anti-inflammatory properties [A32377].', 'Pantothenic acid is a precursor of coenzyme A, which serves as a cofactor for a variety of enzyme-catalyzed reactions involving transfer of acetyl groups. The final step in the synthesis of acetylcholine consists of the choline acetylase transfer of acetyl group from acetylcoenzyme A to choline. Acetylcholine is the neurohumoral transmitter in the parasympathetic system and as such maintains the normal functions of the intestine. Decrease in acetylcholine content would result in decreased peristalsis and in extreme cases adynamic ileus. ', 'DrugBank');
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cempion 14 sachets', 30298, 'سيمبيون 14 كيس', '100', '85', 'Iron supplement', 'Iron supplement', NULL, 'Lactoferrin+colostrum+iron+vitamin b complex+folic acid+vitamin c+vitamin e+cocoa powder+zinc+seleni', 'Medcare > neutra company', 'Sachet', 'أكياس', NULL, '1', NULL, NULL, 'lactoferrin is a bioactive 80-kda iron binding glycoprotein. dosage: 1 sachet to be dissolved in quarter glass of water and taken twice daily before meals.', '6225000486713', 965, '2024-08-16', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Somatropin 4 i.u./ vial', 10696, 'سوماتروبين 4وحدة دولية / فيال', '321', '228', 'Human growth hormone', 'Human growth hormone', NULL, 'Somatropin', 'Sedico', 'Vial', 'فيال', NULL, '1', 'هرمون نمو بشري', NULL, NULL, '6221042593402', 16499, '2024-07-07', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Cephramedin 250 mg vial', 2373, 'سيفرميدين 0.25 جرام فيال', '5', NULL, 'Antibiotic.cephalosporin.first-generation', 'Antibiotic.cephalosporin.first-generation', NULL, 'Cephradine', 'Rameda', 'Vial', 'فيال', '250 mg', '1', NULL, NULL, 'description a semi-synthetic cephalosporin antibiotic. mechanism of action cefradine is a first generation cephalosporin antibiotic with a spectrum of activity similar to cefalexin. cefradine like the penicillins is a beta-lactam antibiotic. by binding to', NULL, 1037, '2022-09-22', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Ampiclozapine 250mg 20 caps.', 14054, 'امبيكلوزابين 250مجم 20 كبسولة', '825', '725', 'Antidepressants', 'Antidepressants', NULL, 'Ampizapine', 'Illupharm', 'Cap', 'كبسولة', '250mg', '2', 'علاج الأمراض والمشاكل النفسية التالية: انفصام الشخصية. اضطراب المزاج ثنائي القطب', NULL, NULL, NULL, 948, '2025-08-20', NULL, 0, NULL, NULL, NULL, NULL);
INSERT OR IGNORE INTO drugs (tradeName, id, arabicName, price, oldPrice, mainCategory, category, category_ar, active, company, dosageForm, dosageForm_ar, concentration, unit, usage, usage_ar, description, barcode, visits, lastPriceUpdate, imageUrl, updatedAt, indication, mechanism_of_action, pharmacodynamics, data_source_pharmacology) VALUES ('Biovit 12 depot 2 amp', 15318, 'بيوفيت 12 ديبو 2 امبول', '28', '19', 'Vitamin b', 'Vitamin b', NULL, 'Folic acid+vitamin b6+vitamin b12', 'Mup', 'Amp', 'أمبول', NULL, '2', 'حالات الضعف العام والخمول والارهاق.', NULL, NULL, '6221508170918', 13307, '2024-12-08', NULL, 0, 'Folic acid is indicated for the treatment of folic acid deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood.', 'Folic acid, as it is biochemically inactive, is converted to tetrahydrofolic acid and methyltetrahydrofolate by dihydrofolate reductase (DHFR). These folic acid congeners are transported across cells by receptor-mediated endocytosis where they are needed to maintain normal erythropoiesis, synthesize purine and thymidylate nucleic acids, interconvert amino acids, methylate tRNA, and generate and use formate. Using vitamin B12 as a cofactor, folic acid can normalize high homocysteine levels by remethylation of homocysteine to methionine via methionine synthetase.', 'Folic acid is a water-soluble B-complex vitamin found in foods such as liver, kidney, yeast, and leafy, green vegetables. Also known as folate or Vitamin B9, folic acid is an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic acid is the precursor of tetrahydrofolic acid, which is involved as a cofactor for transformylation reactions in the biosynthesis of purines and thymidylates of nucleic acids. Impairment of thymidylate synthesis in patients with folic acid deficiency is thought to account for the defective deoxyribonucleic acid (DNA) synthesis that leads to megaloblast formation and megaloblastic and macrocytic anemias. Folic acid is particularly important during phases of rapid cell division, such as infancy, pregnancy, and erythropoiesis, and plays a protective factor in the development of cancer. As humans are unable to synthesize folic acid endogenously, diet and supplementation is necessary to prevent deficiencies. In order to function properly within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted by anti-metabolite therapies such as [DB00563] as they function as DHFR inhibitors to prevent DNA synthesis in rapidly dividing cells, and therefore prevent the formation of DHF and THF. 



In general, folate serum levels below 5 ng/mL indicate folate deficiency, and levels below 2 ng/mL usually result in megaloblastic anemia.', 'DrugBank');
